{
    "id": 673,
    "geneSymbol": "BRAF",
    "terms": [
        "BRAF",
        "B-raf",
        "B-RAF1",
        "BRAF1",
        "NS7",
        "RAFB1"
    ],
    "entrezId": 673,
    "synonyms": [
        "B-raf",
        "B-RAF1",
        "BRAF1",
        "NS7",
        "RAFB1"
    ],
    "chromosome": "7",
    "mapLocation": "7q34",
    "geneDescriptions": [
        {
            "description": "BRAF, serine/threonine-protein kinase B-raf, is a member of the Raf family of serine/threonine protein kinases, which signals through the MAP kinase pathway to regulate cell proliferation and cell growth (PMID: 24737949, PMID: 29540830). BRAF mutations have been identified in a variety of cancers, including, colorectal (PMID: 30122982), lung (PMID: 29729495), thyroid (PMID: 12970315), and melanoma (PMID: 24737949), and a number of mutations have also been demonstrated to confer drug resistance (PMID: 27478040).",
            "references": [
                {
                    "id": 12239,
                    "pubMedId": 30122982,
                    "title": "Development of small-molecule therapeutics and strategies for targeting RAF kinase in BRAF-mutant colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30122982"
                },
                {
                    "id": 12242,
                    "pubMedId": 29540830,
                    "title": "Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29540830"
                },
                {
                    "id": 12241,
                    "pubMedId": 12970315,
                    "title": "Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/12970315"
                },
                {
                    "id": 131,
                    "pubMedId": 24737949,
                    "title": "BRAF and beyond: Tailoring strategies for the individual melanoma patient.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24737949"
                },
                {
                    "id": 12240,
                    "pubMedId": 29729495,
                    "title": "BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29729495"
                },
                {
                    "id": 8124,
                    "pubMedId": 27478040,
                    "title": "High-throughput Phenotyping of Lung Cancer Somatic Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27478040"
                }
            ]
        }
    ],
    "canonicalTranscript": "NM_004333",
    "createDate": "05/26/2013",
    "updateDate": "04/03/2019",
    "clinicalTrials": [
        {
            "nctId": "NCT03839342",
            "title": "Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations (BEAVER)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1100,
                    "therapyName": "Binimetinib + Encorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03843775",
            "title": "A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1100,
                    "therapyName": "Binimetinib + Encorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02465060",
            "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1028,
                    "therapyName": "Erdafitinib",
                    "synonyms": null
                },
                {
                    "id": 995,
                    "therapyName": "Copanlisib",
                    "synonyms": null
                },
                {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                },
                {
                    "id": 706,
                    "therapyName": "Crizotinib",
                    "synonyms": null
                },
                {
                    "id": 930,
                    "therapyName": "Sunitinib",
                    "synonyms": null
                },
                {
                    "id": 1282,
                    "therapyName": "Sapanisertib",
                    "synonyms": null
                },
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 654,
                    "therapyName": "AZD4547",
                    "synonyms": null
                },
                {
                    "id": 717,
                    "therapyName": "Dasatinib",
                    "synonyms": null
                },
                {
                    "id": 1389,
                    "therapyName": "Pertuzumab + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                },
                {
                    "id": 807,
                    "therapyName": "Binimetinib",
                    "synonyms": null
                },
                {
                    "id": 822,
                    "therapyName": "Adavosertib",
                    "synonyms": null
                },
                {
                    "id": 660,
                    "therapyName": "Osimertinib",
                    "synonyms": null
                },
                {
                    "id": 850,
                    "therapyName": "Palbociclib",
                    "synonyms": null
                },
                {
                    "id": 623,
                    "therapyName": "Afatinib",
                    "synonyms": null
                },
                {
                    "id": 655,
                    "therapyName": "Capivasertib",
                    "synonyms": null
                },
                {
                    "id": 958,
                    "therapyName": "Defactinib",
                    "synonyms": null
                },
                {
                    "id": 765,
                    "therapyName": "GSK2636771",
                    "synonyms": null
                },
                {
                    "id": 956,
                    "therapyName": "Vismodegib",
                    "synonyms": null
                },
                {
                    "id": 1402,
                    "therapyName": "Ado-trastuzumab emtansine",
                    "synonyms": null
                },
                {
                    "id": 2650,
                    "therapyName": "Larotrectinib",
                    "synonyms": null
                },
                {
                    "id": 1016,
                    "therapyName": "Taselisib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02693535",
            "title": "TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1657,
                    "therapyName": "Cobimetinib + Vemurafenib",
                    "synonyms": null
                },
                {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 936,
                    "therapyName": "Temsirolimus",
                    "synonyms": null
                },
                {
                    "id": 717,
                    "therapyName": "Dasatinib",
                    "synonyms": null
                },
                {
                    "id": 1389,
                    "therapyName": "Pertuzumab + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 706,
                    "therapyName": "Crizotinib",
                    "synonyms": null
                },
                {
                    "id": 850,
                    "therapyName": "Palbociclib",
                    "synonyms": null
                },
                {
                    "id": 930,
                    "therapyName": "Sunitinib",
                    "synonyms": null
                },
                {
                    "id": 837,
                    "therapyName": "Olaparib",
                    "synonyms": null
                },
                {
                    "id": 694,
                    "therapyName": "Cetuximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03634982",
            "title": "Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7841,
                    "therapyName": "RMC-4630",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03989115",
            "title": "Dose-Escalation and Dose-Expansion of RMC-4630 and Cobimetinib in Relapsed/Refractory Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8478,
                    "therapyName": "Cobimetinib + RMC-4630",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01514864",
            "title": "Trial of Dasatinib in Subjects With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 717,
                    "therapyName": "Dasatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02296112",
            "title": "Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01877811",
            "title": "CEP-32496 in Patients With Advanced Solid Tumors in Phase 1 and Advanced Melanoma and Metastatic Colorectal Cancer in Phase 2",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1002,
                    "therapyName": "RXDX-105",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02860780",
            "title": "A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 4587,
                    "therapyName": "Prexasertib + Ralimetinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03396497",
            "title": "Study of LYC-55716 With Pembrolizumab in Adult Subjects With Non-Small Cell Lung Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6578,
                    "therapyName": "LYC-55716 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01138085",
            "title": "Safety, Pharmacokinetics (PK) of AKT and MEK Combination",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1298,
                    "therapyName": "Trametinib + Uprosertib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03784378",
            "title": "Continued Access to RXDX-105",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1002,
                    "therapyName": "RXDX-105",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03218826",
            "title": "PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6046,
                    "therapyName": "AZD8186 + Docetaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01744652",
            "title": "Dasatinib and Crizotinib in Advanced Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1252,
                    "therapyName": "Crizotinib + Dasatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03555149",
            "title": "A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1201,
                    "therapyName": "Atezolizumab",
                    "synonyms": null
                },
                {
                    "id": 7075,
                    "therapyName": "Atezolizumab + Isatuximab",
                    "synonyms": null
                },
                {
                    "id": 7076,
                    "therapyName": "Atezolizumab + Bevacizumab + PGG beta-glucan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03978611",
            "title": "A Study to Assess Safety and Efficacy of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-PD-1 Treatment",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 8442,
                    "therapyName": "Ipilimumab + Relatlimab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01306045",
            "title": "Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4,
                    "therapyName": "Erlotinib",
                    "synonyms": null
                },
                {
                    "id": 787,
                    "therapyName": "Lapatinib",
                    "synonyms": null
                },
                {
                    "id": 816,
                    "therapyName": "MK2206",
                    "synonyms": null
                },
                {
                    "id": 930,
                    "therapyName": "Sunitinib",
                    "synonyms": null
                },
                {
                    "id": 913,
                    "therapyName": "Selumetinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02648490",
            "title": "An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3939,
                    "therapyName": "Acetaminophen + Dexamethasone + Diphenhydramine + Ondansetron",
                    "synonyms": null
                },
                {
                    "id": 3938,
                    "therapyName": "HLX07",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01231594",
            "title": "A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3,
                    "therapyName": "Dabrafenib",
                    "synonyms": null
                },
                {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03415126",
            "title": "A Study of ASN007 in Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8304,
                    "therapyName": "ASN007",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02610361",
            "title": "Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 4025,
                    "therapyName": "BGB-283",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01719380",
            "title": "Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1916,
                    "therapyName": "Cetuximab + Encorafenib",
                    "synonyms": null
                },
                {
                    "id": 1917,
                    "therapyName": "Alpelisib + Cetuximab + Encorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02974725",
            "title": "A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8343,
                    "therapyName": "LXH 254 + Ribociclib",
                    "synonyms": null
                },
                {
                    "id": 8342,
                    "therapyName": "LXH 254 + Trametinib",
                    "synonyms": null
                },
                {
                    "id": 6765,
                    "therapyName": "LTT462 + LXH 254",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03091257",
            "title": "A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                },
                {
                    "id": 3,
                    "therapyName": "Dabrafenib",
                    "synonyms": null
                },
                {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01841463",
            "title": "Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation",
            "phase": "Phase Ib/II",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 1238,
                    "therapyName": "Vemurafenib + Voruciclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01037790",
            "title": "PHASE II TRIAL OF THE CYCLIN-DEPEDENT KINASE INHIBITOR PD 0332991 IN PATIENTS WITH CANCER",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 850,
                    "therapyName": "Palbociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03972046",
            "title": "Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5481,
                    "therapyName": "Dabrafenib + Talimogene laherparepvec + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02857270",
            "title": "A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4588,
                    "therapyName": "LY3214996",
                    "synonyms": null
                },
                {
                    "id": 4590,
                    "therapyName": "Gemcitabine + LY3214996 + Nab-paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 4589,
                    "therapyName": "LY3214996 + Midazolam",
                    "synonyms": null
                },
                {
                    "id": 4591,
                    "therapyName": "Abemaciclib + LY3214996",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03698994",
            "title": "Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 997,
                    "therapyName": "Ulixertinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01781429",
            "title": "Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 997,
                    "therapyName": "Ulixertinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03051035",
            "title": "First-in-Human Study of KO-947 in Non-Hematological Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5747,
                    "therapyName": "KO-947",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02747537",
            "title": "Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1323,
                    "therapyName": "Irinotecan + Sorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02050321",
            "title": "A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1936,
                    "therapyName": "Acitretin + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02795156",
            "title": "Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 998,
                    "therapyName": "Cabozantinib",
                    "synonyms": null
                },
                {
                    "id": 623,
                    "therapyName": "Afatinib",
                    "synonyms": null
                },
                {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02428712",
            "title": "A Study of PLX8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1041,
                    "therapyName": "PLX8394",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03992456",
            "title": "Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 845,
                    "therapyName": "Panitumumab",
                    "synonyms": null
                },
                {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                },
                {
                    "id": 2426,
                    "therapyName": "trifluridine/tipiracil hydrochloride",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01885195",
            "title": "MEK162 for Patients With RAS/RAF/MEK Activated Tumors",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 807,
                    "therapyName": "Binimetinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03213691",
            "title": "Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 913,
                    "therapyName": "Selumetinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01723202",
            "title": "Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                },
                {
                    "id": 3,
                    "therapyName": "Dabrafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03332589",
            "title": "Study of E6201 for the Treatment of Central Nervous System Metastases (CNS)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1011,
                    "therapyName": "E6201",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03162627",
            "title": "Selumetinib and Olaparib in Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5793,
                    "therapyName": "Olaparib + Selumetinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01351103",
            "title": "A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1937,
                    "therapyName": "LGK974",
                    "synonyms": null
                },
                {
                    "id": 7468,
                    "therapyName": "LGK974 + Spartalizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03664024",
            "title": "Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782) (KEYNOTE-782)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5498,
                    "therapyName": "Pembrolizumab + Pemetrexed",
                    "synonyms": null
                },
                {
                    "id": 2105,
                    "therapyName": "Carboplatin + Pembrolizumab + Pemetrexed",
                    "synonyms": null
                },
                {
                    "id": 6798,
                    "therapyName": "Cisplatin + Pembrolizumab + Pemetrexed",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01531361",
            "title": "Sorafenib or Crizotinib and Vemurafenib in Advanced Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 706,
                    "therapyName": "Crizotinib",
                    "synonyms": null
                },
                {
                    "id": 1326,
                    "therapyName": "Sorafenib + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03559049",
            "title": "Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7054,
                    "therapyName": "Carboplatin + Pembrolizumab + Pemetrexed + Rucaparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03272464",
            "title": "Phase I Study of INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6176,
                    "therapyName": "Dabrafenib + Itacitinib + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03696212",
            "title": "Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7455,
                    "therapyName": "Grapiprant + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03391232",
            "title": "Safety and Immunogenicity of PolyPEPI1018 Vaccine in the Treatment of Metastatic Colorectal Cancer (OBERTO)",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7308,
                    "therapyName": "PolyPEPI1018",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03353753",
            "title": "Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies (invictus)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4316,
                    "therapyName": "DCC-2618",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01449058",
            "title": "A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1311,
                    "therapyName": "Alpelisib + Binimetinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01495988",
            "title": "Trial of Vemurafenib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                },
                {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02224781",
            "title": "Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01940809",
            "title": "Ipilimumab With or Without Dabrafenib, and/or Trametinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed By Surgery",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3,
                    "therapyName": "Dabrafenib",
                    "synonyms": null
                },
                {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                },
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01657591",
            "title": "Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1217,
                    "therapyName": "Vemurafenib + XL888",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03101254",
            "title": "LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5512,
                    "therapyName": "Cobimetinib + LY3022855 + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01512251",
            "title": "BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1322,
                    "therapyName": "Buparlisib + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01781026",
            "title": "Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01585415",
            "title": "Vemurafenib and White Blood Cell Therapy for Advanced Melanoma",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 953,
                    "therapyName": "Vandetanib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03551626",
            "title": "Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes (COMBI-APlus)",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02721459",
            "title": "XL888 + Vemurafenib + Cobimetinib for Unresectable B Rapidly Accelerated Fibrosarcoma (BRAF) Mutated Stage III/IV Melanoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3995,
                    "therapyName": "Cobimetinib + Vemurafenib + XL888",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02097225",
            "title": "Hsp90 Inhibitor AT13387, Dabrafenib, and Trametinib in Treating Patients With Recurrent Melanoma That is Metastatic or Cannot be Removed by Surgery",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1362,
                    "therapyName": "Dabrafenib + Onalespib + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03455764",
            "title": "A Phase I/II Study of MCS110 With BRAF/MEK Inhibition in Patients With Melanoma After Progression on BRAF/MEK Inhibition",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6759,
                    "therapyName": "Dabrafenib + MCS110 + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01767454",
            "title": "Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1258,
                    "therapyName": "Dabrafenib + Ipilimumab + Trametinib",
                    "synonyms": null
                },
                {
                    "id": 1257,
                    "therapyName": "Dabrafenib + Ipilimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01682213",
            "title": "Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3,
                    "therapyName": "Dabrafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02818023",
            "title": "Dose-seeking and Efficacy Study of Pembrolizumab Plus Vemurafenib Advanced Melanoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4406,
                    "therapyName": "Pembrolizumab + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02200562",
            "title": "Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1257,
                    "therapyName": "Dabrafenib + Ipilimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01909453",
            "title": "Study Comparing Combination of LGX818 Plus MEK162 and LGX818 Monotherapy Versus Vemurafenib in BRAF Mutant Melanoma",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                },
                {
                    "id": 796,
                    "therapyName": "Encorafenib",
                    "synonyms": null
                },
                {
                    "id": 1100,
                    "therapyName": "Binimetinib + Encorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01989585",
            "title": "Dabrafenib, Trametinib, and Navitoclax in Treating Patients With Solid Tumors That Are Metastatic or Cannot be Removed by Surgery",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1303,
                    "therapyName": "Dabrafenib + Navitoclax + Trametinib",
                    "synonyms": null
                },
                {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01978236",
            "title": "Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                },
                {
                    "id": 3,
                    "therapyName": "Dabrafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01682083",
            "title": "A Study of the BRAF Inhibitor Dabrafenib in Combination With the MEK Inhibitor Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection.",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02196181",
            "title": "Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02427893",
            "title": "Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma",
            "phase": "Phase III",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 1004,
                    "therapyName": "Cobimetinib",
                    "synonyms": null
                },
                {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02027961",
            "title": "Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1357,
                    "therapyName": "Dabrafenib + Durvalumab + Trametinib",
                    "synonyms": null
                },
                {
                    "id": 1358,
                    "therapyName": "Durvalumab + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01947023",
            "title": "Dabrafenib and Lapatinib Ditosylate in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2478,
                    "therapyName": "Dabrafenib + Lapatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02124772",
            "title": "Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                },
                {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01954043",
            "title": "A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1302,
                    "therapyName": "Dabrafenib + Rabeprazole + Rifampin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01813214",
            "title": "The Effects of Vemurafenib on Immunity in Patients With Melanoma",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01767623",
            "title": "A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Patients",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03297606",
            "title": "Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (CAPTUR)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 690,
                    "therapyName": "Bosutinib",
                    "synonyms": null
                },
                {
                    "id": 850,
                    "therapyName": "Palbociclib",
                    "synonyms": null
                },
                {
                    "id": 956,
                    "therapyName": "Vismodegib",
                    "synonyms": null
                },
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 1657,
                    "therapyName": "Cobimetinib + Vemurafenib",
                    "synonyms": null
                },
                {
                    "id": 936,
                    "therapyName": "Temsirolimus",
                    "synonyms": null
                },
                {
                    "id": 837,
                    "therapyName": "Olaparib",
                    "synonyms": null
                },
                {
                    "id": 4,
                    "therapyName": "Erlotinib",
                    "synonyms": null
                },
                {
                    "id": 706,
                    "therapyName": "Crizotinib",
                    "synonyms": null
                },
                {
                    "id": 930,
                    "therapyName": "Sunitinib",
                    "synonyms": null
                },
                {
                    "id": 623,
                    "therapyName": "Afatinib",
                    "synonyms": null
                },
                {
                    "id": 717,
                    "therapyName": "Dasatinib",
                    "synonyms": null
                },
                {
                    "id": 1389,
                    "therapyName": "Pertuzumab + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 649,
                    "therapyName": "Axitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02039947",
            "title": "Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01656642",
            "title": "A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Vemurafinib (Zelboraf&#174;) in Patients With Previously Untreated BRAFV600-Mutation Positive Metastatic Melanoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1216,
                    "therapyName": "Atezolizumab + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01436656",
            "title": "A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 796,
                    "therapyName": "Encorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02278133",
            "title": "Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2008,
                    "therapyName": "Cetuximab + Encorafenib + LGK974",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02723006",
            "title": "Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 4198,
                    "therapyName": "MLN2480 + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 4200,
                    "therapyName": "MLN1202 + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 4202,
                    "therapyName": "Ipilimumab + Nivolumab + Vedolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03026517",
            "title": "Clinical Trial of Phenformin in Combination With Dabrafenib and Trametinib for Patients With BRAF-mutated Melanoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5270,
                    "therapyName": "Dabrafenib + Phenformin + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02230306",
            "title": "Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1657,
                    "therapyName": "Cobimetinib + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02456701",
            "title": "Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2063,
                    "therapyName": "CDX-3379 + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03911869",
            "title": "An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis (POLARIS)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1100,
                    "therapyName": "Binimetinib + Encorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01907802",
            "title": "Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 3,
                    "therapyName": "Dabrafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01894672",
            "title": "BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 796,
                    "therapyName": "Encorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03864042",
            "title": "Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7997,
                    "therapyName": "Caffeine + Dextromethorphan + Losartan + Midazolam + Omeprazole",
                    "synonyms": null
                },
                {
                    "id": 7995,
                    "therapyName": "Modafinil",
                    "synonyms": null
                },
                {
                    "id": 7996,
                    "therapyName": "Bupropion + Rosuvastatin",
                    "synonyms": null
                },
                {
                    "id": 1100,
                    "therapyName": "Binimetinib + Encorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02094872",
            "title": "Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1009,
                    "therapyName": "Doxorubicin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01738451",
            "title": "A Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3,
                    "therapyName": "Dabrafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02974803",
            "title": "Concurrent Dabrafenib and Trametinib With Sterotactic Radiation in Patients With BRAF Mutation-Positive Malignant Melanoma and Brain Metastases",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02906059",
            "title": "Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1361,
                    "therapyName": "Adavosertib + Irinotecan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01843738",
            "title": "Radiation Use During Vemurafenib Treatment",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01603212",
            "title": "Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1188,
                    "therapyName": "Aldesleukin + Alpha 2 Interferon + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02091141",
            "title": "My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4,
                    "therapyName": "Erlotinib",
                    "synonyms": null
                },
                {
                    "id": 698,
                    "therapyName": "Alectinib",
                    "synonyms": null
                },
                {
                    "id": 1657,
                    "therapyName": "Cobimetinib + Vemurafenib",
                    "synonyms": null
                },
                {
                    "id": 1389,
                    "therapyName": "Pertuzumab + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 956,
                    "therapyName": "Vismodegib",
                    "synonyms": null
                },
                {
                    "id": 1201,
                    "therapyName": "Atezolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03149029",
            "title": "Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1449,
                    "therapyName": "Dabrafenib + Pembrolizumab + Trametinib",
                    "synonyms": null
                },
                {
                    "id": 1450,
                    "therapyName": "Pembrolizumab + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01826448",
            "title": "A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1339,
                    "therapyName": "Pexidartinib + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03543969",
            "title": "Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1657,
                    "therapyName": "Cobimetinib + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01777776",
            "title": "Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 796,
                    "therapyName": "Encorafenib",
                    "synonyms": null
                },
                {
                    "id": 1260,
                    "therapyName": "Encorafenib + Ribociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02263898",
            "title": "Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations",
            "phase": "Phase II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 1100,
                    "therapyName": "Binimetinib + Encorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01974258",
            "title": "Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 1306,
                    "therapyName": "Onartuzumab + Vemurafenib",
                    "synonyms": null
                },
                {
                    "id": 1307,
                    "therapyName": "Cobimetinib + Onartuzumab",
                    "synonyms": null
                },
                {
                    "id": 1308,
                    "therapyName": "Cobimetinib + Onartuzumab + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01524978",
            "title": "A Study of Zelboraf (Vemurafenib) in Patients With BRAF V600 Mutation-Positive Cancers",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                },
                {
                    "id": 694,
                    "therapyName": "Cetuximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03178851",
            "title": "A Study Evaluating Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1343,
                    "therapyName": "Atezolizumab + Cobimetinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03301636",
            "title": "A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab in Subjects With Unresectable or Metastatic Melanoma (NLG2107)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6587,
                    "therapyName": "Indoximod + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 6586,
                    "therapyName": "Indoximod + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03220035",
            "title": "Pediatric MATCH: Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02961283",
            "title": "Study of ASN003 in Subjects With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 5827,
                    "therapyName": "ASN003",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03273153",
            "title": "A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1343,
                    "therapyName": "Atezolizumab + Cobimetinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03155620",
            "title": "Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2683,
                    "therapyName": "Tazemetostat",
                    "synonyms": null
                },
                {
                    "id": 2650,
                    "therapyName": "Larotrectinib",
                    "synonyms": null
                },
                {
                    "id": 1069,
                    "therapyName": "LY3023414",
                    "synonyms": null
                },
                {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                },
                {
                    "id": 850,
                    "therapyName": "Palbociclib",
                    "synonyms": null
                },
                {
                    "id": 837,
                    "therapyName": "Olaparib",
                    "synonyms": null
                },
                {
                    "id": 997,
                    "therapyName": "Ulixertinib",
                    "synonyms": null
                },
                {
                    "id": 1028,
                    "therapyName": "Erdafitinib",
                    "synonyms": null
                },
                {
                    "id": 913,
                    "therapyName": "Selumetinib",
                    "synonyms": null
                },
                {
                    "id": 961,
                    "therapyName": "Ensartinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01519323",
            "title": "BRIM-P",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03592641",
            "title": "Volitinib in Treating Participants With MET Amplified Metastatic or Unresectable Colorectal Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2161,
                    "therapyName": "Savolitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01683188",
            "title": "HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma",
            "phase": "Phase III",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1229,
                    "therapyName": "Aldesleukin + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01981187",
            "title": "LGX818 for Patients With BRAFV600 Mutated Tumors",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 796,
                    "therapyName": "Encorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02145910",
            "title": "Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02082665",
            "title": "Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and Midazolam",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1388,
                    "therapyName": "Dabrafenib + Midazolam + Rosuvastatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03377361",
            "title": "An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Patients With Previously Treated Cancer of the Colon or Rectum That Has Spread",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 6537,
                    "therapyName": "Ipilimumab + Nivolumab + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02145143",
            "title": "Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01946789",
            "title": "A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3060,
                    "therapyName": "ALT-803",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01820364",
            "title": "LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1100,
                    "therapyName": "Binimetinib + Encorafenib",
                    "synonyms": null
                },
                {
                    "id": 1260,
                    "therapyName": "Encorafenib + Ribociclib",
                    "synonyms": null
                },
                {
                    "id": 1337,
                    "therapyName": "Buparlisib + Encorafenib",
                    "synonyms": null
                },
                {
                    "id": 1336,
                    "therapyName": "BGJ398 + Encorafenib",
                    "synonyms": null
                },
                {
                    "id": 1338,
                    "therapyName": "Capmatinib + Encorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01835184",
            "title": "Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1235,
                    "therapyName": "Cabozantinib + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02967692",
            "title": "A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6023,
                    "therapyName": "Dabrafenib + Spartalizumab + Trametinib",
                    "synonyms": null
                },
                {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01902173",
            "title": "GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                },
                {
                    "id": 2200,
                    "therapyName": "Dabrafenib + Uprosertib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02908672",
            "title": "A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1657,
                    "therapyName": "Cobimetinib + Vemurafenib",
                    "synonyms": null
                },
                {
                    "id": 4825,
                    "therapyName": "Atezolizumab + Cobimetinib + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02159066",
            "title": "LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1101,
                    "therapyName": "Binimetinib + Encorafenib + Ribociclib",
                    "synonyms": null
                },
                {
                    "id": 1100,
                    "therapyName": "Binimetinib + Encorafenib",
                    "synonyms": null
                },
                {
                    "id": 2216,
                    "therapyName": "Binimetinib + Capmatinib + Encorafenib",
                    "synonyms": null
                },
                {
                    "id": 2215,
                    "therapyName": "Binimetinib + Buparlisib + Encorafenib",
                    "synonyms": null
                },
                {
                    "id": 2214,
                    "therapyName": "BGJ398 + Binimetinib + Encorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03442569",
            "title": "PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6871,
                    "therapyName": "Ipilimumab + Nivolumab + Panitumumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03087071",
            "title": "Panitumumab in Combination With Trametinib in Cetuximab-Refractory Stage IV Colorectal Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 845,
                    "therapyName": "Panitumumab",
                    "synonyms": null
                },
                {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01619774",
            "title": "An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02036086",
            "title": "Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1657,
                    "therapyName": "Cobimetinib + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01942993",
            "title": "The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02068079",
            "title": "A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 1383,
                    "therapyName": "Trientine + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01701037",
            "title": "Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                },
                {
                    "id": 3,
                    "therapyName": "Dabrafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01739764",
            "title": "An Extension (Rollover) Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01659151",
            "title": "Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer &amp; High Dose IL-2 Metastatic Melanoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1166,
                    "therapyName": "Fludarabine",
                    "synonyms": null
                },
                {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03793179",
            "title": "Firstline Pembrolizumab Alone or in Combination With Pemetrexed and Carboplatin in Induction/Maintenance or Postprogression in Treating Patients With Stage IV Non-squamous Non-small Cell Lung Cancer",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2105,
                    "therapyName": "Carboplatin + Pembrolizumab + Pemetrexed",
                    "synonyms": null
                },
                {
                    "id": 5498,
                    "therapyName": "Pembrolizumab + Pemetrexed",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1602,
                    "therapyName": "Carboplatin + Pemetrexed",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01543698",
            "title": "A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1100,
                    "therapyName": "Binimetinib + Encorafenib",
                    "synonyms": null
                },
                {
                    "id": 1101,
                    "therapyName": "Binimetinib + Encorafenib + Ribociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01787500",
            "title": "Vemurafenib, Cetuximab, and Irinotecan in Advanced Solid Cancers",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1331,
                    "therapyName": "Cetuximab + Irinotecan + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01844674",
            "title": "A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1241,
                    "therapyName": "Tizanidine + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01677741",
            "title": "The Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Pediatric Subjects",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3,
                    "therapyName": "Dabrafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03005639",
            "title": "ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma",
            "phase": "Phase II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 1657,
                    "therapyName": "Cobimetinib + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03446157",
            "title": "Palbociclib and Cetuximab in Metastatic Colorectal Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1705,
                    "therapyName": "Cetuximab + Palbociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03975231",
            "title": "Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02130466",
            "title": "A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022)",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                },
                {
                    "id": 1450,
                    "therapyName": "Pembrolizumab + Trametinib",
                    "synonyms": null
                },
                {
                    "id": 1448,
                    "therapyName": "Dabrafenib + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1449,
                    "therapyName": "Dabrafenib + Pembrolizumab + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02382549",
            "title": "A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib (Mel61)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8248,
                    "therapyName": "6MHP vaccine + Dabrafenib + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03973918",
            "title": "Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG (BRAF)",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 1100,
                    "therapyName": "Binimetinib + Encorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02285439",
            "title": "Phase I/II Study of MEK162 for Children With Ras/Raf Pathway Activated Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 807,
                    "therapyName": "Binimetinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03429803",
            "title": "TAK-580 In Gliomas and Other Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1034,
                    "therapyName": "MLN2480",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02587650",
            "title": "Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 789,
                    "therapyName": "Ceritinib",
                    "synonyms": null
                },
                {
                    "id": 1065,
                    "therapyName": "Capmatinib",
                    "synonyms": null
                },
                {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                },
                {
                    "id": 1455,
                    "therapyName": "Entrectinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02065063",
            "title": "A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1368,
                    "therapyName": "Palbociclib + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02508077",
            "title": "FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1315,
                    "therapyName": "Fluorouracil + Irinotecan + Leucovorin",
                    "synonyms": "FOLFIRI"
                },
                {
                    "id": 845,
                    "therapyName": "Panitumumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02138292",
            "title": "A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1446,
                    "therapyName": "Digoxin + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02318901",
            "title": "Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1909,
                    "therapyName": "Ado-trastuzumab emtansine + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1908,
                    "therapyName": "Pembrolizumab + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1910,
                    "therapyName": "Cetuximab + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03384940",
            "title": "DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4844,
                    "therapyName": "DS-8201a",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02785068",
            "title": "Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 4532,
                    "therapyName": "Fluorouracil + Irinotecan + Leucovorin + MM-151",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03457896",
            "title": "Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1118,
                    "therapyName": "Cetuximab + Neratinib",
                    "synonyms": null
                },
                {
                    "id": 4359,
                    "therapyName": "Neratinib + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03181100",
            "title": "Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 619,
                    "therapyName": "Nab-paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1343,
                    "therapyName": "Atezolizumab + Cobimetinib",
                    "synonyms": null
                },
                {
                    "id": 4595,
                    "therapyName": "Atezolizumab + Bevacizumab",
                    "synonyms": null
                },
                {
                    "id": 3049,
                    "therapyName": "Atezolizumab + Nab-paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 4825,
                    "therapyName": "Atezolizumab + Cobimetinib + Vemurafenib",
                    "synonyms": null
                },
                {
                    "id": 5606,
                    "therapyName": "Atezolizumab + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01802320",
            "title": "Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery",
            "phase": "Phase II",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 816,
                    "therapyName": "MK2206",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03069950",
            "title": "Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver",
            "phase": "Phase II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 5476,
                    "therapyName": "Dexamethasone + Floxuridine + Fluorouracil + Irinotecan + Leucovorin + Panitumumab",
                    "synonyms": "Floxiuridine + Panitumumab + Dexamethasone + FOLFIRI"
                }
            ]
        },
        {
            "nctId": "NCT01960023",
            "title": "Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 1118,
                    "therapyName": "Cetuximab + Neratinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01941927",
            "title": "Trametinib With GSK2141795 in BRAF Wild-type Melanoma",
            "phase": "Phase II",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 1298,
                    "therapyName": "Trametinib + Uprosertib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03580382",
            "title": "Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7105,
                    "therapyName": "CDX-3379 + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02949843",
            "title": "Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4918,
                    "therapyName": "Nivolumab + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03310541",
            "title": "AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 655,
                    "therapyName": "Capivasertib",
                    "synonyms": null
                },
                {
                    "id": 6351,
                    "therapyName": "Capivasertib + Enzalutamide",
                    "synonyms": null
                },
                {
                    "id": 4452,
                    "therapyName": "Capivasertib + Fulvestrant",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02140840",
            "title": "A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib",
            "phase": "Phase II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01636622",
            "title": "Study of Vemurafenib, Carboplatin, and Paclitaxel",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1209,
                    "therapyName": "Carboplatin + Paclitaxel + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02367859",
            "title": "Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01713972",
            "title": "Dabrafenib and Pazopanib Hydrochloride in Treating Patients With Advanced Malignant Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1233,
                    "therapyName": "Dabrafenib + Pazopanib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01586195",
            "title": "Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03516981",
            "title": "A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4213,
                    "therapyName": "MK-4280 + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 4782,
                    "therapyName": "Lenvatinib + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03114319",
            "title": "Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6959,
                    "therapyName": "TNO155",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01765543",
            "title": "A Pharmacokinetics Study to Investigate the Effect of Rifampin on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1256,
                    "therapyName": "Rifampin + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02012231",
            "title": "Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1041,
                    "therapyName": "PLX8394",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03088176",
            "title": "Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5481,
                    "therapyName": "Dabrafenib + Talimogene laherparepvec + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01596140",
            "title": "Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1175,
                    "therapyName": "Temsirolimus + Vemurafenib",
                    "synonyms": null
                },
                {
                    "id": 1174,
                    "therapyName": "Everolimus + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03665129",
            "title": "IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors (STELLAR-001)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7481,
                    "therapyName": "Durvalumab + IPH5401",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03255083",
            "title": "DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6583,
                    "therapyName": "DS-1205c + Osimertinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01721603",
            "title": "A Phase 2 Prospective Trial of Dabrafenib With Stereotactic Radiosurgery in BRAFV600E Melanoma Brain Metastases",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 3,
                    "therapyName": "Dabrafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03260491",
            "title": "U3-1402 in Metastatic or Unresectable EGFR-mutant Non-Small Cell Lung Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6978,
                    "therapyName": "U3-1402",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03668431",
            "title": "Dabrafenib + Trametinib + PDR001 In Colorectal Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6023,
                    "therapyName": "Dabrafenib + Spartalizumab + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03475004",
            "title": "Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6838,
                    "therapyName": "Bevacizumab + Binimetinib + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01750918",
            "title": "BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1715,
                    "therapyName": "Fluorouracil",
                    "synonyms": null
                },
                {
                    "id": 1718,
                    "therapyName": "Dabrafenib + Panitumumab",
                    "synonyms": null
                },
                {
                    "id": 1992,
                    "therapyName": "Dabrafenib + Panitumumab + Trametinib",
                    "synonyms": null
                },
                {
                    "id": 1991,
                    "therapyName": "Panitumumab + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03581292",
            "title": "Veliparib, Radiation Therapy, and Temozolomide in Treating Participants With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600E Mutations",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1193,
                    "therapyName": "Temozolomide + Veliparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02014909",
            "title": "A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2054,
                    "therapyName": "CDX-3379",
                    "synonyms": null
                },
                {
                    "id": 2063,
                    "therapyName": "CDX-3379 + Vemurafenib",
                    "synonyms": null
                },
                {
                    "id": 2064,
                    "therapyName": "CDX-3379 + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 2061,
                    "therapyName": "CDX-3379 + Cetuximab",
                    "synonyms": null
                },
                {
                    "id": 2062,
                    "therapyName": "CDX-3379 + Erlotinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02143050",
            "title": "Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1443,
                    "therapyName": "Dabrafenib + Metformin + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03639714",
            "title": "A Study of a Personalized Neoantigen Cancer Vaccine",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7679,
                    "therapyName": "GRT-C901 + GRT-R902 + Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01726738",
            "title": "LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03224767",
            "title": "Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1657,
                    "therapyName": "Cobimetinib + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02164916",
            "title": "S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1874,
                    "therapyName": "Cetuximab + Irinotecan",
                    "synonyms": null
                },
                {
                    "id": 1331,
                    "therapyName": "Cetuximab + Irinotecan + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01740648",
            "title": "Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1113,
                    "therapyName": "Fluorouracil + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01638676",
            "title": "A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients",
            "phase": "Phase Ib/II",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 1210,
                    "therapyName": "Metformin + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01534897",
            "title": "Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3,
                    "therapyName": "Dabrafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01876641",
            "title": "Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1259,
                    "therapyName": "Decitabine + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01709292",
            "title": "Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01943422",
            "title": "Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1300,
                    "therapyName": "Interferon alpha-2b + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02034110",
            "title": "Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02928224",
            "title": "Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer (BEACON CRC)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1916,
                    "therapyName": "Cetuximab + Encorafenib",
                    "synonyms": null
                },
                {
                    "id": 4886,
                    "therapyName": "Binimetinib + Cetuximab + Encorafenib",
                    "synonyms": null
                },
                {
                    "id": 1874,
                    "therapyName": "Cetuximab + Irinotecan",
                    "synonyms": null
                },
                {
                    "id": 2180,
                    "therapyName": "Cetuximab + Fluorouracil + Irinotecan + Leucovorin",
                    "synonyms": "Cetuximab + FOLFIRI"
                }
            ]
        },
        {
            "nctId": "NCT01897116",
            "title": "A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1281,
                    "therapyName": "Hydroxychloroquine + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03189030",
            "title": "Study of Personalized Immunotherapy in Adults With Metastatic Colorectal Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7307,
                    "therapyName": "pLADD",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01711632",
            "title": "BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03732703",
            "title": "Myeloma-Developing Regimens Using Genomics (MyDRUG) (MyDRUG)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8165,
                    "therapyName": "Dexamethasone + Enasidenib + Ixazomib + Pomalidomide",
                    "synonyms": null
                },
                {
                    "id": 8166,
                    "therapyName": "Cobimetinib + Dexamethasone + Ixazomib + Pomalidomide",
                    "synonyms": null
                },
                {
                    "id": 8167,
                    "therapyName": "Dexamethasone + Erdafitinib + Ixazomib + Pomalidomide",
                    "synonyms": null
                },
                {
                    "id": 8168,
                    "therapyName": "Dexamethasone + Ixazomib + Pomalidomide + Venetoclax",
                    "synonyms": null
                },
                {
                    "id": 8164,
                    "therapyName": "Abemaciclib + Dexamethasone + Ixazomib + Pomalidomide",
                    "synonyms": null
                },
                {
                    "id": 8169,
                    "therapyName": "Daratumumab + Dexamethasone + Ixazomib + Pomalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03365882",
            "title": "S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1874,
                    "therapyName": "Cetuximab + Irinotecan",
                    "synonyms": null
                },
                {
                    "id": 1389,
                    "therapyName": "Pertuzumab + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03631706",
            "title": "M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5860,
                    "therapyName": "M7824",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01089101",
            "title": "Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 913,
                    "therapyName": "Selumetinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02257424",
            "title": "The BAMM Trial: BRAF, Autophagy and MEK Inhibition in Metastatic Melanoma: A Phase I/2 Trial of Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03693170",
            "title": "encorAfenib, biNimetinib and Cetuximab in Subjects witH previOusly Untreated BRAF-mutant ColoRectal Cancer (ANCHOR-CRC)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4886,
                    "therapyName": "Binimetinib + Cetuximab + Encorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04017650",
            "title": "Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8571,
                    "therapyName": "Cetuximab + Encorafenib + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01754376",
            "title": "Combined BRAF-Targeted Therapy and Immunotherapy for Melanoma",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1229,
                    "therapyName": "Aldesleukin + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03840915",
            "title": "M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7870,
                    "therapyName": "Cisplatin + M7824 + Pemetrexed",
                    "synonyms": null
                },
                {
                    "id": 7871,
                    "therapyName": "Docetaxel + M7824",
                    "synonyms": null
                },
                {
                    "id": 7872,
                    "therapyName": "Carboplatin + M7824 + Pemetrexed",
                    "synonyms": null
                },
                {
                    "id": 7873,
                    "therapyName": "Cisplatin + Gemcitabine + M7824",
                    "synonyms": null
                },
                {
                    "id": 7874,
                    "therapyName": "Carboplatin + Gemcitabine + M7824",
                    "synonyms": null
                },
                {
                    "id": 7875,
                    "therapyName": "Carboplatin + M7824 + Nab-paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03915951",
            "title": "An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600E-mutant Non-small Cell Lung Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1100,
                    "therapyName": "Binimetinib + Encorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02915666",
            "title": "A Clinical Trial of Patients With Melanoma",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 4778,
                    "therapyName": "Dabrafenib + Digoxin + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01336634",
            "title": "Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3,
                    "therapyName": "Dabrafenib",
                    "synonyms": null
                },
                {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01748149",
            "title": "Vemurafenib in Children With Recurrent/Refractory BRAFV600E-mutant Gliomas",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                }
            ]
        }
    ],
    "evidence": [
        {
            "id": 4917,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, an ovarian cancer cell line harboring BRAF  N486_P490del was sensitive to Mekinist (trametinib), resulting in inhibition of cell growth in culture (PMID: 26732095).",
            "molecularProfile": {
                "id": 19833,
                "profileName": "BRAF N486_P490del"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4801,
                    "pubMedId": 26732095,
                    "title": "Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26732095"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15628,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Mekinist (trametinib) treatment resulted in partial response in a patient with pancreatic ductal adenocarcinoma harboring BRAF N486_P490del 8 weeks after initiation of treatment and lasted for 6 months (PMID: 29903880).",
            "molecularProfile": {
                "id": 19833,
                "profileName": "BRAF N486_P490del"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13502,
                    "pubMedId": 29903880,
                    "title": "Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903880"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4919,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tafinlar (dabrafenib) resulted in minimal growth inhibitory activity of an ovarian cancer cell line harboring BRAF N486_P490del (PMID: 26732095).",
            "molecularProfile": {
                "id": 19833,
                "profileName": "BRAF N486_P490del"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 4801,
                    "pubMedId": 26732095,
                    "title": "Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26732095"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4916,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, an ovarian cancer cell line harboring BRAF  N486_P490del was sensitive to LY3009120, resulting in inhibition of cell growth and decreased phosphorylation of MEK and ERK in culture (PMID: 26732095).",
            "molecularProfile": {
                "id": 19833,
                "profileName": "BRAF N486_P490del"
            },
            "therapy": {
                "id": 3268,
                "therapyName": "LY3009120",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4801,
                    "pubMedId": 26732095,
                    "title": "Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26732095"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4918,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, an ovarian cancer cell line harboring BRAF N486_P490del was resistant to Zelboraf (vemurafenib), resulting in minimal inhibition of both cell growth and phosphorylation of MEK and ERK in culture (PMID: 26732095).",
            "molecularProfile": {
                "id": 19833,
                "profileName": "BRAF N486_P490del"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4801,
                    "pubMedId": 26732095,
                    "title": "Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26732095"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6829,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing BRAF V600E and the gatepkeeper mutation BRAF T529N were insensitive to RAF265 in culture (PMID: 20538618).",
            "molecularProfile": {
                "id": 23816,
                "profileName": "BRAF V600E BRAF T529N"
            },
            "therapy": {
                "id": 884,
                "therapyName": "RAF265",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5859,
                    "pubMedId": 20538618,
                    "title": "Gatekeeper mutations mediate resistance to BRAF-targeted therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20538618"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6833,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing BRAF V600E and the gatepkeeper mutation BRAF T529N were insensitive to SB590885 in culture (PMID: 20538618).",
            "molecularProfile": {
                "id": 23816,
                "profileName": "BRAF V600E BRAF T529N"
            },
            "therapy": {
                "id": 4281,
                "therapyName": "SB590885",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5859,
                    "pubMedId": 20538618,
                    "title": "Gatekeeper mutations mediate resistance to BRAF-targeted therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20538618"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6838,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing BRAF V600E and the gatepkeeper mutation BRAF T529N were insensitive to Nexavar (sorafenib)-mediated inhibition of Erk phosphorylation but were equally as sensitive to Nexavar (sorafenib)-mediated growth inhibition as transformed cells expressing BRAF V600E in culture (PMID: 20538618).",
            "molecularProfile": {
                "id": 23816,
                "profileName": "BRAF V600E BRAF T529N"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 5859,
                    "pubMedId": 20538618,
                    "title": "Gatekeeper mutations mediate resistance to BRAF-targeted therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20538618"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6841,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CI-1040 (PD184352) inhibited Erk phosphorylation and growth of transformed cells expressing BRAF V600E and the gatekeeper mutation BRAF T529N in culture (PMID: 20538618).",
            "molecularProfile": {
                "id": 23816,
                "profileName": "BRAF V600E BRAF T529N"
            },
            "therapy": {
                "id": 699,
                "therapyName": "CI-1040",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5859,
                    "pubMedId": 20538618,
                    "title": "Gatekeeper mutations mediate resistance to BRAF-targeted therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20538618"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6837,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing BRAF V600E and the gatepkeeper mutation BRAF T529N were insensitive to PLX4720 in culture (PMID: 20538618).",
            "molecularProfile": {
                "id": 23816,
                "profileName": "BRAF V600E BRAF T529N"
            },
            "therapy": {
                "id": 1060,
                "therapyName": "PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5859,
                    "pubMedId": 20538618,
                    "title": "Gatekeeper mutations mediate resistance to BRAF-targeted therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20538618"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 690,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sprycel (dasatinib) induced apoptosis in non-small cell lung carcinoma cells harboring BRAF Y472C in culture (PMID: 22649091).",
            "molecularProfile": {
                "id": 986,
                "profileName": "BRAF Y472C"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 423,
                    "pubMedId": 22649091,
                    "title": "Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22649091"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9615,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) induced apoptosis and inhibited growth of a non-small cell lung cancer cell line harboring BRAF G469A in culture (PMID: 25706985).",
            "molecularProfile": {
                "id": 651,
                "profileName": "BRAF G469A"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7324,
                    "pubMedId": 25706985,
                    "title": "Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25706985"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15566,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tafinlar (dabrafenib) treatment did not result in significant growth inhibition in a non-small lung cancer cell line harboring BRAF G469A in culture (PMID: 29903896).",
            "molecularProfile": {
                "id": 651,
                "profileName": "BRAF G469A"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3933,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAE226 treatment inhibited proliferation of non-small cell lung carcinoma cell lines harboring BRAF G469A mutation in culture (PMID: 26090892).",
            "molecularProfile": {
                "id": 651,
                "profileName": "BRAF G469A"
            },
            "therapy": {
                "id": 2086,
                "therapyName": "TAE226",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4301,
                    "pubMedId": 26090892,
                    "title": "TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26090892"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12700,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, treatment with BVD-523 (ulixertinib) resulted in a partial response in two patients harboring BRAF G469A, including one patient with head and neck cancer and one patient with small bowel cancer (PMID: 29247021).",
            "molecularProfile": {
                "id": 651,
                "profileName": "BRAF G469A"
            },
            "therapy": {
                "id": 997,
                "therapyName": "Ulixertinib",
                "synonyms": null
            },
            "indication": {
                "id": 4907,
                "name": "small intestine carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10607,
                    "pubMedId": 29247021,
                    "title": "First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29247021"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16112,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (MyPathway), Zelboraf (vemurafenib) treatment resulted in an objective response in only 4% (1/23) of patient with advanced solid tumors harboring non-V600 BRAF mutations, 2 of the non-responding patients harbored BRAF G469A (PMID: 29320312; NCT02091141).",
            "molecularProfile": {
                "id": 651,
                "profileName": "BRAF G469A"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13171,
                    "pubMedId": 29320312,
                    "title": "Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29320312"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9413,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF G469A (PMID: 26343582).",
            "molecularProfile": {
                "id": 651,
                "profileName": "BRAF G469A"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 7141,
                    "pubMedId": 26343582,
                    "title": "BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343582"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9611,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) resulted in decreased viability and enhanced ERK inhibition compared to either agent alone, in a non-small cell lung cancer cell line harboring BRAF G469A in culture (PMID: 28947956).",
            "molecularProfile": {
                "id": 651,
                "profileName": "BRAF G469A"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12147,
                    "pubMedId": 28947956,
                    "title": "Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28947956"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9616,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Mekinist (trametinib) and Zelboraf (vemurafenib) inhibited growth of a non-small cell lung cancer cell line harboring BRAF G469A in culture, and prevented Mekinist (trametinib)-related activation of AKT and resulted in increased induction of apoptosis compared to either agent alone (PMID: 25706985).",
            "molecularProfile": {
                "id": 651,
                "profileName": "BRAF G469A"
            },
            "therapy": {
                "id": 4234,
                "therapyName": "Trametinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 7324,
                    "pubMedId": 25706985,
                    "title": "Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25706985"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15543,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Zelboraf (vemurafenib) to treatment with Mekinist (trametinib) resulted in increased proliferation compared to Mekinist (trametinib) alone in a non-small cell lung cancer cell line harboring BRAF G469A in culture (PMID: 29903896).",
            "molecularProfile": {
                "id": 651,
                "profileName": "BRAF G469A"
            },
            "therapy": {
                "id": 4234,
                "therapyName": "Trametinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12699,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, treatment with BVD-523 (ulixertinib) resulted in a partial response in two patients harboring BRAF G469A, including one patient with head and neck cancer and one patient with small bowel cancer (PMID: 29247021).",
            "molecularProfile": {
                "id": 651,
                "profileName": "BRAF G469A"
            },
            "therapy": {
                "id": 997,
                "therapyName": "Ulixertinib",
                "synonyms": null
            },
            "indication": {
                "id": 11934,
                "name": "head and neck cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10607,
                    "pubMedId": 29247021,
                    "title": "First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29247021"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12072,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PLX8394 decreased growth of lung adenocarcinoma cell lines harboring BRAF G469A in culture, and reduced tumor growth in xenograft models (PMID: 27834212).",
            "molecularProfile": {
                "id": 651,
                "profileName": "BRAF G469A"
            },
            "therapy": {
                "id": 1041,
                "therapyName": "PLX8394",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10006,
                    "pubMedId": 27834212,
                    "title": "Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27834212"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9614,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a non-small cell lung cancer cell line harboring BRAF G469A demonstrated resistance to induction of apoptosis by Zelboraf (vemurafenib,) and treatment with Zelboraf (vemurafenib) was not effective in inhibiting growth in culture (PMID: 25706985).",
            "molecularProfile": {
                "id": 651,
                "profileName": "BRAF G469A"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 7324,
                    "pubMedId": 25706985,
                    "title": "Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25706985"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15516,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Braftovi (encorafenib) to treatment with Mekinist (trametinib) resulted in increased growth inhibition in a non-small cell lung cancer cell line harboring BRAF G469A in culture (PMID: 29903896).",
            "molecularProfile": {
                "id": 651,
                "profileName": "BRAF G469A"
            },
            "therapy": {
                "id": 7661,
                "therapyName": "Encorafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15984,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RMC-4550 did not inhibit Erk phosphorylation or proliferation of lung cancer cells harboring BRAF G469A in culture (PMID: 30104724).",
            "molecularProfile": {
                "id": 651,
                "profileName": "BRAF G469A"
            },
            "therapy": {
                "id": 7839,
                "therapyName": "RMC-4550",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 14089,
                    "pubMedId": 30104724,
                    "title": "RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30104724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16582,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cotellic (cobimetinib) inhibited viability of transformed cells expressing BRAF N486_T491delinsK in culture (PMID: 30867592).",
            "molecularProfile": {
                "id": 31686,
                "profileName": "BRAF N486_T491delinsK"
            },
            "therapy": {
                "id": 1004,
                "therapyName": "Cobimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14632,
                    "pubMedId": 30867592,
                    "title": "Efficacy of MEK inhibition in patients with histiocytic neoplasms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30867592"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16572,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, treatment with Cotellic (cobimetinib) in patients with histiocytic neoplasms resulted in a PET overall response rate of 89% (16/18), with complete response in 72% (13/18) and partial response in 17% (3/18), and resulted in stable disease in 6% (1/18) of patients, including a complete response in a patient with Langerhans cell histiocytosis harboring BRAF N486_T491delinsK (PMID: 30867592; NCT01953926).",
            "molecularProfile": {
                "id": 31686,
                "profileName": "BRAF N486_T491delinsK"
            },
            "therapy": {
                "id": 1004,
                "therapyName": "Cobimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 60073,
                "name": "lymphatic system cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14632,
                    "pubMedId": 30867592,
                    "title": "Efficacy of MEK inhibition in patients with histiocytic neoplasms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30867592"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 697,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the MEK inhibitor, Mekinist (trametinib) decreased activation of MEK and ERK in cells expressing BRAF K601E in culture (PMID: 22798288).",
            "molecularProfile": {
                "id": 655,
                "profileName": "BRAF K601E"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3,
                    "pubMedId": 22798288,
                    "title": "BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22798288"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 698,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment of cells expressing BRAF K601E with the BRAF inhibitor, Zelboraf (vemurafenib), decreased activation of MEK and ERK (PMID: 22798288).",
            "molecularProfile": {
                "id": 655,
                "profileName": "BRAF K601E"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 3,
                    "pubMedId": 22798288,
                    "title": "BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22798288"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16108,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (MyPathway), Zelboraf (vemurafenib) treatment resulted in an objective response in only 4% (1/23) of patient with advanced solid tumors harboring non-V600 BRAF mutations, 6 of the non-responding patients harbored BRAF K601E (PMID: 29320312; NCT02091141).",
            "molecularProfile": {
                "id": 655,
                "profileName": "BRAF K601E"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 13171,
                    "pubMedId": 29320312,
                    "title": "Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29320312"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9408,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF K601E (PMID: 26343582).",
            "molecularProfile": {
                "id": 655,
                "profileName": "BRAF K601E"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 7141,
                    "pubMedId": 26343582,
                    "title": "BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343582"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12069,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, no responses were demonstrated among three melanoma patients with non-V600 BRAF mutations, including two patients harboring BRAF K601E, following treatment with Tafinlar (dabrafenib), compared to a confirmed response rate of 50% in patients harboring BRAF V600 mutations (PMID: 22608338).",
            "molecularProfile": {
                "id": 655,
                "profileName": "BRAF K601E"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 467,
                    "pubMedId": 22608338,
                    "title": "Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22608338"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12070,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, a melanoma patient harboring BRAF K601E demonstrated a partial response and a progression free survival of 32 weeks when treated with Mekinist (trametinib) (PMID: 23248257; NCT01037127).",
            "molecularProfile": {
                "id": 655,
                "profileName": "BRAF K601E"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10005,
                    "pubMedId": 23248257,
                    "title": "Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23248257"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12068,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a melanoma patient harboring BRAF K601E demonstrated a 48% reduction in lymphadenopathy when treated with Mekinist (trametinib) and after more than 36 months of treatment showed a complete response (PMID: 28344857).",
            "molecularProfile": {
                "id": 655,
                "profileName": "BRAF K601E"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8660,
                    "pubMedId": 28344857,
                    "title": "Metastatic BRAF K601E-mutated melanoma reaches complete response to MEK inhibitor trametinib administered for over 36\u00a0months.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28344857"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17472,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mektovi (binimetinib) and Erbitux (cetuximab) combination did not inhibit Rsk and Erk phosphorylation, and had no effect on tumor growth in patient-derived xenograft (PDX) models of metastatic colon cancer harboring BRAF K601E and MAP2K1 V211D (PMID: 31227518).",
            "molecularProfile": {
                "id": 32620,
                "profileName": "BRAF K601E MAP2K1 V211D"
            },
            "therapy": {
                "id": 8515,
                "therapyName": "Binimetinib + Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15507,
                    "pubMedId": 31227518,
                    "title": "V211D mutation in MEK1 causes resistance to MEK inhibitors in colon cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31227518"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17465,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with metastatic colon cancer harboring BRAF K601E developed progressive disease after 6 weeks of Mektovi (binimetinib) and Vectibix (panitumumab) combination treatment, MAP2K1 V211D was identified as a co-occuring mutation in the biopsy from the new metastasis site (PMID: 31227518).",
            "molecularProfile": {
                "id": 32620,
                "profileName": "BRAF K601E MAP2K1 V211D"
            },
            "therapy": {
                "id": 8513,
                "therapyName": "Binimetinib + Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 15507,
                    "pubMedId": 31227518,
                    "title": "V211D mutation in MEK1 causes resistance to MEK inhibitors in colon cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31227518"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17468,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MAP955 inhibited Rsk and Erk phosphorylation, and resulted in 30% tumor regression in patient-derived xenograft (PDX) models of metastatic colon cancer harboring BRAF K601E and MAP2K1 V211D (PMID: 31227518).",
            "molecularProfile": {
                "id": 32620,
                "profileName": "BRAF K601E MAP2K1 V211D"
            },
            "therapy": {
                "id": 8514,
                "therapyName": "MAP855",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15507,
                    "pubMedId": 31227518,
                    "title": "V211D mutation in MEK1 causes resistance to MEK inhibitors in colon cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31227518"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17471,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mektovi (binimetinib) did not inhibit Rsk and Erk phosphorylation, and had no effect on tumor growth in patient-derived xenograft (PDX) models of metastatic colon cancer harboring BRAF K601E and MAP2K1 V211D (PMID: 31227518).",
            "molecularProfile": {
                "id": 32620,
                "profileName": "BRAF K601E MAP2K1 V211D"
            },
            "therapy": {
                "id": 807,
                "therapyName": "Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15507,
                    "pubMedId": 31227518,
                    "title": "V211D mutation in MEK1 causes resistance to MEK inhibitors in colon cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31227518"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15623,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) inhibited growth of a melanoma cell line harboring BRAF K601E, as well as BRAF S363F, in culture (PMID: 29903896).",
            "molecularProfile": {
                "id": 31117,
                "profileName": "BRAF K601E BRAF S363F"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15617,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Braftovi (encorafenib) to treatment with Mekinist (trametinib) resulted in increased growth inhibition in a melanoma cell line harboring BRAF K601E, as well as BRAF S363F, in culture (PMID: 29903896).",
            "molecularProfile": {
                "id": 31117,
                "profileName": "BRAF K601E BRAF S363F"
            },
            "therapy": {
                "id": 7661,
                "therapyName": "Encorafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15618,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Braftovi (encorafenib) inhibited growth of a melanoma cell line harboring BRAF K601E, as well as BRAF S363F, in culture (PMID: 29903896).",
            "molecularProfile": {
                "id": 31117,
                "profileName": "BRAF K601E BRAF S363F"
            },
            "therapy": {
                "id": 796,
                "therapyName": "Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15625,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cotellic (cobimetinib) inhibited growth of a melanoma cell line harboring BRAF K601E, as well as BRAF S363F, in culture (PMID: 29903896).",
            "molecularProfile": {
                "id": 31117,
                "profileName": "BRAF K601E BRAF S363F"
            },
            "therapy": {
                "id": 1004,
                "therapyName": "Cobimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15620,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Zelboraf (vemurafenib) to treatment with Mekinist (trametinib) resulted in increased growth inhibition in a melanoma cell line harboring BRAF K601E, as well as BRAF S363F, in culture (PMID: 29903896).",
            "molecularProfile": {
                "id": 31117,
                "profileName": "BRAF K601E BRAF S363F"
            },
            "therapy": {
                "id": 4234,
                "therapyName": "Trametinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15626,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mektovi (binimetinib) inhibited growth of a melanoma cell line harboring BRAF K601E, as well as BRAF S363F, in culture (PMID: 29903896).",
            "molecularProfile": {
                "id": 31117,
                "profileName": "BRAF K601E BRAF S363F"
            },
            "therapy": {
                "id": 807,
                "therapyName": "Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15619,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Tafinlar (dabrafenib) to treatment with Mekinist (trametinib) resulted in increased growth inhibition in a melanoma cell line harboring BRAF K601E, as well as BRAF S363F, in culture (PMID: 29903896).",
            "molecularProfile": {
                "id": 31117,
                "profileName": "BRAF K601E BRAF S363F"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7940,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAK-632 inhibited proliferation of melanoma cell lines harboring BRAF V600R in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 654,
                "profileName": "BRAF V600R"
            },
            "therapy": {
                "id": 3300,
                "therapyName": "TAK-632",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7950,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PLX7904 inhibited proliferation of melanoma cells harboring BRAF V600R in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 654,
                "profileName": "BRAF V600R"
            },
            "therapy": {
                "id": 4606,
                "therapyName": "PLX7904",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7954,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zelboraf (vemurafenib) inhibited proliferation of melanoma cells harboring BRAF V600R in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 654,
                "profileName": "BRAF V600R"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7910,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZ628 inhibited proliferation of melanoma cell lines harboring BRAF V600R in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 654,
                "profileName": "BRAF V600R"
            },
            "therapy": {
                "id": 1093,
                "therapyName": "AZ628",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7962,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tafinlar (dabrafenib) inhibited proliferation of melanoma cells harboring BRAF V600R in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 654,
                "profileName": "BRAF V600R"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9030,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a melanoma patient harboring BRAF V600R treated with Tafinlar (dabrafenib) demonstrated a reduction in lesion size after 2.5 months and at 5 months, stable disease, however, after 7 months progression ensued (PMID: 27255157).",
            "molecularProfile": {
                "id": 654,
                "profileName": "BRAF V600R"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6880,
                    "pubMedId": 27255157,
                    "title": "Dabrafenib in an elderly patient with metastatic melanoma and BRAF V600R mutation: a case report.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27255157"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15613,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Braftovi (encorafenib) inhibited ERK activation and proliferation of patient-derived melanoma cells harboring BRAF L597S, as well as BRAF R239Q, in culture, and delayed tumor growth and induced shrinkage in 8% (1/12) of tumors in a melanoma patient-derived xenograft (PDX) model (PMID: 29903896).",
            "molecularProfile": {
                "id": 31114,
                "profileName": "BRAF L597S BRAF R239Q"
            },
            "therapy": {
                "id": 796,
                "therapyName": "Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15614,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mektovi (binimetinib) inhibited growth of patient-derived melanoma cells harboring BRAF L597S, as well as BRAF R239Q, in culture, and induced tumor shrinkage in 25% (3/12) of tumors and delayed tumor growth in a patient-derived xenograft (PDX) model (PMID: 29903896).",
            "molecularProfile": {
                "id": 31114,
                "profileName": "BRAF L597S BRAF R239Q"
            },
            "therapy": {
                "id": 807,
                "therapyName": "Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15616,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Tafinlar (dabrafenib) to treatment with Mekinist (trametinib) resulted in increased growth inhibition in a patient-derived melanoma cell line harboring BRAF L597S, as well as well as BRAF R239Q, in culture, and resulted in tumor shrinkage in 100% (13/13) of subcutaneous tumors, and decreased growth of intracranial tumors in a patient-derived xenograft (PDX) model (PMID: 29903896).",
            "molecularProfile": {
                "id": 31114,
                "profileName": "BRAF L597S BRAF R239Q"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15612,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Braftovi (encorafenib) to treatment with Mektovi (binimetinib) increased growth inhibition in patient-derived melanoma cells harboring BRAF L597S, as well as BRAF R239Q, in culture, and resulted in tumor shrinkage in 67% of tumors, increased inhibition of ERK phosphorylation, and increased tumor growth delay compared to either agent alone in a patient-derived xenograft (PDX) model (PMID: 29903896).",
            "molecularProfile": {
                "id": 31114,
                "profileName": "BRAF L597S BRAF R239Q"
            },
            "therapy": {
                "id": 1100,
                "therapyName": "Binimetinib + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15536,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Braftovi (encorafenib) to treatment with Mekinist (trametinib) resulted in increased growth inhibition in melanoma cell lines harboring BRAF L597S in culture (PMID: 29903896).",
            "molecularProfile": {
                "id": 994,
                "profileName": "BRAF L597S"
            },
            "therapy": {
                "id": 7661,
                "therapyName": "Encorafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 699,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, one metastatic melanoma patient carrying a BRAF L597S mutation, had a partial response to the MEK inhibitor, TAK-733 (PMID: 22798288).",
            "molecularProfile": {
                "id": 994,
                "profileName": "BRAF L597S"
            },
            "therapy": {
                "id": 932,
                "therapyName": "TAK-733",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3,
                    "pubMedId": 22798288,
                    "title": "BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22798288"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15534,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Braftovi (encorafenib) to treatment with Mektovi (binimetinib) resulted in increased growth inhibition in melanoma cell lines harboring BRAF L597S in culture (PMID: 29903896).",
            "molecularProfile": {
                "id": 994,
                "profileName": "BRAF L597S"
            },
            "therapy": {
                "id": 1100,
                "therapyName": "Binimetinib + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15615,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Tafinlar (dabrafenib) and Mekinist (trametinib) resulted in increased growth inhibition in melanoma cell lines harboring BRAF L597S in culture, and resulted in tumor shrinkage in 89% (17/19) of tumors in a patient-derived xenograft (PDX) model harboring BRAF L597S, and treatment with Tafinlar (dabrafenib) and Mekinist (trametinib) resulted in a objective response with 34% tumor shrinkage in the patient from which the PDX model was derived from (PMID: 29903896).",
            "molecularProfile": {
                "id": 994,
                "profileName": "BRAF L597S"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15506,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Braftovi (encorafenib) inhibited ERK activation and proliferation of melanoma cell lines harboring BRAF L597S in culture (PMID: 29903896).",
            "molecularProfile": {
                "id": 994,
                "profileName": "BRAF L597S"
            },
            "therapy": {
                "id": 796,
                "therapyName": "Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15627,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mektovi (binimetinib) inhibited growth of melanoma cell lines harboring BRAF L597S in culture (PMID: 29903896).",
            "molecularProfile": {
                "id": 994,
                "profileName": "BRAF L597S"
            },
            "therapy": {
                "id": 807,
                "therapyName": "Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15561,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY3009120 inhibited growth of melanoma cells harboring BRAF L597S in culture (PMID: 29903896).",
            "molecularProfile": {
                "id": 994,
                "profileName": "BRAF L597S"
            },
            "therapy": {
                "id": 3268,
                "therapyName": "LY3009120",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15564,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tafinlar (dabrafenib) treatment inhibited ERK activation and proliferation of melanoma cell lines harboring BRAF L597S in culture, but did not result in tumor shrinkage as a single agent in a melanoma patient-derived xenograft (PDX) model harboring BRAF L597S (PMID: 29903896).",
            "molecularProfile": {
                "id": 994,
                "profileName": "BRAF L597S"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15622,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) inhibited growth of melanoma cell lines harboring BRAF L597S in culture, and resulted in tumor shrinkage in 75% (8/12) subcutaneous tumors in one patient-derived xenograft (PDX) model harboring BRAF L597S that also harbored a BRAF variant of unknown significance, BRAF R239Q, however, was not sufficient to induce tumor shrinkage in a second PDX model with BRAF L597S, resulting only in tumor growth delay (PMID: 29903896).",
            "molecularProfile": {
                "id": 994,
                "profileName": "BRAF L597S"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 695,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment of cells expressing BRAF L597S with the BRAF inhibitor, Zelboraf (vemurafenib), decreased activation of MEK and ERK (PMID: 22798288).",
            "molecularProfile": {
                "id": 994,
                "profileName": "BRAF L597S"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3,
                    "pubMedId": 22798288,
                    "title": "BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22798288"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 696,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Preclinical studies demonstrated the MEK inhibitor, Mekinist (trametinib) caused decreased activation of MEK and ERK in cells expressing BRAF L597S (PMID: 22798288).",
            "molecularProfile": {
                "id": 994,
                "profileName": "BRAF L597S"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3,
                    "pubMedId": 22798288,
                    "title": "BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22798288"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15624,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cotellic (cobimetinib) inhibited growth of melanoma cell lines harboring BRAF L597S in culture (PMID: 29903896).",
            "molecularProfile": {
                "id": 994,
                "profileName": "BRAF L597S"
            },
            "therapy": {
                "id": 1004,
                "therapyName": "Cobimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7117,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nerlynx (neratinib) inhibited growth of colorectal cancer cells harboring both BRAF G596R and PIK3CA E545K in culture (PMID: 26243863).",
            "molecularProfile": {
                "id": 24419,
                "profileName": "BRAF G596R PIK3CA E545K"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16111,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (MyPathway), Zelboraf (vemurafenib) treatment resulted in an objective response in only 4% (1/23) of patient with advanced solid tumors harboring non-V600 BRAF mutations, 1 of the non-responding patients harbored BRAF G596R (PMID: 29320312; NCT02091141).",
            "molecularProfile": {
                "id": 2416,
                "profileName": "BRAF G596R"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13171,
                    "pubMedId": 29320312,
                    "title": "Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29320312"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15986,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RMC-4550 inhibited Erk phosphorylation and proliferation of colorectal cancer cells harboring BRAF G596R in culture (PMID: 30104724).",
            "molecularProfile": {
                "id": 2416,
                "profileName": "BRAF G596R"
            },
            "therapy": {
                "id": 7839,
                "therapyName": "RMC-4550",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14089,
                    "pubMedId": 30104724,
                    "title": "RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30104724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11665,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zelboraf (vemurafenib) did not reduce activation of Erk and Mek in a colorectal cancer cell line harboring BRAF G596R in culture (PMID: 28783719).",
            "molecularProfile": {
                "id": 2416,
                "profileName": "BRAF G596R"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9692,
                    "pubMedId": 28783719,
                    "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28783719"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11737,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) resulted in decreased proliferation and increased apoptosis, and enhanced ERK inhibition compared to either agent alone in a colorectal cancer cell line harboring BRAF G596R in culture (PMID: 28947956).",
            "molecularProfile": {
                "id": 2416,
                "profileName": "BRAF G596R"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12147,
                    "pubMedId": 28947956,
                    "title": "Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28947956"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11655,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) reduced Erk signaling and inhibited proliferation of a colorectal cancer cell line harboring BRAF G596R in culture (PMID: 28783719).",
            "molecularProfile": {
                "id": 2416,
                "profileName": "BRAF G596R"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9692,
                    "pubMedId": 28783719,
                    "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28783719"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15987,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of PTPN11 E76K in colorectal cancer cells harboring BRAF G596R abolished their sensitivity to RMC-4550-induced inhibition of Erk phosphorylation and proliferation in culture (PMID: 30104724).",
            "molecularProfile": {
                "id": 31353,
                "profileName": "BRAF G596R PTPN11 E76K"
            },
            "therapy": {
                "id": 7839,
                "therapyName": "RMC-4550",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 14089,
                    "pubMedId": 30104724,
                    "title": "RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30104724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9415,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF L597V (PMID: 26343582).",
            "molecularProfile": {
                "id": 663,
                "profileName": "BRAF L597V"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 7141,
                    "pubMedId": 26343582,
                    "title": "BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343582"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7939,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAK-632 inhibited proliferation of non-small cell lung cancer cells harboring both BRAF L597V and NRAS Q61K in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 26095,
                "profileName": "BRAF L597V NRAS Q61K"
            },
            "therapy": {
                "id": 3300,
                "therapyName": "TAK-632",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7956,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells harboring both BRAF L597V and NRAS Q61K demonstrated decreased sensitivity to Zelboraf (vemurafenib) in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 26095,
                "profileName": "BRAF L597V NRAS Q61K"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7909,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZ628 inhibited proliferation of non-small cell lung cancer cells harboring both BRAF L597V and NRAS Q61K in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 26095,
                "profileName": "BRAF L597V NRAS Q61K"
            },
            "therapy": {
                "id": 1093,
                "therapyName": "AZ628",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7964,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells harboring both BRAF L597V and NRAS Q61K demonstrated decreased sensitivity to Tafinlar (dabrafenib) in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 26095,
                "profileName": "BRAF L597V NRAS Q61K"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7949,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells harboring both BRAF L597V and NRAS Q61L demonstrated decreased sensitivity to PLX7904 in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 26095,
                "profileName": "BRAF L597V NRAS Q61K"
            },
            "therapy": {
                "id": 4606,
                "therapyName": "PLX7904",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9410,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF G464E (PMID: 26343582).",
            "molecularProfile": {
                "id": 1779,
                "profileName": "BRAF G464E"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 7141,
                    "pubMedId": 26343582,
                    "title": "BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343582"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4923,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a pancreatic cancer cell line harboring BRAF V487_P492delinsA was resistant to Tafinlar (dabrafenib) (PMID: 26732095).",
            "molecularProfile": {
                "id": 19834,
                "profileName": "BRAF V487_P492delinsA"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4801,
                    "pubMedId": 26732095,
                    "title": "Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26732095"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4920,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a pancreatic cancer cell line harboring BRAF V487_P492delinsA were sensitive to LY3009120 in culture and in xenograft models, resulting in inhibition of tumor growth and partial tumor regression (PMID: 26732095).",
            "molecularProfile": {
                "id": 19834,
                "profileName": "BRAF V487_P492delinsA"
            },
            "therapy": {
                "id": 3268,
                "therapyName": "LY3009120",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4801,
                    "pubMedId": 26732095,
                    "title": "Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26732095"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4922,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a human pancreatic cancer cell line harboring BRAF V487_P492delinsA was resistant to treatment with Zelboraf (vemurafenib) in both culture and xenograft models (PMID: 26732095).",
            "molecularProfile": {
                "id": 19834,
                "profileName": "BRAF V487_P492delinsA"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4801,
                    "pubMedId": 26732095,
                    "title": "Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26732095"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4921,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a pancreatic cancer cell line harboring BRAF V487_P492delinsA was sensitive to Mekinist (trametinib) in culture, resulting in cell growth inhibition (PMID: 26732095).",
            "molecularProfile": {
                "id": 19834,
                "profileName": "BRAF V487_P492delinsA"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4801,
                    "pubMedId": 26732095,
                    "title": "Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26732095"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10075,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, inhibition of Erk signaling by VX-11e sensitized colorectal cancer cell lines harboring KRAS or BRAF activating mutations to WEHI-539 in culture (PMID: 27974663).",
            "molecularProfile": {
                "id": 696,
                "profileName": "BRAF act mut"
            },
            "therapy": {
                "id": 5374,
                "therapyName": "VX-11e + WEHI-539",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8002,
                    "pubMedId": 27974663,
                    "title": "PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27974663"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1027,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PLX8394 had been shown to block survival and growth of vemurafenib/PLX4720-resistant cells harboring distinct BRAF activating mutations (PMID: 24422853).",
            "molecularProfile": {
                "id": 696,
                "profileName": "BRAF act mut"
            },
            "therapy": {
                "id": 1041,
                "therapyName": "PLX8394",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 195,
                    "pubMedId": 24422853,
                    "title": "Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24422853"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16945,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Zelboraf (vemurafenib) therapy is included in guidelines for differentiated thyroid carcinoma patients with recurrent, advanced, or metastatic disease harboring BRAF activating mutations, in cases that are not surgically resectable or amenable to radioactive iodine (NCCN.org).",
            "molecularProfile": {
                "id": 696,
                "profileName": "BRAF act mut"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1781,
                "name": "thyroid cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 891,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Zelboraf (vemurafenib) demonstrated safety and efficacy in metastatic papillary thyroid cancer patients carrying BRAF activating mutations (PMID: 23489023).",
            "molecularProfile": {
                "id": 696,
                "profileName": "BRAF act mut"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1781,
                "name": "thyroid cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 579,
                    "pubMedId": 23489023,
                    "title": "Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23489023"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16946,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Zelboraf (vemurafenib) demonstrated safety and efficacy in metastatic papillary thyroid cancer patients carrying BRAF activating mutations (PMID: 23489023).",
            "molecularProfile": {
                "id": 696,
                "profileName": "BRAF act mut"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3969,
                "name": "papillary thyroid carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 579,
                    "pubMedId": 23489023,
                    "title": "Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23489023"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16944,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Tafinlar (dabrafenib) therapy is included in guidelines for differentiated thyroid carcinoma patients with recurrent, advanced, or metastatic disease harboring BRAF activating mutations, in cases that are not surgically resectable or amenable to radioactive iodine (NCCN.org).",
            "molecularProfile": {
                "id": 696,
                "profileName": "BRAF act mut"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1781,
                "name": "thyroid cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 14054,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RAF709 inhibited tumor growth in patient-derived xenograft (PDX) models of non-small cell lung cancer harboring BRAF activating mutations (PMID: 29343524).",
            "molecularProfile": {
                "id": 696,
                "profileName": "BRAF act mut"
            },
            "therapy": {
                "id": 6995,
                "therapyName": "RAF709",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11434,
                    "pubMedId": 29343524,
                    "title": "Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29343524"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 510,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II study, Nexavar (sorafenib) displayed negligible efficacy in melanoma patients with BRAF mutations (PMID: 16880785, PMID: 22394203).",
            "molecularProfile": {
                "id": 696,
                "profileName": "BRAF act mut"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 294,
                    "pubMedId": 22394203,
                    "title": "Sorafenib in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22394203"
                },
                {
                    "id": 3156,
                    "pubMedId": 16880785,
                    "title": "Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16880785"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 552,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cobimetinib (GDC-0973) induced cell death in human melanoma cell lines harboring BRAF activating mutations in culture and inhibited tumor growth in xenograft models (PMID: 22084396).",
            "molecularProfile": {
                "id": 696,
                "profileName": "BRAF act mut"
            },
            "therapy": {
                "id": 1004,
                "therapyName": "Cobimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 353,
                    "pubMedId": 22084396,
                    "title": "Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22084396"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1025,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib/II trial, Binimetinib (MEK162), in combination with Encorafenib (LGX818), demonstrated safety and efficacy in patients with BRAF mutant advanced solid tumors (J Clin Oncol 31, 2013 (suppl; abstr 9029)).",
            "molecularProfile": {
                "id": 696,
                "profileName": "BRAF act mut"
            },
            "therapy": {
                "id": 1100,
                "therapyName": "Binimetinib + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 743,
                    "pubMedId": null,
                    "title": "Preliminary results from a phase Ib/II, open-label, dose-escalation study of the oral BRAF inhibitor LGX818 in combination with the oral MEK1/2 inhibitor MEK162 in BRAF V600-dependent advanced solid tumors.",
                    "url": null
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10077,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, inhibition of Erk signaling by VX-11e did not sensitize colorectal cancer cell lines harboring KRAS or BRAF activating mutations to Venclexta (venetoclax) in culture (PMID: 27974663).",
            "molecularProfile": {
                "id": 696,
                "profileName": "BRAF act mut"
            },
            "therapy": {
                "id": 5375,
                "therapyName": "Venetoclax + VX-11e",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 8002,
                    "pubMedId": 27974663,
                    "title": "PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27974663"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16564,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a melanoma patient developed progressive disease after initial response to Tafinlar (dabrafinib) and Mekinist (trametinib) combination treatment, BRAF V47_D380del was identified as an acquired mutation in the progressing lesion along with mutations presented in both primary and progressing lesions, including BRAF V600E, PTEN G129E, CDKN2A/B loss, and TERT promoter mutations (PMID: 29171936).",
            "molecularProfile": {
                "id": 31680,
                "profileName": "BRAF V47_D380del"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14627,
                    "pubMedId": 29171936,
                    "title": "BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29171936"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16586,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with BRAF V600E colorectal cancer developed progressive disease after a partial response lasting 24 weeks to Alpelisib (BYL719), Erbitux (cetuximab), and Braftovi (encorafenib) combination treatment, BRAF V47_D380del (reported as deletion of exons 2-8) was identified as an acquired mutation in peritoneal metastasis at the time of progression (PMID: 28951457).",
            "molecularProfile": {
                "id": 31704,
                "profileName": "BRAF V47_D380del BRAF V600E"
            },
            "therapy": {
                "id": 1917,
                "therapyName": "Alpelisib + Cetuximab + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14634,
                    "pubMedId": 28951457,
                    "title": "Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28951457"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12669,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, the combination therapy of PX-866 and Zelboraf (vemurafenib) demonstrated safety and resulted in an objective response in 28% (5/18) of advanced solid tumor patients harboring BRAF V600E or K, and of those five patients, 80% (4/5) also demonstrated loss of PTEN (PMID: 29051322).",
            "molecularProfile": {
                "id": 28830,
                "profileName": "BRAF V600E/K PTEN loss"
            },
            "therapy": {
                "id": 6571,
                "therapyName": "PX-866 + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10574,
                    "pubMedId": 29051322,
                    "title": "A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29051322"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17036,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Zelboraf (vemurafenib) and Cotellic (cobimetinib) combination therapy is included in melanoma guidelines for patients with metastatic or unresectable disease harboring a BRAF V600 activating mutation (NCCN.org).",
            "molecularProfile": {
                "id": 499,
                "profileName": "BRAF V600E/K"
            },
            "therapy": {
                "id": 1657,
                "therapyName": "Cobimetinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12263,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (coBRIM) that supported FDA approval, treatment with the combination of Zelboraf (vemurafenib) and Cotellic (cobimetinib) resulted in an improved progression-free survival of 12.3 months, compared to 7.2 months with Zelboraf (vemurafenib) plus placebo, among patients with BRAF V600-mutated metastatic melanoma, and BRAF V600E and BRAF V600K are on the companion diagnostic (PMID: 27480103; NCT01689519).",
            "molecularProfile": {
                "id": 499,
                "profileName": "BRAF V600E/K"
            },
            "therapy": {
                "id": 1657,
                "therapyName": "Cobimetinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10226,
                    "pubMedId": 27480103,
                    "title": "Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27480103"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15453,
                    "pubMedId": null,
                    "title": "Cotellic (cobimetinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=206192"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12034,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (COMBI-AD) that supported FDA approval, adjuvant treatment with the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) resulted in an improved estimated 3-year relapse-free survival rate (58% vs 39%, HR=0.47, P<0.001) and 3-year overall survival rate (86% vs 77%, HR=0.57; 95% CI, 0.42 to 0.79, P=0.0006) compared to placebo in stage III melanoma patients harboring BRAF V600E or V600K mutations (PMID: 28891408; NCT01682083).",
            "molecularProfile": {
                "id": 499,
                "profileName": "BRAF V600E/K"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9986,
                    "pubMedId": 28891408,
                    "title": "Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28891408"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15458,
                    "pubMedId": null,
                    "title": "Tafinlar (dabrafenib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=202806"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1909,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (COMBI-v) that supported FDA approval, the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) resulted in an improved overall survival rate at 12 months (72% vs 65%, HR=0.69, p=0.005), median progression-free survival (11.4 vs 7.3 months, HR=0.56, p<0.001), and objective response rate (64% vs 51%, p<0.001) compared to Zelboraf (vemurafenib) in melanoma patients harboring BRAF V600E or V600K (PMID: 25399551; NCT01597908).",
            "molecularProfile": {
                "id": 499,
                "profileName": "BRAF V600E/K"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10781,
                    "pubMedId": 25399551,
                    "title": "Improved overall survival in melanoma with combined dabrafenib and trametinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25399551"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15458,
                    "pubMedId": null,
                    "title": "Tafinlar (dabrafenib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=202806"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 15865,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, combined Zelboraf (vemurafenib) and XL888 treatment in patients with unresectable, BRAF inhibitor naive, metastatic melanoma harboring BRAF V600E (n=20) or V600K (n=1) resulted in complete and partial responses in 15% (3/20) and 60% (12/20) of evaluable patients, respectively, a 9.2-month median progression free survival, and a 34.6-month overall survival (PMID: 29674508).",
            "molecularProfile": {
                "id": 499,
                "profileName": "BRAF V600E/K"
            },
            "therapy": {
                "id": 1217,
                "therapyName": "Vemurafenib + XL888",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13853,
                    "pubMedId": 29674508,
                    "title": "Combined BRAF and HSP90 Inhibition in Patients with Unresectable BRAFV600E-Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29674508"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16948,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "The combination of Tafinlar (dabrafenib) and Mekinist (trametinib) is included in guidelines as first or second-line therapy in patients with metastatic non-small cell lung cancer harboring a BRAF V600 mutation (PMID: 30715168, PMID: 30285222; ESMO.org).",
            "molecularProfile": {
                "id": 499,
                "profileName": "BRAF V600E/K"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15115,
                    "pubMedId": null,
                    "title": "ESMO Clinical Practice Guidelines",
                    "url": "https://www.esmo.org/Guidelines"
                },
                {
                    "id": 15431,
                    "pubMedId": 30715168,
                    "title": "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30715168"
                },
                {
                    "id": 15432,
                    "pubMedId": 30285222,
                    "title": "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30285222"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 178,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Mekinist (trametinib) resulted in complete response in 7% (2/30), partial response in 33% (10/30), and stable disease in 37% (11/30) of BRAF-mutant melanoma patients (PMID: 22805292; NCT00687622).",
            "molecularProfile": {
                "id": 499,
                "profileName": "BRAF V600E/K"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 233,
                    "pubMedId": 22805292,
                    "title": "Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22805292"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1912,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (METRIC) that supported FDA approval, Mekinist (trametinib) treatment, as compared to Deticine (dacarbazine) or Taxol (paclitaxel) treatment, resulted in improved progression-free survival of 4.8 months versus 1.5 months and an overall six month survival rate of 81% versus 67% in patients with BRAF V600E/K positive metastatic melanoma (PMID: 22663011; NCT01245062).",
            "molecularProfile": {
                "id": 499,
                "profileName": "BRAF V600E/K"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 468,
                    "pubMedId": 22663011,
                    "title": "Improved survival with MEK inhibition in BRAF-mutated melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22663011"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15457,
                    "pubMedId": null,
                    "title": "Mekinist (trametinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=204114"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 14235,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III (COLUMBUS) trial that supported FDA approval, Braftovi (encorafenib) in combination with Mektovi (binimetinib) demonstrated improved tolerability profile and efficacy, resulted in a progression-free survival of 14.9 months in patients with advanced melanoma harboring BRAF V600E/K mutations, comparing to 7.3 months in the Zelboraf (vemurafenib) group (HR=0.54, p<0.0001) (PMID: 29573941; NCT01909453) and both BRAF V600E and V600K are on the companion diagnostic.",
            "molecularProfile": {
                "id": 499,
                "profileName": "BRAF V600E/K"
            },
            "therapy": {
                "id": 1100,
                "therapyName": "Binimetinib + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11562,
                    "pubMedId": 29573941,
                    "title": "Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29573941"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15455,
                    "pubMedId": null,
                    "title": "Braftovi (encorafenib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210496"
                },
                {
                    "id": 15456,
                    "pubMedId": null,
                    "title": "Mektovi (binimetinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210498"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16337,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III (COLUMBUS) trial that supported FDA approval, Braftovi (encorafenib) in combination with Mektovi (binimetinib) resulted in a median overall survival (OS) of 33.6 months, a 1-year OS rate of 77.5%, and a 2-year OS rate of 57.7% in patients with advanced melanoma harboring BRAF V600E/K mutations compared to a median OS of 16.9 months and 1- and 2-year OS rates of 63.1% and 43.2%, respectively, in the Zelboraf (vemurafenib) treated group (PMID: 30219628; NCT01909453).",
            "molecularProfile": {
                "id": 499,
                "profileName": "BRAF V600E/K"
            },
            "therapy": {
                "id": 1100,
                "therapyName": "Binimetinib + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14457,
                    "pubMedId": 30219628,
                    "title": "Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30219628"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15455,
                    "pubMedId": null,
                    "title": "Braftovi (encorafenib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210496"
                },
                {
                    "id": 15456,
                    "pubMedId": null,
                    "title": "Mektovi (binimetinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210498"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 14531,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Braftovi (encorafenib) in combination with Mektovi (binimetinib) is included in guidelines as first-line and second-line therapy for patients with metastatic or unresectable melanoma harboring BRAF V600E or V600K mutations (PMID: 30959471; NCCN.org).",
            "molecularProfile": {
                "id": 499,
                "profileName": "BRAF V600E/K"
            },
            "therapy": {
                "id": 1100,
                "therapyName": "Binimetinib + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                },
                {
                    "id": 15109,
                    "pubMedId": 30959471,
                    "title": "Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30959471"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 5192,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zydelig (idelalisib) did not inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).",
            "molecularProfile": {
                "id": 20300,
                "profileName": "BRAF V600E/K PIK3CA wild-type"
            },
            "therapy": {
                "id": 1023,
                "therapyName": "Idelalisib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4903,
                    "pubMedId": 26137449,
                    "title": "Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26137449"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5190,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, A66 did not inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).",
            "molecularProfile": {
                "id": 20300,
                "profileName": "BRAF V600E/K PIK3CA wild-type"
            },
            "therapy": {
                "id": 617,
                "therapyName": "A66",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4903,
                    "pubMedId": 26137449,
                    "title": "Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26137449"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5185,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BEZ235 and Zelboraf (vemurafenib) worked synergistically to inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).",
            "molecularProfile": {
                "id": 20300,
                "profileName": "BRAF V600E/K PIK3CA wild-type"
            },
            "therapy": {
                "id": 3774,
                "therapyName": "BEZ235 + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4903,
                    "pubMedId": 26137449,
                    "title": "Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26137449"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5191,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TGX-221 did not inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).",
            "molecularProfile": {
                "id": 20300,
                "profileName": "BRAF V600E/K PIK3CA wild-type"
            },
            "therapy": {
                "id": 2514,
                "therapyName": "TGX-221",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4903,
                    "pubMedId": 26137449,
                    "title": "Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26137449"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5184,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) and Zelboraf (vemurafenib) worked synergistically to inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).",
            "molecularProfile": {
                "id": 20300,
                "profileName": "BRAF V600E/K PIK3CA wild-type"
            },
            "therapy": {
                "id": 3773,
                "therapyName": "Selumetinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4903,
                    "pubMedId": 26137449,
                    "title": "Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26137449"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5188,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment inhibited proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture, and synergitically inhibited tumor growth in cell line xenograft models (PMID: 26137449).",
            "molecularProfile": {
                "id": 20300,
                "profileName": "BRAF V600E/K PIK3CA wild-type"
            },
            "therapy": {
                "id": 1420,
                "therapyName": "BEZ235 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4903,
                    "pubMedId": 26137449,
                    "title": "Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26137449"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5186,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ZSTK474 and Zelboraf (vemurafenib) worked synergistically to inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).",
            "molecularProfile": {
                "id": 20300,
                "profileName": "BRAF V600E/K PIK3CA wild-type"
            },
            "therapy": {
                "id": 3772,
                "therapyName": "Vemurafenib + ZSTK474",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4903,
                    "pubMedId": 26137449,
                    "title": "Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26137449"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5187,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) and ZSTK474 combination treatment inhibited proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture, and synergistically inhibited tumor growth in cell line xenograft models (PMID: 26137449).",
            "molecularProfile": {
                "id": 20300,
                "profileName": "BRAF V600E/K PIK3CA wild-type"
            },
            "therapy": {
                "id": 3771,
                "therapyName": "Selumetinib + ZSTK474",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4903,
                    "pubMedId": 26137449,
                    "title": "Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26137449"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6826,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing BRAF V600E and the gatepkeeper mutation BRAF T529I were insensitive to SB590885-mediated inhibition of ERK signaling in culture (PMID: 20538618).",
            "molecularProfile": {
                "id": 23818,
                "profileName": "BRAF V600E BRAF T529I"
            },
            "therapy": {
                "id": 4281,
                "therapyName": "SB590885",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 5859,
                    "pubMedId": 20538618,
                    "title": "Gatekeeper mutations mediate resistance to BRAF-targeted therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20538618"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6840,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nexavar (sorafenib) inhibited kinase activity in vitro, and downstream Erk phosphorylation in cells expressing BRAF V600E and the gatekeeper mutation BRAF T529I to a similar degree as transformed cells expressing BRAF V600E in culture (PMID: 20538618).",
            "molecularProfile": {
                "id": 23818,
                "profileName": "BRAF V600E BRAF T529I"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5859,
                    "pubMedId": 20538618,
                    "title": "Gatekeeper mutations mediate resistance to BRAF-targeted therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20538618"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6835,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing BRAF V600E and the gatepkeeper mutation BRAF T529I were insensitive to PLX4720-mediated inhibition of ERK signaling in culture (PMID: 20538618).",
            "molecularProfile": {
                "id": 23818,
                "profileName": "BRAF V600E BRAF T529I"
            },
            "therapy": {
                "id": 1060,
                "therapyName": "PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 5859,
                    "pubMedId": 20538618,
                    "title": "Gatekeeper mutations mediate resistance to BRAF-targeted therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20538618"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6830,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RAF265 inhibited kinase activity in vitro, and downstream Erk phosphorylation in cells expressing BRAF V600E and the gatekeeper mutation BRAF T529I to a similar degree as transformed cells expressing BRAF V600E in culture (PMID: 20538618).",
            "molecularProfile": {
                "id": 23818,
                "profileName": "BRAF V600E BRAF T529I"
            },
            "therapy": {
                "id": 884,
                "therapyName": "RAF265",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5859,
                    "pubMedId": 20538618,
                    "title": "Gatekeeper mutations mediate resistance to BRAF-targeted therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20538618"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6843,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CI-1040 (PD184352) inhibited Erk phosphorylation in transformed cells expressing BRAF V600E and the gatekeeper mutation BRAF T529I in culture (PMID: 20538618).",
            "molecularProfile": {
                "id": 23818,
                "profileName": "BRAF V600E BRAF T529I"
            },
            "therapy": {
                "id": 699,
                "therapyName": "CI-1040",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5859,
                    "pubMedId": 20538618,
                    "title": "Gatekeeper mutations mediate resistance to BRAF-targeted therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20538618"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 693,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Preclinical studies demonstrated the MEK inhibitor, Mekinist (trametinib) caused decreased activation of MEK and ERK in cells expressing BRAF L597R (PMID: 22798288).",
            "molecularProfile": {
                "id": 992,
                "profileName": "BRAF L597R"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3,
                    "pubMedId": 22798288,
                    "title": "BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22798288"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 694,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment of cells expressing BRAF L597R with the BRAF inhibitor, Zelboraf (vemurafenib), decreased activation of MEK and ERK (PMID: 22798288).",
            "molecularProfile": {
                "id": 992,
                "profileName": "BRAF L597R"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3,
                    "pubMedId": 22798288,
                    "title": "BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22798288"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12293,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, patient-derived BRAF V600E mutant lung adenocarcinoma cells that acquired resistance to Erk inhibitor through BRAF amplification were less sensitive to SCH772984 in culture (PMID: 28714990).",
            "molecularProfile": {
                "id": 25928,
                "profileName": "BRAF amp BRAF V600E"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 10283,
                    "pubMedId": 28714990,
                    "title": "An approach to suppress the evolution of resistance in BRAF(V600E)-mutant cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28714990"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7630,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Selumetinib (AZD6244) and Erbitux (cetuximab) combination treatment in culture, likely due to the acquired BRAF V600E amplification (PMID: 27312529).",
            "molecularProfile": {
                "id": 25928,
                "profileName": "BRAF amp BRAF V600E"
            },
            "therapy": {
                "id": 4536,
                "therapyName": "Cetuximab + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16585,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with BRAF V600E colorectal cancer developed progressive disease after a partial response lasting 24 weeks to Vectibix (panitumumab) and Zelboraf (vemurafenib) combination treatment, amplification of BRAF V600E was identified as an acquired alteration at the time of progression (PMID: 28951457).",
            "molecularProfile": {
                "id": 25928,
                "profileName": "BRAF amp BRAF V600E"
            },
            "therapy": {
                "id": 1717,
                "therapyName": "Panitumumab + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14634,
                    "pubMedId": 28951457,
                    "title": "Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28951457"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12294,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of Tafinlar (dabrafenib), SCH772984, and Mekinist (trametinib) resulted in durable tumor inhibition in cell line xenograft models of BRAF V600E mutated lung adenocarcinoma cells that acquired resistance to Erk inhibitors through BRAF amplification (PMID: 28714990).",
            "molecularProfile": {
                "id": 25928,
                "profileName": "BRAF amp BRAF V600E"
            },
            "therapy": {
                "id": 6430,
                "therapyName": "Dabrafenib + SCH772984 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10283,
                    "pubMedId": 28714990,
                    "title": "An approach to suppress the evolution of resistance in BRAF(V600E)-mutant cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28714990"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7705,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired BRAF V600E amplification and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25928,
                "profileName": "BRAF amp BRAF V600E"
            },
            "therapy": {
                "id": 1711,
                "therapyName": "Cetuximab + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16588,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with BRAF V600E colorectal cancer developed progressive disease after a partial response lasting 16 weeks to Erbitux (cetuximab) and Zelboraf (vemurafenib) combination treatment, amplification of BRAF V600E was identified as an acquired alteration at the time of progression (PMID: 28951457).",
            "molecularProfile": {
                "id": 25928,
                "profileName": "BRAF amp BRAF V600E"
            },
            "therapy": {
                "id": 1711,
                "therapyName": "Cetuximab + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 14634,
                    "pubMedId": 28951457,
                    "title": "Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28951457"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7706,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired BRAF V600E amplification and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to SCH772984 in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25928,
                "profileName": "BRAF amp BRAF V600E"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7070,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a melanoma patient harboring a BRAF V600 mutation developed resistant mutations, BRAF amplification and NRAS Q61K, during treatment with Zelboraf (vemurafenib) (PMID: 24265153).",
            "molecularProfile": {
                "id": 24387,
                "profileName": "BRAF amp BRAF V600X NRAS Q61K"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3564,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a melanoma patient harboring BRAF V600E  treated with Zelboraf (vemurafenib) subsequently demonstrated resistance likely due to the secondary resistance mutation, BRAF L505H (PMID: 25515853).",
            "molecularProfile": {
                "id": 13538,
                "profileName": "BRAF V600E BRAF L505H"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 3825,
                    "pubMedId": 25515853,
                    "title": "Detailed imaging and genetic analysis reveal a secondary BRAF(L505H) resistance mutation and extensive intrapatient heterogeneity in metastatic BRAF mutant melanoma patients treated with vemurafenib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25515853"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1475,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells expressing BRAF L505H were resistant to Zelboraf (vemurafenib) (PMID: 24283590).",
            "molecularProfile": {
                "id": 2594,
                "profileName": "BRAF L505H"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 1371,
                    "pubMedId": 24283590,
                    "title": "Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24283590"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7938,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAK-632 inhibited proliferation of melanoma cell lines harboring BRAF G466E in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 3324,
                "profileName": "BRAF G466E"
            },
            "therapy": {
                "id": 3300,
                "therapyName": "TAK-632",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7963,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF G466E demonstrated decreased sensitivity to Tafinlar (dabrafenib) in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 3324,
                "profileName": "BRAF G466E"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7955,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF G466E demonstrated decreased sensitivity to Zelboraf (vemurafenib) in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 3324,
                "profileName": "BRAF G466E"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7948,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF G466E demonstrated decreased sensitivity to PLX7904 in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 3324,
                "profileName": "BRAF G466E"
            },
            "therapy": {
                "id": 4606,
                "therapyName": "PLX7904",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7908,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZ628 inhibited proliferation of melanoma cell lines harboring BRAF G466E in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 3324,
                "profileName": "BRAF G466E"
            },
            "therapy": {
                "id": 1093,
                "therapyName": "AZ628",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11656,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) reduced ERK signaling and inhibited proliferation of a melanoma cell line harboring BRAF G466E and HRAS Q61K in culture (PMID: 28783719).",
            "molecularProfile": {
                "id": 28179,
                "profileName": "BRAF G466E HRAS Q61K"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9692,
                    "pubMedId": 28783719,
                    "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28783719"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15567,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tafinlar (dabrafenib) treatment did not result in significant growth inhibition in a melanoma cell line harboring BRAF G469V and NRAS Q61K in culture (PMID: 29903896).",
            "molecularProfile": {
                "id": 31086,
                "profileName": "BRAF G469V NRAS Q61K"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15532,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Braftovi (encorafenib) to treatment with Mektovi (binimetinib) resulted in increased growth inhibition in a melanoma cell line harboring BRAF G469V and NRAS Q61K in culture (PMID: 29903896).",
            "molecularProfile": {
                "id": 31086,
                "profileName": "BRAF G469V NRAS Q61K"
            },
            "therapy": {
                "id": 1100,
                "therapyName": "Binimetinib + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15547,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY3009120 inhibited growth of a melanoma cell line harboring BRAF G469V and NRAS Q61K in culture (PMID: 29903896).",
            "molecularProfile": {
                "id": 31086,
                "profileName": "BRAF G469V NRAS Q61K"
            },
            "therapy": {
                "id": 3268,
                "therapyName": "LY3009120",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15519,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Braftovi (encorafenib) to treatment with Mekinist (trametinib) resulted in increased growth inhibition in a melanoma cell line harboring BRAF G469V and NRAS Q61K in culture (PMID: 29903896).",
            "molecularProfile": {
                "id": 31086,
                "profileName": "BRAF G469V NRAS Q61K"
            },
            "therapy": {
                "id": 7661,
                "therapyName": "Encorafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15540,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Zelboraf (vemurafenib) to treatment with Mekinist (trametinib) resulted in increased proliferation compared to Mekinist (trametinib) alone in a melanoma cell line harboring BRAF G469V and NRAS Q61K in culture (PMID: 29903896).",
            "molecularProfile": {
                "id": 31086,
                "profileName": "BRAF G469V NRAS Q61K"
            },
            "therapy": {
                "id": 4234,
                "therapyName": "Trametinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9414,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF G469V (PMID: 26343582).",
            "molecularProfile": {
                "id": 1777,
                "profileName": "BRAF G469V"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 7141,
                    "pubMedId": 26343582,
                    "title": "BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343582"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15511,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Braftovi (encorafenib) did not inhibit ERK phosphorylation or proliferation of a melanoma cell line harboring BRAF G469V (PMID: 29903896).",
            "molecularProfile": {
                "id": 1777,
                "profileName": "BRAF G469V"
            },
            "therapy": {
                "id": 796,
                "therapyName": "Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9613,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with synchronous BRAF wild-type hepatocellular carcinoma (HCC) and non-small cell lung cancer harboring BRAF G469V demonstrated a partial response in primary lung lesions, complete response in the lung metastasis, and stability of the HCC following treatment with Nexavar (sorafenib) (PMID: 27388325).",
            "molecularProfile": {
                "id": 1777,
                "profileName": "BRAF G469V"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7323,
                    "pubMedId": 27388325,
                    "title": "Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27388325"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3308,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CCT196969 inhibited MEK and ERK phosphorylation and growth of melanoma cells harboring BRAF V600D in culture (PMID: 25500121, PMID: 17210691).",
            "molecularProfile": {
                "id": 653,
                "profileName": "BRAF V600D"
            },
            "therapy": {
                "id": 3105,
                "therapyName": "CCT196969",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3714,
                    "pubMedId": 25500121,
                    "title": "Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25500121"
                },
                {
                    "id": 3730,
                    "pubMedId": 17210691,
                    "title": "Tumor necrosis factor-alpha blocks apoptosis in melanoma cells when BRAF signaling is inhibited.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17210691"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7947,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PLX7904 inhibited proliferation of melanoma cell lines harboring BRAF V600D in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 653,
                "profileName": "BRAF V600D"
            },
            "therapy": {
                "id": 4606,
                "therapyName": "PLX7904",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7961,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tafinlar (dabrafenib) inhibited proliferation of melanoma cells harboring BRAF V600D in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 653,
                "profileName": "BRAF V600D"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7953,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zelboraf (vemurafenib) inhibited proliferation of melanoma cells harboring BRAF V600D in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 653,
                "profileName": "BRAF V600D"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11711,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, single Tafinlar (dabrafenib) and subsequent Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment resulted in disease stablization in a patient with pilocytic astrocytoma harboring BRAF V600D (PMID: 28784858).",
            "molecularProfile": {
                "id": 653,
                "profileName": "BRAF V600D"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 4851,
                "name": "pilocytic astrocytoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9723,
                    "pubMedId": 28784858,
                    "title": "Targeted MAPK Pathway Inhibitors in Patients With Disseminated Pilocytic Astrocytomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28784858"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7907,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZ628 inhibited proliferation of melanoma cell lines harboring BRAF V600D in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 653,
                "profileName": "BRAF V600D"
            },
            "therapy": {
                "id": 1093,
                "therapyName": "AZ628",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7937,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAK-632 inhibited proliferation of melanoma cell lines harboring BRAF V600D in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 653,
                "profileName": "BRAF V600D"
            },
            "therapy": {
                "id": 3300,
                "therapyName": "TAK-632",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3309,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CCT241161 inhibited MEK and ERK phosphorylation and growth of melanoma cells harboring BRAF V600D in culture (PMID: 25500121, PMID: 17210691).",
            "molecularProfile": {
                "id": 653,
                "profileName": "BRAF V600D"
            },
            "therapy": {
                "id": 3106,
                "therapyName": "CCT241161",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3714,
                    "pubMedId": 25500121,
                    "title": "Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25500121"
                },
                {
                    "id": 3730,
                    "pubMedId": 17210691,
                    "title": "Tumor necrosis factor-alpha blocks apoptosis in melanoma cells when BRAF signaling is inhibited.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17210691"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16315,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma cell line harboring BRAF V600D and knockdown of NRAS demonstrated a decreased response to Mektovi (binimetinib) relative to cells without NRAS knockdown in culture (PMID: 29245078).",
            "molecularProfile": {
                "id": 31592,
                "profileName": "BRAF V600D NRAS dec exp"
            },
            "therapy": {
                "id": 807,
                "therapyName": "Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 14368,
                    "pubMedId": 29245078,
                    "title": "Analysis of NRAS gain in 657 patients with melanoma and evaluation of its sensitivity to a MEK inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29245078"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6320,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, XL147 inhibited tumor growth in xenograft models of a PTEN-deficient human melanoma cell line harboring BRAF V600D (PMID: 25637314).",
            "molecularProfile": {
                "id": 23100,
                "profileName": "BRAF V600D PTEN loss"
            },
            "therapy": {
                "id": 1050,
                "therapyName": "XL147",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5522,
                    "pubMedId": 25637314,
                    "title": "The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25637314"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12268,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Zelboraf (vemurafenib) and Cotellic (cobimetinib) combination therapy is included in guidelines for patients with metastatic or unresectable melanoma harboring a BRAF V600 activating mutation (NCCN.org).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 1657,
                "therapyName": "Cobimetinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1211,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, combination treatment with Zelboraf (vemurafenib) and Cotellic (cobimetinib) resulted in an improved progression-free survival of 12.3 months compared to 7.2 months with Zelboraf (vemurafenib) alone among patients with BRAF V600-mutated metastatic melanoma (PMID: 27480103; NCT01689519).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 1657,
                "therapyName": "Cobimetinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10226,
                    "pubMedId": 27480103,
                    "title": "Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27480103"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16947,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "The combination of Tafinlar (dabrafenib) and Mekinist (trametinib) is included in guidelines as first or second-line therapy in patients with metastatic non-small cell lung cancer harboring a BRAF V600 mutation (PMID: 30715168, PMID: 30285222; ESMO.org).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15115,
                    "pubMedId": null,
                    "title": "ESMO Clinical Practice Guidelines",
                    "url": "https://www.esmo.org/Guidelines"
                },
                {
                    "id": 15431,
                    "pubMedId": 30715168,
                    "title": "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30715168"
                },
                {
                    "id": 15432,
                    "pubMedId": 30285222,
                    "title": "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30285222"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 8164,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Buparlisib (BKM120) and Mekinist (trametinib) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 1974,
                "therapyName": "Buparlisib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6551,
                    "pubMedId": 24265152,
                    "title": "A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265152"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1511,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Zelboraf (vemurafenib) therapy is included in guidelines for melanoma patients with unresectable or metastatic disease harboring BRAF V600 activating mutations, in cases where BRAF/MEK inhibitor combination therapy is contraindicated (NCCN.org).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11096,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, the combination therapy of AMG 232, Mekinist (trametinib), and Tafinlar (dabrafenib) in 6 patients with metastatic cutaneous melanoma harboring a BRAF V600 mutation resulted in 4 patients with a partial response and 2 patients with stable disease, and of the 6 patients, all experienced tumor reduction (J Clin Oncol 35, 2017 (suppl; abstr 2575)).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 1453,
                "therapyName": "AMG 232 + Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9073,
                    "pubMedId": null,
                    "title": "Phase 1 study of the p53-MDM2 inhibitor AMG 232 combined with trametinib plus dabrafenib or trametinib in patients (Pts) with TP53 wild type (TP53WT) metastatic cutaneous melanoma (MCM)",
                    "url": "http://abstracts.asco.org/199/AbstView_199_181299.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2525,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib/II trial, treatment with the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) resulted in partial response or better in 12% (5/43), including 1 complete response, and stable disease in 51% (22/43) of patients with BRAF V600-mutant colorectal cancer (PMID: 26392102).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3250,
                    "pubMedId": null,
                    "title": "Phase 1-2 trial of the BRAF inhibitor dabrafenib (D) plus MEK inhibitor trametinib (T) in BRAF V600 mutant colorectal cancer (CRC): Updated efficacy and biomarker analysis.",
                    "url": "http://meetinglibrary.asco.org/content/131743-144"
                },
                {
                    "id": 3713,
                    "pubMedId": 26392102,
                    "title": "Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26392102"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3301,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, treatment with the combination of Zelboraf (vemurafenib) and Erbitux (cetuximab) resulted in an overall response rate of 4% (1/26), stable disease in 69% (18/26), and a median progression-free survival of 3.7 months in patients with BRAF V600-mutant colorectal cancer (PMID: 26287849).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 1711,
                "therapyName": "Cetuximab + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3720,
                    "pubMedId": 26287849,
                    "title": "Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26287849"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 8166,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of MK2206 and Zelboraf (vemurafenib) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 4635,
                "therapyName": "MK2206 + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6551,
                    "pubMedId": 24265152,
                    "title": "A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265152"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3302,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, treatment with Zelboraf (vemurafenib) resulted in an overall response rate of 29% (2/7), with 1 complete response and 1 partial response, in patients with anaplastic thyroid cancer patients with BRAF V600 mutations (PMID:     26287849).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1781,
                "name": "thyroid cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3720,
                    "pubMedId": 26287849,
                    "title": "Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26287849"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 9868,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, the addition of Zelboraf (vemurafenib) to Camptosar (irinotecan) plus Erbitux (cetuximab) improved progression-free survival (4.4 mo vs. 2.0 mo), and disease control rate (67% vs. 22%), compared to Camptosar (irinotecan) plus Erbitux (cetuximab) without Zelboraf (vemurafenib), in patients with BRAF V600-mutant colorectal cancer (J Clin Oncol 35, 2017 (suppl 4S; abstract 520)).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 1331,
                "therapyName": "Cetuximab + Irinotecan + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7724,
                    "pubMedId": null,
                    "title": "Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406).",
                    "url": "http://abstracts.asco.org/195/AbstView_195_176737.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11112,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, the combination of Tecentriq (atezolizumab), Cotellic (cobimetinib), and Zelboraf (vemurafenib) resulted in antitumor efficacy in BRAF V600 positive melanoma patients, demonstrating an unconfirmed RECIST response in 85.3% (29/34) of patients, including 6 CRs and 23 PRs, and confirmed PRs in three patients (J Clin Oncol 35, 2017 (suppl; abstr 3063)).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 4825,
                "therapyName": "Atezolizumab + Cobimetinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9081,
                    "pubMedId": null,
                    "title": "Atezolizumab (A) + cobimetinib (C) + vemurafenib (V) in BRAFV600-mutant metastatic melanoma (mel): Updated safety and clinical activity.",
                    "url": "http://abstracts.asco.org/199/AbstView_199_186773.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1509,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Tafinlar (dabrafenib) therapy is included in guidelines for melanoma patients with unresectable or metastatic disease harboring BRAF V600 activating mutations, in cases where BRAF/MEK inhibitor combination therapy is contraindicated (NCCN.org).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 3300,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, treatment with Zelboraf (vemurafenib) in colorectal cancer patients with BRAF V600 mutations did not result in clinical benefit, with no patients achieving response, and 50% (5/10) demonstrating progressive disease (PMID: 26287849).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 3720,
                    "pubMedId": 26287849,
                    "title": "Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26287849"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1519,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Tafinlar (dabrafenib) and Mekinist (trametinib) combination therapy is included in guidelines for melanoma patients harboring a BRAF V600 activating mutation, as adjuvant treatment for patients with Stage III disease, or as systemic therapy for patients with unresectable or metastatic disease (NCCN.org).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 4933,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II clinical trial, patients with BRAF V600 mutant melanoma (n=78) treated with the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) had a median overall survival of greater than 2 years (PMID: 26811525).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4804,
                    "pubMedId": 26811525,
                    "title": "Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26811525"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8167,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of MK2206 and Mekinist (trametinib) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 4653,
                "therapyName": "MK2206 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6551,
                    "pubMedId": 24265152,
                    "title": "A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265152"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3303,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, treatment with Zelboraf (vemurafenib) resulted in partial response in 12% (1/8) and stable disease in 50% (4/8) of cholangiocarcinoma patients with BRAF V600 mutations (PMID: 26287849).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 4947,
                "name": "cholangiocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3720,
                    "pubMedId": 26287849,
                    "title": "Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26287849"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11044,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma patient derived xenograft (PDX) model harboring a BRAF V600 mutation demonstrated antitumor activity when treated with ASN003 (J Clin Oncol 35, 2017 (suppl; abstr e14102)).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 5827,
                "therapyName": "ASN003",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9034,
                    "pubMedId": null,
                    "title": "ASN003, a highly selective BRAF and PI3K inhibitor: Preclinical and phase 1 clinical data in patients with advanced solid tumors",
                    "url": "http://abstracts.asco.org/199/AbstView_199_186123.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1120,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, 20% (8/41) of melanoma patients with BRAF V600 mutations had a partial response to Binimetinib (MEK162) (PMID: 23414587).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 807,
                "therapyName": "Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 180,
                    "pubMedId": 23414587,
                    "title": "MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23414587"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 8160,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Mekinist (trametinib) and Zelboraf (vemurafenib) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 4234,
                "therapyName": "Trametinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6551,
                    "pubMedId": 24265152,
                    "title": "A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265152"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8165,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Buparlisib (BKM120) and Selumetinib (AZD6244) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 4652,
                "therapyName": "Buparlisib + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6551,
                    "pubMedId": 24265152,
                    "title": "A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265152"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8161,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Selumetinib (AZD6244) and Zelboraf (vemurafenib) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 3773,
                "therapyName": "Selumetinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6551,
                    "pubMedId": 24265152,
                    "title": "A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265152"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8163,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Buparlisib (BKM120) and Zelboraf (vemurafenib) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 1322,
                "therapyName": "Buparlisib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6551,
                    "pubMedId": 24265152,
                    "title": "A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265152"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7068,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a melanoma patient harboring a BRAF V600 mutation developed resistance-associated mutations, MAP2K1 V60E, NRAS T58I, and NRAS Q61R, after 18 weeks of treatment with Zelboraf (vemurafenib) (PMID: 24265153).",
            "molecularProfile": {
                "id": 24385,
                "profileName": "BRAF V600X MAP2K1 V60E NRAS T58I NRAS Q61R"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7082,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a melanoma patient harboring PTEN Y86fs and BRAF V600X developed the resistance-associated mutation, PIK3CA H1047R, after treatment with Zelboraf (vemurafenib) (PMID: 24265153).",
            "molecularProfile": {
                "id": 24398,
                "profileName": "BRAF V600X PIK3CA H1047R PTEN Y86fs"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8106,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of AKT1 Q79K in a wild-type PTEN-expressing BRAF V600-mutant melanoma cell line conferred resistance to Zelboraf (vemurafenib) in culture (PMID: 24265152).",
            "molecularProfile": {
                "id": 26173,
                "profileName": "AKT1 Q79K BRAF V600X PTEN pos"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6551,
                    "pubMedId": 24265152,
                    "title": "A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265152"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8125,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of MK2206 and Zelboraf (vemurafenib) inhibited AKT activation and growth of PTEN-expressing BRAF V600-mutant melanoma cells expressing AKT1 Q79K in culture, with increased efficacy over either agent alone (PMID: 24265152).",
            "molecularProfile": {
                "id": 26173,
                "profileName": "AKT1 Q79K BRAF V600X PTEN pos"
            },
            "therapy": {
                "id": 4635,
                "therapyName": "MK2206 + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6551,
                    "pubMedId": 24265152,
                    "title": "A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265152"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8103,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of AKT1 E17K in a wild-type PTEN-expressing BRAF V600-mutant melanoma cell line conferred resistance to Zelboraf (vemurafenib) in culture (PMID: 24265152).",
            "molecularProfile": {
                "id": 26172,
                "profileName": "AKT1 E17K BRAF V600X PTEN pos"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6551,
                    "pubMedId": 24265152,
                    "title": "A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265152"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7083,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a melanoma patient harboring a BRAF V600 mutation and PTEN H93D treated with Zelboraf (vemurafenib) for 66 weeks demonstrated a partial response (PMID: 24265153).",
            "molecularProfile": {
                "id": 24401,
                "profileName": "BRAF V600X PTEN H93D"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3381,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, the combination of Torisel (temsirolimus) plus Avastin (bevacizumab) and Doxil (pegylated liposomal-doxorubicin) resulted in a partial response in a patient with ovarian clear cell carcinoma harboring PIK3CA H1047 and BRAF V600 mutations (PMID: 21216929).",
            "molecularProfile": {
                "id": 13306,
                "profileName": "PIK3CA H1047X BRAF V600X"
            },
            "therapy": {
                "id": 1121,
                "therapyName": "Bevacizumab + Pegylated liposomal-doxorubicin + Temsirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 4001,
                "name": "ovarian carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3726,
                    "pubMedId": 21216929,
                    "title": "PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21216929"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8168,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lack of PTEN expression was associated with increased sensitivity to GSK2141795 in BRAF V600-mutant melanoma cell lines in culture (PMID: 24265152).",
            "molecularProfile": {
                "id": 26183,
                "profileName": "BRAF V600X PTEN neg"
            },
            "therapy": {
                "id": 764,
                "therapyName": "Uprosertib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6551,
                    "pubMedId": 24265152,
                    "title": "A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265152"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15999,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RMC-4550 treatment resulted in decreased Erk phosphorylation and dose-dependent tumor growth inhibition in patient-derived xenograft (PDX) models of non-small cell lung cancer harboring BRAF D594N (PMID: 30104724).",
            "molecularProfile": {
                "id": 23803,
                "profileName": "BRAF N581D"
            },
            "therapy": {
                "id": 7839,
                "therapyName": "RMC-4550",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14089,
                    "pubMedId": 30104724,
                    "title": "RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30104724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16117,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (MyPathway), Zelboraf (vemurafenib) treatment resulted in an objective response in only 4% (1/23) of patient with advanced solid tumors harboring non-V600 BRAF mutations, 1 of the non-responding patients harbored BRAF P731T (PMID: 29320312; NCT02091141).",
            "molecularProfile": {
                "id": 31506,
                "profileName": "BRAF P731T"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13171,
                    "pubMedId": 29320312,
                    "title": "Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29320312"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10122,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Binimetinib (MEK162) and Buparlisib (BKM120) resulted in improved cell growth inhibition compared to either agent alone in a metastatic melanoma cell line with wild-type BRAF and wild-type NRAS in culture (PMID: 27307593).",
            "molecularProfile": {
                "id": 15933,
                "profileName": "BRAF wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 5400,
                "therapyName": "Binimetinib + Buparlisib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8051,
                    "pubMedId": 27307593,
                    "title": "PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27307593"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3798,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, Lenvima (lenvatinib) treatment resulted in stable disease in 44% (4/9) and partial response in 22% (2/9) of melanoma patients carrying wild-type BRAF and NRAS (PMID: 26169970).",
            "molecularProfile": {
                "id": 15933,
                "profileName": "BRAF wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 792,
                "therapyName": "Lenvatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3994,
                    "pubMedId": 26169970,
                    "title": "Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26169970"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7945,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAK-632 inhibited proliferation of BRAF and NRAS wild-type melanoma cells in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 15933,
                "profileName": "BRAF wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 3300,
                "therapyName": "TAK-632",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7952,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BRAF and NRAS wild-type melanoma cells were resistant to PLX7904 in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 15933,
                "profileName": "BRAF wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 4606,
                "therapyName": "PLX7904",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7960,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BRAF and NRAS wild-type melanoma cells were resistant to Zelboraf (vemurafenib) in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 15933,
                "profileName": "BRAF wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7935,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZ628 inhibited proliferation of BRAF and NRAS wild-type melanoma cells in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 15933,
                "profileName": "BRAF wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 1093,
                "therapyName": "AZ628",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7889,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type melanoma cells harboring NRAS Q61K in patient-derived xenograft models (PMID: 19276360).",
            "molecularProfile": {
                "id": 26086,
                "profileName": "BRAF wild-type NRAS Q61K"
            },
            "therapy": {
                "id": 1095,
                "therapyName": "GDC0879",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6516,
                    "pubMedId": 19276360,
                    "title": "Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19276360"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 504,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PLX4720 did not inhibit growth of BRAF wild-type melanoma cells in culture or in cell line xenograft models (PMID: 18287029).",
            "molecularProfile": {
                "id": 4,
                "profileName": "BRAF wild-type"
            },
            "therapy": {
                "id": 1060,
                "therapyName": "PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 291,
                    "pubMedId": 18287029,
                    "title": "Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18287029"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8544,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a BRAF wild-type melanoma cell line demonstrated minimal sensitivity when treated with the combination of Ibrance (palbociclib) and Mekinist (trametinib) in culture (PMID: 27488531).",
            "molecularProfile": {
                "id": 4,
                "profileName": "BRAF wild-type"
            },
            "therapy": {
                "id": 1368,
                "therapyName": "Palbociclib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6683,
                    "pubMedId": 27488531,
                    "title": "An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27488531"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16439,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (CheckMate-066), Opdivo (nivolumab) treatment resulted in improved overall survival and response compared to treatment with Deticene (dacarbazine) in melanoma patients with wild-type BRAF, including a 3-year overall survival (OS) rate of 51.2% vs. 21.6%, a median OS of 37.5 months vs. 11.2 months, a complete response in 19% (40/210) vs. 1.4% (3/208), and a partial response in 23.8% (50/210) vs. 13% (27/208), respectively (PMID: 30422243; NCT01721772).",
            "molecularProfile": {
                "id": 4,
                "profileName": "BRAF wild-type"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14511,
                    "pubMedId": 30422243,
                    "title": "Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30422243"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1256,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I study, 10% (4/39) of wild-type BRAF melanoma patients had a partial response to Mekinist (trametinib) (PMID: 22805292; NCT00687622).",
            "molecularProfile": {
                "id": 4,
                "profileName": "BRAF wild-type"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 233,
                    "pubMedId": 22805292,
                    "title": "Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22805292"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7890,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type melanoma cells in cell culture, cell line xenograft models, and patient-derived xenograft models (PMID: 19276360).",
            "molecularProfile": {
                "id": 4,
                "profileName": "BRAF wild-type"
            },
            "therapy": {
                "id": 1095,
                "therapyName": "GDC0879",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6516,
                    "pubMedId": 19276360,
                    "title": "Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19276360"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8068,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a variety of BRAF wild-type tumor cell lines were insensitive to BGB-283 in culture (PMID: 26208524).",
            "molecularProfile": {
                "id": 4,
                "profileName": "BRAF wild-type"
            },
            "therapy": {
                "id": 4025,
                "therapyName": "BGB-283",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5280,
                    "pubMedId": 26208524,
                    "title": "BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26208524"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 714,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, a favorable response rate to Selumetinib (AZD6244) was observed in mutant BRAF, but not BRAF wild-type, melanoma patients (PMID: 22048237).",
            "molecularProfile": {
                "id": 4,
                "profileName": "BRAF wild-type"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 228,
                    "pubMedId": 22048237,
                    "title": "Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22048237"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 452,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RAF265 inhibited the growth of melanoma tumors orthotopically implanted in mice, including tumors wild-type for BRAF (PMID: 22351689).",
            "molecularProfile": {
                "id": 4,
                "profileName": "BRAF wild-type"
            },
            "therapy": {
                "id": 884,
                "therapyName": "RAF265",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 61,
                    "pubMedId": 22351689,
                    "title": "RAF265 inhibits the growth of advanced human melanoma tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22351689"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12624,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, treatment with RAF265 in melanoma patients resulted in an objective response rate of 12.1% (8/66), including a partial response in four patients harboring BRAF V600E, two partial responses and one complete response in patients with wild-type BRAF, and one complete response in a patient with unknown mutational status (PMID: 28719152).",
            "molecularProfile": {
                "id": 4,
                "profileName": "BRAF wild-type"
            },
            "therapy": {
                "id": 884,
                "therapyName": "RAF265",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10503,
                    "pubMedId": 28719152,
                    "title": "A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28719152"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8534,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BRAF wild-type melanoma cells demonstrated decreased cell viability when treated with Ibrance (palbociclib) in culture (PMID: 27488531).",
            "molecularProfile": {
                "id": 4,
                "profileName": "BRAF wild-type"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6683,
                    "pubMedId": 27488531,
                    "title": "An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27488531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4418,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CLM3 inhibited growth, Egfr signaling, and CCND1 expression, in BRAF wild-type thyroid cancer cells in culture (PMID: 24423321).",
            "molecularProfile": {
                "id": 4,
                "profileName": "BRAF wild-type"
            },
            "therapy": {
                "id": 3502,
                "therapyName": "CLM3",
                "synonyms": null
            },
            "indication": {
                "id": 1781,
                "name": "thyroid cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4527,
                    "pubMedId": 24423321,
                    "title": "CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24423321"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7891,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type non-small cell lung cancer cells in culture and in patient-derived xenograft models (PMID: 19276360).",
            "molecularProfile": {
                "id": 4,
                "profileName": "BRAF wild-type"
            },
            "therapy": {
                "id": 1095,
                "therapyName": "GDC0879",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6516,
                    "pubMedId": 19276360,
                    "title": "Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19276360"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9109,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Afinitor (everolimus) and Selumetinib (AZD6244) synergistically inhibited growth and induced apoptosis in glioma cell lines in culture (PMID: 27217440).",
            "molecularProfile": {
                "id": 4,
                "profileName": "BRAF wild-type"
            },
            "therapy": {
                "id": 4901,
                "therapyName": "Everolimus + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3070,
                "name": "malignant glioma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6921,
                    "pubMedId": 27217440,
                    "title": "BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27217440"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3797,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, Lenvima (lenvatinib) treatment resulted in stable disease in 83% (5/6) of melanoma patients harboring NRAS mutations and wild-type BRAF (PMID: 26169970).",
            "molecularProfile": {
                "id": 1299,
                "profileName": "BRAF wild-type NRAS mutant"
            },
            "therapy": {
                "id": 792,
                "therapyName": "Lenvatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3994,
                    "pubMedId": 26169970,
                    "title": "Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26169970"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11664,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Zelboraf (vemurafenib) did not reduce activation of Mek and Erk by BRAF F595L in transformed cells in culture (PMID: 26582644).",
            "molecularProfile": {
                "id": 2417,
                "profileName": "BRAF F595L"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9695,
                    "pubMedId": 26582644,
                    "title": "Cooperation of BRAF(F595L) and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26582644"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6831,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RAF265 inhibited kinase activity in vitro, and downstream Erk phosphorylation in cells expressing BRAF V600E and the gatekeeper mutation BRAF T529M to a similar degree as transformed cells expressing BRAF V600E in culture (PMID: 20538618).",
            "molecularProfile": {
                "id": 23817,
                "profileName": "BRAF V600E BRAF T529M"
            },
            "therapy": {
                "id": 884,
                "therapyName": "RAF265",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5859,
                    "pubMedId": 20538618,
                    "title": "Gatekeeper mutations mediate resistance to BRAF-targeted therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20538618"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6828,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing BRAF V600E and the gatepkeeper mutation BRAF T529M were insensitive to SB590885-mediated inhibition of ERK signaling in culture (PMID: 20538618).",
            "molecularProfile": {
                "id": 23817,
                "profileName": "BRAF V600E BRAF T529M"
            },
            "therapy": {
                "id": 4281,
                "therapyName": "SB590885",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 5859,
                    "pubMedId": 20538618,
                    "title": "Gatekeeper mutations mediate resistance to BRAF-targeted therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20538618"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6842,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CI-1040 (PD184352) inhibited Erk phosphorylation in transformed cells expressing BRAF V600E and the gatekeeper mutation BRAF T529M in culture (PMID: 20538618).",
            "molecularProfile": {
                "id": 23817,
                "profileName": "BRAF V600E BRAF T529M"
            },
            "therapy": {
                "id": 699,
                "therapyName": "CI-1040",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5859,
                    "pubMedId": 20538618,
                    "title": "Gatekeeper mutations mediate resistance to BRAF-targeted therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20538618"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6839,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nexavar (sorafenib) inhibited kinase activity in vitro, and downstream Erk phosphorylation in cells expressing BRAF V600E and the gatekeeper mutation BRAF T529M to a similar degree as transformed cells expressing BRAF V600E in culture (PMID: 20538618).",
            "molecularProfile": {
                "id": 23817,
                "profileName": "BRAF V600E BRAF T529M"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5859,
                    "pubMedId": 20538618,
                    "title": "Gatekeeper mutations mediate resistance to BRAF-targeted therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20538618"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6834,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing BRAF V600E and the gatepkeeper mutation BRAF T529M were insensitive to PLX4720-mediated inhibition of ERK signaling in culture (PMID: 20538618).",
            "molecularProfile": {
                "id": 23817,
                "profileName": "BRAF V600E BRAF T529M"
            },
            "therapy": {
                "id": 1060,
                "therapyName": "PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 5859,
                    "pubMedId": 20538618,
                    "title": "Gatekeeper mutations mediate resistance to BRAF-targeted therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20538618"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9417,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF K601T (PMID: 26343582).",
            "molecularProfile": {
                "id": 3573,
                "profileName": "BRAF K601T"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 7141,
                    "pubMedId": 26343582,
                    "title": "BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343582"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17516,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed human embryonic kidney cells overexpressing Braf V504_R506dup were resistant to Nexavar (sorafenib) in culture (PMID: 30575814).",
            "molecularProfile": {
                "id": 13544,
                "profileName": "BRAF V504_R506dup"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15556,
                    "pubMedId": 30575814,
                    "title": "Recurrent somatic BRAF insertion (p.V504_R506dup): a tumor marker and a potential therapeutic target in pilocytic astrocytoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30575814"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17518,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed human embryonic kidney cells overexpressing Braf V504_R506dup were resistant to Mekinist (trametinib) in culture (PMID: 30575814).",
            "molecularProfile": {
                "id": 13544,
                "profileName": "BRAF V504_R506dup"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15556,
                    "pubMedId": 30575814,
                    "title": "Recurrent somatic BRAF insertion (p.V504_R506dup): a tumor marker and a potential therapeutic target in pilocytic astrocytoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30575814"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17517,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed human embryonic kidney cells overexpressing Braf V504_R506dup were resistant to Zelboraf (vemurafenib) in culture (PMID: 30575814).",
            "molecularProfile": {
                "id": 13544,
                "profileName": "BRAF V504_R506dup"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15556,
                    "pubMedId": 30575814,
                    "title": "Recurrent somatic BRAF insertion (p.V504_R506dup): a tumor marker and a potential therapeutic target in pilocytic astrocytoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30575814"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9412,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF G464R (PMID: 26343582).",
            "molecularProfile": {
                "id": 2961,
                "profileName": "BRAF G464R"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 7141,
                    "pubMedId": 26343582,
                    "title": "BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343582"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6603,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) modestly inhibited proliferation of human melanoma cells harboring BRAF G469R and NRAS Q61K in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 23638,
                "profileName": "BRAF G469R NRAS Q61K"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6592,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY3009120 inhibited soft agar growth of human melanoma cancer cells harboring BRAF G469R and NRAS Q61K in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 23638,
                "profileName": "BRAF G469R NRAS Q61K"
            },
            "therapy": {
                "id": 3268,
                "therapyName": "LY3009120",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6612,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cells harboring BRAF G469R and NRAS G61K were insensitive to Zelboraf (vemurafenib) in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 23638,
                "profileName": "BRAF G469R NRAS Q61K"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7602,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) inhibited ERK signaling and reduced growth of a melanoma cell line harboring BRAF V600K and MAP2K1 P124Q in culture (PMID: 25370473).",
            "molecularProfile": {
                "id": 25913,
                "profileName": "BRAF V600K MAP2K1 P124Q"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6439,
                    "pubMedId": 25370473,
                    "title": "Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25370473"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7598,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma cell line harboring BRAF V600K and MAP2K1 P124Q demonstrated decreased sensitivity to Tafinlar (dabrafenib) in culture (PMID: 25370473).",
            "molecularProfile": {
                "id": 25913,
                "profileName": "BRAF V600K MAP2K1 P124Q"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6439,
                    "pubMedId": 25370473,
                    "title": "Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25370473"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7601,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, VX-11e inhibited ERK signaling and reduced growth of a melanoma cell line harboring BRAF V600K and MAP2K1 P124Q in culture (PMID: 25370473).",
            "molecularProfile": {
                "id": 25913,
                "profileName": "BRAF V600K MAP2K1 P124Q"
            },
            "therapy": {
                "id": 2804,
                "therapyName": "VX-11e",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6439,
                    "pubMedId": 25370473,
                    "title": "Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25370473"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16954,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III (COLUMBUS) trial that supported FDA approval, Braftovi (encorafenib) in combination with Mektovi (binimetinib) resulted in a median overall survival (OS) of 33.6 months, a 1-year OS rate of 77.5%, and a 2-year OS rate of 57.7% in patients with advanced melanoma harboring BRAF V600E/K mutations compared to a median OS of 16.9 months and 1- and 2-year OS rates of 63.1% and 43.2%, respectively, in the Zelboraf (vemurafenib) treated group (PMID: 30219628; NCT01909453).",
            "molecularProfile": {
                "id": 2,
                "profileName": "BRAF V600K"
            },
            "therapy": {
                "id": 1100,
                "therapyName": "Binimetinib + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14457,
                    "pubMedId": 30219628,
                    "title": "Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30219628"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15455,
                    "pubMedId": null,
                    "title": "Braftovi (encorafenib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210496"
                },
                {
                    "id": 15456,
                    "pubMedId": null,
                    "title": "Mektovi (binimetinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210498"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16951,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Braftovi (encorafenib) in combination with Mektovi (binimetinib) is included in guidelines as first-line and second-line therapy for patients with metastatic or unresectable melanoma harboring BRAF V600E or V600K mutations (PMID: 30959471; NCCN.org).",
            "molecularProfile": {
                "id": 2,
                "profileName": "BRAF V600K"
            },
            "therapy": {
                "id": 1100,
                "therapyName": "Binimetinib + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                },
                {
                    "id": 15109,
                    "pubMedId": 30959471,
                    "title": "Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30959471"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16955,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III (COLUMBUS) trial that supported FDA approval, Braftovi (encorafenib) in combination with Mektovi (binimetinib) demonstrated improved tolerability profile and efficacy, resulted in a progression-free survival of 14.9 months in patients with advanced melanoma harboring BRAF V600E/K mutations, comparing to 7.3 months in the Zelboraf (vemurafenib) group (HR=0.54, p<0.0001) (PMID: 29573941; NCT01909453) and both BRAF V600E and BRAF V600K are on the companion diagnostic.",
            "molecularProfile": {
                "id": 2,
                "profileName": "BRAF V600K"
            },
            "therapy": {
                "id": 1100,
                "therapyName": "Binimetinib + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11562,
                    "pubMedId": 29573941,
                    "title": "Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29573941"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15455,
                    "pubMedId": null,
                    "title": "Braftovi (encorafenib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210496"
                },
                {
                    "id": 15456,
                    "pubMedId": null,
                    "title": "Mektovi (binimetinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210498"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 15735,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, patients with melanoma harboring BRAF V600K (n=19) had increased tumor mutational burden and greater response rates (53% vs. 29%, p=0.059), progression-free survival (19 vs. 2.7 months, p=0.049), and overall survival  (20.4 vs. 11.7 months, p=0.081) relative to patients with BRAF V600E (n=84) when treated with Keytruda (pembrolizumab) (n=17 and 62 for BRAF V600K and V600E, respectively) or Opdivo (nivolumab) (n=2 and 22 for BRAF V600K and V600E, respectively) (PMID: 30630828).",
            "molecularProfile": {
                "id": 2,
                "profileName": "BRAF V600K"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13705,
                    "pubMedId": 30630828,
                    "title": "Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30630828"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1508,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Tafinlar (dabrafenib) therapy is included in guidelines for melanoma patients with unresectable or metastatic disease harboring BRAF V600 activating mutations, such as BRAF V600K, in cases where BRAF/MEK inhibitor combination therapy is contraindicated (NCCN.org).",
            "molecularProfile": {
                "id": 2,
                "profileName": "BRAF V600K"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12927,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Tafinlar (dabrafenib) and Mekinist (trametinib) combination therapy is included in guidelines for melanoma patients harboring a BRAF V600 activating mutation, such as BRAF V600K, as adjuvant therapy for stage III disease and as systemic therapy for patients with unresectable or metastatic disease (NCCN.org).",
            "molecularProfile": {
                "id": 2,
                "profileName": "BRAF V600K"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12835,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (COMBI-v) that supported FDA approval, the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) resulted in an improved overall survival rate at 12 months (72% vs 65%, HR=0.69, p=0.005), median progression-free survival (11.4 vs 7.3 months, HR=0.56, p<0.001), and objective response rate (64% vs 51%, p<0.001) compared to Zelboraf (vemurafenib) in melanoma patients harboring BRAF V600E or V600K (PMID: 25399551; NCT01597908).",
            "molecularProfile": {
                "id": 2,
                "profileName": "BRAF V600K"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10781,
                    "pubMedId": 25399551,
                    "title": "Improved overall survival in melanoma with combined dabrafenib and trametinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25399551"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15458,
                    "pubMedId": null,
                    "title": "Tafinlar (dabrafenib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=202806"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 5973,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Omipalisib (GSK2126458) inhibited the growth of melanoma cell lines harboring BRAF V600K in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 2,
                "profileName": "BRAF V600K"
            },
            "therapy": {
                "id": 763,
                "therapyName": "GSK2126458",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12839,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (METRIC) that supported FDA approval, Mekinist (trametinib) treatment, as compared to Deticine (dacarbazine) or Taxol (paclitaxel) treatment, resulted in improved progression-free survival of 4.8 months versus 1.5 months and an overall six month survival rate of 81% versus 67% in patients with BRAF V600E/K-positive metastatic melanoma (PMID: 22663011; NCT01245062).",
            "molecularProfile": {
                "id": 2,
                "profileName": "BRAF V600K"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 468,
                    "pubMedId": 22663011,
                    "title": "Improved survival with MEK inhibition in BRAF-mutated melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22663011"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15457,
                    "pubMedId": null,
                    "title": "Mekinist (trametinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=204114"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 15734,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, patients with melanoma harboring BRAF V600K (n=19) had increased tumor mutational burden and greater response rates (53% vs. 29%, p=0.059), progression-free survival (19 vs. 2.7 months, p=0.049), and overall survival  (20.4 vs. 11.7 months, p=0.081) relative to patients with BRAF V600E (n=84) when treated with Keytruda (pembrolizumab) (n=17 and 62 for BRAF V600K and V600E, respectively) or Opdivo (nivolumab) (n=2 and 22 for BRAF V600K and V600E, respectively) (PMID: 30630828).",
            "molecularProfile": {
                "id": 2,
                "profileName": "BRAF V600K"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13705,
                    "pubMedId": 30630828,
                    "title": "Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30630828"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12925,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Zelboraf (vemurafenib) therapy is included in guidelines for melanoma patients with unresectable or metastatic disease harboring BRAF V600 activating mutations, such as BRAF V600K, in cases where BRAF/MEK inhibitor combination therapy is contraindicated (NCCN.org).",
            "molecularProfile": {
                "id": 2,
                "profileName": "BRAF V600K"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17035,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Zelboraf (vemurafenib) and Cotellic (cobimetinib) combination therapy is included in melanoma guidelines for patients with metastatic or unresectable disease harboring a BRAF V600 activating mutation (NCCN.org).",
            "molecularProfile": {
                "id": 2,
                "profileName": "BRAF V600K"
            },
            "therapy": {
                "id": 1657,
                "therapyName": "Cobimetinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12270,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (coBRIM) that supported FDA approval, treatment with the combination of Zelboraf (vemurafenib) and Cotellic (cobimetinib) resulted in an improved progression-free survival of 12.3 months, compared to 7.2 months with Zelboraf (vemurafenib) plus placebo, among patients with BRAF V600-mutated metastatic melanoma, and BRAF V600E and BRAF V600K are on the companion diagnostic (PMID: 27480103; NCT01689519).",
            "molecularProfile": {
                "id": 2,
                "profileName": "BRAF V600K"
            },
            "therapy": {
                "id": 1657,
                "therapyName": "Cobimetinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10226,
                    "pubMedId": 27480103,
                    "title": "Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27480103"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15453,
                    "pubMedId": null,
                    "title": "Cotellic (cobimetinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=206192"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16949,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "The combination of Tafinlar (dabrafenib) and Mekinist (trametinib) is included in guidelines as first or second-line therapy in patients with metastatic non-small cell lung cancer harboring a BRAF V600 mutation (PMID: 30715168, PMID: 30285222; ESMO.org).",
            "molecularProfile": {
                "id": 2,
                "profileName": "BRAF V600K"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15115,
                    "pubMedId": null,
                    "title": "ESMO Clinical Practice Guidelines",
                    "url": "https://www.esmo.org/Guidelines"
                },
                {
                    "id": 15431,
                    "pubMedId": 30715168,
                    "title": "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30715168"
                },
                {
                    "id": 15432,
                    "pubMedId": 30285222,
                    "title": "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30285222"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 7600,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, VX-11e inhibited ERK signaling and reduced growth of a melanoma cell line harboring BRAF V600K and MAP2K1 P124L in culture (PMID: 25370473).",
            "molecularProfile": {
                "id": 25916,
                "profileName": "BRAF V600K MAP2K1 P124L"
            },
            "therapy": {
                "id": 2804,
                "therapyName": "VX-11e",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6439,
                    "pubMedId": 25370473,
                    "title": "Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25370473"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7603,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) inhibited ERK signaling and reduced growth of a melanoma cell line harboring BRAF V600K and MAP2K1 P124L in culture (PMID: 25370473).",
            "molecularProfile": {
                "id": 25916,
                "profileName": "BRAF V600K MAP2K1 P124L"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6439,
                    "pubMedId": 25370473,
                    "title": "Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25370473"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7599,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma cell line harboring BRAF V600K and MAP2K1 P124L demonstrated decreased sensitivity to Tafinlar (dabrafenib) in culture (PMID: 25370473).",
            "molecularProfile": {
                "id": 25916,
                "profileName": "BRAF V600K MAP2K1 P124L"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6439,
                    "pubMedId": 25370473,
                    "title": "Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25370473"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5974,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Omipalisib (GSK2126458) inhibited the growth of melanoma cell lines harboring BRAF V600K in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22095,
                "profileName": "BRAF V600K NRAS Q61K"
            },
            "therapy": {
                "id": 763,
                "therapyName": "GSK2126458",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5972,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cell lines harboring BRAF V600K and NRAS Q61K were 3-7 fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600K in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22095,
                "profileName": "BRAF V600K NRAS Q61K"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5971,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cell lines harboring BRAF V600K and NRAS Q61K were resistant to Tafinlar (dabrafenib) growth inhibition in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22095,
                "profileName": "BRAF V600K NRAS Q61K"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5981,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tafinlar (dabrafenib) in combination with Mekinist (trametinib) inhibited growth of melanoma cell lines harboring BRAF V600K and NRAS Q61K in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22095,
                "profileName": "BRAF V600K NRAS Q61K"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5996,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tafinlar (dabrafenib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600K and NRAS Q61K in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22095,
                "profileName": "BRAF V600K NRAS Q61K"
            },
            "therapy": {
                "id": 4004,
                "therapyName": "Dabrafenib + GSK2126458",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5995,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition in melanoma cell lines harboring BRAF V600K and NRAS Q61K in culture, compared to either agent alone (PMID: 22389471).",
            "molecularProfile": {
                "id": 22095,
                "profileName": "BRAF V600K NRAS Q61K"
            },
            "therapy": {
                "id": 3027,
                "therapyName": "GSK2126458 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7002,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 V60E demonstrated sensitivity to treatment with VRT11E, resulting in decreased cell growth in culture (PMID: 24265153).",
            "molecularProfile": {
                "id": 24281,
                "profileName": "BRAF V600E MAP2K1 V60E"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7056,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 V60E demonstrated resistance to treatment with Tafinlar (dabrafenib) in culture, resulting in sustained Map2k1/2 and Erk1/2 phosphorylation (PMID: 24265153).",
            "molecularProfile": {
                "id": 24281,
                "profileName": "BRAF V600E MAP2K1 V60E"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11042,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colorectal cancer cell line xenograft model co-harboring BRAF V600E and a PIK3CA mutation demonstrated tumor growth inhibition when treated with ASN003 (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B100).",
            "molecularProfile": {
                "id": 27895,
                "profileName": "BRAF V600E PIK3CA mut"
            },
            "therapy": {
                "id": 5827,
                "therapyName": "ASN003",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9035,
                    "pubMedId": null,
                    "title": "Abstract B100: ASN003, a unique B-RAF inhibitor with additional selective activity against PI3K and mTOR kinases, shows strong antitumor activity in multiple xenograft models",
                    "url": "http://mct.aacrjournals.org/content/14/12_Supplement_2/B100.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15709,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a single patient with hairy cell leukemia who relapsed after initial response to Zelboraf (vemurafenib) was found to have acquired multiple clones with Mek/Erk activating mutations, of which the MAP2K1 K57T clone became dominant, and demonstrated a sustained response greater than 12 months to combined Zelboraf (vemurafenib) and Cotellic (cobimetinib) treatment (PMID: 30341394).",
            "molecularProfile": {
                "id": 31172,
                "profileName": "BRAF V600E MAP2K1 K57T"
            },
            "therapy": {
                "id": 1657,
                "therapyName": "Cobimetinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 711,
                "name": "refractory hairy cell leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13685,
                    "pubMedId": 30341394,
                    "title": "Targeting MEK in vemurafenib-resistant hairy cell leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30341394"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15710,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a single patient with hairy cell leukemia harboring BRAF V600E, who relapsed after a 38 week remission in response to Zelboraf (vemurafenib) treatment, was found to have acquired multiple clones with Mek/Erk activating mutations, of which the MAP2K1 K57T clone became dominant (PMID: 30341394).",
            "molecularProfile": {
                "id": 31172,
                "profileName": "BRAF V600E MAP2K1 K57T"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 285,
                "name": "hairy cell leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 13685,
                    "pubMedId": 30341394,
                    "title": "Targeting MEK in vemurafenib-resistant hairy cell leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30341394"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7635,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Erbitux (cetuximab) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25921,
                "profileName": "BRAF V600E EGFR amp"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7664,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to combination therapy consisting of Tafinlar (dabrafenib) and Mekinist (trametinib) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25921,
                "profileName": "BRAF V600E EGFR amp"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7633,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25921,
                "profileName": "BRAF V600E EGFR amp"
            },
            "therapy": {
                "id": 4536,
                "therapyName": "Cetuximab + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7637,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Selumetinib (AZD6244) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25921,
                "profileName": "BRAF V600E EGFR amp"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7621,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment in culture, likely due to the acquired EGFR amplification (PMID: 27312529).",
            "molecularProfile": {
                "id": 25921,
                "profileName": "BRAF V600E EGFR amp"
            },
            "therapy": {
                "id": 3773,
                "therapyName": "Selumetinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7665,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to SCH772984 in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25921,
                "profileName": "BRAF V600E EGFR amp"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7632,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Erbitux (cetuximab) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25921,
                "profileName": "BRAF V600E EGFR amp"
            },
            "therapy": {
                "id": 1711,
                "therapyName": "Cetuximab + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7634,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Selumetinib (AZD6244), and Zelboraf (vemurafenib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25921,
                "profileName": "BRAF V600E EGFR amp"
            },
            "therapy": {
                "id": 4540,
                "therapyName": "Cetuximab + Selumetinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7636,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Zelboraf (vemurafenib) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25921,
                "profileName": "BRAF V600E EGFR amp"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7663,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Encorafenib (LGX818) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25921,
                "profileName": "BRAF V600E EGFR amp"
            },
            "therapy": {
                "id": 1916,
                "therapyName": "Cetuximab + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7666,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25921,
                "profileName": "BRAF V600E EGFR amp"
            },
            "therapy": {
                "id": 4542,
                "therapyName": "Cetuximab + Dabrafenib + SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13931,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with lung adenocarcinoma harboring EGFR exon 19 deletion treated with Tagrisso (osimertinib) showed progression after 16 months, and was subsequently found to have acquired BRAF V600E and MET amplification (PMID: 29596911).",
            "molecularProfile": {
                "id": 29877,
                "profileName": "BRAF V600E EGFR exon 19 del MET amp"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11362,
                    "pubMedId": 29596911,
                    "title": "Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29596911"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5962,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S were >20-fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600E in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22043,
                "profileName": "BRAF V600E MAP2K1 P387S NRAS Q61K"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5993,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E, NRAS Q61K, and MAP2K1 P387S in culture, compared to either agent alone (PMID: 22389471).",
            "molecularProfile": {
                "id": 22043,
                "profileName": "BRAF V600E MAP2K1 P387S NRAS Q61K"
            },
            "therapy": {
                "id": 3027,
                "therapyName": "GSK2126458 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5967,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22043,
                "profileName": "BRAF V600E MAP2K1 P387S NRAS Q61K"
            },
            "therapy": {
                "id": 763,
                "therapyName": "GSK2126458",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5961,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S were resistant to growth inhibition by Zelboraf (vemurafenib) in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22043,
                "profileName": "BRAF V600E MAP2K1 P387S NRAS Q61K"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5990,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the response of human melanoma cell lines harboring BRAF V600E, NRAS Q61K, and MAP2K1 P387S to Tafinlar (dabrafenib) in combination with Omipalisib (GSK2126458) was conflicting as one cell line with this mutation profile responded to the combination and another cell line with the mutation profile did not (PMID: 22389471).",
            "molecularProfile": {
                "id": 22043,
                "profileName": "BRAF V600E MAP2K1 P387S NRAS Q61K"
            },
            "therapy": {
                "id": 4004,
                "therapyName": "Dabrafenib + GSK2126458",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5952,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S were resistant to Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22043,
                "profileName": "BRAF V600E MAP2K1 P387S NRAS Q61K"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7025,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) inhibited growth of BRAF V600E-mutant melanoma cells expressing MAP2K2 P162S in culture (PMID: 24265154).",
            "molecularProfile": {
                "id": 24366,
                "profileName": "BRAF V600E MAP2K1 P162S"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6036,
                    "pubMedId": 24265154,
                    "title": "MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265154"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7030,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) inhibited growth of BRAF V600E-mutant melanoma cells expressing MAP2K2 P162S in culture (PMID: 24265154).",
            "molecularProfile": {
                "id": 24366,
                "profileName": "BRAF V600E MAP2K1 P162S"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6036,
                    "pubMedId": 24265154,
                    "title": "MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265154"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7027,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tafinlar (dabrafenib) inhibited growth of BRAF V600E-mutant melanoma cells expressing MAP2K2 P162S in culture (PMID: 24265154).",
            "molecularProfile": {
                "id": 24366,
                "profileName": "BRAF V600E MAP2K1 P162S"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6036,
                    "pubMedId": 24265154,
                    "title": "MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265154"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7057,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124S demonstrated resistance to treatment with Tafinlar (dabrafenib) in culture (PMID: 24265153).",
            "molecularProfile": {
                "id": 24282,
                "profileName": "BRAF V600E MAP2K1 P124S"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7004,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124S demonstrated sensitivity to treatment with VRT11E, resulting in decreased cell growth in culture (PMID: 24265153).",
            "molecularProfile": {
                "id": 24282,
                "profileName": "BRAF V600E MAP2K1 P124S"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7061,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124S demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 24265153).",
            "molecularProfile": {
                "id": 24282,
                "profileName": "BRAF V600E MAP2K1 P124S"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7035,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and MAP2K1 P124S demonstrated decreased sensitivity to Selumetinib (AZD6244) compared to cells harboring BRAF V600E alone in culture (PMID: 22197931).",
            "molecularProfile": {
                "id": 24282,
                "profileName": "BRAF V600E MAP2K1 P124S"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 429,
                    "pubMedId": 22197931,
                    "title": "Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22197931"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10288,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma patient-derived xenograft (PDX) model harboring BRAF V600E and PIK3CA H1047K was sensitive to the combination treatment of Miransertib (ARQ092) and Mekinist (trametinib), demonstrating a greater inhibition of tumor growth when compared to either agent alone (PMID: 26469692).",
            "molecularProfile": {
                "id": 27343,
                "profileName": "BRAF V600E PIK3CA H1047K"
            },
            "therapy": {
                "id": 5456,
                "therapyName": "ARQ092 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8234,
                    "pubMedId": 26469692,
                    "title": "Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26469692"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5786,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DEL-22379 inhibited growth of a melanoma cell line harboring BRAF V600E and over expressing NRAS G12V in culture (PMID: 26267534).",
            "molecularProfile": {
                "id": 21619,
                "profileName": "BRAF V600E NRAS G12V"
            },
            "therapy": {
                "id": 3769,
                "therapyName": "DEL-22379",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4897,
                    "pubMedId": 26267534,
                    "title": "Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26267534"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5785,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of NRAS G12V in melanoma cells harboring BRAF V600E conferred resistance to Zelboraf (vemurafenib) in culture (PMID: 26267534).",
            "molecularProfile": {
                "id": 21619,
                "profileName": "BRAF V600E NRAS G12V"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4897,
                    "pubMedId": 26267534,
                    "title": "Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26267534"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7627,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) combination treatment in culture, likely due to the acquired secondary resistance mutation of EGFR G465R (PMID: 27312529).",
            "molecularProfile": {
                "id": 25926,
                "profileName": "BRAF V600E EGFR G465R"
            },
            "therapy": {
                "id": 1711,
                "therapyName": "Cetuximab + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7641,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Zelboraf (vemurafenib) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25926,
                "profileName": "BRAF V600E EGFR G465R"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7692,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination therapy consisting of Tafinlar (dabrafenib) and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25926,
                "profileName": "BRAF V600E EGFR G465R"
            },
            "therapy": {
                "id": 4544,
                "therapyName": "Dabrafenib + SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7645,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination therapy consisting of Iressa (gefitinib) and Zelboraf (vemurafenib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25926,
                "profileName": "BRAF V600E EGFR G465R"
            },
            "therapy": {
                "id": 1709,
                "therapyName": "Gefitinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7643,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Vectibix (panitumumab) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25926,
                "profileName": "BRAF V600E EGFR G465R"
            },
            "therapy": {
                "id": 1717,
                "therapyName": "Panitumumab + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7642,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Iressa (gefitinib) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25926,
                "profileName": "BRAF V600E EGFR G465R"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7694,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib) and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25926,
                "profileName": "BRAF V600E EGFR G465R"
            },
            "therapy": {
                "id": 4542,
                "therapyName": "Cetuximab + Dabrafenib + SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7640,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Vectibix (panitumumab) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25926,
                "profileName": "BRAF V600E EGFR G465R"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7639,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Erbitux (cetuximab) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25926,
                "profileName": "BRAF V600E EGFR G465R"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8569,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, induced apoptosis in TP53-wild-type colorectal cancer cells harboring BRAF V600E and PTEN loss in culture and in cell line xenograft models (PMID: 26272063).",
            "molecularProfile": {
                "id": 26362,
                "profileName": "BRAF V600E PTEN loss TP53 wild-type"
            },
            "therapy": {
                "id": 4771,
                "therapyName": "PD-0325901 + Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10814,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with anaplastic thyroid carcinoma co-harboring BRAF V600E and PIK3CA H1047R demonstrated resistance to treatment with Afinitor (everolimus) (PMID: 27797976).",
            "molecularProfile": {
                "id": 26356,
                "profileName": "BRAF V600E PIK3CA H1047R"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 3963,
                "name": "thyroid carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8849,
                    "pubMedId": 27797976,
                    "title": "Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27797976"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10815,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with anaplastic thyroid carcinoma co-harboring BRAF V600E and PIK3CA H1047R demonstrated resistance to the combination therapy, Mekinist (trametinib) and Tafinlar (dabrafenib) (PMID: 27797976).",
            "molecularProfile": {
                "id": 26356,
                "profileName": "BRAF V600E PIK3CA H1047R"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3963,
                "name": "thyroid carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8849,
                    "pubMedId": 27797976,
                    "title": "Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27797976"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10812,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with anaplastic thyroid carcinoma co-harboring BRAF V600E and PIK3CA H1047R demonstrated tumor regression when treated with the triple combination, Tafinlar (dabrafenib), Mekinist (trametinib), and Afinitor (everolimus) (PMID: 27797976).",
            "molecularProfile": {
                "id": 26356,
                "profileName": "BRAF V600E PIK3CA H1047R"
            },
            "therapy": {
                "id": 5650,
                "therapyName": "Dabrafenib + Everolimus + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3963,
                "name": "thyroid carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8849,
                    "pubMedId": 27797976,
                    "title": "Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27797976"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5954,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S were resistant Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22046,
                "profileName": "BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5963,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S were resistant to growth inhibition by Mekinist (trametinib) in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22046,
                "profileName": "BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5958,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, A146T and MAP2K1 P387S were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22046,
                "profileName": "BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5994,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition in melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S in culture, compared to either agent alone (PMID: 22389471).",
            "molecularProfile": {
                "id": 22046,
                "profileName": "BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S"
            },
            "therapy": {
                "id": 3027,
                "therapyName": "GSK2126458 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5968,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22046,
                "profileName": "BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S"
            },
            "therapy": {
                "id": 763,
                "therapyName": "GSK2126458",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15190,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells expressing BRAF L514V in cis with V600E demonstrated decreased response to PLX8394-induced inhibition of Erk phosphorylation and colony formation compared to cells expressing BRAF V600E in culture (PMID: 29880583).",
            "molecularProfile": {
                "id": 30813,
                "profileName": "BRAF L514V BRAF V600E"
            },
            "therapy": {
                "id": 1041,
                "therapyName": "PLX8394",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 12771,
                    "pubMedId": 29880583,
                    "title": "A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29880583"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15189,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells expressing BRAF L514V in cis with V600E demonstrated decreased response to Tafinlar (dabrafenib)-induced inhibition of Erk phosphorylation and colony formation compared to cells expressing BRAF V600E in culture (PMID: 29880583).",
            "molecularProfile": {
                "id": 30813,
                "profileName": "BRAF L514V BRAF V600E"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 12771,
                    "pubMedId": 29880583,
                    "title": "A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29880583"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15188,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells expressing BRAF L514V in cis with V600E demonstrated decreased response to Zelboraf (vemurafenib)-induced inhibition of Erk phosphorylation and colony formation compared to cells expressing BRAF V600E in culture (PMID: 29880583).",
            "molecularProfile": {
                "id": 30813,
                "profileName": "BRAF L514V BRAF V600E"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 12771,
                    "pubMedId": 29880583,
                    "title": "A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29880583"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15193,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGB3290 resulted in similar inhibition of Erk phosphorylation and colony formation in melanoma cells expressing BRAF L514V in cis with V600E and cells expressing BRAF V600E alone in culture (PMID: 29880583).",
            "molecularProfile": {
                "id": 30813,
                "profileName": "BRAF L514V BRAF V600E"
            },
            "therapy": {
                "id": 7464,
                "therapyName": "BGB3290",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 12771,
                    "pubMedId": 29880583,
                    "title": "A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29880583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15175,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a pediatric patient with anaplastic ganglioglioma harboring BRAF V600E progressed after initial response to Tafinlar (dabrafenib) treatment, and was found to have acquired a BRAF L514V in cis with BRAF V600E, which conferred dabrafenib resistance in culture (PMID: 29880583).",
            "molecularProfile": {
                "id": 30813,
                "profileName": "BRAF L514V BRAF V600E"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 5078,
                "name": "ganglioglioma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 12771,
                    "pubMedId": 29880583,
                    "title": "A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29880583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15194,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SCH772984 resulted in similar inhibition of Erk phosphorylation and colony formation in melanoma cells expressing BRAF L514V in cis with V600E and cells expressing BRAF V600E alone in culture (PMID: 29880583).",
            "molecularProfile": {
                "id": 30813,
                "profileName": "BRAF L514V BRAF V600E"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 12771,
                    "pubMedId": 29880583,
                    "title": "A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29880583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15195,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells expressing BRAF L514V in cis with V600E demonstrated decreased response to Mekinist (trametinib)-induced inhibition of Erk phosphorylation and colony formation compared to cells expressing BRAF V600E in culture (PMID: 29880583).",
            "molecularProfile": {
                "id": 30813,
                "profileName": "BRAF L514V BRAF V600E"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 12771,
                    "pubMedId": 29880583,
                    "title": "A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29880583"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15192,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGB3245 resulted in similar inhibition of Erk phosphorylation and colony formation in melanoma cells expressing BRAF L514V in cis with V600E and cells expressing BRAF V600E alone in culture (PMID: 29880583).",
            "molecularProfile": {
                "id": 30813,
                "profileName": "BRAF L514V BRAF V600E"
            },
            "therapy": {
                "id": 7465,
                "therapyName": "BGB3245",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 12771,
                    "pubMedId": 29880583,
                    "title": "A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29880583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15191,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells expressing BRAF L514V in cis with V600E demonstrated decreased response to TAK-632-induced inhibition of Erk phosphorylation and colony formation compared to cells expressing BRAF V600E in culture (PMID: 29880583).",
            "molecularProfile": {
                "id": 30813,
                "profileName": "BRAF L514V BRAF V600E"
            },
            "therapy": {
                "id": 3300,
                "therapyName": "TAK-632",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 12771,
                    "pubMedId": 29880583,
                    "title": "A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29880583"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 505,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring the MAP2K1 Q56P mutation in the presence of BRAF V600E were resistant to the B-RAF inhibitor PLX4720 in culture (PMID: 19915144).",
            "molecularProfile": {
                "id": 520,
                "profileName": "MAP2K1 Q56P BRAF V600E"
            },
            "therapy": {
                "id": 1060,
                "therapyName": "PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 134,
                    "pubMedId": 19915144,
                    "title": "MEK1 mutations confer resistance to MEK and B-RAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19915144"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 183,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring the MAP2K1 Q56P mutation in the presence of BRAF V600E were resistant to the MEK inhibitor, selumetinib (AZD6244), in cell culture (PMID: 19915144).",
            "molecularProfile": {
                "id": 520,
                "profileName": "MAP2K1 Q56P BRAF V600E"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 134,
                    "pubMedId": 19915144,
                    "title": "MEK1 mutations confer resistance to MEK and B-RAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19915144"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 506,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combined treatment with selumetinib and PLX4720 strongly suppressed the emergence of resistant MAP2K1 mutations in BRAF V600E cells in culture (PMID: 19915144).",
            "molecularProfile": {
                "id": 520,
                "profileName": "MAP2K1 Q56P BRAF V600E"
            },
            "therapy": {
                "id": 1061,
                "therapyName": "PLX4720 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 134,
                    "pubMedId": 19915144,
                    "title": "MEK1 mutations confer resistance to MEK and B-RAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19915144"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12153,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zelboraf (vemurafenib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 I111N  in culture (PMID: 28655712).",
            "molecularProfile": {
                "id": 28495,
                "profileName": "BRAF V600E MAP2K1 I111N"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10118,
                    "pubMedId": 28655712,
                    "title": "BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28655712"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12149,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 I111N demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).",
            "molecularProfile": {
                "id": 28495,
                "profileName": "BRAF V600E MAP2K1 I111N"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10118,
                    "pubMedId": 28655712,
                    "title": "BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28655712"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8189,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pimasertib (MSC1936369B) inhibited proliferation of colorectal cancer cells harboring BRAF V600E and PIK3CA P449T in culture (PMID: 23629727).",
            "molecularProfile": {
                "id": 19841,
                "profileName": "BRAF V600E PIK3CA P449T"
            },
            "therapy": {
                "id": 871,
                "therapyName": "Pimasertib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 337,
                    "pubMedId": 23629727,
                    "title": "Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23629727"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4940,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human colorectal cancer cells harboring BRAF V600E and PIK3CA P449T were resistant to Stivarga (regorafenib) in culture (PMID: 25838391).",
            "molecularProfile": {
                "id": 19841,
                "profileName": "BRAF V600E PIK3CA P449T"
            },
            "therapy": {
                "id": 890,
                "therapyName": "Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4805,
                    "pubMedId": 25838391,
                    "title": "Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25838391"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8199,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E and PIK3CA P449T in culture (PMID: 23629727).",
            "molecularProfile": {
                "id": 19841,
                "profileName": "BRAF V600E PIK3CA P449T"
            },
            "therapy": {
                "id": 1659,
                "therapyName": "Pimasertib + Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 337,
                    "pubMedId": 23629727,
                    "title": "Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23629727"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8194,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E and PIK3CA P449T in culture (PMID: 23629727).",
            "molecularProfile": {
                "id": 19841,
                "profileName": "BRAF V600E PIK3CA P449T"
            },
            "therapy": {
                "id": 4656,
                "therapyName": "Everolimus + Pimasertib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 337,
                    "pubMedId": 23629727,
                    "title": "Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23629727"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8204,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E and PIK3CA P449T in culture (PMID: 23629727).",
            "molecularProfile": {
                "id": 19841,
                "profileName": "BRAF V600E PIK3CA P449T"
            },
            "therapy": {
                "id": 4657,
                "therapyName": "Pimasertib + Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 337,
                    "pubMedId": 23629727,
                    "title": "Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23629727"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4950,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Erbitux (cetuximab) and Stivarga (regorafenib) inhibited growth, reduced Akt and Mapk phosphorylation, and induced apoptosis of human colorectal cancer cell lines harboring BRAF V600E and PIK3CA P449T in culture (PMID: 25838391).",
            "molecularProfile": {
                "id": 19841,
                "profileName": "BRAF V600E PIK3CA P449T"
            },
            "therapy": {
                "id": 1305,
                "therapyName": "Cetuximab + Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4805,
                    "pubMedId": 25838391,
                    "title": "Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25838391"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4936,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human colorectal cancer cells harboring BRAF V600E and PIK3CA P449T were resistant to Erbitux (cetuximab) in culture (PMID: 25838391).",
            "molecularProfile": {
                "id": 19841,
                "profileName": "BRAF V600E PIK3CA P449T"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4805,
                    "pubMedId": 25838391,
                    "title": "Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25838391"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6075,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma mouse model harboring BRAF V600E treated with Zelboraf (vemurafenib) demonstrated a greater drug induced sensitivity when treatment was combined with PLX3397, resulting in increased infiltration of lymphocytes via Csf1r inhibition and elevated antitumor activity (PMID: 25939769).",
            "molecularProfile": {
                "id": 22385,
                "profileName": "BRAF V600E CSF1R positive"
            },
            "therapy": {
                "id": 1339,
                "therapyName": "Pexidartinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5274,
                    "pubMedId": 25939769,
                    "title": "Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25939769"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12166,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BVD-523 (ulixertinib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 E203K in culture (PMID: 28655712).",
            "molecularProfile": {
                "id": 28497,
                "profileName": "BRAF V600E MAP2K1 E203K"
            },
            "therapy": {
                "id": 997,
                "therapyName": "Ulixertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10118,
                    "pubMedId": 28655712,
                    "title": "BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28655712"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12161,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 E203K demonstrated resistance to treatment with Zelboraf (vemurafenib) in culture (PMID: 28655712).",
            "molecularProfile": {
                "id": 28497,
                "profileName": "BRAF V600E MAP2K1 E203K"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10118,
                    "pubMedId": 28655712,
                    "title": "BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28655712"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12160,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 E203K demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).",
            "molecularProfile": {
                "id": 28497,
                "profileName": "BRAF V600E MAP2K1 E203K"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10118,
                    "pubMedId": 28655712,
                    "title": "BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28655712"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16631,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, emergence of MET amplification was detected in colorectal cancer cells harboring BRAF V600E that acquired resistance to Alpelisib (BYL719), Erbitux (cetuximab), and Braftovi (encorafenib) combination treatment in culture (PMID: 27325282).",
            "molecularProfile": {
                "id": 31714,
                "profileName": "BRAF V600E MET amp"
            },
            "therapy": {
                "id": 1917,
                "therapyName": "Alpelisib + Cetuximab + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 6560,
                    "pubMedId": 27325282,
                    "title": "MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27325282"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8152,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with microsatellite-stable mucinous rectal cancer harboring BRAF V600E and acquired MET amplification responded to the combination treatment of Xalkori (crizotinib) and Zelboraf (vemurafenib), resulting in a rapid clinical and metabolic response (PMID: 27325282).",
            "molecularProfile": {
                "id": 31714,
                "profileName": "BRAF V600E MET amp"
            },
            "therapy": {
                "id": 4648,
                "therapyName": "Crizotinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3709,
                "name": "rectum mucinous adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6560,
                    "pubMedId": 27325282,
                    "title": "MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27325282"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8153,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with microsatellite-stable mucinous rectal cancer harboring BRAF V600E eventually developed resistance to Vectibix (panitumumab) and Zelboraf (vemurafenib) combination therapy, potentially due to acquiring amplification of MET (PMID: 27325282).",
            "molecularProfile": {
                "id": 31714,
                "profileName": "BRAF V600E MET amp"
            },
            "therapy": {
                "id": 1717,
                "therapyName": "Panitumumab + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3709,
                "name": "rectum mucinous adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 6560,
                    "pubMedId": 27325282,
                    "title": "MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27325282"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5966,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22037,
                "profileName": "BRAF V600E NRAS A146T MAP2K1 P387S"
            },
            "therapy": {
                "id": 763,
                "therapyName": "GSK2126458",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5950,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S were resistant to Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22037,
                "profileName": "BRAF V600E NRAS A146T MAP2K1 P387S"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5960,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S were >20-fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600E and also had reduced sensitivity in comparison to cell lines harboring BRAF V600E and NRAS A146T in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22037,
                "profileName": "BRAF V600E NRAS A146T MAP2K1 P387S"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5956,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22037,
                "profileName": "BRAF V600E NRAS A146T MAP2K1 P387S"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5992,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition in melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S in culture, compared to either agent alone (PMID: 22389471).",
            "molecularProfile": {
                "id": 22037,
                "profileName": "BRAF V600E NRAS A146T MAP2K1 P387S"
            },
            "therapy": {
                "id": 3027,
                "therapyName": "GSK2126458 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5989,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Talfinlar (dabrafenib) in combination with Omipalisib (GSK2126458) did not improve the response to human melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22037,
                "profileName": "BRAF V600E NRAS A146T MAP2K1 P387S"
            },
            "therapy": {
                "id": 4004,
                "therapyName": "Dabrafenib + GSK2126458",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1121,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, 20% (8/41) of melanoma patients with BRAF V600 mutations had a partial response to Binimetinib (MEK162) (PMID: 23414587).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 807,
                "therapyName": "Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 180,
                    "pubMedId": 23414587,
                    "title": "MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23414587"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 8548,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Ibrance (palbociclib) in a melanoma cell line xenograft model harboring BRAF V600E resulted in no benefit, demonstrating low but continuous growth (PMID: 27488531).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6683,
                    "pubMedId": 27488531,
                    "title": "An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27488531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10191,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a glioblastoma cell line harboring BRAF V600E demonstrated a decreased response to treatment with PD-0325901, demonstrating increased viability of CD133 positive cells in culture (PMID: 26573800).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 849,
                "therapyName": "PD-0325901",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 8161,
                    "pubMedId": 26573800,
                    "title": "Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26573800"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17027,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Braftovi (encorafenib), Mektovi (binimetinib), Erbitux (cetuximab), combination therapy is included in guidelines as a second-line therapy for advanced or metastatic rectum cancer patients harboring BRAF V600E (NCCN.org).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4886,
                "therapyName": "Binimetinib + Cetuximab + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1993,
                "name": "rectum cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 7861,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sprycel (dasatinib) and Mekinist (trametinib) synergistically inhibited proliferation and induced apoptosis in both parental thyroid cancer cell lines harboring BRAF V600E and those acquired Sprycel (dasatinib)-resistance in culture (PMID: 27222538).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4599,
                "therapyName": "Dasatinib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1781,
                "name": "thyroid cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6508,
                    "pubMedId": 27222538,
                    "title": "The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27222538"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8549,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination treatment of PD-0325901 and Ibrance (palbociclib) resulted in significant tumor regression in melanoma cell line xenograft models harboring BRAF V600E and demonstrated a 56% (5/9) complete response rate (PMID: 27488531).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1823,
                "therapyName": "Palbociclib + PD-0325901",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6683,
                    "pubMedId": 27488531,
                    "title": "An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27488531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10192,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a glioblastoma cell line harboring BRAF V600E demonstrated a decreased response to treatment with PLX4720, demonstrating increased viability of CD133 positive cells in culture and in xenograft models (PMID: 26573800).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1060,
                "therapyName": "PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 8161,
                    "pubMedId": 26573800,
                    "title": "Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26573800"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13020,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vectibix (panitumumab), as a monotherapy, is not indicated for use in rectum cancer patients with BRAF V600E (NCCN.org).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 1993,
                "name": "rectum cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 9947,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Erbitux (cetuximab), as a monotherapy, is not indicated for use in colon cancer patients with BRAF V600E (NCCN.org).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11415,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib/II trial, Encorafenib (LGX818) and Kisqali (ribociclib) combination treatment resulted in confirmed partial response in 7.1% (2/28), unconfirmed partial response in 10.7% (3/28), and stable disease in 35.7% (10/28) of patients with melanoma harboring BRAF V600E (PMID: 28351928).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1260,
                "therapyName": "Encorafenib + Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9298,
                    "pubMedId": 28351928,
                    "title": "Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28351928"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7649,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination therapy consisting of Tafinlar (dabrafenib) and Mekinist (trametinib) inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12269,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (coBRIM) that supported FDA approval, treatment with the combination of Zelboraf (vemurafenib) and Cotellic (cobimetinib) resulted in an improved progression-free survival of 12.3 months, compared to 7.2 months with Zelboraf (vemurafenib) plus placebo, among patients with BRAF V600-mutated metastatic melanoma, and BRAF V600E and BRAF V600K are on the companion diagnostic (PMID: 27480103; NCT01689519).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1657,
                "therapyName": "Cobimetinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10226,
                    "pubMedId": 27480103,
                    "title": "Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27480103"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15453,
                    "pubMedId": null,
                    "title": "Cotellic (cobimetinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=206192"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17034,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Zelboraf (vemurafenib) and Cotellic (cobimetinib) combination therapy is included in melanoma guidelines for patients with metastatic or unresectable disease harboring a BRAF V600 activating mutation (NCCN.org).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1657,
                "therapyName": "Cobimetinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 10250,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited growth of transformed cells over expressing BRAF V600E in culture, while single agent inhibition had no effect (PMID: 26140595).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 5443,
                "therapyName": "PF-00477736 + PF3644022",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8232,
                    "pubMedId": 26140595,
                    "title": "A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26140595"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7944,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAK-632 inhibited proliferation of thyroid cancer cells harboring BRAF V600E in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3300,
                "therapyName": "TAK-632",
                "synonyms": null
            },
            "indication": {
                "id": 1781,
                "name": "thyroid cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15737,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, patients with melanoma harboring BRAF V600E (n=84) had decreased response rates (29% vs. 53%, p=0.059), progression-free survival (2.7 vs. 19 months, p=0.049), and overall survival  (11.7 vs. 20.4 months, p=0.081) relative to patients with BRAF V600K (n=19) when treated with Keytruda (pembrolizumab) (n=62 and 17 for BRAF V600E and V600K, respectively) or Opdivo (nivolumab) (n=22 and 2 for BRAF V600E and V600K, respectively) (PMID: 30630828).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 13705,
                    "pubMedId": 30630828,
                    "title": "Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30630828"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11939,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Cotellic (cobimetinib) and Zelboraf (vemurafenib) inhibited tumor growth in a cell line xenograft model of colorectal cancer harboring BRAF V600E (PMID: 28649441).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1657,
                "therapyName": "Cobimetinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9924,
                    "pubMedId": 28649441,
                    "title": "Clinical responses to ERK inhibition in BRAF(V600E)-mutant colorectal cancer predicted using a computational model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28649441"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12170,
            "approvalStatus": "Guideline",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "BRAF V600E is diagnostic and aids distinguishing classic hairy cell leukemia (HCL-C) from variant hairy cell leukemia (HCL-V) and other B-cell lymphomas and leukemias (PMID: 29118233).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 285,
                "name": "hairy cell leukemia",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10462,
                    "pubMedId": 29118233,
                    "title": "Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29118233"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13022,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Zelboraf (vemurafenib), Vectibix (panitumumab), and Irinotecan combination therapy is included in guidelines for advanced or metastatic rectum cancer patients harboring BRAF V600E (NCCN.org).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 6709,
                "therapyName": "Irinotecan + Panitumumab + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1993,
                "name": "rectum cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6673,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DETD-35 inhibited proliferation and colony formation of melanoma cells harboring BRAF V600E in culture and reduced tumor size in xenograft models (PMID: 27048951).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4230,
                "therapyName": "DETD-35",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5730,
                    "pubMedId": 27048951,
                    "title": "A Novel Plant Sesquiterpene Lactone Derivative, DETD-35, Suppresses BRAFV600E Mutant Melanoma Growth and Overcomes Acquired Vemurafenib Resistance in Mice.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27048951"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7874,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GDC0879 inhibited survival of colon cancer cell lines harboring BRAF V600E in cell culture and cell line xenograft models (PMID: 19276360).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1095,
                "therapyName": "GDC0879",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6516,
                    "pubMedId": 19276360,
                    "title": "Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19276360"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 503,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PLX4720 inhibited growth of melanoma cells harboring BRAF V600E in culture and in cell line xenograft models (PMID: 18287029).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1060,
                "therapyName": "PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 291,
                    "pubMedId": 18287029,
                    "title": "Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18287029"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6680,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Mekinist (trametinib) and Tafinlar (dabrafenib) combination treatment resulted in a rapid and sustained clinical response in a patient with a rectal neuroendocrine tumor harboring a BRAF V600E mutation (PMID: 27048246).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 169,
                "name": "neuroendocrine tumor",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5733,
                    "pubMedId": 27048246,
                    "title": "BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27048246"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3341,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, S3I-201 inhibited cell invasion and Stat3 signaling in human melanoma cell lines harboring BRAF V600E that are resistant to Braf inhibition in culture (PMID: 23242808).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3124,
                "therapyName": "S3I-201",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3755,
                    "pubMedId": 23242808,
                    "title": "Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23242808"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15903,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial (VE-BASKET), treatment of patients with gliomas harboring BRAF V600E mutations with Zelboraf (vemurafenib) resulted in a 25% (6/24) objective response rate, 5.5-month median progression free survival, 28.2 month median overall survival, and best overall response rates of 4.2% (1/24) for complete response, 20.8% (5/24) for partial response, and 41.7% (10/24) for stable disease (PMID: 30351999; NCT01524978).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3070,
                "name": "malignant glioma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13949,
                    "pubMedId": 30351999,
                    "title": "BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30351999"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11929,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of PLX4720 and Erbitux (cetuximab) inhibited tumor growth in colorectal cancer cell line xenograft models harboring BRAF V600E (PMID: 22281684).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 6208,
                "therapyName": "Cetuximab + PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9911,
                    "pubMedId": 22281684,
                    "title": "Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22281684"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3130,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gedatolisib (PKI-587) inhibited Braf V600E in vitro and inhibited growth of human colon cancer cells harboring BRAF V600E in culture (PMID: 21325073, PMID: 24042735).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1040,
                "therapyName": "Gedatolisib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 220,
                    "pubMedId": 21325073,
                    "title": "Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21325073"
                },
                {
                    "id": 3639,
                    "pubMedId": 24042735,
                    "title": "Epigenetic and genetic features of 24 colon cancer cell lines.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24042735"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13890,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, combination therapy consisting of Vectibix (panitumumab) and Mekinist (trametinib) resulted in an overall response rate of 0% (0/31), stable disease in 55% (17/31), and a median progression-free survival of 2.6 months in patients with BRAF V600E colorectal cancer (PMID: 29431699; NCT01750918).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1991,
                "therapyName": "Panitumumab + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 11333,
                    "pubMedId": 29431699,
                    "title": "Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29431699"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12057,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, INU-152 reduced MEK and ERK phosphorylation and growth of a melanona cell line harboring BRAF V600E in culture, and inhibited tumor growth in xenograft models (PMID: 28645859).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 6241,
                "therapyName": "INU-152",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9993,
                    "pubMedId": 28645859,
                    "title": "Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAF(V600E) mutant cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28645859"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3307,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CCT241161 inhibited growth of a human melanoma cell line harboring BRAF V600E in culture, and induced tumor regression in several BRAF V600E-mutant melanoma patient-derived xenograft models (PMID: 25500121).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3106,
                "therapyName": "CCT241161",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3714,
                    "pubMedId": 25500121,
                    "title": "Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25500121"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9108,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Afinitor (everolimus) and PLX4720 synergistically inhibited growth and induced apoptosis in glioma cell lines in culture (PMID: 27217440).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4902,
                "therapyName": "Everolimus + PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 3070,
                "name": "malignant glioma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6921,
                    "pubMedId": 27217440,
                    "title": "BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27217440"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5777,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PD-0325901 inhibited growth of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 26267534).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 849,
                "therapyName": "PD-0325901",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4897,
                    "pubMedId": 26267534,
                    "title": "Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26267534"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 509,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II study, Nexavar (sorafenib) displayed negligible efficacy in melanoma patients with BRAF V600E mutations (PMID: 16880785, PMID: 22394203).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 294,
                    "pubMedId": 22394203,
                    "title": "Sorafenib in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22394203"
                },
                {
                    "id": 3156,
                    "pubMedId": 16880785,
                    "title": "Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16880785"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1324,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Zelboraf (vemurafenib) and Iressa (gefitinib) decreased the number of viable colorectal cancer cells harboring a BRAF V600E mutation in cell culture (PMID: 22448344).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1709,
                "therapyName": "Gefitinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1032,
                    "pubMedId": 22448344,
                    "title": "EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22448344"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3784,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SBI-0640756 inhibited proliferation and Akt/mTOR signaling in human melanoma cell lines harboring BRAF V600E in culture (PMID: 26603897, PMID: 20531415).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3306,
                "therapyName": "SBI-0640756",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4137,
                    "pubMedId": 26603897,
                    "title": "SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603897"
                },
                {
                    "id": 4139,
                    "pubMedId": 20531415,
                    "title": "Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20531415"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 706,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, 33% (26/78) of previously treated non-small cell lung carcinoma patients harboring BRAF V600E demonstrated an overall response, which included all partial responses, when treated with Tafinlar (dabrafenib) while 67% (4/6) receiving Tafinlar (dabrafenib) as a first-line treatment achieved partial responses (PMID: 27080216; NCT01336634).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6410,
                    "pubMedId": 27080216,
                    "title": "Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27080216"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12982,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Tafinlar (dabrafenib) is in guidelines for metastatic non-small cell lung cancer patients with BRAF V600E mutations who can not tolerate the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) (NCCN.org).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 306,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In preclinical studies, CEP-32496 (RXDX-105) reduced tumor volume and promoted tumor regression in xenograft models of a BRAF V600E mutant human melanoma cell line (PMID: 22319199).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1002,
                "therapyName": "RXDX-105",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 203,
                    "pubMedId": 22319199,
                    "title": "CEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22319199"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4533,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TW-37 enhanced the inhibitory effect of Zelboraf (vemurafenib) on human melanoma cells harboring BRAF V600E in culture (PMID: 25665005).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3531,
                "therapyName": "TW-37 + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4582,
                    "pubMedId": 25665005,
                    "title": "The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25665005"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11041,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma xenograft model harboring BRAF V600E demonstrated tumor regression when treated with ASN003 (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B100).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 5827,
                "therapyName": "ASN003",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9035,
                    "pubMedId": null,
                    "title": "Abstract B100: ASN003, a unique B-RAF inhibitor with additional selective activity against PI3K and mTOR kinases, shows strong antitumor activity in multiple xenograft models",
                    "url": "http://mct.aacrjournals.org/content/14/12_Supplement_2/B100.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 554,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III clinical trial (BREAK-3) that supported FDA approval, Tafinlar (dabrafenib) improved median progression-free survival compared to Deticene (dacarbazine) (5.1 vs 2.7 months, HR=0.3, p<0.0001) in patients with BRAF V600E positive melanoma (PMID: 22735384; NCT01227889).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 232,
                    "pubMedId": 22735384,
                    "title": "Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22735384"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15458,
                    "pubMedId": null,
                    "title": "Tafinlar (dabrafenib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=202806"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1507,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Tafinlar (dabrafenib) therapy is included in guidelines for melanoma patients with unresectable or metastatic disease harboring BRAF V600 activating mutations, such as BRAF V600E, in cases where BRAF/MEK inhibitor combination therapy is contraindicated (NCCN.org).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 8198,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E in culture (PMID: 23629727).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1659,
                "therapyName": "Pimasertib + Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 337,
                    "pubMedId": 23629727,
                    "title": "Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23629727"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7863,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sprycel (dasatinib) and SCH772984 synergistically inhibited proliferation and induced apoptosis in both parental thyroid cancer cell lines harboring BRAF V600E and those acquired Sprycel (dasatinib)-resistance in culture (PMID: 27222538).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4601,
                "therapyName": "Dasatinib + SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1781,
                "name": "thyroid cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6508,
                    "pubMedId": 27222538,
                    "title": "The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27222538"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5779,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SCH772984 inhibited growth of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 26267534).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4897,
                    "pubMedId": 26267534,
                    "title": "Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26267534"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5986,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tafinlar (dabrafenib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4004,
                "therapyName": "Dabrafenib + GSK2126458",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4981,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, xenograft models of melanoma harboring BRAF V600E treated with the combination of BI 882370 and Mekinist (trametinib) demonstrated tumor regression with no regrowth during the 5 weeks of treatment (PMID: 26916115).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3709,
                "therapyName": "BI 882370 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4823,
                    "pubMedId": 26916115,
                    "title": "A Novel RAF Kinase Inhibitor with DFG-Out-Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26916115"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12192,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LSN3074753 demonstrated modest efficacy in patient-derived xenograft models of colorectal cancer harboring BRAF V600E, resulted in tumor growth inhibition or regression, but relapse upon discontinuation of treatment (PMID: 28611205).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 6337,
                "therapyName": "LSN3074753",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10143,
                    "pubMedId": 28611205,
                    "title": "Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28611205"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1849,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, 83% (10/12) of patients with colorectal cancer carrying a BRAF V600E mutation demonstrated tumor regression when treated with a combination of Zelboraf (vemurafenib) and Vectibix (panitumumab) (PMID: 25589621).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1717,
                "therapyName": "Panitumumab + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2277,
                    "pubMedId": 25589621,
                    "title": "Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25589621"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1341,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Encorafenib (LGX818) showed activity in patients with advanced metastatic colorectal cancer harboring a BRAF V600E mutation, resulting in a median progression-free survival of 4 months and a best response of stable disease in 66.7% (12/18) (Ann Oncol (2014) 25 (suppl 4): iv182-iv183).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 796,
                "therapyName": "Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1050,
                    "pubMedId": null,
                    "title": "53P Encorafenib (LGX818), an oral BRAF inhibitor, in patients (PTS) WITH BRAF V600E metastatic colorectal cancer (MCRC): results of dose expansion in an open-label, phase I study.",
                    "url": null
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 692,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sprycel (dasatinib) failed to induce apoptosis in lung carcinoma cells expressing BRAF V600E (PMID: 22649091).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3905,
                "name": "lung carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 423,
                    "pubMedId": 22649091,
                    "title": "Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22649091"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14003,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Mekinist (trametinib) and Tafinlar (dabrafenib) combination treatment resulted in clinical benefit that lasted for more than 14 months in a patient with pleomorphic xanthoastrocytoma harboring BRAF V600E (PMID: 29632053).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 4852,
                "name": "pleomorphic xanthoastrocytoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11407,
                    "pubMedId": 29632053,
                    "title": "Concurrent BRAF/MEK Inhibitors in BRAF V600-Mutant High-Grade Primary Brain Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29632053"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17520,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Zelboraf (vemurafenib) treatment resulted in tumor regression as confirmed by MRI after 3-weeks of treatment in a patient with epithelioid glioblastoma harboring BRAF V600E (PMID: 31217909).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15565,
                    "pubMedId": 31217909,
                    "title": "Regression of BRAFV600E mutant adult glioblastoma after primary combined BRAF-MEK inhibitor targeted therapy: a report of two cases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31217909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11710,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Tafinlar (dabrafenib) treatment resulted in a near complete response and resolution of leptomeningeal dissemination in a patient with pilocytic astrocytoma harboring BRAF V600E (PMID: 28784858).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 4851,
                "name": "pilocytic astrocytoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9723,
                    "pubMedId": 28784858,
                    "title": "Targeted MAPK Pathway Inhibitors in Patients With Disseminated Pilocytic Astrocytomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28784858"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12292,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of Tafinlar (dabrafenib), SCH772984, and Mekinist (trametinib) resulted in durable inhibition of Erk signaling and proliferation of melanoma cells overexpressing BRAF V600E in culture (PMID: 28714990).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 6430,
                "therapyName": "Dabrafenib + SCH772984 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 10283,
                    "pubMedId": 28714990,
                    "title": "An approach to suppress the evolution of resistance in BRAF(V600E)-mutant cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28714990"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8193,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E in culture (PMID: 23629727).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4656,
                "therapyName": "Everolimus + Pimasertib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 337,
                    "pubMedId": 23629727,
                    "title": "Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23629727"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3310,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CCT196969 inhibited growth of BRAF-mutant colorectal cancer cell lines in culture (PMID: 25500121), which have been reported to harbor BRAF V600E (PMID: 15294323).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3105,
                "therapyName": "CCT196969",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3714,
                    "pubMedId": 25500121,
                    "title": "Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25500121"
                },
                {
                    "id": 3729,
                    "pubMedId": 15294323,
                    "title": "Real-time allele-specific amplification for sensitive detection of the BRAF mutation V600E.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15294323"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7650,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4541,
                "therapyName": "Cetuximab + Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3335,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sprycel (dasatinib) inhibited cell invasion, cell signaling, and proliferation in human melanoma cell lines harboring BRAF V600E that are resistant to Braf inhibition in culture and in animal models (PMID: 23242808).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3755,
                    "pubMedId": 23242808,
                    "title": "Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23242808"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9106,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) and Afinitor (everolimus) synergistically inhibited growth and induced apoptosis in glioma cell lines in culture, resulted in prolonged survival in cell line xenograft models (PMID: 27217440).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4901,
                "therapyName": "Everolimus + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3070,
                "name": "malignant glioma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6921,
                    "pubMedId": 27217440,
                    "title": "BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27217440"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5564,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DEL-22379 inhibited growth of melanoma cells harboring BRAF V600E with high levels of ERK dimerization in culture and inhibited tumor progression in melanoma xenograft models harboring BRAF V600E (PMID: 26267534).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3769,
                "therapyName": "DEL-22379",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4897,
                    "pubMedId": 26267534,
                    "title": "Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26267534"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14004,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, an epithelioid glioblastoma patient harboring BRAF V600E treated with Mekinist (trametinib) and Tafinlar (dabrafenib) combination therapy resulted in stable disease, and the patient continued to demonstrate stable disease at least 16 months after initiation of therapy (PMID: 29632053).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11407,
                    "pubMedId": 29632053,
                    "title": "Concurrent BRAF/MEK Inhibitors in BRAF V600-Mutant High-Grade Primary Brain Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29632053"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17519,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Mekinist (trametinib) and Tafinlar (dabrafenib) combination treatment resulted in significant clinical improvement in a patient with epithelioid glioblastoma harboring BRAF V600E, however, her disease progressed after 3 months of therapy (PMID: 31217909).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15565,
                    "pubMedId": 31217909,
                    "title": "Regression of BRAFV600E mutant adult glioblastoma after primary combined BRAF-MEK inhibitor targeted therapy: a report of two cases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31217909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7838,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) inhibited growth of both parental thyroid cancer cell lines harboring BRAF V600E and those acquired Sprycel (dasatinib)-resistance in culture (PMID: 27222538).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1781,
                "name": "thyroid cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6508,
                    "pubMedId": 27222538,
                    "title": "The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27222538"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4526,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Navitoclax (ABT-263) enhanced the inhibitory effect of Zelboraf (vemurafenib) on human melanoma cells harboring BRAF V600E in culture (PMID: 25665005).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3530,
                "therapyName": "Navitoclax + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4582,
                    "pubMedId": 25665005,
                    "title": "The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25665005"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4527,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Navitoclax (ABT-263) enhanced the inhibitory effect of Mekinist (trametinib) on human non-small cell lung cancer cells harboring BRAF V600E in culture (PMID: 25665005).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1386,
                "therapyName": "Navitoclax + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4582,
                    "pubMedId": 25665005,
                    "title": "The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25665005"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7648,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Encorafenib (LGX818) and Alpelisib (BYL719) inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1917,
                "therapyName": "Alpelisib + Cetuximab + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7652,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination therapy consisting of Tafinlar (dabrafenib) and SCH772984 inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4544,
                "therapyName": "Dabrafenib + SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6844,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CI-1040 (PD184352) inhibited Erk phosphorylation and growth of transformed cells expressing BRAF V600E in culture (PMID: 20538618).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 699,
                "therapyName": "CI-1040",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5859,
                    "pubMedId": 20538618,
                    "title": "Gatekeeper mutations mediate resistance to BRAF-targeted therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20538618"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7936,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAK-632 inhibited proliferation of melanoma cell lines harboring either monomeric BRAF V600E or dimeric isoform of V600E which conferred Zelboraf (vemurafenib)-resistance in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3300,
                "therapyName": "TAK-632",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 705,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a non-small cell lung cancer patient harboring a BRAF V600E mutation had a complete response after treatment with Zelboraf (vemurafenib) (PMID: 23733758).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1011,
                    "pubMedId": 23733758,
                    "title": "Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23733758"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16104,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (MyPathway), Zelboraf (vemurafenib) treatment resulted in an objective response of 43% (6/14, 1 complete response, 5 partial response) in patients with non-small cell lung cancer harboring BRAF V600E, and stable disease lasting more than 120 days in 2 patients (PMID: 29320312; NCT02091141).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13171,
                    "pubMedId": 29320312,
                    "title": "Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29320312"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12983,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Zelboraf (vemurafenib) is in guidelines for metastatic non-small cell lung cancer patients with BRAF V600E mutations who can not tolerate the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) (NCCN.org).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 2614,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PLX4720 and navitoclax (ABT-263) worked synergistically to inhibit growth and increase apoptosis of BRAF V600E mutant melanoma cells in culture and in xenografts (PMID: 24983357).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 2960,
                "therapyName": "Navitoclax + PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3334,
                    "pubMedId": 24983357,
                    "title": "Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24983357"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4529,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Navitoclax (ABT-263) enhanced the inhibitory effect of Mekinist (trametinib) on human melanoma cells harboring BRAF V600E in culture (PMID: 25665005).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1386,
                "therapyName": "Navitoclax + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4582,
                    "pubMedId": 25665005,
                    "title": "The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25665005"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1131,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, a favorable response rate to selumetinib (AZD6244) was observed in mutant BRAF but not BRAF wild-type melanoma patients (PMID: 22048237).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 228,
                    "pubMedId": 22048237,
                    "title": "Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22048237"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6180,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DT01 increased sensitivity of human colorectal cancer (CRC) cells harboring BRAF V600E to Eloxatin (oxaliplatin) and Adrucil (5-fluorouracil), and the combination resulted in decreased liver tumor growth in CRC cell line xenograft metastasis models (PMID: 26637369).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4083,
                "therapyName": "DT01 + Fluorouracil + Oxaliplatin",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5384,
                    "pubMedId": 26637369,
                    "title": "The DNA Repair Inhibitor DT01 as a Novel Therapeutic Strategy for Chemosensitization of Colorectal Liver Metastasis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26637369"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12981,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Combination of Mekinist (trametinib) and Tafinlar (dabrafenib) is in guidelines for metastatic non-small cell lung cancer patients with BRAF V600E mutations (NCCN.org).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11287,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial that supported FDA approval, treatment with the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) in patients with non-small cell lung cancer harboring BRAF V600E resulted in an overall response rate of 66.7% (38/57) in previously treated patients and 64% (23/36) in untreated patients, versus 33% (26/78) treated with Tafinlar (dabrafenib) alone (PMID: 27080216, PMID: 27283860, PMID: 28919011; NCT01336634).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6410,
                    "pubMedId": 27080216,
                    "title": "Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27080216"
                },
                {
                    "id": 9207,
                    "pubMedId": null,
                    "title": "Updated survival of patients (pts) with previously treated BRAF V600E\u2013mutant advanced non-small cell lung cancer (NSCLC) who received dabrafenib (D) or D + trametinib (T) in the phase II BRF113928 study.",
                    "url": "http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.9075"
                },
                {
                    "id": 10772,
                    "pubMedId": 27283860,
                    "title": "Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27283860"
                },
                {
                    "id": 10773,
                    "pubMedId": 28919011,
                    "title": "Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28919011"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15458,
                    "pubMedId": null,
                    "title": "Tafinlar (dabrafenib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=202806"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 15706,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ulixertinib (BVD-523) inhibited Erk signaling in colorectal cancer cells harboring BRAF V600E, resulted in cell cycle arrest in culture and tumor growth inhibition in cell line xenograft models (PMID: 28939558).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 997,
                "therapyName": "Ulixertinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11466,
                    "pubMedId": 28939558,
                    "title": "Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28939558"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6437,
            "approvalStatus": "Phase III",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In a post-hoc analysis of a Phase III trial, BRAF V600E mutations in colon adenocarcinoma patients with microsatellite stable tumors were associated with a shorter disease-free survival and overall survival compared to those patients with microsatellite instability tumors, suggesting that BRAF V600E may serve as a future prognostic biomarker in this patient population (PMID: 26768652).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 234,
                "name": "colon adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5600,
                    "pubMedId": 26768652,
                    "title": "Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab: A Post Hoc Analysis of the PETACC-8 Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26768652"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1312,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Stivarga (regorafenib) inhibited proliferation of colorectal cancer cells harboring BRAF V600E in culture and suppressed angiogenesis and tumor growth in cell line xenograft models (PMID: 21170960).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 890,
                "therapyName": "Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 318,
                    "pubMedId": 21170960,
                    "title": "Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21170960"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1320,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cell lines harboring a BRAF V600E mutation were sensitive to Nexavar (sorafenib) in culture (PMID: 24885690).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1028,
                    "pubMedId": 24885690,
                    "title": "Genetic targeting of B-RafV600E affects survival and proliferation and identifies selective agents against BRAF-mutant colorectal cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24885690"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7646,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and Encorafenib (LGX818) inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1916,
                "therapyName": "Cetuximab + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16194,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In Phase II trial, Mektovi (binimetinib) therapy in a patient with recurrent neuroendocrine carcinoma of the colon harboring a BRAF V600E mutation who had previously progressed on Tafinlar (dabrafinib) resulted in disease progression after two cycles (PMID: 30181415; NCT01885195).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 807,
                "therapyName": "Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 4118,
                "name": "colon neuroendocrine neoplasm",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 14304,
                    "pubMedId": 30181415,
                    "title": "Targeting BRAF Mutations in High-Grade Neuroendocrine Carcinoma of the Colon.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30181415"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4985,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E were sensitive to the combination of BI 882370 and Gilotrif (afatinib) in xenograft models, resulting in tumor growth inhibition and partial tumor regression (PMID: 26916115).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3712,
                "therapyName": "Afatinib + BI 882370",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4823,
                    "pubMedId": 26916115,
                    "title": "A Novel RAF Kinase Inhibitor with DFG-Out-Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26916115"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4028,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, E6201 inhibited Mapk pathway activation and proliferation of melanoma cell lines harboring BRAF V600E mutation in culture (PMID: 24448821).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1011,
                "therapyName": "E6201",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4380,
                    "pubMedId": 24448821,
                    "title": "Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation in a preclinical model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24448821"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2528,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) decreased tumor growth in a cell line xenograft model of colorectal cancer harboring BRAF V600E (PMID: 23942066).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3253,
                    "pubMedId": 23942066,
                    "title": "Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23942066"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7872,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of PAC-1 to Mekinist (trametinib) and Zelboraf (vemurafenib) led to greater levels of caspase-3 activity and apoptosis in melanoma cells harboring BRAF V600E when compared to Zelboraf (vemurafenib) and Mekinist (trametinib) treatment without PAC-1 (PMID: 27297867).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4603,
                "therapyName": "PAC-1 + Trametinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6518,
                    "pubMedId": 27297867,
                    "title": "The Combination of Vemurafenib and Procaspase-3 Activation Is Synergistic in Mutant BRAF Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27297867"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15174,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Tafinlar (dabrafenib) treatment resulted in partial response 8 weeks after therapy initiation in a pediatric patient with anaplastic ganglioglioma harboring BRAF V600E, but disease progression occurred at 40 weeks due to acquired resistance (PMID: 29880583).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 5078,
                "name": "ganglioglioma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 12771,
                    "pubMedId": 29880583,
                    "title": "A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29880583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9663,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of PLX4720 and Zolinza (vorinostat) resulted in antitumor efficacy in a melanoma cell line harboring BRAF V600E, demonstrating decreased cell survival and increased apoptotic activity in xenograft models, and decreased Rb phosphorylation in culture (PMID: 27924459).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 5121,
                "therapyName": "PLX4720 + Vorinostat",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7369,
                    "pubMedId": 27924459,
                    "title": "Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27924459"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10196,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of BI 2536 and PLX4720 resulted in suppression of downstream signaling, increased apoptotic activity, inhibition of cell proliferation, and tumor growth suppression in glioblastoma cell line xenograft models harboring BRAF V600E (PMID: 26573800).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 5422,
                "therapyName": "BI2536 + PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8161,
                    "pubMedId": 26573800,
                    "title": "Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26573800"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4525,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Navitoclax (ABT-263) enhanced the inhibitory effect of Zelboraf (vemurafenib) on human colon cancer cells harboring BRAF V600E in culture (PMID: 25665005).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3530,
                "therapyName": "Navitoclax + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4582,
                    "pubMedId": 25665005,
                    "title": "The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25665005"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 686,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In preclinical studies, Encorafenib (LGX818) treatment of human melanoma xenograft models with BRAF V600E significantly decreased Mek activation and resulted in tumor regression (Cancer Res: 72(8) Suppl 1, Abstract #3790).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 796,
                "therapyName": "Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 417,
                    "pubMedId": null,
                    "title": "Abstract 3790: Preclinical profile of LGX818: A potent and selective RAF kinase inhibitor",
                    "url": "http://cancerres.aacrjournals.org/cgi/content/short/72/8_MeetingAbstracts/3790"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3334,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iressa (gefitinib) in combination with PLX4720 inhibited proliferation and tumorigenicity in human melanoma cell line harboring BRAF V600E and resistant to Braf inhibition in culture and in animal models (PMID: 23242808).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3131,
                "therapyName": "Gefitinib + PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3755,
                    "pubMedId": 23242808,
                    "title": "Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23242808"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7653,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and SCH772984 inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4542,
                "therapyName": "Cetuximab + Dabrafenib + SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13889,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, combination therapy consisting of Tafinlar (dabrafenib), Vectibix (panitumumab), and Mekinist (trametinib) resulted in an overall response rate of 21% (19/91, 1 complete response, 18 partial response), stable disease in 65% (59/91), and a median progression-free survival of 4.2 months in patients with BRAF V600E colorectal cancer (PMID: 29431699; NCT01750918).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1992,
                "therapyName": "Dabrafenib + Panitumumab + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11333,
                    "pubMedId": 29431699,
                    "title": "Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29431699"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7856,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) inhibited growth of both parental thyroid cancer cell lines harboring BRAF V600E and those acquired Sprycel (dasatinib)-resistance in culture (PMID: 27222538).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1781,
                "name": "thyroid cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6508,
                    "pubMedId": 27222538,
                    "title": "The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27222538"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6589,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY3009120 inhibited growth, downstream MAPK signaling and soft agar growth in human melanoma cell lines harboring BRAF V600E in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3268,
                "therapyName": "LY3009120",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8547,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma cell line xenograft model harboring BRAF V600E treated with PD-0325901 demonstrated stable tumor growth, but by day 44, growth ensued and thus, demonstrated no benefit (PMID: 27488531).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 849,
                "therapyName": "PD-0325901",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 6683,
                    "pubMedId": 27488531,
                    "title": "An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27488531"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5778,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PD-0325901 inhibited growth of melanoma cell lines harboring BRAF V600E in culture (PMID: 26267534).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 849,
                "therapyName": "PD-0325901",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 4897,
                    "pubMedId": 26267534,
                    "title": "Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26267534"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9182,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RO5126766 inhibited Mek signaling and increased radioiodide uptake and response in transgenic animal models of papillary thyroid carcinoma driven by BRAF V600E (PMID: 27669459).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 2011,
                "therapyName": "RO5126766",
                "synonyms": null
            },
            "indication": {
                "id": 3969,
                "name": "papillary thyroid carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6994,
                    "pubMedId": 27669459,
                    "title": "Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27669459"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11927,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cell lines were not sensitive to growth inhibition by Zelboraf (vemurafenib) in culture or xenograft models, due to feedback activation of EGFR signaling (PMID: 22281684).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 9911,
                    "pubMedId": 22281684,
                    "title": "Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22281684"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9421,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Zelboraf (vemurafenib) did not demonstrate meaningful clinical activity as a single agent, resulted in partial response in 5% (1/21) and stable disease in 33% (7/21) of patients with metastatic colorectal cancer harboring BRAF V600E (PMID: 26460303; NCT00405587).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 7183,
                    "pubMedId": 26460303,
                    "title": "Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26460303"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 7615,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cell lines harboring BRAF V600E demonstrated decreased response to Zelboraf (vemurafenib) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8711,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case report, Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment resulted in a clinical and radiologic response that lasted for 9 months in an anaplastic thyroid cancer patient harboring BRAF V600E (PMID: 27697975).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 80522,
                "name": "thyroid gland anaplastic carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6714,
                    "pubMedId": 27697975,
                    "title": "Response to Targeted Therapy in BRAF Mutant Anaplastic Thyroid Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27697975"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12685,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (ROAR) that supported FDA approval, the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) resulted in an overall response rate of 69% (11/16; 1 complete response and 10 partial responses) in patients with anaplastic thyroid cancer harboring BRAF V600E (PMID: 29072975; NCT02034110).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 80522,
                "name": "thyroid gland anaplastic carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10600,
                    "pubMedId": 29072975,
                    "title": "Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29072975"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15458,
                    "pubMedId": null,
                    "title": "Tafinlar (dabrafenib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=202806"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 7946,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SB590885 inhibited proliferation of melanoma cell lines harboring either monomeric BRAF V600E or dimeric isoform of V600E which conferred Zelboraf (vemurafenib)-resistance in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4281,
                "therapyName": "SB590885",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5985,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) inhibited growth of melanoma cell lines harboring BRAF V600E in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3027,
                "therapyName": "GSK2126458 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13000,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Zelboraf (vemurafenib), Vectibix (panitumumab), and Irinotecan combination therapy is included in guidelines for advanced or metastatic colon cancer patients harboring BRAF V600E (NCCN.org).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 6709,
                "therapyName": "Irinotecan + Panitumumab + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 8056,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGB-283 inhibited Braf phosphorylation and cell proliferation in melanoma cell lines harboring BRAF V600E in culture (PMID: 26208524).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4025,
                "therapyName": "BGB-283",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5280,
                    "pubMedId": 26208524,
                    "title": "BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26208524"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7229,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, BGB-283 resulted in partial response in 1 of 2 melanoma patients harboring BRAF V600E, who remained on treatment for over 249 days (AACR Annual Meeting, Apr 2016, abstract # CT005).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4025,
                "therapyName": "BGB-283",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6230,
                    "pubMedId": null,
                    "title": "Phase I study of RAF dimer inhibitor BGB-283 in patients with B-RAF or K-RAS/N-RAS mutated solid tumors",
                    "url": "http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=dc4584a4-d39b-485a-9579-be210c4876e9&cKey=46a0776a-1444-49d6-b533-4f68e298c39d&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 307,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In preclinical studies, CEP-32496 (RXDX-105) reduced tumor volume and promoted tumor regression in xenograft models of a BRAF V600E mutant human colon carcinoma cell line (PMID: 22319199).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1002,
                "therapyName": "RXDX-105",
                "synonyms": null
            },
            "indication": {
                "id": 1520,
                "name": "colon carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 203,
                    "pubMedId": 22319199,
                    "title": "CEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22319199"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4534,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TW-37 enhanced the inhibitory effect of Zelboraf (vemurafenib) on human non-small cell lung cancer cells harboring BRAF V600E in culture (PMID: 25665005).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3531,
                "therapyName": "TW-37 + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4582,
                    "pubMedId": 25665005,
                    "title": "The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25665005"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4986,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E were sensitive to the combination of BI 882370 and Mekinist (trametinib) in xenograft models, resulting in tumor growth inhibition and partial tumor regression (PMID: 26916115).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3709,
                "therapyName": "BI 882370 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4823,
                    "pubMedId": 26916115,
                    "title": "A Novel RAF Kinase Inhibitor with DFG-Out-Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26916115"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12838,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (METRIC) that supported FDA approval, Mekinist (trametinib) treatment, as compared to Deticine (dacarbazine) or Taxol (paclitaxel) treatment, resulted in improved progression-free survival of 4.8 months versus 1.5 months and an overall six month survival rate of 81% versus 67% in patients with BRAF V600E/K-positive metastatic melanoma (PMID: 22663011; NCT01245062).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 468,
                    "pubMedId": 22663011,
                    "title": "Improved survival with MEK inhibition in BRAF-mutated melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22663011"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15457,
                    "pubMedId": null,
                    "title": "Mekinist (trametinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=204114"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 7651,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and SCH772984 inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4543,
                "therapyName": "Cetuximab + SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16980,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Braftovi (encorafenib), Mektovi (binimetinib), Vectibix (panitumumab), combination therapy is included in guidelines as a second-line therapy for advanced or metastatic colon cancer patients harboring BRAF V600E (NCCN.org).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 8361,
                "therapyName": "Binimetinib + Encorafenib + Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16105,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (MyPathway), Zelboraf (vemurafenib) treatment resulted in an objective response of 50% (2/4, 2 partial response) in patients with ovarian cancer harboring BRAF V600E, and stable disease lasting more than 120 days in 1 patient (PMID: 29320312; NCT02091141).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13171,
                    "pubMedId": 29320312,
                    "title": "Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29320312"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1321,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cell lines harboring a BRAF V600E mutation had increased sensitivity to Tafinlar (dabrafenib) in culture compared to cell lines with wild-type BRAF (PMID: 24885690).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1028,
                    "pubMedId": 24885690,
                    "title": "Genetic targeting of B-RafV600E affects survival and proliferation and identifies selective agents against BRAF-mutant colorectal cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24885690"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3311,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CCT241161 inhibited growth of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 25500121, PMID: 15294323).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3106,
                "therapyName": "CCT241161",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3714,
                    "pubMedId": 25500121,
                    "title": "Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25500121"
                },
                {
                    "id": 3729,
                    "pubMedId": 15294323,
                    "title": "Real-time allele-specific amplification for sensitive detection of the BRAF mutation V600E.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15294323"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7862,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sprycel (dasatinib) and Selumetinib (AZD6244) synergistically inhibited proliferation and induced apoptosis in both parental thyroid cancer cell lines harboring BRAF V600E and those acquired Sprycel (dasatinib)-resistance in culture (PMID: 27222538).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4600,
                "therapyName": "Dasatinib + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1781,
                "name": "thyroid cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6508,
                    "pubMedId": 27222538,
                    "title": "The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27222538"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7873,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GDC0879 inhibited survival of melanoma cell lines harboring BRAF V600E in cell culture, cell line xenograft and patient-derived xenograft (PDX) models (PMID: 19276360).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1095,
                "therapyName": "GDC0879",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6516,
                    "pubMedId": 19276360,
                    "title": "Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19276360"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12222,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EBI-907 inhibited BRAF and ERK signaling, resulted in growth inhibition of colorectal cancer cells harboring BRAF V600E in culture and in cell line xenograft models (PMID: 26810733).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 6368,
                "therapyName": "EBI-907",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10177,
                    "pubMedId": 26810733,
                    "title": "EBI-907, a novel BRAF(V600E) inhibitor, has potent oral anti-tumor activity and a broad kinase selectivity profile.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26810733"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8461,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RO4987655 inhibited proliferation of melanoma cells harboring BRAF V600E in culture (PMID: 26438159).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 903,
                "therapyName": "RO4987655",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4382,
                    "pubMedId": 26438159,
                    "title": "ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26438159"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4954,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PLX4720 and Selumetinib (AZD6244) worked synergistically to inhibit cell growth in PLX4720-resistant melanoma cell lines harboring BRAF V600E in culture (PMID: 26461489).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1061,
                "therapyName": "PLX4720 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4807,
                    "pubMedId": 26461489,
                    "title": "Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26461489"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16978,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Tafinlar (dabrafenib), Mekinist (trametinib), Erbitux (cetuximab), combination therapy is included in guidelines as a second-line therapy for advanced or metastatic colon cancer patients harboring BRAF V600E (NCCN.org).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4541,
                "therapyName": "Cetuximab + Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1782,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PD-0325901 demonstrated antitumor activity against BRAF V600E colon cancer cell line xenografts (PMID: 16273091).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 849,
                "therapyName": "PD-0325901",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2074,
                    "pubMedId": 16273091,
                    "title": "BRAF mutation predicts sensitivity to MEK inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16273091"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6681,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Mekinist (trametinib) and Zelboraf (vemurafenib) combination treatment resulted in a rapid and sustained clinical response in a patient with a rectal neuroendocrine tumor harboring a BRAF V600E mutation (PMID: 27048246).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4234,
                "therapyName": "Trametinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 169,
                "name": "neuroendocrine tumor",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5733,
                    "pubMedId": 27048246,
                    "title": "BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27048246"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8069,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGB-283 in combination with Erbitux (cetuximab) demonstrated enhanced tumor suppression in colorectal cancer cell line xenograft models harboring BRAF V600E (PMID: 26208524).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4628,
                "therapyName": "BGB-283 + Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5280,
                    "pubMedId": 26208524,
                    "title": "BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26208524"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9664,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of PLX4720 and Adriamycin (doxorubicin) resulted in antitumor efficacy in a melanoma cell line harboring BRAF V600E, demonstrating decreased cell survival and increased apoptotic activity in xenograft models, and inhibition of cell growth in culture (PMID: 27924459).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 5122,
                "therapyName": "Doxorubicin + PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7369,
                    "pubMedId": 27924459,
                    "title": "Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27924459"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4417,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CLM3 inhibited growth, Egfr signaling, and CCND1 expression in thyroid cancer cells harboring BRAF V600E in culture (PMID: 24423321).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3502,
                "therapyName": "CLM3",
                "synonyms": null
            },
            "indication": {
                "id": 1781,
                "name": "thyroid cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4527,
                    "pubMedId": 24423321,
                    "title": "CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24423321"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15736,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, patients with melanoma harboring BRAF V600E (n=84) had decreased response rates (29% vs. 53%, p=0.059), progression-free survival (2.7 vs. 19 months, p=0.049), and overall survival  (11.7 vs. 20.4 months, p=0.081) relative to patients with BRAF V600K (n=19) when treated with Keytruda (pembrolizumab) (n=62 and 17 for BRAF V600E and V600K, respectively) or Opdivo (nivolumab) (n=22 and 2 for BRAF V600E and V600K, respectively) (PMID: 30630828).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 13705,
                    "pubMedId": 30630828,
                    "title": "Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30630828"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7231,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, BGB-283 resulted in partial response in 1 thyroid cancer patient harboring BRAF V600E, who remained on treatment for over 481 days (AACR Annual Meeting, Apr 2016, abstract # CT005).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4025,
                "therapyName": "BGB-283",
                "synonyms": null
            },
            "indication": {
                "id": 1781,
                "name": "thyroid cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6230,
                    "pubMedId": null,
                    "title": "Phase I study of RAF dimer inhibitor BGB-283 in patients with B-RAF or K-RAS/N-RAS mutated solid tumors",
                    "url": "http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=dc4584a4-d39b-485a-9579-be210c4876e9&cKey=46a0776a-1444-49d6-b533-4f68e298c39d&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7647,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and Tafinlar (dabrafenib) inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4525,
                "therapyName": "Cetuximab + Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1319,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring a BRAF V600E mutation had increased sensitivity to Mekinist (trametinib) compared to other colorectal cancer lines in culture (PMID: 25309914).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1025,
                    "pubMedId": 25309914,
                    "title": "Biological and molecular effects of small molecule kinase inhibitors on low-passage human colorectal cancer cell lines.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25309914"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9944,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vectibix (panitumumab), as a monotherapy, is not indicated for use in colon cancer patients with BRAF V600E (NCCN.org).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 14352,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III (BEACON CRC) trial, Braftovi (encorafenib), Mektovi (binimetinib), and Erbitux (cetuximab) combination treatment resulted in an objective response rate of 48% (14/29, 3 complete responses), and stable disease in 52% (15/29) of patients with BRAF V600E metastatic colorectal cancer, with a median progression-free survival of 8.0 months, and a median overall survival of 15.3 months (PMID: 30892987; NCT02928224).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4886,
                "therapyName": "Binimetinib + Cetuximab + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15302,
                    "pubMedId": 30892987,
                    "title": "Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30892987"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13891,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, combination therapy consisting of Tafinlar (dabrafenib) and Vectibix (panitumumab) resulted in an overall response rate of 10% (2/20, 1 complete response, 1 partial response), stable disease in 80% (16/20), and a median progression-free survival of 3.5 months in patients with BRAF V600E colorectal cancer (PMID: 29431699; NCT01750918).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1718,
                "therapyName": "Dabrafenib + Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11333,
                    "pubMedId": 29431699,
                    "title": "Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29431699"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1345,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib/II trial, treatment with the combination of Vectibix (panitumumab) and Tafinlar (dabrafenib) resulted in stable disease in 7/8 colorectal cancer patients harboring a BRAF V600E mutation (J Clin Oncol 32:5s, 2014 (suppl; abstr 3515)).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1718,
                "therapyName": "Dabrafenib + Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1051,
                    "pubMedId": null,
                    "title": "Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC).",
                    "url": "http://meetinglibrary.asco.org/content/131642-144"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2742,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CI-1040 inhibited growth of a human ovarian cancer cell line harboring BRAF V600E in culture, and inhibited tumor growth in xenograft models (PMID: 19018267).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 699,
                "therapyName": "CI-1040",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3448,
                    "pubMedId": 19018267,
                    "title": "KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19018267"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 442,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PLX8394 had been shown to block survival and growth of vemurafenib/PLX4720-resistant cells harboring distinct BRAF V600E splice variants (PMID: 24422853).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1041,
                "therapyName": "PLX8394",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 195,
                    "pubMedId": 24422853,
                    "title": "Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24422853"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8057,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGB-283 inhibited Braf phosphorylation and cell proliferation in colorectal cancer cell lines harboring BRAF V600E in culture, and resulted in partial tumor regression in both cell line and patient-derived xenograft models (PMID: 26208524).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4025,
                "therapyName": "BGB-283",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5280,
                    "pubMedId": 26208524,
                    "title": "BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26208524"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16103,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (MyPathway), Zelboraf (vemurafenib) treatment resulted in an objective response of 46% (12/26, 2 complete response, 10 partial response) in patients with advanced solid tumors harboring BRAF V600E, but only 4% (1/23, 1 partial response) in patients harboring non-V600 BRAF mutations (PMID: 29320312; NCT02091141).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13171,
                    "pubMedId": 29320312,
                    "title": "Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29320312"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1326,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, the combination of Zelboraf (vemurafenib) and Erbitux (cetuximab) was tolerated and showed clinical benefit in a patient with BRAF V600E mutant colorectal cancer (PMID: 24523613).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1711,
                "therapyName": "Cetuximab + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1033,
                    "pubMedId": 24523613,
                    "title": "Anticancer activity of combination targeted therapy using cetuximab plus vemurafenib for refractory BRAF (V600E)-mutant metastatic colorectal carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24523613"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7616,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zelboraf (vemurafenib) and Erbitux (cetuximab) combination treatment inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1711,
                "therapyName": "Cetuximab + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5780,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DEL-22379 inhibited tumor growth in a colorectal adenocarcinoma patient-derived xenograft model harboring BRAF V600E (PMID: 26267534).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3769,
                "therapyName": "DEL-22379",
                "synonyms": null
            },
            "indication": {
                "id": 50861,
                "name": "colorectal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4897,
                    "pubMedId": 26267534,
                    "title": "Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26267534"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1325,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Zelboraf (vemurafenib) and Tarceva (erlotinib) resulted in improved inhibition of tumor growth in BRAF V600E mutant human colon cancer cell line xenograft models compared to either drug as monotherapy (PMID: 22448344).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1710,
                "therapyName": "Erlotinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1032,
                    "pubMedId": 22448344,
                    "title": "EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22448344"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8203,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E in culture (PMID: 23629727).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4657,
                "therapyName": "Pimasertib + Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 337,
                    "pubMedId": 23629727,
                    "title": "Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23629727"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5648,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with metastatic renal cell carcinoma harboring BRAF V600E demonstrated a partial response following treatment with Zelboraf (vemurafenib) (PMID: 26918217).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 4450,
                "name": "renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5134,
                    "pubMedId": 26918217,
                    "title": "A Rare Finding of a BRAF Mutation in Renal Cell Carcinoma with Response to BRAF-Directed Targeted Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26918217"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6674,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DETD-35 and Zelboraf (vemurafenib) synergistically inhibited proliferation and colony formation of melanoma cells harboring BRAF V600E in culture and reduced tumor size in xenograft models (PMID: 27048951).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4232,
                "therapyName": "DETD-35 + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5730,
                    "pubMedId": 27048951,
                    "title": "A Novel Plant Sesquiterpene Lactone Derivative, DETD-35, Suppresses BRAFV600E Mutant Melanoma Growth and Overcomes Acquired Vemurafenib Resistance in Mice.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27048951"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12221,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EBI-907 inhibited BRAF and ERK signaling, resulted in growth inhibition of melanoma cells harboring BRAF V600E in culture and in cell line xenograft models (PMID: 26810733).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 6368,
                "therapyName": "EBI-907",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10177,
                    "pubMedId": 26810733,
                    "title": "EBI-907, a novel BRAF(V600E) inhibitor, has potent oral anti-tumor activity and a broad kinase selectivity profile.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26810733"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15904,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial (VE-BASKET), Zelboraf (vemurafenib) treatment of BRAF V600E mutant pleomorphic xanthoastrocytomas resulted in a 42.9% (3/7) objective response rate, a 5.7-month median progression-free survival, and best overall response rates of 14.3% (1/7) for complete response, 28.6% (2/7) for partial response, and 42.9% (3/7) for stable disease (PMID: 30351999; NCT01524978).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 4852,
                "name": "pleomorphic xanthoastrocytoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13949,
                    "pubMedId": 30351999,
                    "title": "BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30351999"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 3306,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CCT196969 inhibited growth of a human melanoma cell line harboring BRAF V600E in culture, and induced tumor regression in several BRAF V600E-mutant melanoma patient-derived xenograft models (PMID: 25500121).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3105,
                "therapyName": "CCT196969",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3714,
                    "pubMedId": 25500121,
                    "title": "Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25500121"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4956,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PLX4720 and Tivozanib (AV-951) worked synergistically to inhibit cell growth in PLX4720-resistant melanoma cell lines harboring BRAF V600E in culture (PMID: 26461489).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3700,
                "therapyName": "PLX4720 + Tivozanib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4807,
                    "pubMedId": 26461489,
                    "title": "Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26461489"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4524,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Navitoclax (ABT-263) enhanced the inhibitory effect of Zelboraf (vemurafenib) on human non-small cell lung cancer cells harboring BRAF V600E in culture (PMID: 25665005).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3530,
                "therapyName": "Navitoclax + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4582,
                    "pubMedId": 25665005,
                    "title": "The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25665005"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1322,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Tykerb (lapatinib) and Zelboraf (vemurafenib) inhibited growth of thyroid cancer cells harboring a BRAF V600E mutation in culture and in BRAF-mutant mouse models of thyroid cancer (PMID: 23365119).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1707,
                "therapyName": "Lapatinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1781,
                "name": "thyroid cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1029,
                    "pubMedId": 23365119,
                    "title": "Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23365119"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3790,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zelboraf (vemurafenib) in combination with SBI-0640756 inhibited the association of eIF4G1 and eIF4E in Zelboraf (vemurafenib) resistant human melanoma cell lines harboring BRAF V600E in culture and reduced tumor growth in xenograft models (PMID: 26603897).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3310,
                "therapyName": "SBI-0640756 + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4137,
                    "pubMedId": 26603897,
                    "title": "SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603897"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the Hsp90 inhibitor Ganetespib destabilized BRAF, especially BRAF V600E, resulted in loss of cell viability in culture and antitumor effects in cell line xenograft models of melanoma (PMID: 24398428).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 745,
                "therapyName": "Ganetespib",
                "synonyms": null
            },
            "indication": {
                "id": 8923,
                "name": "skin melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 249,
                    "pubMedId": 24398428,
                    "title": "Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24398428"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7618,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) and Erbitux (cetuximab) combination treatment inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4536,
                "therapyName": "Cetuximab + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9660,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Gleevec (imatinib) and PLX4720 enhanced antitumor efficacy of melanoma cells harboring BRAF V600E, demonstrating decreased cell survival in xenograft models, and decreased phosphorylation of Mapk1 in culture (PMID: 27924459).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 5118,
                "therapyName": "Imatinib + PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7369,
                    "pubMedId": 27924459,
                    "title": "Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27924459"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16193,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Tafinlar (dabrafinib) treatment of a patient with recurrent neuroendocrine carcinoma of the colon harboring a BRAF V600E mutation resulted in stable disease for 6 months before disease progression (PMID: 30181415).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 4118,
                "name": "colon neuroendocrine neoplasm",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14304,
                    "pubMedId": 30181415,
                    "title": "Targeting BRAF Mutations in High-Grade Neuroendocrine Carcinoma of the Colon.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30181415"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12698,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, treatment with BVD-523 (Ulixertinib) resulted in a partial response in a patient with glioblastoma harboring BRAF V600E (PMID: 29247021).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 997,
                "therapyName": "Ulixertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10607,
                    "pubMedId": 29247021,
                    "title": "First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29247021"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16235,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case report, combined Tafinlar (dabrafenib) and Mekinist (trametinib) treatment of a patient with salivary duct carcinoma harboring BRAF V600E resulted in a reduction of metastatic lesions and stable disease lasting 13 months followed by disease progression (PMID: 30323086).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 50904,
                "name": "salivary gland carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14375,
                    "pubMedId": 30323086,
                    "title": "First-Line Treatment of Widely Metastatic BRAF-Mutated Salivary Duct Carcinoma With Combined BRAF and MEK Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30323086"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3783,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BI-69A11 inhibited proliferation and Akt/mTOR signaling in human melanoma cell lines harboring BRAF V600E in culture (PMID: 26603897, PMID: 20531415).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3308,
                "therapyName": "BI-69A11",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4137,
                    "pubMedId": 26603897,
                    "title": "SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603897"
                },
                {
                    "id": 4139,
                    "pubMedId": 20531415,
                    "title": "Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20531415"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14046,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RAF709 inhibited Erk signaling and proliferation of melanoma cells harboring BRAF V600E in culture (PMID: 29343524).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 6995,
                "therapyName": "RAF709",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11434,
                    "pubMedId": 29343524,
                    "title": "Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29343524"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8188,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pimasertib (MSC1936369B) inhibited proliferation of colorectal cancer cells harboring BRAF V600E in culture (PMID: 23629727).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 871,
                "therapyName": "Pimasertib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 337,
                    "pubMedId": 23629727,
                    "title": "Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23629727"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7900,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PLX7904 inhibited survival of melanoma cell lines harboring monomeric BRAF V600E as well as cells harboring the Zelboraf (vemurafenib)-resistant dimeric BRAF V600E in culture (PMID: 26466569).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4606,
                "therapyName": "PLX7904",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6521,
                    "pubMedId": 26466569,
                    "title": "RAF inhibitors that evade paradoxical MAPK pathway activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26466569"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12623,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, treatment with RAF265 in melanoma patients resulted in an objective response rate of 12.1% (8/66), including a partial response in four patients harboring BRAF V600E, two partial responses and one complete response in patients with wild-type BRAF, and one complete response in a patient with unknown mutational status (PMID: 28719152).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 884,
                "therapyName": "RAF265",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10503,
                    "pubMedId": 28719152,
                    "title": "A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28719152"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16106,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (MyPathway), Zelboraf (vemurafenib) treatment resulted in complete response in a patient with anaplastic thyroid cancer harboring BRAF V600E (PMID: 29320312; NCT02091141).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1781,
                "name": "thyroid cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 13171,
                    "pubMedId": 29320312,
                    "title": "Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29320312"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7959,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, thyroid cancer cells harboring BRAF V600E demonstrated decreased sensitivity to Zelboraf (vemurafenib) in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1781,
                "name": "thyroid cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 586,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (BRIM-3) that supported FDA approval, Zelboraf (vemurafenib), as compared to Deticene (dacarbazine), resulted in an improved overall survival (OS) (13.6 vs 9.7 months, HR=0.81, p=0.03) in patients with BRAF V600E-positive metastatic melanoma, with estimated OS rates of 56%, 30%, 21%, and 17% at 1, 2, 3, and 4 years, respectively (PMID: 28961848, PMID: 21639808; NCT01006980), and BRAF V600E is included on the companion diagnostic (FDA.gov).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 222,
                    "pubMedId": 21639808,
                    "title": "Improved survival with vemurafenib in melanoma with BRAF V600E mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21639808"
                },
                {
                    "id": 11411,
                    "pubMedId": 28961848,
                    "title": "Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28961848"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15452,
                    "pubMedId": null,
                    "title": "Zelboraf (vemurafenib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=202429"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1510,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Zelboraf (vemurafenib) therapy is included in guidelines for melanoma patients with unresectable or metastatic disease harboring BRAF V600 activating mutations, such as BRAF V600E, in cases where BRAF/MEK inhibitor combination therapy is contraindicated (NCCN.org).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 7966,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PLX4720 and TAK-632 combination treatment resulted in durable inhibition of Erk signaling and tumor growth in xenograft models of colorectal cancer cells harboring BRAF V600E (PMID: 27523909).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4607,
                "therapyName": "PLX4720 + TAK-632",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7823,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with BI-847325 resulted in decreased expression of Mcl-1 and Mek, and inhibited growth of melanoma cell lines harboring BRAF V600E in culture, and inhibited tumor growth in xenograft models of BRAF V600E-positive melanoma, including models with BRAF-inhibitor resistance (PMID: 25873592).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1059,
                "therapyName": "BI-847325",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6506,
                    "pubMedId": 25873592,
                    "title": "The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25873592"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4531,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TW-37 enhanced the inhibitory effect of Mekinist (trametinib) on human non-small cell lung cancer cells harboring BRAF V600E in culture (PMID: 25665005).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3532,
                "therapyName": "Trametinib + TW-37",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4582,
                    "pubMedId": 25665005,
                    "title": "The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25665005"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17028,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Braftovi (encorafenib), Mektovi (binimetinib), Vectibix (panitumumab), combination therapy is included in guidelines as a second-line therapy for advanced or metastatic rectum cancer patients harboring BRAF V600E (NCCN.org).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 8361,
                "therapyName": "Binimetinib + Encorafenib + Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 1993,
                "name": "rectum cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 4984,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E were sensitive to the combination of BI 882370 and Erbitux (cetuximab) in xenograft models, resulting in tumor growth inhibition and partial tumor regression (PMID: 26916115).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3711,
                "therapyName": "BI 882370 + Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4823,
                    "pubMedId": 26916115,
                    "title": "A Novel RAF Kinase Inhibitor with DFG-Out-Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26916115"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8066,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGB-283 inhibited viability of a variety of cancer cell lines harboring BRAF V600E in culture (PMID: 26208524).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4025,
                "therapyName": "BGB-283",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5280,
                    "pubMedId": 26208524,
                    "title": "BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26208524"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7515,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SHP099 did not inhibit proliferation or ERK activation in a melanoma cell line harboring BRAF V600E in culture (PMID: 27362227).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4504,
                "therapyName": "SHP099",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6394,
                    "pubMedId": 27362227,
                    "title": "Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27362227"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5970,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Omipalisib (GSK2126458) inhibited the growth of melanoma cell lines harboring BRAF V600E in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 763,
                "therapyName": "GSK2126458",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12998,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Zelboraf (vemurafenib), Erbitux (cetuximab), and Camptosar (irinotecan) combination therapy is included in guidelines for advanced or metastatic colon cancer patients harboring BRAF V600E (NCCN.org).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1331,
                "therapyName": "Cetuximab + Irinotecan + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1323,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tykerb (lapatinib) and Faridak (panobinostat) worked synergistically to inhibit growth of BRAF V600E mutant colorectal cancer cells in culture (PMID: 21464044).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1708,
                "therapyName": "Lapatinib + Panobinostat",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1031,
                    "pubMedId": 21464044,
                    "title": "The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21464044"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15983,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RMC-4550 did not inhibit Erk phosphorylation or proliferation of melanoma cells harboring BRAF V600E in culture (PMID: 30104724).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 7839,
                "therapyName": "RMC-4550",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 14089,
                    "pubMedId": 30104724,
                    "title": "RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30104724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7943,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAK-632 inhibited proliferation of colorectal cancer cells harboring BRAF V600E in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3300,
                "therapyName": "TAK-632",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3789,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SBI-755199 induced cell death in human melanoma cell lines harboring BRAF V600E in culture (PMID: 26603897).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3309,
                "therapyName": "SBI-755199",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4137,
                    "pubMedId": 26603897,
                    "title": "SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603897"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1267,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the Hsp90 inhibitor, Ganetespib, in combination with the MEK1/2 inhibitor TAK-733, caused the regression of tumors in vemurafenib-resistant cell line xenograft models of melanoma (PMID: 24398428).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1684,
                "therapyName": "Ganetespib + TAK-733",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 249,
                    "pubMedId": 24398428,
                    "title": "Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24398428"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6832,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RAF265 inhibited Erk phosphorylation and cell proliferation in BRAF V600E expressing cells in culture (PMID: 20538618).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 884,
                "therapyName": "RAF265",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5859,
                    "pubMedId": 20538618,
                    "title": "Gatekeeper mutations mediate resistance to BRAF-targeted therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20538618"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10549,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, BRAF V600E positive melanoma patients who progressed on treatment with BRAF inhibitors or the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) were treated again with the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) after 12 weeks off treatment, which resulted in a partial response in 35% (8/25) and stable disease in 40% (10/25) (PMID: 28268064).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8631,
                    "pubMedId": 28268064,
                    "title": "Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF(V600)-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28268064"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12837,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (COMBI-v) that supported FDA approval, the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) resulted in an improved overall survival rate at 12 months (72% vs 65%, HR=0.69, p=0.005), median progression-free survival (11.4 vs 7.3 months, HR=0.56, p<0.001), and objective response rate (64% vs 51%, p<0.001) compared to Zelboraf (vemurafenib) in melanoma patients harboring BRAF V600E or V600K (PMID: 25399551; NCT01597908).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10781,
                    "pubMedId": 25399551,
                    "title": "Improved overall survival in melanoma with combined dabrafenib and trametinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25399551"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15458,
                    "pubMedId": null,
                    "title": "Tafinlar (dabrafenib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=202806"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 5987,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tafinlar (dabrafenib) in combination with Mekinist (trametinib) inhibited growth of melanoma cells harboring BRAF V600E in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12926,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Tafinlar (dabrafenib) and Mekinist (trametinib) combination therapy is included in guidelines for melanoma patients harboring a BRAF V600 activating mutation, such as BRAF V600E, as adjuvant therapy for stage III disease and as systemic therapy for patients with unresectable or metastatic disease (NCCN.org).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 4528,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Navitoclax (ABT-263) enhanced the inhibitory effect of Mekinist (trametinib) on human colon cancer cells harboring BRAF V600E in culture (PMID: 25665005).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1386,
                "therapyName": "Navitoclax + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4582,
                    "pubMedId": 25665005,
                    "title": "The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25665005"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4530,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TW-37 enhanced the inhibitory effect of Mekinist (trametinib) on human melanoma cells harboring BRAF V600E in culture (PMID: 25665005).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3532,
                "therapyName": "Trametinib + TW-37",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4582,
                    "pubMedId": 25665005,
                    "title": "The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25665005"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15705,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ulixertinib (BVD-523) inhibited Erk signaling in melanoma cells harboring BRAF V600E, resulted in cell cycle arrest in culture and tumor growth inhibition in cell line xenograft models (PMID: 28939558).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 997,
                "therapyName": "Ulixertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11466,
                    "pubMedId": 28939558,
                    "title": "Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28939558"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6836,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PLX4720 inhibited Erk phosphorylation and cell proliferation of transformed cells expression BRAF V600E in culture (PMID: 20538618).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1060,
                "therapyName": "PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5859,
                    "pubMedId": 20538618,
                    "title": "Gatekeeper mutations mediate resistance to BRAF-targeted therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20538618"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12695,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, treatment with BVD-523 (ulixertinib) resulted in a partial response in two patients with lung cancer each harboring BRAF V600E (PMID: 29247021).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 997,
                "therapyName": "Ulixertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10607,
                    "pubMedId": 29247021,
                    "title": "First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29247021"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9665,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of PLX4720 and Tarceva (erlotinib) resulted in antitumor efficacy in a melanoma cell line harboring BRAF V600E, demonstrating decreased cell survival and increased apoptotic activity in xenograft models and culture (PMID: 27924459).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 5120,
                "therapyName": "Erlotinib + PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7369,
                    "pubMedId": 27924459,
                    "title": "Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27924459"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11930,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with metastatic colon cancer harboring BRAF V600E demonstrated mixed radiographic response with slight progression in some locations and stable disease in other locations for 7 months following treatment with the combination of Nexavar (sorafenib) and Erbitux (cetuximab) (PMID: 23792568).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 6209,
                "therapyName": "Cetuximab + Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9915,
                    "pubMedId": 23792568,
                    "title": "Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23792568"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5776,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SCH772984 inhibited growth of melanoma cell lines harboring BRAF V600E in culture (PMID: 26267534).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4897,
                    "pubMedId": 26267534,
                    "title": "Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26267534"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9107,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) and PLX4720 synergistically inhibited growth and induced apoptosis in glioma cell lines in culture, resulted in prolonged survival in cell line xenograft models (PMID: 27217440).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1061,
                "therapyName": "PLX4720 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3070,
                "name": "malignant glioma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6921,
                    "pubMedId": 27217440,
                    "title": "BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27217440"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6827,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SB590885 inhibited inhibited Erk phosphorylation and cell proliferation of transformed cells expression BRAF V600E in culture (PMID: 20538618).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4281,
                "therapyName": "SB590885",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5859,
                    "pubMedId": 20538618,
                    "title": "Gatekeeper mutations mediate resistance to BRAF-targeted therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20538618"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7521,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclincial study, colorectal cancer cell lines harboring BRAF V600E demonstrated resistance to SHP099 in culture (PMID: 27362227).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4504,
                "therapyName": "SHP099",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6394,
                    "pubMedId": 27362227,
                    "title": "Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27362227"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7901,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PLX7904 inhibited survival of colorectal cancer cells harboring BRAF V600E in culture and demonstrated anti-tumor activity in cell line xenograft models (PMID: 26466569).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4606,
                "therapyName": "PLX7904",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6521,
                    "pubMedId": 26466569,
                    "title": "RAF inhibitors that evade paradoxical MAPK pathway activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26466569"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4955,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PLX4720, Cediranib (AZD-2171) and Selumetinib (AZD6244) worked synergistically to inhibit cell growth in PLX4720-resistant melanoma cell lines harboring BRAF V600E in culture (PMID: 26461489).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3699,
                "therapyName": "Cediranib + PLX4720 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4807,
                    "pubMedId": 26461489,
                    "title": "Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26461489"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12087,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Cotellic (cobimetinib) treatment resulted in a confirmed partial response in six melanoma patients harboring BRAF V600E (PMID: 27424159).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1004,
                "therapyName": "Cobimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10025,
                    "pubMedId": 27424159,
                    "title": "A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27424159"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12058,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, INU-152 inhibited growth of colorectal cancer cell lines harboring BRAF V600E in culture, and reduced tumor growth in BRAF V600E-mutant colorectal cancer cell line xenograft models (PMID: 28645859).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 6241,
                "therapyName": "INU-152",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9993,
                    "pubMedId": 28645859,
                    "title": "Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAF(V600E) mutant cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28645859"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16571,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, treatment with Cotellic (cobimetinib) in patients with histiocytic neoplasms resulted in a PET overall response rate of 89% (16/18), with complete response in 72% (13/18) and partial response in 17% (3/18), and resulted in stable disease in 6% (1/18) of patients, including 1 partial response and 3 complete responses in 4 patients with Erdheim-Chester disease harboring BRAF V600E (PMID: 30867592; NCT01953926).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1004,
                "therapyName": "Cobimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 60073,
                "name": "lymphatic system cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14632,
                    "pubMedId": 30867592,
                    "title": "Efficacy of MEK inhibition in patients with histiocytic neoplasms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30867592"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8478,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RO5126766 inhibited proliferation of melanoma cells harboring BRAF V600E in culture (PMID: 26438159).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 2011,
                "therapyName": "RO5126766",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4382,
                    "pubMedId": 26438159,
                    "title": "ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26438159"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9662,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Alpelisib (BYL719) and PLX4720 enhanced antitumor activity in a melanoma cell line harboring BRAF V600E, demonstrating decreased cell survival and increased apoptotic activity in xenograft models, and decreased Akt signaling in culture (PMID: 27924459).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 5119,
                "therapyName": "Alpelisib + PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7369,
                    "pubMedId": 27924459,
                    "title": "Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27924459"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17521,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with epithelioid glioblastoma harboring BRAF V600E continued to response as Cotellic (cobimetinib) was added to Zelboraf (vemurafenib) treatment (PMID: 31217909).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1657,
                "therapyName": "Cobimetinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15565,
                    "pubMedId": 31217909,
                    "title": "Regression of BRAFV600E mutant adult glioblastoma after primary combined BRAF-MEK inhibitor targeted therapy: a report of two cases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31217909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7871,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of PAC-1 and Zelboraf (vemurafenib) resulted in a synergistic effect when treating melanoma cells harboring BRAF V600E in culture and xenograft models, demonstrating increased apoptosis and decreased tumor volume (PMID: 27297867).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4604,
                "therapyName": "PAC-1 + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6518,
                    "pubMedId": 27297867,
                    "title": "The Combination of Vemurafenib and Procaspase-3 Activation Is Synergistic in Mutant BRAF Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27297867"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7906,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZ628 inhibited proliferation of melanoma cell lines harboring either monomeric BRAF V600E or dimeric isoform of V600E which conferred Zelboraf (vemurafenib)-resistance in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1093,
                "therapyName": "AZ628",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13019,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Erbitux (cetuximab), as a monotherapy, is not indicated for use in rectum cancer patients with BRAF V600E (NCCN.org).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 1993,
                "name": "rectum cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 3785,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SBI-0640726 inhibited proliferation and Akt/mTOR signaling in human melanoma cell lines harboring BRAF V600E in culture (PMID: 26603897, PMID: 20531415).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3307,
                "therapyName": "SBI-0640726",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4137,
                    "pubMedId": 26603897,
                    "title": "SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603897"
                },
                {
                    "id": 4139,
                    "pubMedId": 20531415,
                    "title": "Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20531415"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17589,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a papillary thyroid carcinoma patient who progressed on Lenvima (lenvatinib) was found to harbor BRAF V600E and was treated with the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) on a clinical trial, resulting in partial response in the thyroid bed, cervical and intrathoracic lymph nodes, and pulmonary lesions, with a decrease in target lesion size of 67%, and the patient remained on treatment for 18 months before stopping due to progression (PMID: 31085763).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3969,
                "name": "papillary thyroid carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15690,
                    "pubMedId": 31085763,
                    "title": "KRAS G12V Mutation in Acquired Resistance to Combined BRAF and MEK Inhibition in Papillary Thyroid Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31085763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16107,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (MyPathway), Zelboraf (vemurafenib) treatment resulted in complete response in a patient with larynx cancer harboring BRAF V600E (PMID: 29320312; NCT02091141).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 2596,
                "name": "larynx cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13171,
                    "pubMedId": 29320312,
                    "title": "Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29320312"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10194,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a glioblastoma cell line harboring BRAF V600E demonstrated sensitivity to BI2536 in culture (PMID: 26573800).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 676,
                "therapyName": "BI2536",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8161,
                    "pubMedId": 26573800,
                    "title": "Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26573800"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4953,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PLX4720 and Cediranib (AZD-2171) worked synergistically to inhibit cell growth and induce apoptosis in PLX4720-resistant human melanoma cell lines harboring BRAF V600E in culture and to suppress tumor growth in xenograft models (PMID: 26461489).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3698,
                "therapyName": "Cediranib + PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4807,
                    "pubMedId": 26461489,
                    "title": "Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26461489"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3336,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, saracatinib inhibited proliferation of human melanoma cell lines harboring BRAF V600E that are resistant to Braf inhibition in culture (PMID: 23242808).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 912,
                "therapyName": "Saracatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3755,
                    "pubMedId": 23242808,
                    "title": "Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23242808"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17026,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Tafinlar (dabrafenib), Mekinist (trametinib), Erbitux (cetuximab), combination therapy is included in guidelines as a second-line therapy for advanced or metastatic rectum cancer patients harboring BRAF V600E (NCCN.org).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4541,
                "therapyName": "Cetuximab + Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1993,
                "name": "rectum cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1343,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Refametinib (BAY86-9766) inhibited growth of colorectal cancer cell lines harboring BRAF V600E in culture and suppressed tumor growth in cell line xenograft models (PMID: 19706763).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 888,
                "therapyName": "Refametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 877,
                    "pubMedId": 19706763,
                    "title": "RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19706763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16953,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III (COLUMBUS) trial that supported FDA approval, Braftovi (encorafenib) in combination with Mektovi (binimetinib) demonstrated improved tolerability profile and efficacy, resulted in a progression-free survival of 14.9 months in patients with advanced melanoma harboring BRAF V600E/K mutations, comparing to 7.3 months in the Zelboraf (vemurafenib) group (HR=0.54, p<0.0001) (PMID: 29573941; NCT01909453), and both BRAF V600E and V600K are on the companion diagnostic.",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1100,
                "therapyName": "Binimetinib + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11562,
                    "pubMedId": 29573941,
                    "title": "Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29573941"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15455,
                    "pubMedId": null,
                    "title": "Braftovi (encorafenib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210496"
                },
                {
                    "id": 15456,
                    "pubMedId": null,
                    "title": "Mektovi (binimetinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210498"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16952,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III (COLUMBUS) trial that supported FDA approval, Braftovi (encorafenib) in combination with Mektovi (binimetinib) resulted in a median overall survival (OS) of 33.6 months, a 1-year OS rate of 77.5%, and a 2-year OS rate of 57.7% in patients with advanced melanoma harboring BRAF V600E/K mutations compared to a median OS of 16.9 months and 1- and 2-year OS rates of 63.1% and 43.2%, respectively, in the Zelboraf (vemurafenib) treated group (PMID: 30219628; NCT01909453).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1100,
                "therapyName": "Binimetinib + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14457,
                    "pubMedId": 30219628,
                    "title": "Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30219628"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15455,
                    "pubMedId": null,
                    "title": "Braftovi (encorafenib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210496"
                },
                {
                    "id": 15456,
                    "pubMedId": null,
                    "title": "Mektovi (binimetinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210498"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16950,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Braftovi (encorafenib) in combination with Mektovi (binimetinib) is included in guidelines as first-line and second-line therapy for patients with metastatic or unresectable melanoma harboring BRAF V600E or V600K mutations (PMID: 30959471; NCCN.org).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1100,
                "therapyName": "Binimetinib + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                },
                {
                    "id": 15109,
                    "pubMedId": 30959471,
                    "title": "Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30959471"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13021,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Zelboraf (vemurafenib), Erbitux (cetuximab), and Camptosar (irinotecan) combination therapy is included in guidelines for advanced or metastatic rectum cancer patients harboring BRAF V600E (NCCN.org).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1331,
                "therapyName": "Cetuximab + Irinotecan + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1993,
                "name": "rectum cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 8002,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PLX4720 inhibited growth of colon cancer cells harboring BRAF V600E in culture and in cell line xenograft models (PMID: 18287029).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1060,
                "therapyName": "PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 291,
                    "pubMedId": 18287029,
                    "title": "Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18287029"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3620,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In two Phase II clinical studies, patients with refractory hairy cell leukemia harboring BRAF V600E responded to Zelboraf (vemurafenib) with overall response rates of 96% (25/26) and 100% (24/24) as well as complete response rates of 35% (9/26) and 42% (10/24) with median follow up times of 8 and 12 weeks, respectively (PMID: 26352686).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 285,
                "name": "hairy cell leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3911,
                    "pubMedId": 26352686,
                    "title": "Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26352686"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1130,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Refametinib (BAY86-9766) inhibited growth of melanoma cell lines harboring BRAF V600E in culture and suppressed tumor growth in cell line xenograft models (PMID: 19706763).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 888,
                "therapyName": "Refametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 877,
                    "pubMedId": 19706763,
                    "title": "RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19706763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16977,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Tafinlar (dabrafenib), Mekinist (trametinib), Vectibix (panitumumab), combination therapy is included in guidelines as a second-line therapy for advanced or metastatic colon cancer patients harboring BRAF V600E (NCCN.org).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1992,
                "therapyName": "Dabrafenib + Panitumumab + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16979,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Braftovi (encorafenib), Mektovi (binimetinib), Erbitux (cetuximab), combination therapy is included in guidelines as a second-line therapy for advanced or metastatic colon cancer patients harboring BRAF V600E (NCCN.org).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4886,
                "therapyName": "Binimetinib + Cetuximab + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17025,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Tafinlar (dabrafenib), Mekinist (trametinib), Vectibix (panitumumab), combination therapy is included in guidelines as a second-line therapy for advanced or metastatic rectum cancer patients harboring BRAF V600E (NCCN.org).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1992,
                "therapyName": "Dabrafenib + Panitumumab + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1993,
                "name": "rectum cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 5965,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cell lines harboring BRAF V600E and NRAS A146T had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22042,
                "profileName": "BRAF V600E NRAS A146T"
            },
            "therapy": {
                "id": 763,
                "therapyName": "GSK2126458",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5977,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tafinlar (dabrafenib) in combination with Mekinist (trametinib) resulted in improved growth inhibition of melanoma cell lines harboring BRAF V600E and NRAS A146T in culture, compared to either agent alone (PMID: 22389471).",
            "molecularProfile": {
                "id": 22042,
                "profileName": "BRAF V600E NRAS A146T"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5955,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cell lines harboring BRAF V600E and NRAS A146T were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22042,
                "profileName": "BRAF V600E NRAS A146T"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5959,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cell lines harboring BRAF V600E and NRAS A146T were >10-fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600E in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22042,
                "profileName": "BRAF V600E NRAS A146T"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5951,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines harboring BRAF V600E and NRAS A146T were resistant to Tafinlar (dabrafenib) growth inhibition in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22042,
                "profileName": "BRAF V600E NRAS A146T"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5988,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Talfinlar (dabrafenib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E and NRAS A146T in culture, compared to either agent alone (PMID: 22389471).",
            "molecularProfile": {
                "id": 22042,
                "profileName": "BRAF V600E NRAS A146T"
            },
            "therapy": {
                "id": 4004,
                "therapyName": "Dabrafenib + GSK2126458",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5991,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition in melanoma cell lines harboring BRAF V600E and NRAS A146T in culture, compared to either agent alone (PMID: 22389471).",
            "molecularProfile": {
                "id": 22042,
                "profileName": "BRAF V600E NRAS A146T"
            },
            "therapy": {
                "id": 3027,
                "therapyName": "GSK2126458 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12164,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 Q56P demonstrated resistance to treatment with Zelboraf (vemurafenib) in culture (PMID: 28655712).",
            "molecularProfile": {
                "id": 22096,
                "profileName": "BRAF V600E MAP2K1 Q56P"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10118,
                    "pubMedId": 28655712,
                    "title": "BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28655712"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5976,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines harboring BRAF V600E expressing MAP2K1 Q56P displayed reduced sensitivity to Mekinist (trametinib) mediated growth inhibition and retained MEK and ERK signaling (PMID: 22389471).",
            "molecularProfile": {
                "id": 22096,
                "profileName": "BRAF V600E MAP2K1 Q56P"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5982,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Talfinlar (dabrafenib)    and Mekinist (trametinib) resulted in improved growth inhibition in melanoma cells harboring BRAF V600E and expressing MAP2K1 Q56P in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22096,
                "profileName": "BRAF V600E MAP2K1 Q56P"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5975,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cell lines harboring BRAF V600E expressing MAP2K1 Q56P were resistant to Tafinlar (dabrafenib) mediated growth inhibition and retained MEK and ERK signaling in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22096,
                "profileName": "BRAF V600E MAP2K1 Q56P"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12165,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BVD-523 (ulixertinib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 Q56P in culture (PMID: 28655712).",
            "molecularProfile": {
                "id": 22096,
                "profileName": "BRAF V600E MAP2K1 Q56P"
            },
            "therapy": {
                "id": 997,
                "therapyName": "Ulixertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10118,
                    "pubMedId": 28655712,
                    "title": "BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28655712"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16591,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with BRAF V600E colorectal cancer developed progressive disease after achieving stable disease for 16 weeks with Vectibix (panitumumab) and Zelboraf (vemurafenib) combination treatment, NRAS amplification was identified as an acquired alteration at the time of progression (PMID: 28951457).",
            "molecularProfile": {
                "id": 31708,
                "profileName": "BRAF V600E NRAS amp"
            },
            "therapy": {
                "id": 1717,
                "therapyName": "Panitumumab + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14634,
                    "pubMedId": 28951457,
                    "title": "Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28951457"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5964,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del were resistant to growth inhibition by Mekinist (trametinib) in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22045,
                "profileName": "BRAF V600E MAP2K1 K59del"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5984,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del in culture, compared to either agent alone (PMID: 22389471).",
            "molecularProfile": {
                "id": 22045,
                "profileName": "BRAF V600E MAP2K1 K59del"
            },
            "therapy": {
                "id": 3027,
                "therapyName": "GSK2126458 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5969,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22045,
                "profileName": "BRAF V600E MAP2K1 K59del"
            },
            "therapy": {
                "id": 763,
                "therapyName": "GSK2126458",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5957,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22045,
                "profileName": "BRAF V600E MAP2K1 K59del"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5983,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tafinlar (dabrafenib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del in culture, compared to either agent alone (PMID: 22389471).",
            "molecularProfile": {
                "id": 22045,
                "profileName": "BRAF V600E MAP2K1 K59del"
            },
            "therapy": {
                "id": 4004,
                "therapyName": "Dabrafenib + GSK2126458",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5953,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del were resistant to Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22045,
                "profileName": "BRAF V600E MAP2K1 K59del"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5980,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Talfinlar (dabrafenib) in combination with Mekinist (trametinib) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E harboring MAP2K1 K59del in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22045,
                "profileName": "BRAF V600E MAP2K1 K59del"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7038,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAP2K1 C121S conferred resistance to PLX4720 in melanoma cells harboring BRAF V600E in culture (PMID: 21383288).",
            "molecularProfile": {
                "id": 17135,
                "profileName": "BRAF V600E MAP2K1 C121S"
            },
            "therapy": {
                "id": 1060,
                "therapyName": "PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4378,
                    "pubMedId": 21383288,
                    "title": "Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21383288"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7032,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MAP2K1 C121S conferred resistance to the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) in BRAF V600E-mutant melanoma cells in culture (PMID: 24265154).",
            "molecularProfile": {
                "id": 17135,
                "profileName": "BRAF V600E MAP2K1 C121S"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6036,
                    "pubMedId": 24265154,
                    "title": "MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265154"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12159,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 C121S demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).",
            "molecularProfile": {
                "id": 17135,
                "profileName": "BRAF V600E MAP2K1 C121S"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10118,
                    "pubMedId": 28655712,
                    "title": "BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28655712"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4031,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cell lines harboring BRAF V600E mutation and overexpressing MAP2K1 C121S were less sensitive than those overexpressing wild-type MAP2K1 to Selumetinib (AZD6244)-induced inhibition of Mapk pathway activation and cell proliferation in culture (PMID: 24448821).",
            "molecularProfile": {
                "id": 17135,
                "profileName": "BRAF V600E MAP2K1 C121S"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4380,
                    "pubMedId": 24448821,
                    "title": "Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation in a preclinical model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24448821"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4029,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, E6201 inhibited Mapk pathway activation and proliferation of melanoma cell line harboring BRAF V600E mutation and overexpressing MAP2K1 C121S in culture (PMID: 24448821).",
            "molecularProfile": {
                "id": 17135,
                "profileName": "BRAF V600E MAP2K1 C121S"
            },
            "therapy": {
                "id": 1011,
                "therapyName": "E6201",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4380,
                    "pubMedId": 24448821,
                    "title": "Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation in a preclinical model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24448821"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7037,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient harboring BRAF V600E demonstrated an initial response to treatment with Zelboraf (vemurafenib), but progressed following emergence of a MAP2K1 C121S mutation (PMID: 21383288).",
            "molecularProfile": {
                "id": 17135,
                "profileName": "BRAF V600E MAP2K1 C121S"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4378,
                    "pubMedId": 21383288,
                    "title": "Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21383288"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4030,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAP2K1 C121S conferred resistance to Zelboraf (vemurafenib) in melanoma cell lines harboring BRAF V600, resulting in decreased sensitivity to Zelboraf (vemurafenib)-induced inhibition of MAPK pathway activation and cell proliferation in culture (PMID: 24448821).",
            "molecularProfile": {
                "id": 17135,
                "profileName": "BRAF V600E MAP2K1 C121S"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4380,
                    "pubMedId": 24448821,
                    "title": "Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation in a preclinical model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24448821"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7003,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 C121S demonstrated sensitivity to treatment with VRT11E, resulting in decreased cell growth in culture (PMID: 24265153).",
            "molecularProfile": {
                "id": 17135,
                "profileName": "BRAF V600E MAP2K1 C121S"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8568,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, induced apoptosis in TP53-wild-type colorectal cancer cells harboring BRAF V600E and PIK3CA H1047R in culture (PMID: 26272063).",
            "molecularProfile": {
                "id": 26361,
                "profileName": "BRAF V600E PIK3CA H1047R TP53 wild-type"
            },
            "therapy": {
                "id": 4771,
                "therapyName": "PD-0325901 + Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7593,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P124Q demonstrated decreased sensitivity to Tafinlar (dabrafenib) in cell culture (PMID: 25370473).",
            "molecularProfile": {
                "id": 25915,
                "profileName": "BRAF V600E MAP2K1 P124Q"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6439,
                    "pubMedId": 25370473,
                    "title": "Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25370473"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2275,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with XL888 resulted in increased apoptosis and decreased growth of Zelboraf (vemurafenib)-resistant melanoma cells harboring BRAF V600E along with NRAS Q61K in cell culture (PMID: 22351686).",
            "molecularProfile": {
                "id": 6906,
                "profileName": "BRAF V600E NRAS Q61K"
            },
            "therapy": {
                "id": 970,
                "therapyName": "XL888",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2956,
                    "pubMedId": 22351686,
                    "title": "The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22351686"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16584,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with BRAF V600E colorectal cancer developed progressive disease after a partial response lasting 40 weeks to Vectibix (panitumumab) and Zelboraf (vemurafenib) combination treatment, NRAS Q61K was identified as an acquired mutation at the time of progression (PMID: 28951457).",
            "molecularProfile": {
                "id": 6906,
                "profileName": "BRAF V600E NRAS Q61K"
            },
            "therapy": {
                "id": 1717,
                "therapyName": "Panitumumab + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14634,
                    "pubMedId": 28951457,
                    "title": "Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28951457"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2279,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a NRAS Q61K mutation conferred resistance to Zelboraf (vemurafenib) in melanoma cells harboring BRAF V600E in culture (PMID: 21107323).",
            "molecularProfile": {
                "id": 6906,
                "profileName": "BRAF V600E NRAS Q61K"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2959,
                    "pubMedId": 21107323,
                    "title": "Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21107323"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15028,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a breast cancer patient with metastatic lung adenocarcinoma harboring BRAF V600E developed progressive disease after initial response to Talfinlar (dabrafenib) and Mekinist (trametinib) combination therapy, NRAS Q61K was identified as an acquired mutation after disease progression (PMID: 29631033).",
            "molecularProfile": {
                "id": 6906,
                "profileName": "BRAF V600E NRAS Q61K"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 12311,
                    "pubMedId": 29631033,
                    "title": "An Acquired NRAS Q61K Mutation in BRAF V600E-Mutant Lung Adenocarcinoma Resistant to\u00a0Dabrafenib Plus Trametinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29631033"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5949,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines harboring BRAF V600E expressing NRAS Q61K were resistant to Tafinlar (dabrafenib) mediated growth inhibition and retained MEK and ERK signaling (PMID: 22389471).",
            "molecularProfile": {
                "id": 6906,
                "profileName": "BRAF V600E NRAS Q61K"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5978,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Talfinlar (dabrafenib) in combination with Mekinist (trametinib) resulted in improved growth inhibition of melanoma cell lines harboring BRAF V600E and NRAS Q61K in culture, compared to either agent alone (PMID: 22389471).",
            "molecularProfile": {
                "id": 6906,
                "profileName": "BRAF V600E NRAS Q61K"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16594,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression of wild-type NRAS in colorectal cancer cell lines harboring BRAF V600E induced Ras activation and Braf/Craf dimerization, conferred resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) combination treatment in culture and in cell line xenograft models (PMID: 28951457).",
            "molecularProfile": {
                "id": 31710,
                "profileName": "BRAF V600E NRAS over exp"
            },
            "therapy": {
                "id": 1711,
                "therapyName": "Cetuximab + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 14634,
                    "pubMedId": 28951457,
                    "title": "Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28951457"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16597,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGB659 and Erbitux (cetuximab) combination treatment demonstrated enhanced inhibition of Erk phosphorylation and growth in BRAF V600E colorectal cancer cell lines overexpressing Nras in culture (PMID: 28951457).",
            "molecularProfile": {
                "id": 31710,
                "profileName": "BRAF V600E NRAS over exp"
            },
            "therapy": {
                "id": 8106,
                "therapyName": "BGB659 + Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14634,
                    "pubMedId": 28951457,
                    "title": "Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28951457"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7631,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, over expression of wild type EGFR in colorectal cancer cells harboring BRAF V600E resulted in sustained activation of Mapk signaling and resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25929,
                "profileName": "BRAF V600E EGFR over exp"
            },
            "therapy": {
                "id": 3773,
                "therapyName": "Selumetinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12224,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EBI-907 inhibited growth of colorectal cancer cells harboring BRAF V600E and EGFR overexpression in culture (PMID: 26810733).",
            "molecularProfile": {
                "id": 25929,
                "profileName": "BRAF V600E EGFR over exp"
            },
            "therapy": {
                "id": 6368,
                "therapyName": "EBI-907",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10177,
                    "pubMedId": 26810733,
                    "title": "EBI-907, a novel BRAF(V600E) inhibitor, has potent oral anti-tumor activity and a broad kinase selectivity profile.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26810733"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7033,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MAP2K1 G128V conferred resistance to the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) in BRAF V600E-mutant melanoma cells in culture (PMID: 24265154).",
            "molecularProfile": {
                "id": 24283,
                "profileName": "BRAF V600E MAP2K1 G128V"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6036,
                    "pubMedId": 24265154,
                    "title": "MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265154"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7058,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 G128V demonstrated resistance to treatment with Tafinlar (dabrafenib) in culture, resulting in sustained Map2k1/2 and Erk1/2 phosphorylation (PMID: 24265153).",
            "molecularProfile": {
                "id": 24283,
                "profileName": "BRAF V600E MAP2K1 G128V"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7059,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 G128V demonstrated resistance to treatment with Mekinist (trametinib) in culture, resulting in sustained Map2k1/2 and Erk1/2 phosphorylation (PMID: 24265153).",
            "molecularProfile": {
                "id": 24283,
                "profileName": "BRAF V600E MAP2K1 G128V"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7005,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 G128V demonstrated sensitivity to treatment with VRT11E, resulting in decreased cell growth in culture (PMID: 24265153).",
            "molecularProfile": {
                "id": 24283,
                "profileName": "BRAF V600E MAP2K1 G128V"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16630,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) and Zelboraf (vemurafenib) combination treatment inhibited growth of colorectal cancer cells harboring BRAF V600E and overexpressing Met in culture (PMID: 27325282).",
            "molecularProfile": {
                "id": 31715,
                "profileName": "BRAF V600E MET over exp"
            },
            "therapy": {
                "id": 4648,
                "therapyName": "Crizotinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6560,
                    "pubMedId": 27325282,
                    "title": "MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27325282"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16629,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpressing Met in colorectal cancer cells harboring BRAF V600E conferred resistance to Vectibix (panitumumab) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27325282).",
            "molecularProfile": {
                "id": 31715,
                "profileName": "BRAF V600E MET over exp"
            },
            "therapy": {
                "id": 1717,
                "therapyName": "Panitumumab + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6560,
                    "pubMedId": 27325282,
                    "title": "MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27325282"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16598,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGB659 and Erbitux (cetuximab) combination treatment resulted in sustained inhibition of Mek and Erk phosphorylation, lead to tumor regression in patient-derived xenograft models of colorectal cancer harboring BRAF V600E and NRAS G13R (PMID: 28951457).",
            "molecularProfile": {
                "id": 31705,
                "profileName": "BRAF V600E NRAS G13R"
            },
            "therapy": {
                "id": 8106,
                "therapyName": "BGB659 + Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14634,
                    "pubMedId": 28951457,
                    "title": "Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28951457"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16587,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with BRAF V600E colorectal cancer developed progressive disease after a partial response lasting 24 weeks to Alpelisib (BYL719), Erbitux (cetuximab), and Braftovi (encorafenib) combination treatment, NRAS G13R was identified as an acquired mutation in liver metastasis at the time of progression (PMID: 28951457).",
            "molecularProfile": {
                "id": 31705,
                "profileName": "BRAF V600E NRAS G13R"
            },
            "therapy": {
                "id": 1917,
                "therapyName": "Alpelisib + Cetuximab + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14634,
                    "pubMedId": 28951457,
                    "title": "Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28951457"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6895,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E treated with Selumetinib (AZD6244) in culture demonstrated resistance, which was a result of the resistance mutation, MAP2K1 H119P (PMID: 19915144).",
            "molecularProfile": {
                "id": 23996,
                "profileName": "BRAF V600E MAP2K1 H119P"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 134,
                    "pubMedId": 19915144,
                    "title": "MEK1 mutations confer resistance to MEK and B-RAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19915144"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15868,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a lung adenocarcinoma patient harboring an EGFR exon 19 deletion and EGFR T790M demonstrated a partial response to treatment with Nazartinib (CO-1686), but developed progression in the liver after 11 months, and a post-progression biopsy identified the EGFR exon 19 deletion without EGFR T790M, and emergence of BRAF V600E (PMID: 30123863; NCT02108964).",
            "molecularProfile": {
                "id": 31305,
                "profileName": "EGFR exon 19 del BRAF V600E"
            },
            "therapy": {
                "id": 1309,
                "therapyName": "Nazartinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 13872,
                    "pubMedId": 30123863,
                    "title": "Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30123863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7700,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 V211D mutation and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Encorafenib (LGX818) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 21654,
                "profileName": "BRAF V600E MAP2K1 V211D"
            },
            "therapy": {
                "id": 1916,
                "therapyName": "Cetuximab + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7703,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 V211D mutation and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 21654,
                "profileName": "BRAF V600E MAP2K1 V211D"
            },
            "therapy": {
                "id": 4541,
                "therapyName": "Cetuximab + Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7704,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 V211D mutation and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to SCH772984 in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 21654,
                "profileName": "BRAF V600E MAP2K1 V211D"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5820,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K V211D demonstrated resistance to growth inhibition by CI-1040 in cell culture (PMID: 19915144).",
            "molecularProfile": {
                "id": 21654,
                "profileName": "BRAF V600E MAP2K1 V211D"
            },
            "therapy": {
                "id": 699,
                "therapyName": "CI-1040",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 134,
                    "pubMedId": 19915144,
                    "title": "MEK1 mutations confer resistance to MEK and B-RAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19915144"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7629,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Selumetinib (AZD6244) and Erbitux (cetuximab) combination treatment in culture, likely due to the acquired secondary resistant mutation of MAP2K1 V211D (PMID: 27312529).",
            "molecularProfile": {
                "id": 21654,
                "profileName": "BRAF V600E MAP2K1 V211D"
            },
            "therapy": {
                "id": 4536,
                "therapyName": "Cetuximab + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5821,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K V211D demonstrated resistance to growth inhibition by Selumetinib (AZD6244) in cell culture (PMID: 19915144).",
            "molecularProfile": {
                "id": 21654,
                "profileName": "BRAF V600E MAP2K1 V211D"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 134,
                    "pubMedId": 19915144,
                    "title": "MEK1 mutations confer resistance to MEK and B-RAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19915144"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12158,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BVD-523 (Ulixertinib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 V211D in culture (PMID: 28655712).",
            "molecularProfile": {
                "id": 21654,
                "profileName": "BRAF V600E MAP2K1 V211D"
            },
            "therapy": {
                "id": 997,
                "therapyName": "Ulixertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10118,
                    "pubMedId": 28655712,
                    "title": "BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28655712"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7702,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 V211D mutation and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to combination therapy consisting of Tafinlar (dabrafenib) and Mekinist (trametinib) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 21654,
                "profileName": "BRAF V600E MAP2K1 V211D"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12152,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 V211D demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).",
            "molecularProfile": {
                "id": 21654,
                "profileName": "BRAF V600E MAP2K1 V211D"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10118,
                    "pubMedId": 28655712,
                    "title": "BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28655712"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12155,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zelboraf (vemurafenib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 V211D in culture (PMID: 28655712).",
            "molecularProfile": {
                "id": 21654,
                "profileName": "BRAF V600E MAP2K1 V211D"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10118,
                    "pubMedId": 28655712,
                    "title": "BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28655712"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8565,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and growth of colorectal cancer cells harboring BRAF V600E, PIK3CA P449T, and TP53 R273H in culture and in cell line xenograft models, but did not have synergistic effect on apoptosis (PMID: 26272063).",
            "molecularProfile": {
                "id": 26358,
                "profileName": "BRAF V600E PIK3CA P449T TP53 R273H"
            },
            "therapy": {
                "id": 4771,
                "therapyName": "PD-0325901 + Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3221,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, EGFR S492R was detected in the post-Erbitux (cetuximab) sample from a colorectal cancer patient harboring EGFR amplification and BRAF V600E who progressed on an Erbitux (cetuximab) regimen (PMID: 22270724).",
            "molecularProfile": {
                "id": 12768,
                "profileName": "EGFR amp EGFR S492R BRAF V600E"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3682,
                    "pubMedId": 22270724,
                    "title": "Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22270724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6318,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, XL147 inhibited tumor growth in xenograft models of a PTEN-deficient human melanoma cell line harboring BRAF V600E (PMID: 25637314).",
            "molecularProfile": {
                "id": 23099,
                "profileName": "BRAF V600E PTEN loss"
            },
            "therapy": {
                "id": 1050,
                "therapyName": "XL147",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5522,
                    "pubMedId": 25637314,
                    "title": "The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25637314"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10891,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of GSK2636771 and a PD-1 antibody resulted in greater tumor infiltration of T-cells and tumor growth inhibition in mouse melanoma models expressing BRAF V600E with PTEN loss compared to either agent alone (PMID: 26645196).",
            "molecularProfile": {
                "id": 23099,
                "profileName": "BRAF V600E PTEN loss"
            },
            "therapy": {
                "id": 5673,
                "therapyName": "GSK2636771 + unspecified PD-1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4556,
                    "pubMedId": 26645196,
                    "title": "Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26645196"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1233,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, a melanoma patient harboring PTEN loss and BRAF V600E demonstrated resistance to Afinitor (everolimus) treatment, resulting in progressive disease (PMID: 20664172).",
            "molecularProfile": {
                "id": 23099,
                "profileName": "BRAF V600E PTEN loss"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 1067,
                    "pubMedId": 20664172,
                    "title": "Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20664172"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7899,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GDC0879 and Pictilisib (GDC-0941) synergistically inhibited survival of melanoma cell lines harboring BFAF V600E and PTEN loss in cell culture (PMID: 19276360).",
            "molecularProfile": {
                "id": 23099,
                "profileName": "BRAF V600E PTEN loss"
            },
            "therapy": {
                "id": 4605,
                "therapyName": "GDC0879 + Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6516,
                    "pubMedId": 19276360,
                    "title": "Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19276360"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7081,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma cell line harboring BRAF V600E and PTEN loss demonstrated sensitivity when treated with a combination of Pictilisib (GDC-0941) and PLX4720, resulting in decreased cell proliferation in culture (PMID: 24265153).",
            "molecularProfile": {
                "id": 23099,
                "profileName": "BRAF V600E PTEN loss"
            },
            "therapy": {
                "id": 4358,
                "therapyName": "Pictilisib + PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7592,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAP2K1 K57E in a melanoma cell line harboring BRAF V600E conferred resistance to Tafinlar (dabrafenib) in culture (PMID: 25370473).",
            "molecularProfile": {
                "id": 25914,
                "profileName": "BRAF V600E MAP2K1 K57E"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6439,
                    "pubMedId": 25370473,
                    "title": "Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25370473"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12163,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124L demonstrated a decreased response to treatment with Zelboraf (vemurafenib) in culture (PMID: 28655712).",
            "molecularProfile": {
                "id": 28498,
                "profileName": "BRAF V600E MAP2K1 P124L"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 10118,
                    "pubMedId": 28655712,
                    "title": "BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28655712"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12162,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124L demonstrated a decreased response to treatment with Mekinist (trametinib) in culture (PMID: 28655712).",
            "molecularProfile": {
                "id": 28498,
                "profileName": "BRAF V600E MAP2K1 P124L"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 10118,
                    "pubMedId": 28655712,
                    "title": "BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28655712"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5811,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, over expression of MAPK21 I103N in melanoma cells harboring BRAF V600E resulted in insensitivity to growth inhibition by PD-0325901 in cell culture (PMID: 26267534).",
            "molecularProfile": {
                "id": 21628,
                "profileName": "BRAF V600E MAP2K1 I103N"
            },
            "therapy": {
                "id": 849,
                "therapyName": "PD-0325901",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4897,
                    "pubMedId": 26267534,
                    "title": "Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26267534"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5816,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DEL-22379 inhibited growth of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 I103N in culture (PMID: 26267534).",
            "molecularProfile": {
                "id": 21628,
                "profileName": "BRAF V600E MAP2K1 I103N"
            },
            "therapy": {
                "id": 3769,
                "therapyName": "DEL-22379",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4897,
                    "pubMedId": 26267534,
                    "title": "Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26267534"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11052,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a colon cancer patient harboring BRAF V600E and TP53 Q192K demonstrated a partial response when treated with a combination of Zelboraf (vemurafenib) and Vectibix (panitumumab) (PMID: 28514312).",
            "molecularProfile": {
                "id": 27902,
                "profileName": "BRAF V600E TP53 Q192K"
            },
            "therapy": {
                "id": 1717,
                "therapyName": "Panitumumab + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9046,
                    "pubMedId": 28514312,
                    "title": "Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28514312"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11043,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma cell line xenograft model co-harboring BRAF V600E and a PTEN mutation demonstrated tumor growth inhibition when treated with ASN003 (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B100).",
            "molecularProfile": {
                "id": 27896,
                "profileName": "BRAF V600E PTEN mut"
            },
            "therapy": {
                "id": 5827,
                "therapyName": "ASN003",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9035,
                    "pubMedId": null,
                    "title": "Abstract B100: ASN003, a unique B-RAF inhibitor with additional selective activity against PI3K and mTOR kinases, shows strong antitumor activity in multiple xenograft models",
                    "url": "http://mct.aacrjournals.org/content/14/12_Supplement_2/B100.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7661,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination therapy consisting of Tafinlar (dabrafenib) and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 21627,
                "profileName": "BRAF V600E MAP2K1 L115P"
            },
            "therapy": {
                "id": 4544,
                "therapyName": "Dabrafenib + SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7656,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and Zelboraf (vemurafenib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 21627,
                "profileName": "BRAF V600E MAP2K1 L115P"
            },
            "therapy": {
                "id": 1711,
                "therapyName": "Cetuximab + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7660,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 21627,
                "profileName": "BRAF V600E MAP2K1 L115P"
            },
            "therapy": {
                "id": 4543,
                "therapyName": "Cetuximab + SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12151,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 L115P demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).",
            "molecularProfile": {
                "id": 21627,
                "profileName": "BRAF V600E MAP2K1 L115P"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10118,
                    "pubMedId": 28655712,
                    "title": "BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28655712"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12154,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zelboraf (vemurafenib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 L115P in culture (PMID: 28655712).",
            "molecularProfile": {
                "id": 21627,
                "profileName": "BRAF V600E MAP2K1 L115P"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10118,
                    "pubMedId": 28655712,
                    "title": "BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28655712"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5812,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, over expression of MAPK21 L115P in melanoma cells harboring BRAF V600E resulted in insensitivity to growth inhibition by PD-0325901 in cell culture (PMID: 26267534).",
            "molecularProfile": {
                "id": 21627,
                "profileName": "BRAF V600E MAP2K1 L115P"
            },
            "therapy": {
                "id": 849,
                "therapyName": "PD-0325901",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4897,
                    "pubMedId": 26267534,
                    "title": "Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26267534"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7659,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 21627,
                "profileName": "BRAF V600E MAP2K1 L115P"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5817,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DEL-22379 inhibited growth of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 L115P in culture (PMID: 26267534).",
            "molecularProfile": {
                "id": 21627,
                "profileName": "BRAF V600E MAP2K1 L115P"
            },
            "therapy": {
                "id": 3769,
                "therapyName": "DEL-22379",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4897,
                    "pubMedId": 26267534,
                    "title": "Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26267534"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7654,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and Encorafenib (LGX818) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 21627,
                "profileName": "BRAF V600E MAP2K1 L115P"
            },
            "therapy": {
                "id": 1916,
                "therapyName": "Cetuximab + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7620,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture, likely due to the acquired secondary resistance mutation MAP2K1 L115P (PMID: 27312529).",
            "molecularProfile": {
                "id": 21627,
                "profileName": "BRAF V600E MAP2K1 L115P"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7657,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Encorafenib (LGX818) and Alpelisib (BYL719) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 21627,
                "profileName": "BRAF V600E MAP2K1 L115P"
            },
            "therapy": {
                "id": 1917,
                "therapyName": "Alpelisib + Cetuximab + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7658,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 21627,
                "profileName": "BRAF V600E MAP2K1 L115P"
            },
            "therapy": {
                "id": 4541,
                "therapyName": "Cetuximab + Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7662,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 21627,
                "profileName": "BRAF V600E MAP2K1 L115P"
            },
            "therapy": {
                "id": 4542,
                "therapyName": "Cetuximab + Dabrafenib + SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7655,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and Tafinlar (dabrafenib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 21627,
                "profileName": "BRAF V600E MAP2K1 L115P"
            },
            "therapy": {
                "id": 4525,
                "therapyName": "Cetuximab + Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5979,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Talfinlar (dabrafenib) in combination with Mekinist (trametinib) resulted in improved growth inhibition of human melanoma cells harboring BRAF V600E and NRAS A146T and NRAS Q61K in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22097,
                "profileName": "BRAF V600E NRAS Q61K NRAS A146T"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17382,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with advanced non-small cell lung cancer who lost EGFR T790M, but still harbors EGFR E746_A750del and acquired BRAF V600E demonstrated an improved metabolic response when treated with the combination therapy of Sprycel (dabrafenib) and Tagrisso (osimertinib) (Journal of Clinical Oncology, 2019, 37, no. 15_suppl).",
            "molecularProfile": {
                "id": 32523,
                "profileName": "BRAF V600E EGFR E746_A750del"
            },
            "therapy": {
                "id": 8472,
                "therapyName": "Dabrafenib + Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15403,
                    "pubMedId": null,
                    "title": "Overcoming acquired osimertinib-resistance in EGFR-mutant advanced non-small lung cancer mediated by activating BRAF V600E mutation.",
                    "url": "https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.e20682"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17381,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with advanced non-small cell lung cancer who lost EGFR T790M, but still harbors EGFR E746_A750del and acquired BRAF V600E demonstrated continued progression while being treated with the combination therapy of Sprycel (dabrafenib) and Mekinist (trametinib) (Journal of Clinical Oncology, 2019, 37, no. 15_suppl).",
            "molecularProfile": {
                "id": 32523,
                "profileName": "BRAF V600E EGFR E746_A750del"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 15403,
                    "pubMedId": null,
                    "title": "Overcoming acquired osimertinib-resistance in EGFR-mutant advanced non-small lung cancer mediated by activating BRAF V600E mutation.",
                    "url": "https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.e20682"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7875,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colon cancer cells harboring BRAF N581Y were resistant to GDC0879 induced growth inhibition in culture (PMID: 19276360).",
            "molecularProfile": {
                "id": 23804,
                "profileName": "BRAF N581Y"
            },
            "therapy": {
                "id": 1095,
                "therapyName": "GDC0879",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6516,
                    "pubMedId": 19276360,
                    "title": "Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19276360"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16115,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (MyPathway), Zelboraf (vemurafenib) treatment resulted in an objective response in only 4% (1/23) of patient with advanced solid tumors harboring non-V600 BRAF mutations, 1 of the non-responding patients harbored BRAF G606E (PMID: 29320312; NCT02091141).",
            "molecularProfile": {
                "id": 2964,
                "profileName": "BRAF G606E"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13171,
                    "pubMedId": 29320312,
                    "title": "Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29320312"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13397,
            "approvalStatus": "Guideline",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "BRAF fusions aid in the diagnosis of pilocytic astrocytoma (NCCN.org).",
            "molecularProfile": {
                "id": 3287,
                "profileName": "BRAF fusion"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 4851,
                "name": "pilocytic astrocytoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13774,
            "approvalStatus": "Guideline",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "BRAF fusions are associated with indolent disease in patients with pilocytic astrocytoma (NCCN.org).",
            "molecularProfile": {
                "id": 3287,
                "profileName": "BRAF fusion"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 4851,
                "name": "pilocytic astrocytoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16110,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (MyPathway), Zelboraf (vemurafenib) treatment resulted in an objective response in only 4% (1/23) of patient with advanced solid tumors harboring non-V600 BRAF mutations, 2 of the non-responding patients harbored BRAF G464V (PMID: 29320312; NCT02091141).",
            "molecularProfile": {
                "id": 664,
                "profileName": "BRAF G464V"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13171,
                    "pubMedId": 29320312,
                    "title": "Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29320312"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9411,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF G464V (PMID: 26343582).",
            "molecularProfile": {
                "id": 664,
                "profileName": "BRAF G464V"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 7141,
                    "pubMedId": 26343582,
                    "title": "BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343582"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7957,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring both BRAF D594G and NRAS G12D demonstrated decreased sensitivity to Zelboraf (vemurafenib) in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 26096,
                "profileName": "BRAF D594G NRAS G12D"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7941,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAK-632 inhibited proliferation of melanoma cell lines harboring both BRAF D594G and NRAS G12D in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 26096,
                "profileName": "BRAF D594G NRAS G12D"
            },
            "therapy": {
                "id": 3300,
                "therapyName": "TAK-632",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7965,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring both BRAF D594G and NRAS G12D demonstrated decreased sensitivity to Tafinlar (dabrafenib) in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 26096,
                "profileName": "BRAF D594G NRAS G12D"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7951,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring both BRAF D594G and NRAS G12D demonstrated decreased sensitivity to PLX7904 in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 26096,
                "profileName": "BRAF D594G NRAS G12D"
            },
            "therapy": {
                "id": 4606,
                "therapyName": "PLX7904",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7911,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZ628 inhibited proliferation of melanoma cell lines harboring both BRAF D594G and NRAS G12D in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 26096,
                "profileName": "BRAF D594G NRAS G12D"
            },
            "therapy": {
                "id": 1093,
                "therapyName": "AZ628",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11654,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) reduced ERK signaling and inhibited proliferation of a melanoma cell line harboring BRAF D594G in culture (PMID: 28783719).",
            "molecularProfile": {
                "id": 989,
                "profileName": "BRAF D594G"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9692,
                    "pubMedId": 28783719,
                    "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28783719"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15621,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tafinlar (dabrafenib) did not inhibit Erk and Mek signaling in breast cancer cells expressing BRAF L514V in culture (PMID: 29880583).",
            "molecularProfile": {
                "id": 30812,
                "profileName": "BRAF L514V"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 12771,
                    "pubMedId": 29880583,
                    "title": "A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29880583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11662,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Mekinist (trametinib) and Capmatinib (INC280) induced tumor regression in a patient-derived xenograft (PDX) model derived from the ovarian metastasis of a patient with collecting duct carcinoma, which harbored BRAF D594N and BRAF G466A and had high levels of MET and EGFR expression (PMID: 28783719).",
            "molecularProfile": {
                "id": 28180,
                "profileName": "BRAF D594N BRAF G466A EGFR over exp MET over exp"
            },
            "therapy": {
                "id": 6103,
                "therapyName": "Capmatinib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 4464,
                "name": "collecting duct carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9692,
                    "pubMedId": 28783719,
                    "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28783719"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11660,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Capmatinib (INC280) inhibited tumor growth and reduced ERK signaling in a patient-derived xenograft (PDX) model derived from the ovarian metastasis of a patient with collecting duct carcinoma, which harbored BRAF D594N and BRAF G466A and had high levels of MET and EGFR expression (PMID: 28783719).",
            "molecularProfile": {
                "id": 28180,
                "profileName": "BRAF D594N BRAF G466A EGFR over exp MET over exp"
            },
            "therapy": {
                "id": 1065,
                "therapyName": "Capmatinib",
                "synonyms": null
            },
            "indication": {
                "id": 4464,
                "name": "collecting duct carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9692,
                    "pubMedId": 28783719,
                    "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28783719"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11661,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Mekinist (trametinib) inhibited tumor growth and reduced ERK signaling in a patient-derived xenograft (PDX) model derived from the ovarian metastasis of a patient with collecting duct carcinoma, which harbored BRAF D594N and BRAF G466A and had high levels of MET and EGFR expression (PMID: 28783719).",
            "molecularProfile": {
                "id": 28180,
                "profileName": "BRAF D594N BRAF G466A EGFR over exp MET over exp"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 4464,
                "name": "collecting duct carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9692,
                    "pubMedId": 28783719,
                    "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28783719"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11666,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zelboraf (vemurafenib) did not reduce activation of Mek in transformed cells expressing BRAF D594N in culture (PMID: 28783719).",
            "molecularProfile": {
                "id": 987,
                "profileName": "BRAF D594N"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 9692,
                    "pubMedId": 28783719,
                    "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28783719"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15998,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RMC-4550 treatment resulted in decreased Erk phosphorylation and dose-dependent tumor growth inhibition in patient-derived xenograft (PDX) models of non-small cell lung cancer harboring BRAF D594N (PMID: 30104724).",
            "molecularProfile": {
                "id": 987,
                "profileName": "BRAF D594N"
            },
            "therapy": {
                "id": 7839,
                "therapyName": "RMC-4550",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14089,
                    "pubMedId": 30104724,
                    "title": "RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30104724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11667,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) growth of a non-small cell lung cancer cell line harboring BRAF G466V and expressing NRAS Q61K in culture (PMID: 28783719).",
            "molecularProfile": {
                "id": 28181,
                "profileName": "BRAF G466V NRAS Q61K"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9692,
                    "pubMedId": 28783719,
                    "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28783719"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11663,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with metastatic colorectal cancer harboring BRAF G466V, and with wild-type RAS and NF1, demonstrated tumor regression following treatment with Vectibix (panitumumab) plus Camptosar (irinotecan) (PMID: 28783719).",
            "molecularProfile": {
                "id": 669,
                "profileName": "BRAF G466V"
            },
            "therapy": {
                "id": 4138,
                "therapyName": "Irinotecan + Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9692,
                    "pubMedId": 28783719,
                    "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28783719"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11653,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) reduced ERK signaling and inhibited proliferation of non-small cell lung cancer cell lines harboring BRAF G466V in culture (PMID: 28783719).",
            "molecularProfile": {
                "id": 669,
                "profileName": "BRAF G466V"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9692,
                    "pubMedId": 28783719,
                    "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28783719"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12073,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PLX8394 decreased growth of lung adenocarcinoma cell lines harboring BRAF G466V in culture (PMID: 27834212).",
            "molecularProfile": {
                "id": 669,
                "profileName": "BRAF G466V"
            },
            "therapy": {
                "id": 1041,
                "therapyName": "PLX8394",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10006,
                    "pubMedId": 27834212,
                    "title": "Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27834212"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11736,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) resulted in decreased proliferation and increased apoptosis, and enhanced ERK inhibition compared to either agent alone in a non-small cell lung cancer cell line harboring BRAF G466V in culture (PMID: 28947956).",
            "molecularProfile": {
                "id": 669,
                "profileName": "BRAF G466V"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12147,
                    "pubMedId": 28947956,
                    "title": "Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28947956"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 691,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sprycel (dasatinib) induced apoptosis in non-small cell lung cancer cells expressing BRAF G466V in culture (PMID: 22649091).",
            "molecularProfile": {
                "id": 669,
                "profileName": "BRAF G466V"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 423,
                    "pubMedId": 22649091,
                    "title": "Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22649091"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16114,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (MyPathway), Zelboraf (vemurafenib) treatment resulted in an objective response in only 4% (1/23) of patient with advanced solid tumors harboring non-V600 BRAF mutations, 1 of the non-responding patients harbored BRAF G466V (PMID: 29320312; NCT02091141).",
            "molecularProfile": {
                "id": 669,
                "profileName": "BRAF G466V"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13171,
                    "pubMedId": 29320312,
                    "title": "Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29320312"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7942,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAK-632 inhibited proliferation of non-small cell lung cancer cells harboring BRAF G466V in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 669,
                "profileName": "BRAF G466V"
            },
            "therapy": {
                "id": 3300,
                "therapyName": "TAK-632",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11657,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Erbitux (cetuximab) reduced ERK signaling and resulted in tumor regression in a colorectal cancer patient-derived xenograft (PDX) model harboring BRAF G466V, and wild-type RAS and NF1 (PMID: 28783719).",
            "molecularProfile": {
                "id": 669,
                "profileName": "BRAF G466V"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9692,
                    "pubMedId": 28783719,
                    "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28783719"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15985,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RMC-4550 inhibited Erk phosphorylation and proliferation of lung cancer cells harboring BRAF G466V in culture (PMID: 30104724).",
            "molecularProfile": {
                "id": 669,
                "profileName": "BRAF G466V"
            },
            "therapy": {
                "id": 7839,
                "therapyName": "RMC-4550",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14089,
                    "pubMedId": 30104724,
                    "title": "RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30104724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11658,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Mekinist (trametinib) delayed tumor growth in a colorectal cancer patient-derived xenograft (PDX) model harboring BRAF G466V, and wild-type RAS and NF1 (PMID: 28783719).",
            "molecularProfile": {
                "id": 669,
                "profileName": "BRAF G466V"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9692,
                    "pubMedId": 28783719,
                    "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28783719"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7958,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells harboring BRAF G466V demonstrated decreased sensitivity to Zelboraf (vemurafenib) in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 669,
                "profileName": "BRAF G466V"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3934,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAE226 treatment inhibited proliferation of non-small cell lung carcinoma cell lines harboring BRAF G466V mutation in culture (PMID: 26090892).",
            "molecularProfile": {
                "id": 669,
                "profileName": "BRAF G466V"
            },
            "therapy": {
                "id": 2086,
                "therapyName": "TAE226",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4301,
                    "pubMedId": 26090892,
                    "title": "TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26090892"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11659,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zelboraf (vemurafenib) did not inhibit ERK signaling or tumor growth in a colorectal cancer patient-derived xenograft (PDX) model harboring BRAF G466V, and wild-type RAS and NF1 (PMID: 28783719).",
            "molecularProfile": {
                "id": 669,
                "profileName": "BRAF G466V"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 9692,
                    "pubMedId": 28783719,
                    "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28783719"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8231,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ganetespib treatment resulted in decreased activation of MEK, AKT, and ERK and inhibited growth of a non-small cell lung cancer cell line with wild-type EGFR and BRAF G466V in culture, and inhibited tumor growth in xenograft models (PMID: 25077897).",
            "molecularProfile": {
                "id": 26202,
                "profileName": "BRAF G466V EGFR wild-type"
            },
            "therapy": {
                "id": 745,
                "therapyName": "Ganetespib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2971,
                    "pubMedId": 25077897,
                    "title": "The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25077897"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10261,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 combination treatment resulted in significant apoptosis in primary tumor cells isolated from a lung adenocarcinoma patient harboring BRAF N581S in culture (PMID: 26140595).",
            "molecularProfile": {
                "id": 3326,
                "profileName": "BRAF N581S"
            },
            "therapy": {
                "id": 5443,
                "therapyName": "PF-00477736 + PF3644022",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8232,
                    "pubMedId": 26140595,
                    "title": "A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26140595"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16113,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (MyPathway), Zelboraf (vemurafenib) treatment resulted in an objective response in only 4% (1/23) of patient with advanced solid tumors harboring non-V600 BRAF mutations, 2 of the non-responding patients harbored BRAF N581S (PMID: 29320312; NCT02091141).",
            "molecularProfile": {
                "id": 3326,
                "profileName": "BRAF N581S"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13171,
                    "pubMedId": 29320312,
                    "title": "Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29320312"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9333,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a rectal adenocarcinoma patient harboring APC Q1429fs, BRAF N581S, and ERBB2 L755S did not respond to Herceptin (trastuzumab) treatment in combination with Fluorouracil and Wellcovorin (leucovorin) (PMID: 27626067).",
            "molecularProfile": {
                "id": 26822,
                "profileName": "APC Q1429fs BRAF N581S ERBB2 L755S"
            },
            "therapy": {
                "id": 4970,
                "therapyName": "Fluorouracil + Leucovorin + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 1996,
                "name": "rectum adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 7088,
                    "pubMedId": 27626067,
                    "title": "Testing ERBB2 p.L755S kinase domain mutation as a druggable target in a patient with advanced colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27626067"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12697,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, treatment with BVD-523 (Ulixertinib) resulted in a complete response lasting almost 1 year in a gallbladder cancer patient harboring BRAF L485W (PMID: 29247016, PMID: 29247021).",
            "molecularProfile": {
                "id": 28841,
                "profileName": "BRAF L485W"
            },
            "therapy": {
                "id": 997,
                "therapyName": "Ulixertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3121,
                "name": "gallbladder cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10607,
                    "pubMedId": 29247021,
                    "title": "First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29247021"
                },
                {
                    "id": 10750,
                    "pubMedId": 29247016,
                    "title": "Accelerating Discovery of Functional Mutant Alleles in Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29247016"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12696,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, treatment with BVD-523 (ulixertinib) resulted in a partial response in a lung cancer patient harboring BRAF L597Q (PMID: 29247021).",
            "molecularProfile": {
                "id": 993,
                "profileName": "BRAF L597Q"
            },
            "therapy": {
                "id": 997,
                "therapyName": "Ulixertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10607,
                    "pubMedId": 29247021,
                    "title": "First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29247021"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16116,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (MyPathway), Zelboraf (vemurafenib) treatment resulted in an objective response in only 4% (1/23) of patient with advanced solid tumors harboring non-V600 BRAF mutations, 1 of the non-responding patients harbored BRAF L597Q (PMID: 29320312; NCT02091141).",
            "molecularProfile": {
                "id": 993,
                "profileName": "BRAF L597Q"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13171,
                    "pubMedId": 29320312,
                    "title": "Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29320312"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9416,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF L597Q (PMID: 26343582).",
            "molecularProfile": {
                "id": 993,
                "profileName": "BRAF L597Q"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 7141,
                    "pubMedId": 26343582,
                    "title": "BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343582"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4924,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a non-small cell lung carcinoma cell line harboring BRAF L485_P490delinsY was sensitive to LY3009120 in both culture and xenograft models, resulting in significant tumor regression and inhibition of MEK and ERK phosphorylation (PMID: 26732095).",
            "molecularProfile": {
                "id": 19835,
                "profileName": "BRAF L485_P490delinsY"
            },
            "therapy": {
                "id": 3268,
                "therapyName": "LY3009120",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4801,
                    "pubMedId": 26732095,
                    "title": "Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26732095"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4926,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a non-small cell lung carcinoma cell line harboring BRAF L485_P490delinsY was resistant to Tafinlar (dabrafenib) (PMID: 26732095).",
            "molecularProfile": {
                "id": 19835,
                "profileName": "BRAF L485_P490delinsY"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4801,
                    "pubMedId": 26732095,
                    "title": "Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26732095"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4925,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a non-small cell lung carcinoma cell line harboring BRAF L485_P490delinsY was sensitive to Mekinist (trametinib), resulting in cell growth inhibition (PMID: 26732095).",
            "molecularProfile": {
                "id": 19835,
                "profileName": "BRAF L485_P490delinsY"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4801,
                    "pubMedId": 26732095,
                    "title": "Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26732095"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11370,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing BRAF F247L demonstrated sensitivity to Mekinist (trametinib) in culture (PMID: 28512244).",
            "molecularProfile": {
                "id": 27972,
                "profileName": "BRAF F247L"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9257,
                    "pubMedId": 28512244,
                    "title": "Engineering and Functional Characterization of Fusion Genes Identifies Novel Oncogenic Drivers of Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28512244"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11371,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing BRAF F247L demonstrated sensitivity to Tafinlar (dabrafenib) in culture (PMID: 28512244).",
            "molecularProfile": {
                "id": 27972,
                "profileName": "BRAF F247L"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9257,
                    "pubMedId": 28512244,
                    "title": "Engineering and Functional Characterization of Fusion Genes Identifies Novel Oncogenic Drivers of Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28512244"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7876,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells harboring BRAF L485Y were resistant to GDC0879 induced growth inhibition in culture (PMID: 19276360).",
            "molecularProfile": {
                "id": 26081,
                "profileName": "BRAF L485Y"
            },
            "therapy": {
                "id": 1095,
                "therapyName": "GDC0879",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6516,
                    "pubMedId": 19276360,
                    "title": "Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19276360"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4457,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Keytruda (pembrolizumab) resulted in no benefit in a melanoma mouse model co-harboring a BRAF mutation and PTEN loss (PMID: 26645196).",
            "molecularProfile": {
                "id": 18163,
                "profileName": "BRAF mut PTEN loss"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4556,
                    "pubMedId": 26645196,
                    "title": "Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26645196"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4456,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK2636771 resulted in no benefit in a melanoma mouse model co-harboring a BRAF mutation and PTEN loss (PMID: 26645196).",
            "molecularProfile": {
                "id": 18163,
                "profileName": "BRAF mut PTEN loss"
            },
            "therapy": {
                "id": 765,
                "therapyName": "GSK2636771",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4556,
                    "pubMedId": 26645196,
                    "title": "Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26645196"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7773,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SAR260301 and Zelboraf (vemurafenib) synergistically inhibited proliferation of PTEN deficient melanoma cells harboring BRAF mutations in culture and suppressed tumor growth in cell line xenograft models (PMID: 27196754).",
            "molecularProfile": {
                "id": 18163,
                "profileName": "BRAF mut PTEN loss"
            },
            "therapy": {
                "id": 1225,
                "therapyName": "SAR260301 + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6491,
                    "pubMedId": 27196754,
                    "title": "Concomitant Inhibition of PI3K\u03b2 and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3K\u03b2-Selective Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196754"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4455,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma mouse model harboring a BRAF mutation and PTEN loss was sensitive to the combination of GSK2636771 and Keytruda (pembrolizumab), demonstrating greater tumor growth inhibition and improved survival when compared to either therapy alone (PMID: 26645196).",
            "molecularProfile": {
                "id": 18163,
                "profileName": "BRAF mut PTEN loss"
            },
            "therapy": {
                "id": 3518,
                "therapyName": "GSK2636771 + Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4556,
                    "pubMedId": 26645196,
                    "title": "Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26645196"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7771,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SAR260301 inhibited proliferation of PTEN deficient melanoma cells harboring BRAF mutations in culture and suppressed tumor growth in cell line xenograft models (PMID: 27196754).",
            "molecularProfile": {
                "id": 18163,
                "profileName": "BRAF mut PTEN loss"
            },
            "therapy": {
                "id": 1052,
                "therapyName": "SAR260301",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6491,
                    "pubMedId": 27196754,
                    "title": "Concomitant Inhibition of PI3K\u03b2 and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3K\u03b2-Selective Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196754"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7774,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SAR260301 and Selumetinib (AZD6244) synergistically inhibited proliferation of PTEN deficient melanoma cells harboring BRAF mutations in culture and suppressed tumor growth in cell line xenograft models (PMID: 27196754).",
            "molecularProfile": {
                "id": 18163,
                "profileName": "BRAF mut PTEN loss"
            },
            "therapy": {
                "id": 4573,
                "therapyName": "SAR260301 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6491,
                    "pubMedId": 27196754,
                    "title": "Concomitant Inhibition of PI3K\u03b2 and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3K\u03b2-Selective Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196754"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8676,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) and AZ628 synergistically inhibited Mapk signaling and cell proliferation in BRAF mutant colorectal cancer cell lines in culture (PMID: 26351322).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 4791,
                "therapyName": "AZ628 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6708,
                    "pubMedId": 26351322,
                    "title": "Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351322"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2529,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PLX8394 blocked survival and growth of vemurafenib/PLX4720-resistant melanoma cells harboring BRAF V600E splice variants in culture (PMID: 24422853).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 1041,
                "therapyName": "PLX8394",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 195,
                    "pubMedId": 24422853,
                    "title": "Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24422853"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11932,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, treatment with the triple combination of Tafinlar (dabrafenib), Mekinist (trametinib), and Vectibix (panitumumab) resulted in an objective response rate (ORR) of 21% and median progression-free survival (mPFS) of 4.2 mo, compared with 0% ORR and mPFS of 2.6 mo with Mekinist (trametinib) plus Vectibix (panitumumab), and 10% ORR and mPFS of 3.5 mo with Tafinlar (dabrafenib) plus Vectibix (panitumumab) in patients with BRAF-mutant colorectal cancer (PMID: 27770002; NCT01750918).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 1992,
                "therapyName": "Dabrafenib + Panitumumab + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9918,
                    "pubMedId": 27770002,
                    "title": "Triple Therapy Improves Colorectal Cancer Response.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27770002"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14051,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cancer cell lines harboring BRAF mutations demonstrated increased sensitivity to RAF709 compared to BRAF wild-type cells in culture (PMID: 29343524).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 6995,
                "therapyName": "RAF709",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11434,
                    "pubMedId": 29343524,
                    "title": "Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29343524"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5624,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, E6201 inhibited proliferation of several melanoma cell lines in culture and hypersensitivity was associated with BRAF mutations (PMID: 23039341).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 1011,
                "therapyName": "E6201",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1840,
                    "pubMedId": 23039341,
                    "title": "Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23039341"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7228,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, BGB-283 demonstrated safety and preliminary efficacy, resulted in partial response in 14% (4/29), and prolonged stable disease in 48% (14/29) of advanced solid tumor patients harboring mutations in KRAS, NRAS, and/or BRAF (AACR Annual Meeting, Apr 2016, abstract # CT005).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 4025,
                "therapyName": "BGB-283",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6230,
                    "pubMedId": null,
                    "title": "Phase I study of RAF dimer inhibitor BGB-283 in patients with B-RAF or K-RAS/N-RAS mutated solid tumors",
                    "url": "http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=dc4584a4-d39b-485a-9579-be210c4876e9&cKey=46a0776a-1444-49d6-b533-4f68e298c39d&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9612,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) resulted in decreased proliferation and increased apoptosis and enhanced ERK inhibition compared to either agent alone in non-small cell lung cancer cell lines harboring non-BRAF V600 mutations in culture (PMID: 28947956).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 12147,
                    "pubMedId": 28947956,
                    "title": "Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28947956"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6738,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a majority of human colorectal cancer cell lines (4/7) harboring mutant BRAF were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7827,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with BI-847325 resulted in decreased expression of Mcl-1 and Mek, and inhibited growth of BRAF-mutant melanoma cell lines in culture, and inhibited tumor growth melanoma cell line xenograft models harboring BRAF mutations, including models with BRAF inhibitor resistance (PMID: 25873592).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 1059,
                "therapyName": "BI-847325",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6506,
                    "pubMedId": 25873592,
                    "title": "The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25873592"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6302,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, tumor cell lines harboring BRAF mutations demonstrated limited sensitivity to XL147 treatment in culture (PMID: 25637314).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 1050,
                "therapyName": "XL147",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 5522,
                    "pubMedId": 25637314,
                    "title": "The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25637314"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9609,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MLN2480 inhibited downstream signaling and proliferation of several BRAF mutant solid tumor cell lines in culture (EJC Supp, Nov 2010, Vol 8(7), p40-41).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 1034,
                "therapyName": "MLN2480",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7320,
                    "pubMedId": null,
                    "title": "105 BIIB024, a potent pan-Raf kinase inhibitor for melanoma and solid tumors",
                    "url": "http://www.ejcancersupplements.com/article/S1359-6349%2810%2971810-3/abstract"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12133,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Encorafenib (LGX818) treatment resulted in an overall response rate (ORR) of 60% (15/25) and a median progression-free survival (mPFS) of 12.4 months in BRAF inhibitor-na\u00efve melanoma patients harboring BRAF mutations, and an ORR of 22% (6/29) and mPFS of 1.9 months in BRAF inhibitor-pretreated patients (PMID: 28611198; NCT01436656).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 796,
                "therapyName": "Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10108,
                    "pubMedId": 28611198,
                    "title": "Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28611198"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11701,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of BRAF-mutant gastric carcinoma (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 5747,
                "therapyName": "KO-947",
                "synonyms": null
            },
            "indication": {
                "id": 5517,
                "name": "stomach carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9707,
                    "pubMedId": null,
                    "title": "KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors",
                    "url": "http://cancerres.aacrjournals.org/content/77/13_Supplement/5168.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14941,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Belvarafenib (HM95573) inhibited growth of BRAF mutant thyroid cancer cells in culture (Cancer Res 2015;75(15 Suppl):Abstract nr 2607).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 7209,
                "therapyName": "Belvarafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1781,
                "name": "thyroid cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11830,
                    "pubMedId": null,
                    "title": "Antitumor activity of the selective RAF inhibitor HM95573 in solid tumors and hematologic malignancies",
                    "url": "http://cancerres.aacrjournals.org/content/75/15_Supplement/2607"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13934,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, patient-derived xenograft (PDX) models of colorectal cancer harboring KRAS, NRAS or BRAF mutations demonstrated poor response to SYM004 treatment compared to wild-type models (PMID: 29423521).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 931,
                "therapyName": "SYM004",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11366,
                    "pubMedId": 29423521,
                    "title": "Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29423521"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11699,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of BRAF-mutant colorectal cancer (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 5747,
                "therapyName": "KO-947",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9707,
                    "pubMedId": null,
                    "title": "KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors",
                    "url": "http://cancerres.aacrjournals.org/content/77/13_Supplement/5168.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8542,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma cell line harboring a BRAF mutation demonstrated greater sensitivity to the combination treatment of Mekinist (trametinib) and Ibrance (palbociclib) in culture when compared to either agent alone (PMID: 27488531).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 1368,
                "therapyName": "Palbociclib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6683,
                    "pubMedId": 27488531,
                    "title": "An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27488531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11066,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ia trial, CC-90003 treatment did not result in any objective responses and demonstrated toxicity in advanced solid tumor patients harboring KRAS, NRAS, or BRAF mutations (AJ Clin Oncol 35, 2017 (suppl; abstr 2577)).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 2874,
                "therapyName": "CC-90003",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 9060,
                    "pubMedId": null,
                    "title": "A phase Ia study of CC-90003, a selective extracellular signal-regulated kinase (ERK) inhibitor, in patients with relapsed or refractory BRAF or RAS-mutant tumors.",
                    "url": "http://abstracts.asco.org/199/AbstView_199_186986.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17310,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, LXH 254 treatment resulted in partial response in 2.6% (2/75) and stable disease in 33% (25/75) of patients with advanced solid tumors harboring MAPK pathway alterations, one of the patient achieved partial response harbored a BRAF mutation (J Clin Oncol 36, no. 15_suppl (May 20 2018) 2586-2586; NCT02607813).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 4442,
                "therapyName": "LXH 254",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15361,
                    "pubMedId": null,
                    "title": "A phase I study of LXH254 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations.",
                    "url": "https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.2586"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12194,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LSN3074753 and Erbitux (cetuximab) synergistically inhibited tumor growth in patient-derived xenograft models of colorectal cancer harboring BRAF mutations, resulted in a disease control rate of 41.7% (5/12) (PMID: 28611205).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 6338,
                "therapyName": "Cetuximab + LSN3074753",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10143,
                    "pubMedId": 28611205,
                    "title": "Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28611205"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5891,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Voruciclib (P1446A-05) and Zelboraf (vemurafenib) combination therapy demonstrated safety and preliminary efficacy, resulted in complete response in 33% (1/3) and partial response in 67% (2/3) of BRAFi-na\u00efve melanoma patients harboring BRAF mutations (J Clin Oncol 33, 2015 (suppl; abstr 9076)).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 1238,
                "therapyName": "Vemurafenib + Voruciclib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5185,
                    "pubMedId": null,
                    "title": "Phase I trial of the CDK 4/6 inhibitor, P1446A-05 (voruciclib) in combination with the BRAF inhibitor (BRAFi), vemurafenib in advanced, BRAF-mutant melanoma.",
                    "url": "http://meetinglibrary.asco.org/content/153239-156"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10124,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Buparlisib (BKM120) treatment in human melanoma cell line xenograft models with brain metastases and harboring a BRAF mutation resulted in inhibition of brain tumor growth (PMID: 27307593).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 680,
                "therapyName": "Buparlisib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8051,
                    "pubMedId": 27307593,
                    "title": "PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27307593"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6697,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) inhibited growth of lung adenocarcinoma cells harboring mutant BRAF in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10123,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Buparlisib (BKM120) and Encorafenib (LGX818) resulted in improved cell growth inhibition compared to either agent alone in a metastatic melanoma cell line harboring a BRAF mutation in culture (PMID: 27307593).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 1337,
                "therapyName": "Buparlisib + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8051,
                    "pubMedId": 27307593,
                    "title": "PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27307593"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1823,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, obatoclax decreased proliferation in human tumor cell lines with BRAF mutation in culture (PMID: 22460902).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 834,
                "therapyName": "Obatoclax",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2158,
                    "pubMedId": 22460902,
                    "title": "Systematic identification of genomic markers of drug sensitivity in cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22460902"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1028,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I study, selumetinib demonstrated an increase in iodine uptake and retention in a subgroup of patients with thyroid cancer that was refractory to radioiodine; including patients with BRAF and NRAS mutations disease (PMID: 23406027).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1781,
                "name": "thyroid cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 744,
                    "pubMedId": 23406027,
                    "title": "Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23406027"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11703,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of BRAF-mutant cervical carcinoma (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 5747,
                "therapyName": "KO-947",
                "synonyms": null
            },
            "indication": {
                "id": 2893,
                "name": "cervix carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9707,
                    "pubMedId": null,
                    "title": "KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors",
                    "url": "http://cancerres.aacrjournals.org/content/77/13_Supplement/5168.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11203,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib/II trial, the combination therapy of Erbitux (cetuximab) and Encorafenib (LGX818) in colorectal cancer patients harboring a BRAF mutation resulted in an overall response rate of 19% (5/26), including 1 patient with a complete response and 4 patients with a partial response, and led to a median progression free survival of 3.7 months and response duration of 46 weeks (PMID: 28363909).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 1916,
                "therapyName": "Cetuximab + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9149,
                    "pubMedId": 28363909,
                    "title": "A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28363909"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10254,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited growth of various cancer cell lines harboring BRAF mutations in culture and in cell line xenograft models (PMID: 26140595).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 5443,
                "therapyName": "PF-00477736 + PF3644022",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8232,
                    "pubMedId": 26140595,
                    "title": "A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26140595"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1127,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MLN2480 demonstrated efficacy in BRAF mutant xenograft models of melanoma and colorectal cancer (J Clin Oncol 31, 2013 (suppl; abstr e13529)).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 1034,
                "therapyName": "MLN2480",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 876,
                    "pubMedId": null,
                    "title": "Use of combination treatment with the investigational RAF kinase inhibitor MLN2480 and the investigational MEK kinase inhibitor TAK-733 on the growth of BRAF-mutant and RAS-mutant preclinical models of melanoma and CRC.",
                    "url": "http://meetinglibrary.asco.org/content/114757-132"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14940,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Belvarafenib (HM95573) inhibited growth of BRAF mutant colorectal cancer cell lines in culture and in cell line xenograft models (Cancer Res 2015;75(15 Suppl):Abstract nr 2607).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 7209,
                "therapyName": "Belvarafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11830,
                    "pubMedId": null,
                    "title": "Antitumor activity of the selective RAF inhibitor HM95573 in solid tumors and hematologic malignancies",
                    "url": "http://cancerres.aacrjournals.org/content/75/15_Supplement/2607"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12099,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, mutant BRAF correlated with prolonged duration on immune checkpoint inhibitor therapy compared to wild-type BRAF in non-small cell lung cancer patients (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #1138PD).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 3890,
                "therapyName": "unspecified PD-1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10039,
                    "pubMedId": null,
                    "title": "Immune checkpoint inhibitor (ICPI) efficacy and resistance detected by comprehensive genomic profiling (CGP) in non-small cell lung cancer (NSCLC)",
                    "url": "http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15662,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial (PREVIUM), Stivarga (regorafenib) treatment resulted in 0% (0/15) 6-month progression free survival (PFS), a 2.2-month median PFS, and a median overall survival of 3.3 months in metastatic colorectal cancer patients with KRAS (n=9), NRAS (n=3) or BRAF (n=2) mutations who failed first line therapy; however, the trial was terminated early due to poor accrual (PMID: 30120161; NCT02175654).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 890,
                "therapyName": "Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13568,
                    "pubMedId": 30120161,
                    "title": "Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30120161"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 10259,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited tumor growth in cell line xenograft models of BRAF mutant colon cancer (PMID: 26140595).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 5443,
                "therapyName": "PF-00477736 + PF3644022",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8232,
                    "pubMedId": 26140595,
                    "title": "A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26140595"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10459,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Binimetinib (MEK162) treatment resulted in an estimated progression free survival of 1.4 months and overall survival of 7.1 months in colorectal cancer patients harboring BRAF mutations (PMID: 28152546).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 807,
                "therapyName": "Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8465,
                    "pubMedId": 28152546,
                    "title": "A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28152546"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4764,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tubastatin A inhibited proliferation of BRAF mutant melanoma cell lines in culture (PMID: 25957812).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 3635,
                "therapyName": "Tubastatin A",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4713,
                    "pubMedId": 25957812,
                    "title": "Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25957812"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5627,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, E6201 and LY294002 synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations in culture, regardless of PTEN mutation status (PMID: 23039341).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 3911,
                "therapyName": "E6201 + LY294002",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1840,
                    "pubMedId": 23039341,
                    "title": "Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23039341"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11697,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of BRAF-mutant pancreatic cancer (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 5747,
                "therapyName": "KO-947",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9707,
                    "pubMedId": null,
                    "title": "KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors",
                    "url": "http://cancerres.aacrjournals.org/content/77/13_Supplement/5168.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6961,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib/II trial, the triple combination therapy of Encorafenib (LGX818), Erbitux (cetuximab), and Alpelisib (BYL719) resulted in an overall response rate of 18% (5/28), including 5 patients with a partial response, and led to a median progression free survival of 4.2 months and response duration of 12 weeks (PMID: 28363909).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 1917,
                "therapyName": "Alpelisib + Cetuximab + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5987,
                    "pubMedId": null,
                    "title": "Phase 2 results: Encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC).",
                    "url": "http://meetinglibrary.asco.org/content/166237-176"
                },
                {
                    "id": 9149,
                    "pubMedId": 28363909,
                    "title": "A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28363909"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12282,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ST-162 treatment resulted in tumor regression in BRAF mutant-melanoma cell line xenograft models (PMID: 28775144).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 6418,
                "therapyName": "ST-162",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10258,
                    "pubMedId": 28775144,
                    "title": "A Bifunctional MAPK/PI3K Antagonist for Inhibition of Tumor Growth and Metastasis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28775144"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6731,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) inhibited growth of human pancreatic adenocarcinoma cells harboring mutant BRAF in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 4074,
                "name": "pancreatic adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11695,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of BRAF-mutant non-small cell lung cancer harboring (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 5747,
                "therapyName": "KO-947",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9707,
                    "pubMedId": null,
                    "title": "KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors",
                    "url": "http://cancerres.aacrjournals.org/content/77/13_Supplement/5168.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11693,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of BRAF-mutant melanoma (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 5747,
                "therapyName": "KO-947",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9707,
                    "pubMedId": null,
                    "title": "KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors",
                    "url": "http://cancerres.aacrjournals.org/content/77/13_Supplement/5168.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10965,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KO-947 resulted in tumor regression in patient derived xenograft (PDX) models harboring either a BRAF mutation, NRAS mutation, or KRAS mutation (EJC Dec 2016, 69:1; S126).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 5747,
                "therapyName": "KO-947",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8965,
                    "pubMedId": null,
                    "title": "KO-947, a potent and selective ERK inhibitor with slow dissociation kinetics",
                    "url": "http://www.ejcancer.com/article/S0959-8049(16)32974-4/abstract"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 701,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, Tafinlar (dabrafenib) demonstrated safety and efficacy in patients with BRAF V600E positive solid tumors (PMID: 22608338).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 467,
                    "pubMedId": 22608338,
                    "title": "Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22608338"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 713,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial in patients with advanced melanoma, 5/6 patients exhibiting a response to selumetinib had BRAF-mutant tumors (PMID: 22048237).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 228,
                    "pubMedId": 22048237,
                    "title": "Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22048237"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17210,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In Phase I trials, Belvarafenib (HM95573) treatment resulted in partial response in a patients with BRAF-mutant melanoma in a dose escalation study, and partial response in 33% (2/6) of BRAF-mutant melanoma patients in a dose expansion study (J Clin Oncol 37, 2019 (suppl; abstr 3000); NCT02405065, NCT03118817).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 7209,
                "therapyName": "Belvarafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15236,
                    "pubMedId": null,
                    "title": "Belvarafenib, a novel pan-RAF inhibitor, in solid tumor patients harboring BRAF, KRAS, or NRAS mutations: Phase I study.",
                    "url": "http://abstracts.asco.org/239/AbstView_239_248211.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8667,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BRAF mutant colorectal cancer cell lines demonstrated reduced sensitivity to PLX4720 in culture (PMID: 26351322).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 1060,
                "therapyName": "PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6708,
                    "pubMedId": 26351322,
                    "title": "Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351322"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9041,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of S63845 and Zelboraf (vemurafenib) resulted in potent cytotoxic effects in BRAF-mutated melanoma cells in culture compared to the cytostatic effect of Zelboraf (vemurafenib) alone (PMID: 27760111).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 4865,
                "therapyName": "S63845 + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6851,
                    "pubMedId": 27760111,
                    "title": "The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760111"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10120,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Binimetinib (MEK162) and Buparlisib (BKM120) resulted in improved cell growth inhibition compared to either agent alone in a metastatic melanoma cell line harboring a BRAF mutation in culture (PMID: 27307593).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 5400,
                "therapyName": "Binimetinib + Buparlisib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8051,
                    "pubMedId": 27307593,
                    "title": "PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27307593"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11223,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PET-16 and Zelboraf (vemurafenib) synergistically inhibited growth of melanoma cell lines in culture, resulted in enhanced tumor growth inhibition in cell ine xenograft models (PMID: 26984758).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 5911,
                "therapyName": "PET-16 + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8968,
                    "pubMedId": 26984758,
                    "title": "HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26984758"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11978,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, MLN2480 resulted in a median progression free survival of 4.6 months and a partial response in 50% (8/16) of melanoma patients harboring a BRAF mutation (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 410P; NCT01425008).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 1034,
                "therapyName": "MLN2480",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9943,
                    "pubMedId": null,
                    "title": "Phase I study of the investigational, oral pan-RAF kinase inhibitor TAK- 580 (MLN2480) in patients with advanced solid tumors (ST) or melanoma (MEL): Final analysis",
                    "url": "http://www.esmo.org/Conferences/ESMO-2017-Congress/Abstracts"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1128,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MLN2480 demonstrated efficacy in BRAF mutant xenograft models of melanoma and colorectal cancer (J Clin Oncol 31, 2013 (suppl; abstr e13529)).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 1034,
                "therapyName": "MLN2480",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 876,
                    "pubMedId": null,
                    "title": "Use of combination treatment with the investigational RAF kinase inhibitor MLN2480 and the investigational MEK kinase inhibitor TAK-733 on the growth of BRAF-mutant and RAS-mutant preclinical models of melanoma and CRC.",
                    "url": "http://meetinglibrary.asco.org/content/114757-132"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16511,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, mutant BRAF correlated with prolonged duration on immune checkpoint inhibitor therapy compared to wild-type BRAF in non-small cell lung cancer patients (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #1138PD).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 5248,
                "therapyName": "unspecified PD-L1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10039,
                    "pubMedId": null,
                    "title": "Immune checkpoint inhibitor (ICPI) efficacy and resistance detected by comprehensive genomic profiling (CGP) in non-small cell lung cancer (NSCLC)",
                    "url": "http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9039,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of S63845 and Mekinist (trametinib) resulted in potent cytotoxic effects in BRAF-mutated melanoma cells in culture compared to the cytostatic effect of Mekinist (trametinib) alone (PMID: 27760111).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 4864,
                "therapyName": "S63845 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6851,
                    "pubMedId": 27760111,
                    "title": "The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760111"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6687,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) inhibited growth of human multiple myeloma cells harboring mutant BRAF in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12701,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, treatment with BVD-523 (ulixertinib) resulted in a best response of stable disease in six melanoma patients and a partial response in three melanoma patients all harboring a BRAF mutation (PMID: 29247021).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 997,
                "therapyName": "Ulixertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10607,
                    "pubMedId": 29247021,
                    "title": "First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29247021"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10057,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) resulted in some reduced cell growth in colon cancer cells harboring a BRAF mutation in culture (PMID: 27655129).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7992,
                    "pubMedId": 27655129,
                    "title": "MEK and TAK1 Regulate Apoptosis in Colon Cancer Cells with KRAS-Dependent Activation of Proinflammatory Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27655129"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12191,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LSN3074753 resulted in a disease control rate of 8.3% (1/12) in BRAF mutant patient-derived xenograft models of colorectal cancer (PMID: 28611205).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 6337,
                "therapyName": "LSN3074753",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10143,
                    "pubMedId": 28611205,
                    "title": "Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28611205"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8536,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma cell line harboring a BRAF mutation and loss of RB1 demonstrated a decreased response to Ibrance (palbociclib) treatment in culture when compared to treatment of melanoma cell lines wild-type for BRAF (PMID: 27488531).",
            "molecularProfile": {
                "id": 26352,
                "profileName": "BRAF mut RB1 loss"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6683,
                    "pubMedId": 27488531,
                    "title": "An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27488531"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8546,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma cell line with a BRAF mutation and loss of RB1 demonstrated minimal sensitivity when treated with the combination of Ibrance (palbociclib) and Mekinist (trametinib) in culture (PMID: 27488531).",
            "molecularProfile": {
                "id": 26352,
                "profileName": "BRAF mut RB1 loss"
            },
            "therapy": {
                "id": 1368,
                "therapyName": "Palbociclib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6683,
                    "pubMedId": 27488531,
                    "title": "An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27488531"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8539,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma cell line harboring a BRAF mutation and RB1 loss demonstrated reduced sensitivity when treated with Mekinist (trametinib) in culture (PMID: 27488531).",
            "molecularProfile": {
                "id": 26352,
                "profileName": "BRAF mut RB1 loss"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6683,
                    "pubMedId": 27488531,
                    "title": "An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27488531"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6100,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclincal study, melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations were less sensitive to Alpelisib (BYL719)-induced growth inhibition in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 691,
                "therapyName": "Alpelisib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6115,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pictilisib (GDC-0941) and Binimetinib (MEK162) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4053,
                "therapyName": "Binimetinib + Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6130,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination treatment consists of AZD6482, Binimetinib (MEK162), Encorafenib (LGX818), and NVP-AEW541 efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4064,
                "therapyName": "AZD6482 + Binimetinib + Encorafenib + NVP-AEW541",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6101,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD6482 and Alpelisib (BYL719) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 3714,
                "therapyName": "Alpelisib + AZD6482",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6099,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclincal study, Pictilisib (GDC-0941) inhibited Akt activation and proliferation in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 749,
                "therapyName": "Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6136,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination treatment consisting of GSK2636771 and a figitumumab-like antibody inhibited tumor growth in xenograft models of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4067,
                "therapyName": "GSK2636771 + unspecified IGF-1R antibody",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6137,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination treatment consists of Encorafenib (LGX818) and a figitumumab-like antibody inhibited tumor growth in xenograft models of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4068,
                "therapyName": "Encorafenib + unspecified IGF-1R antibody",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6110,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD6482 and Encorafenib (LGX818) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4048,
                "therapyName": "AZD6482 + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6126,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination treatment consists of AZD6482, Encorafenib (LGX818), and NVP-AEW541 efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4061,
                "therapyName": "AZD6482 + Encorafenib + NVP-AEW541",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6127,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination treatment consisting of AZD6482, Binimetinib (MEK162), and Alpelisib (BYL719) efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4059,
                "therapyName": "Alpelisib + AZD6482 + Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6131,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination treatment consisting of AZD6482, Binimetinib (MEK162), Encorafenib (LGX818), and Alpelisib (BYL719) efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4063,
                "therapyName": "Alpelisib + AZD6482 + Binimetinib + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6102,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of GSK2636771 and Alpelisib (BYL719) synergized to inhibit proliferation of human melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture, and inhibited tumor growth in xenograft models of one cell line harboring these mutations (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4042,
                "therapyName": "Alpelisib + GSK2636771",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6133,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of GSK2636771, Encorafenib (LGX818), and Alpelisib (BYL719) efficiently inhibited tumor growth in xenograft models of a human melanoma cell line harboring BRAF mutations and PTEN inactivating mutations (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4065,
                "therapyName": "Alpelisib + Encorafenib + GSK2636771",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6109,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pictilisib (GDC-0941) and Encorafenib (LGX818) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4056,
                "therapyName": "Encorafenib + Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6119,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alpelisib (BYL719) and Binimetinib (MEK162) combination treatment did not enhance growth inhibition compared to single agent in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 1311,
                "therapyName": "Alpelisib + Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6111,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK2636771 and Encorafenib (LGX818) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4055,
                "therapyName": "Encorafenib + GSK2636771",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6125,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination treatment consisting of AZD6482, Encorafenib (LGX818), and Alpelisib (BYL719) efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4062,
                "therapyName": "Alpelisib + AZD6482 + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6138,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination treatment consisting of GSK2636771, Encorafenib (LGX818), and a figitumumab-like antibody inhibited tumor growth in xenograft models of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4069,
                "therapyName": "Encorafenib + GSK2636771 + unspecified IGF-1R antibody",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6113,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alpelisib (BYL719) and Encorafenib (LGX818) combination treatment did not enhance growth inhibition in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4049,
                "therapyName": "Alpelisib + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6118,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK2636771 and Binimetinib (MEK162) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4052,
                "therapyName": "Binimetinib + GSK2636771",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6098,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclincal study, TGX-221 inhibited Akt activation and proliferation in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 2514,
                "therapyName": "TGX-221",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6117,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD6482 and Binimetinib (MEK162) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4054,
                "therapyName": "AZD6482 + Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6105,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pictilisib (GDC-0941) and NVP-AEW541 synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4046,
                "therapyName": "NVP-AEW541 + Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6128,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination treatment consists of AZD6482, Binimetinib (MEK162), and NVP-AEW541 efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4060,
                "therapyName": "AZD6482 + Binimetinib + NVP-AEW541",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6097,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclincal study, AZD6482 inhibited Akt activation and proliferation in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 659,
                "therapyName": "AZD6482",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6106,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alpelisib (BYL719) and NVP-AEW541 combination treatment did not enhance growth inhibition compared to single agent in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4047,
                "therapyName": "Alpelisib + NVP-AEW541",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6103,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD6482 and NVP-AEW541 synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4044,
                "therapyName": "AZD6482 + NVP-AEW541",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6104,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK2636771 and NVP-AEW541 synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4045,
                "therapyName": "GSK2636771 + NVP-AEW541",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1787,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of CGM097 and Encorafenib (LGX818) synergized to inhibit cell growth of a human melanoma cell line harboring mutant BRAF and wild-type TP53 in culture, and promoted tumor regression in xenograft models (Cancer Res October 1, 2014 74; 5466).",
            "molecularProfile": {
                "id": 3307,
                "profileName": "BRAF mut + TP53 wild-type"
            },
            "therapy": {
                "id": 2285,
                "therapyName": "CGM097 + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7241,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://cancerres.aacrjournals.org/content/74/19_Supplement/5466"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8097,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AMG 232 inhibited growth of a melanoma cell line with wild-type TP53, that also harbored a BRAF mutation, in culture and inhibited tumor growth in a TP53 wild-type BRAF-mutant melanoma cell line xenograft model (PMID: 25567130).",
            "molecularProfile": {
                "id": 3307,
                "profileName": "BRAF mut + TP53 wild-type"
            },
            "therapy": {
                "id": 1452,
                "therapyName": "AMG 232",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2082,
                    "pubMedId": 25567130,
                    "title": "The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25567130"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9933,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Navitoclax (ABT-263), CGM097, Tafinlar (dabrafenib), and PF04217903 resulted in the greatest synergistic effect and inhibition of cell growth in colorectal cancer cells harboring a BRAF mutation and wild-type TP53 in culture compared to the double or triple combinations of the therapies (PMID: 27659046).",
            "molecularProfile": {
                "id": 3307,
                "profileName": "BRAF mut + TP53 wild-type"
            },
            "therapy": {
                "id": 5317,
                "therapyName": "CGM097 + Dabrafenib + Navitoclax + PF-04217903",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7782,
                    "pubMedId": 27659046,
                    "title": "High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27659046"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10776,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, mutations in BRAF, KRAS, or NRAS were associated with sensitivity to TAK-733 in colorectal cancer cell lines in culture, and patient-derived xenograft models harboring KRAS or BRAF mutations with wild-type PIK3CA demonstrated a trend toward higher tumor growth inhibition following TAK-733 treatment (PMID: 26439693).",
            "molecularProfile": {
                "id": 27794,
                "profileName": "BRAF mut PIK3CA wild-type"
            },
            "therapy": {
                "id": 932,
                "therapyName": "TAK-733",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8454,
                    "pubMedId": 26439693,
                    "title": "Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26439693"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8668,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knocking down of Ptpn11 expression via shRNA sensitized BRAF mutant colorectal cancer cell lines to PLX4720 in culture (PMID: 26351322).",
            "molecularProfile": {
                "id": 26402,
                "profileName": "BRAF mut PTPN11 dec exp"
            },
            "therapy": {
                "id": 1060,
                "therapyName": "PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6708,
                    "pubMedId": 26351322,
                    "title": "Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351322"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3796,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, Lenvima (lenvatinib) treatment resulted in stable disease in 100% (5/5) of melanoma patients harboring BRAF mutations and wild-type NRAS (PMID: 26169970).",
            "molecularProfile": {
                "id": 15931,
                "profileName": "BRAF mut NRAS wild-type"
            },
            "therapy": {
                "id": 792,
                "therapyName": "Lenvatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3994,
                    "pubMedId": 26169970,
                    "title": "Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26169970"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9934,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Navitoclax (ABT-263), Alpelisib (BYL719), Tafinlar (dabrafenib), and Tarceva (erlotinib) resulted in the greatest synergistic effect and inhibition of cell growth in colorectal cancer cells harboring a BRAF mutation and TP53 mutation in culture compared to the double or triple combinations of the therapies (PMID: 27659046).",
            "molecularProfile": {
                "id": 27213,
                "profileName": "BRAF mut TP53 mut"
            },
            "therapy": {
                "id": 5318,
                "therapyName": "Alpelisib + Dabrafenib + Erlotinib + Navitoclax",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7782,
                    "pubMedId": 27659046,
                    "title": "High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27659046"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7793,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in BRAF mutated melanoma cells resulted in decreased response to Mekinist (trametinib) and Tafinlar (dabrafenib) combination treatment in culture (PMID: 27500726).",
            "molecularProfile": {
                "id": 26042,
                "profileName": "BRAF mut STAG2 dec exp"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6497,
                    "pubMedId": 27500726,
                    "title": "Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27500726"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7792,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in BRAF mutated melanoma cells resulted in decreased response to Mekinist (trametinib) in culture (PMID: 27500726).",
            "molecularProfile": {
                "id": 26042,
                "profileName": "BRAF mut STAG2 dec exp"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6497,
                    "pubMedId": 27500726,
                    "title": "Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27500726"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7790,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in BRAF mutated melanoma cell lines resulted in decreased response to Tafinlar (dabrafenib) in culture (PMID: 27500726).",
            "molecularProfile": {
                "id": 26042,
                "profileName": "BRAF mut STAG2 dec exp"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6497,
                    "pubMedId": 27500726,
                    "title": "Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27500726"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7791,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in BRAF mutated melanoma cell lines resulted in decreased response to Zelboraf (vemurafenib) both in culture and in cell line xenograft models (PMID: 27500726).",
            "molecularProfile": {
                "id": 26042,
                "profileName": "BRAF mut STAG2 dec exp"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6497,
                    "pubMedId": 27500726,
                    "title": "Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27500726"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6107,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD6482 and NVP-AEW541 combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 21308,
                "profileName": "BRAF mut PTEN wild-type"
            },
            "therapy": {
                "id": 4044,
                "therapyName": "AZD6482 + NVP-AEW541",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6124,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK2636771 and Encorafenib (LGX818) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 21308,
                "profileName": "BRAF mut PTEN wild-type"
            },
            "therapy": {
                "id": 4055,
                "therapyName": "Encorafenib + GSK2636771",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6121,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD6482 and Binimetinib (MEK162) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 21308,
                "profileName": "BRAF mut PTEN wild-type"
            },
            "therapy": {
                "id": 4054,
                "therapyName": "AZD6482 + Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6108,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK2636771 and NVP-AEW541 combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 21308,
                "profileName": "BRAF mut PTEN wild-type"
            },
            "therapy": {
                "id": 4045,
                "therapyName": "GSK2636771 + NVP-AEW541",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6122,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK2636771 and Binimetinib (MEK162) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 21308,
                "profileName": "BRAF mut PTEN wild-type"
            },
            "therapy": {
                "id": 4052,
                "therapyName": "Binimetinib + GSK2636771",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5629,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, E6201 resulted in a cytocidal response in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture and inhibited tumor growth in cell line xenograft models (PMID: 23039341).",
            "molecularProfile": {
                "id": 21308,
                "profileName": "BRAF mut PTEN wild-type"
            },
            "therapy": {
                "id": 1011,
                "therapyName": "E6201",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1840,
                    "pubMedId": 23039341,
                    "title": "Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23039341"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6123,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD6482 and Encorafenib (LGX818) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 21308,
                "profileName": "BRAF mut PTEN wild-type"
            },
            "therapy": {
                "id": 4048,
                "therapyName": "AZD6482 + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5628,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, E6201 resulted in a cytostatic response in melanoma cell lines harboring both BRAF and PTEN mutations in culture and only inhibited tumor growth at very high doses in cell line xenograft models (PMID: 23039341).",
            "molecularProfile": {
                "id": 21306,
                "profileName": "BRAF mut PTEN mut"
            },
            "therapy": {
                "id": 1011,
                "therapyName": "E6201",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 1840,
                    "pubMedId": 23039341,
                    "title": "Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23039341"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12283,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ST-162 resulted in tumor regression in a melanoma cell line xenograft model co-harboring mutations in BRAF and PTEN (PMID: 28775144).",
            "molecularProfile": {
                "id": 21306,
                "profileName": "BRAF mut PTEN mut"
            },
            "therapy": {
                "id": 6418,
                "therapyName": "ST-162",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10258,
                    "pubMedId": 28775144,
                    "title": "A Bifunctional MAPK/PI3K Antagonist for Inhibition of Tumor Growth and Metastasis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28775144"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16068,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, MAPK pathway mutations were significantly enriched in patients with IDH1 wild-type glioblastoma who responded to anti-PD-1 therapy with either Keytruda (pembrolizumab) or Opdivo (nivolumab), compared to those who did not respond (odds ratio=12.8, p=0.019), with 4 MAPK pathway mutations (2 in BRAF, 2 in PTPN11) identified in 13 responders and 1 (BRAF) in 32 non-responders (PMID: 30742119).",
            "molecularProfile": {
                "id": 31466,
                "profileName": "BRAF mutant IDH1 wild-type"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14204,
                    "pubMedId": 30742119,
                    "title": "Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30742119"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16069,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, MAPK pathway mutations were significantly enriched in patients with IDH1 wild-type glioblastoma who responded to anti-PD-1 therapy with either Keytruda (pembrolizumab) or Opdivo (nivolumab), compared to those who did not respond (odds ratio=12.8, p=0.019), with 4 MAPK pathway mutations (2 in BRAF, 2 in PTPN11) identified in 13 responders and 1 (BRAF) in 32 non-responders (PMID: 30742119).",
            "molecularProfile": {
                "id": 31466,
                "profileName": "BRAF mutant IDH1 wild-type"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14204,
                    "pubMedId": 30742119,
                    "title": "Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30742119"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2135,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a rapamycin-resistant colorectal cancer cell line harboring mutations in APC, BRAF, PIK3CA, SMAD4 and TP53 was sensitive to Sapanisertib (MLN0128) resulting in inhibition of MTORC1 signaling (PMID: 25261369).",
            "molecularProfile": {
                "id": 5415,
                "profileName": "APC mut BRAF mut PIK3CA mut SMAD4 mut TP53 mut"
            },
            "therapy": {
                "id": 1282,
                "therapyName": "Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2380,
                    "pubMedId": 25261369,
                    "title": "Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25261369"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7829,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with BI-847325 inhibited growth of a BRAF-mutant melanoma cell line with BRAF-inhibitor resistance due to an NRAS mutation in culture (PMID: 25873592).",
            "molecularProfile": {
                "id": 14782,
                "profileName": "BRAF mut NRAS mut"
            },
            "therapy": {
                "id": 1059,
                "therapyName": "BI-847325",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6506,
                    "pubMedId": 25873592,
                    "title": "The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25873592"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3688,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, Lenvima (lenvatinib) treatment resulted in stable disease in 50% (1/2) of melanoma patients harboring both BRAF and NRAS mutations (PMID: 26169970).",
            "molecularProfile": {
                "id": 14782,
                "profileName": "BRAF mut NRAS mut"
            },
            "therapy": {
                "id": 792,
                "therapyName": "Lenvatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3994,
                    "pubMedId": 26169970,
                    "title": "Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26169970"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12197,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LSN3074753 and Erbitux (cetuximab) worked synergistically, resulting in tumor regression in a patient-derived xenograft model of colorectal cancer harboring BRAF G596V and NRAS G13R (PMID: 28611205).",
            "molecularProfile": {
                "id": 28547,
                "profileName": "BRAF G596V NRAS G13R"
            },
            "therapy": {
                "id": 6338,
                "therapyName": "Cetuximab + LSN3074753",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10143,
                    "pubMedId": 28611205,
                    "title": "Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28611205"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9610,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a lung adenocarcinoma patient harboring BRAF G469L did not respond to Zelboraf (vemurafenib) therapy (PMID: 24035431).",
            "molecularProfile": {
                "id": 4782,
                "profileName": "BRAF G469L"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 7321,
                    "pubMedId": 24035431,
                    "title": "Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24035431"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9418,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF K601N (PMID: 26343582).",
            "molecularProfile": {
                "id": 2437,
                "profileName": "BRAF K601N"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 7141,
                    "pubMedId": 26343582,
                    "title": "BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343582"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12071,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a hematological tumor cell line harboring BRAF K601N demonstrated sensitivity to LY3009120 in culture (PMID: 26732095).",
            "molecularProfile": {
                "id": 2437,
                "profileName": "BRAF K601N"
            },
            "therapy": {
                "id": 3268,
                "therapyName": "LY3009120",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4801,
                    "pubMedId": 26732095,
                    "title": "Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26732095"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "variants": [
        {
            "id": 27728,
            "fullName": "BRAF S602F",
            "impact": "missense",
            "proteinEffect": "no effect - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF S602F lies within the protein kinase domain of the Braf protein (UniProt.org). S602F has not been biochemically characterized, but results in\u00a0similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function.",
                    "references": [
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 27734,
            "fullName": "BRAF V639I",
            "impact": "missense",
            "proteinEffect": "no effect - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF V639I lies within the protein kinase domain of the Braf protein (UniProt.org). V639I has not been biochemically characterized, but results in\u00a0similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function.",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        }
                    ]
                }
            ]
        },
        {
            "id": 23672,
            "fullName": "BRAF amp",
            "impact": "none",
            "proteinEffect": "no effect",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF amplification indicates an increased number of copies of the Braf gene. However, the mechanism causing the increase is unspecified.",
                    "references": [
                        {
                            "id": 275,
                            "pubMedId": 10,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/10"
                        }
                    ]
                }
            ]
        },
        {
            "id": 27711,
            "fullName": "BRAF L711F",
            "impact": "missense",
            "proteinEffect": "no effect - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF L711F lies within the protein kinase domain of the Braf protein (UniProt.org). L711F has not been biochemically characterized, but results in\u00a0similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function.",
                    "references": [
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 3127,
            "fullName": "BRAF A598V",
            "impact": "missense",
            "proteinEffect": "gain of function - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF A598V lies within the protein kinase domain of the Braf protein (UniProt.org). A598V is associated with increased activation of Braf and downstream Mek and Erk in human tumor samples (PMID: 19200582), and is therefore predicted to confer a gain of function to the Braf protein.",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 1894,
                            "pubMedId": 19200582,
                            "title": "Detection and molecular characterization of a novel BRAF activated domain mutation in follicular variant of papillary thyroid carcinoma.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/19200582"
                        }
                    ]
                }
            ]
        },
        {
            "id": 28207,
            "fullName": "BRAF N581K",
            "impact": "missense",
            "proteinEffect": "loss of function - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF N581K lies within the protein kinase domain of the Braf protein (UniProt.org). N581K has not been biochemically characterized, but demonstrates decreased transformation ability in cell culture (PMID: 29533785), and is therefore predicted to confer a loss of function to the Braf protein.",
                    "references": [
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 28189,
            "fullName": "BRAF G258V",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF G258V lies within the protein kinase domain of the Braf protein (UniProt.org). G258V has not been biochemically characterized, but results in increased transformation ability compared to wild-type Braf in one of two different cell lines in culture (PMID: 29533785), and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019).",
                    "references": [
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 28192,
            "fullName": "BRAF G606W",
            "impact": "missense",
            "proteinEffect": "loss of function - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF G606W lies within the protein kinase domain of the Braf protein (UniProt.org). G606W has not been biochemically characterized, but demonstrates decreased transformation ability in cell culture (PMID: 29533785), and is therefore predicted to confer a loss of function to the Braf protein.",
                    "references": [
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 23128,
            "fullName": "BRAF N581Y",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF N581Y lies within the protein kinase domain of the Braf protein (UniProt.org). N581Y has been identified in the scientific literature (PMID: 19474002, PMID: 26084293), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, May 2019).",
                    "references": [
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 10345,
                            "pubMedId": 26084293,
                            "title": "ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/26084293"
                        },
                        {
                            "id": 7500,
                            "pubMedId": 19474002,
                            "title": "Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/19474002"
                        }
                    ]
                }
            ]
        },
        {
            "id": 28210,
            "fullName": "BRAF Q609E",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF Q609E lies within the protein kinase domain of the Braf protein (UniProt.org). Q609E results in increased transformation ability compared to wild-type Braf in one of two different cell lines in culture (PMID: 29533785), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019).",
                    "references": [
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        }
                    ]
                }
            ]
        },
        {
            "id": 27720,
            "fullName": "BRAF R188T",
            "impact": "missense",
            "proteinEffect": "no effect - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF R188T lies within the protein kinase domain of the Braf protein (UniProt.org). R188T has not been biochemically characterized, but results in similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function.",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        }
                    ]
                }
            ]
        },
        {
            "id": 1226,
            "fullName": "BRAF inact mut",
            "impact": "unknown",
            "proteinEffect": "loss of function",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF inact mut indicates that this variant results in a loss of function of the Braf protein. However, the specific amino acid change has not been identified.",
                    "references": [
                        {
                            "id": 275,
                            "pubMedId": 10,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/10"
                        }
                    ]
                }
            ]
        },
        {
            "id": 28204,
            "fullName": "BRAF M517I",
            "impact": "missense",
            "proteinEffect": "loss of function - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF M517I lies within the protein kinase domain of the Braf protein (UniProt.org). M517I has not been biochemically characterized, but demonstrates decreased transformation ability in cell culture (PMID: 29533785), and is therefore predicted to confer a loss of function to the Braf protein.",
                    "references": [
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 28590,
            "fullName": "BRAF H574Q",
            "impact": "missense",
            "proteinEffect": "gain of function",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF H574Q lies within the protein kinase domain of the Braf protein (UniProt.org). H574Q confers a gain of function to the Braf protein as indicated by increased Erk phosphorylation in culture and tumor formation in animal models, and confers resistance to Egfr inhibitors in culture (PMID: 27478040).",
                    "references": [
                        {
                            "id": 8124,
                            "pubMedId": 27478040,
                            "title": "High-throughput Phenotyping of Lung Cancer Somatic Mutations.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/27478040"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 23125,
            "fullName": "BRAF K499E",
            "impact": "missense",
            "proteinEffect": "gain of function",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF K499E lies within the protein kinase domain of the Braf protein (UniProt.org). K499E confers a gain of function to the Braf protein as demonstrated by increased Braf kinase activity and downstream signaling, activation of ELK-dependent signaling in reporter assays, and foci formation in cultured cells (PMID: 16474404, PMID: 18413255, PMID: 26065894).",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 12145,
                            "pubMedId": 18413255,
                            "title": "Biochemical characterization of novel germline BRAF and MEK mutations in cardio-facio-cutaneous syndrome.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/18413255"
                        },
                        {
                            "id": 5844,
                            "pubMedId": 16474404,
                            "title": "Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/16474404"
                        },
                        {
                            "id": 5843,
                            "pubMedId": 26065894,
                            "title": "Mitogen-Inducible Gene-6 Mediates Feedback Inhibition from Mutated BRAF towards the Epidermal Growth Factor Receptor and Thereby Limits Malignant Transformation.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/26065894"
                        }
                    ]
                }
            ]
        },
        {
            "id": 3184,
            "fullName": "BRAF W450*",
            "impact": "nonsense",
            "proteinEffect": "loss of function - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF W450* results in a premature truncation the Braf protein at amino acid 450 of 766 (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), R450* is predicted to lead to a loss of Braf protein function.",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 19431,
            "fullName": "BRAF T488_P492del",
            "impact": "deletion",
            "proteinEffect": "gain of function - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF T488_P492del results in the deletion of five amino acids near the alphaC-helix region of the protein kinase domain in the Braf protein from amino acids 488 to 492 (PMID: 26732095). T488_P492del results in activation of Mek in cell culture (PMID: 26996308), and similar Braf deletions are activating (PMID: 26996308, PMID: 26732095), and therefore T488_P492del is predicted to confer a gain of function to the Braf function.",
                    "references": [
                        {
                            "id": 4801,
                            "pubMedId": 26732095,
                            "title": "Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/26732095"
                        },
                        {
                            "id": 12174,
                            "pubMedId": 26996308,
                            "title": "Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/26996308"
                        }
                    ]
                }
            ]
        },
        {
            "id": 27714,
            "fullName": "BRAF P162S",
            "impact": "missense",
            "proteinEffect": "no effect - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF P162S lies within the protein kinase domain of the Braf protein (UniProt.org). P162S has not been biochemically characterized, but results in similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function.",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        }
                    ]
                }
            ]
        },
        {
            "id": 29179,
            "fullName": "BRAF S363F",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF S363F does not lie within any known functional domains of the Braf protein (UniProt.org). S363F has been identified in the scientific literature (PMID: 29903896), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Jan 2019).",
                    "references": [
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 13465,
                            "pubMedId": 29903896,
                            "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                        }
                    ]
                }
            ]
        },
        {
            "id": 27722,
            "fullName": "BRAF R389C",
            "impact": "missense",
            "proteinEffect": "no effect - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF R389C lies within the protein kinase domain of the Braf protein (UniProt.org). R389C has not been biochemically characterized, but results in similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function.",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        }
                    ]
                }
            ]
        },
        {
            "id": 28200,
            "fullName": "BRAF L245F",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF L245F lies within the Phorbol-ester/DAG-type zinc finger domain of the Braf protein (UniProt.org). L245F results in increased transformation ability compared to wild-type Braf in one of two different cell lines in culture (PMID: 29533785), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019).",
                    "references": [
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        }
                    ]
                }
            ]
        },
        {
            "id": 29457,
            "fullName": "BRAF T599X",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF T599X indicates any Braf missense mutation that results in replacement of the threonine (T) at amino acid 599 by a different amino acid.",
                    "references": [
                        {
                            "id": 275,
                            "pubMedId": 10,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/10"
                        }
                    ]
                }
            ]
        },
        {
            "id": 3520,
            "fullName": "BRAF R462I",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF R462I lies within the protein kinase domain of the Braf protein (UniProt.org). R462I results in activation of Braf and increased Erk signaling in cell culture (PMID: 15035987) but, in two different cell lines, induced similar cell proliferation and cell viability as wild-type Braf (PMID: 29533785), and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019).",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 146,
                            "pubMedId": 15035987,
                            "title": "Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/15035987"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        }
                    ]
                }
            ]
        },
        {
            "id": 895,
            "fullName": "BRAF D594N",
            "impact": "missense",
            "proteinEffect": "loss of function - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF D594N lies within the protein kinase domain of the Braf protein (UniProt.org). D594N results in impaired Braf kinase activity, but leads to activation of Erk signaling through CRAF in cell culture (PMID: 28783719), and demonstrates decreased transforming ability compared to wild-type Braf in one of two cell lines in culture (PMID: 29533785), and therefore is predicted to confer a loss of function to the Braf protein.",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 9692,
                            "pubMedId": 28783719,
                            "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/28783719"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        }
                    ]
                }
            ]
        },
        {
            "id": 3136,
            "fullName": "BRAF F595S",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF F595S lies within the protein kinase domain of the Braf protein (UniProt.org). F595S has been identified in sequencing studies (PMID: 15331929), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019).",
                    "references": [
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 7101,
                            "pubMedId": 15331929,
                            "title": "B-raf exon 15 mutations are common in primary melanoma resection specimens but not associated with clinical outcome.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/15331929"
                        }
                    ]
                }
            ]
        },
        {
            "id": 29443,
            "fullName": "BRAF R462X",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF R462X indicates any Braf missense mutation that results in replacement of the arginine (R) at amino acid 462 by a different amino acid.",
                    "references": [
                        {
                            "id": 275,
                            "pubMedId": 10,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/10"
                        }
                    ]
                }
            ]
        },
        {
            "id": 23138,
            "fullName": "BRAF T599dup",
            "impact": "duplication",
            "proteinEffect": "gain of function",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF T599dup (also referred to T599_V600insT) indicates the insertion of the duplicate amino acid, tyrosine (T)-599, in the protein kinase domain of the Braf protein (UniProt.org). T599dup confers a gain of function to the Braf protein as demonstrated by increased kinase activity and phosphorylation of downstream Mek and Erk, and is transforming in cell culture (PMID: 21190184).",
                    "references": [
                        {
                            "id": 1910,
                            "pubMedId": 21190184,
                            "title": "Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/21190184"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 3138,
            "fullName": "BRAF G469S",
            "impact": "missense",
            "proteinEffect": "gain of function",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF G469S is a hotspot mutation within the protein kinase domain of the Braf protein (UniProt.org). G469S results in increased Erk phosphorylation (PMID: 27478040) and induces increased cell proliferation and cell viability compared to wild-type Braf in culture (PMID: 29533785).",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 8124,
                            "pubMedId": 27478040,
                            "title": "High-throughput Phenotyping of Lung Cancer Somatic Mutations.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/27478040"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        }
                    ]
                }
            ]
        },
        {
            "id": 13358,
            "fullName": "BRAF V504_R506dup",
            "impact": "duplication",
            "proteinEffect": "gain of function",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF V504_R506dup (also referred to as R506_K507insVLR) lies within the protein kinase domain (UniProt.org). V504_R506dup confers a gain of function to the Braf protein as demonstrated by stabilization of Braf homodimers and increased downstream Erk phosphorylation in cultured cells (PMID: 23817572, PMID: 30575814), and is associated with increased Erk1/2 phosphorylation in human tumor samples (PMID: 29544532).",
                    "references": [
                        {
                            "id": 1902,
                            "pubMedId": 23817572,
                            "title": "Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/23817572"
                        },
                        {
                            "id": 15556,
                            "pubMedId": 30575814,
                            "title": "Recurrent somatic BRAF insertion (p.V504_R506dup): a tumor marker and a potential therapeutic target in pilocytic astrocytoma.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/30575814"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 12166,
                            "pubMedId": 29544532,
                            "title": "BRAF activating mutations involving the \u03b23-\u03b1C loop in V600E-negative anaplastic pleomorphic xanthoastrocytoma.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29544532"
                        }
                    ]
                }
            ]
        },
        {
            "id": 23122,
            "fullName": "BRAF G469del",
            "impact": "deletion",
            "proteinEffect": "loss of function",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF G469del results in the deletion of an amino acid in the protein kinase domain of the Braf protein at amino acid 469 (UniProt.org). G469del demonstrates decreased Braf kinase activity, does not activate downstream ERK, and is minimally transforming in cell culture (PMID: 23833300).",
                    "references": [
                        {
                            "id": 5855,
                            "pubMedId": 23833300,
                            "title": "Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/23833300"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 27723,
            "fullName": "BRAF R509G",
            "impact": "missense",
            "proteinEffect": "no effect - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF R509G lies within the protein kinase domain of the Braf protein (UniProt.org). R509C has not been biochemically characterized, but results in similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function.",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        }
                    ]
                }
            ]
        },
        {
            "id": 894,
            "fullName": "BRAF Y472C",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF Y472C lies within the protein kinase domain of the Braf protein (UniProt.org). Y472C results in impaired Braf kinase activity, but paradoxically increases Mek and Erk signaling through C-raf transactivation (PMID: 22649091), however, in two different cell lines, Y472C induces similar cell proliferation and cell viability as compared to wild-type Braf (PMID: 29533785), and therefore, its effect on Braf protein function is unknown.",
                    "references": [
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 423,
                            "pubMedId": 22649091,
                            "title": "Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/22649091"
                        }
                    ]
                }
            ]
        },
        {
            "id": 3137,
            "fullName": "BRAF G464R",
            "impact": "missense",
            "proteinEffect": "gain of function",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF G464R (also reported as G463R) lies within the protein kinase domain of the Braf protein (UniProt.org). G464R results in increased Braf kinase activity, increased downstream Erk signaling (PMID: 15046639), and induces cell proliferation and cell viability in culture (PMID: 29533785).",
                    "references": [
                        {
                            "id": 1166,
                            "pubMedId": 15046639,
                            "title": "Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/15046639"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        }
                    ]
                }
            ]
        },
        {
            "id": 4984,
            "fullName": "BRAF D594A",
            "impact": "missense",
            "proteinEffect": "loss of function",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF D594A lies within the protein kinase domain of the Braf protein (UniProt.org). D594A results in a lack of Braf kinase activity (PMID: 20141835, PMID: 20978199, PMID: 28783719), promotes aneupolidy (PMID: 20978199), and in one of two cell lines demonstrated decreased transformation ability compared to wild-type Braf in culture (PMID: 29533785), but leads to activation of Mek and Erk through cooperation with activated RAS and transactivation of CRAF in cell culture and mouse models (PMID: 20141835, PMID: 20978199, PMID: 28783719).",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 424,
                            "pubMedId": 20141835,
                            "title": "Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/20141835"
                        },
                        {
                            "id": 2517,
                            "pubMedId": 20978199,
                            "title": "BRAF inactivation drives aneuploidy by deregulating CRAF.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/20978199"
                        },
                        {
                            "id": 9692,
                            "pubMedId": 28783719,
                            "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/28783719"
                        }
                    ]
                }
            ]
        },
        {
            "id": 29618,
            "fullName": "BRAF A81_M438del",
            "impact": "deletion",
            "proteinEffect": "gain of function - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF A81_M438del results in the deletion of 358 amino acids of the Braf protein from amino acids 81 to 438 (UniProt.org). A81_M438del (reported as internal deletion of exons 3-10) has not been characterized, however, due to the deletion of the CR1 autoinhibitory domain and preservation of the protein kinase domain (PMID: 23890088, PMID: 22113612, PMID: 29171936), A81_M438del is predicted to lead to a gain of Braf protein function.",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 14626,
                            "pubMedId": 22113612,
                            "title": "RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/22113612"
                        },
                        {
                            "id": 14627,
                            "pubMedId": 29171936,
                            "title": "BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29171936"
                        },
                        {
                            "id": 3413,
                            "pubMedId": 23890088,
                            "title": "Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/23890088"
                        }
                    ]
                }
            ]
        },
        {
            "id": 902,
            "fullName": "BRAF L597S",
            "impact": "missense",
            "proteinEffect": "gain of function",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF L597S lies within the protein kinase domain of the Braf protein (UniProt.org). L597S results in activation of Braf as indicated by increased phosphorylation of Mek and Erk in cell culture (PMID: 22798288) and induces cell proliferation and cell viability in culture (PMID: 29533785).",
                    "references": [
                        {
                            "id": 3,
                            "pubMedId": 22798288,
                            "title": "BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/22798288"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        }
                    ]
                }
            ]
        },
        {
            "id": 27721,
            "fullName": "BRAF R271H",
            "impact": "missense",
            "proteinEffect": "no effect - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF R271H lies within the protein kinase domain of the Braf protein (UniProt.org). R271H has not been biochemically characterized, but results in similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function.",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        }
                    ]
                }
            ]
        },
        {
            "id": 3182,
            "fullName": "BRAF V600L",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF V600L (previously reported as V599L) lies within the activation segment of the protein kinase domain of the Braf protein (PMID: 15035987). V600L results in increased cell proliferation and cell viability compared to wild-type Braf in one of two cell lines in culture (PMID: 29533785), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019).",
                    "references": [
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 146,
                            "pubMedId": 15035987,
                            "title": "Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/15035987"
                        }
                    ]
                }
            ]
        },
        {
            "id": 23120,
            "fullName": "BRAF F468C",
            "impact": "missense",
            "proteinEffect": "gain of function",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF F468C (also referred to as F467C) lies within the protein kinase domain of the Braf protein (UniProt.org). F468C confers a gain of function to the Braf protein as demonstrated by increased Braf kinase activity and downstream Erk phosphorylation, activation of NFkappaB signaling in reporter assays, and transformation of cultured cells (PMID: 15150094).",
                    "references": [
                        {
                            "id": 147,
                            "pubMedId": 15150094,
                            "title": "Different effects of point mutations within the B-Raf glycine-rich loop in colorectal tumors on mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase and nuclear factor kappaB pathway and cellular transformation.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/15150094"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 27717,
            "fullName": "BRAF P407L",
            "impact": "missense",
            "proteinEffect": "no effect - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF P407L lies within the protein kinase domain of the Braf protein (UniProt.org). P407L has not been biochemically characterized, but results in similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function.",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        }
                    ]
                }
            ]
        },
        {
            "id": 19430,
            "fullName": "BRAF P490_Q494del",
            "impact": "deletion",
            "proteinEffect": "gain of function - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF P490_Q494del results in the deletion of five amino acids near the alphaC-helix region of the protein kinase domain in the Braf protein from amino acids 490 to 494 (PMID: 26732095). P490_Q494del results in activation of Mek in cell culture (PMID: 26996308), and similar Braf deletions are activating (PMID: 26996308, PMID: 26732095), and therefore P490_Q494del is predicted to confer a gain of function to the Braf function.",
                    "references": [
                        {
                            "id": 12174,
                            "pubMedId": 26996308,
                            "title": "Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/26996308"
                        },
                        {
                            "id": 4801,
                            "pubMedId": 26732095,
                            "title": "Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/26732095"
                        }
                    ]
                }
            ]
        },
        {
            "id": 25796,
            "fullName": "BRAF A598S",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF A598S lies within the protein kinase domain of the Braf protein (UniProt.org). A598S has not been characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019).",
                    "references": [
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 29626,
            "fullName": "BRAF V47_G393del",
            "impact": "deletion",
            "proteinEffect": "gain of function - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF V47_G393del results in the deletion of 347 amino acids of the Braf protein from amino acids 47 to 393 (UniProt.org). V47_G393del (reported as internal deletion of exons 2-9) has not been characterized, however, due to the deletion of the CR1 autoinhibitory domain and preservation of the protein kinase domain (PMID: 23890088, PMID: 22113612, PMID: 29171936), V47_G393del is predicted to lead to a gain of Braf protein function.",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 14626,
                            "pubMedId": 22113612,
                            "title": "RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/22113612"
                        },
                        {
                            "id": 14627,
                            "pubMedId": 29171936,
                            "title": "BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29171936"
                        },
                        {
                            "id": 3413,
                            "pubMedId": 23890088,
                            "title": "Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/23890088"
                        }
                    ]
                }
            ]
        },
        {
            "id": 19426,
            "fullName": "BRAF N486_P490del",
            "impact": "deletion",
            "proteinEffect": "gain of function",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF N486_P490del results in the deletion of five amino acids near the alphaC-helix region of the kinase domain (PMID: 26732095). N486_P490del confers a gain of function to the Braf protein as indicated by activation of the MAPK signaling pathway and increased cell proliferation in culture (PMID: 26732095).",
                    "references": [
                        {
                            "id": 4801,
                            "pubMedId": 26732095,
                            "title": "Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/26732095"
                        }
                    ]
                }
            ]
        },
        {
            "id": 4983,
            "fullName": "BRAF D587G",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF D587G lies within the protein kinase domain of the Braf protein (UniProt.org). D587G has been identified in the scientific literature (PMID: 24803665), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019).",
                    "references": [
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 12613,
                            "pubMedId": 24803665,
                            "title": "Structure-energy-based predictions and network modelling of RASopathy and cancer missense mutations.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/24803665"
                        }
                    ]
                }
            ]
        },
        {
            "id": 2635,
            "fullName": "BRAF K601Q",
            "impact": "missense",
            "proteinEffect": "gain of function",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF K601Q lies within the activation loop in the kinase domain of the Braf protein (PMID: 19206169). K601Q confers a gain of function on Braf, as indicated by increased MEK and ERK phosphorylation, and is transforming in cell culture (PMID: 19206169, PMID: 29533785). ",
                    "references": [
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 760,
                            "pubMedId": 19206169,
                            "title": "Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/19206169"
                        }
                    ]
                }
            ]
        },
        {
            "id": 29458,
            "fullName": "BRAF K601X",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF K601X indicates any Braf missense mutation that results in replacement of the lysine (K) at amino acid 601 by a different amino acid.",
                    "references": [
                        {
                            "id": 275,
                            "pubMedId": 10,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/10"
                        }
                    ]
                }
            ]
        },
        {
            "id": 29449,
            "fullName": "BRAF L485X",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF L485X indicates any Braf missense mutation that results in replacement of the leucine (L) at amino acid 485 by a different amino acid.",
                    "references": [
                        {
                            "id": 275,
                            "pubMedId": 10,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/10"
                        }
                    ]
                }
            ]
        },
        {
            "id": 897,
            "fullName": "BRAF D594G",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF D594G lies within the protein kinase domain of the Braf protein (UniProt.org). D594G has been demonstrated to result in impaired Braf kinase activity, but leads to increased activation of Erk signaling through CRAF in cell culture (PMID: 18794803, PMID: 28783719), however, has increased transforming ability in one of two cell lines in culture (PMID: 29533785), and therefore its effect on Braf protein function is unknown.",
                    "references": [
                        {
                            "id": 7,
                            "pubMedId": 18794803,
                            "title": "CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/18794803"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 9692,
                            "pubMedId": 28783719,
                            "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/28783719"
                        }
                    ]
                }
            ]
        },
        {
            "id": 1789,
            "fullName": "BRAF W531C",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF W531C lies within the protein kinase domain of the Braf protein (UniProt.org). W531C results in the weak activation of MEK signaling and does not induce transformation in cell culture (PMID: 19206169), but in two different cell lines, W531C demonstrates increased cell proliferation and viability as compared to wild-type Braf (PMID: 29533785), and therefore, its effect on Braf protein function is unknown.",
                    "references": [
                        {
                            "id": 760,
                            "pubMedId": 19206169,
                            "title": "Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/19206169"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 28197,
            "fullName": "BRAF H725Y",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF H725Y does not lie with any known functional domains of the Braf protein (UniProt.org). H725Y has not been biochemically characterized, but results in increased transformation ability compared to wild-type Braf in one of two different cell lines in culture (PMID: 29533785), and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019).",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        }
                    ]
                }
            ]
        },
        {
            "id": 23131,
            "fullName": "BRAF L485_P490del",
            "impact": "deletion",
            "proteinEffect": "gain of function",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF L485_P490del results in the deletion of six amino acids within the beta-3/alpha-C helix loop in the protein kinase domain of the Braf protein (PMID: 26732095, UniProt.org). L485_P490del confers a gain of function to the Braf protein as demonstrated by increased kinase activity, phosphorylation of downstream Mek and Erk, and transformation ability in cell culture (PMID: 26732095, PMID: 26996308), and is associated with resistance to vemurafenib in cell culture (PMID: 26996308).",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 4801,
                            "pubMedId": 26732095,
                            "title": "Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/26732095"
                        },
                        {
                            "id": 12174,
                            "pubMedId": 26996308,
                            "title": "Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/26996308"
                        }
                    ]
                }
            ]
        },
        {
            "id": 3143,
            "fullName": "BRAF I592M",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF I592M lies within the protein kinase domain of the Braf protein (UniProt.org). I592M has been identified in sequencing studies (PMID: 15331929), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar  2019).",
                    "references": [
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 7101,
                            "pubMedId": 15331929,
                            "title": "B-raf exon 15 mutations are common in primary melanoma resection specimens but not associated with clinical outcome.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/15331929"
                        }
                    ]
                }
            ]
        },
        {
            "id": 27725,
            "fullName": "BRAF R719S",
            "impact": "missense",
            "proteinEffect": "no effect - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF R719S lies within the protein kinase domain of the Braf protein (UniProt.org). R719S has not been biochemically characterized, but results in similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function.",
                    "references": [
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 25027,
            "fullName": "BRAF N20T",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF N20T does not lie within any known functional domains of the Braf protein (UniProt.org). N20T has not been characterized in the scientific literature and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019).",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        }
                    ]
                }
            ]
        },
        {
            "id": 27700,
            "fullName": "BRAF A762V",
            "impact": "missense",
            "proteinEffect": "no effect - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF A762V lies within the protein kinase domain of the Braf protein (UniProt.org). A762V has not been biochemically characterized, but results in similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function.",
                    "references": [
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 28898,
            "fullName": "BRAF L514V",
            "impact": "missense",
            "proteinEffect": "gain of function - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF L514V lies within the protein kinase domain of the Braf protein (UniProt.org). L514V is predicted to lead to a gain of Braf function as indicated by moderate increase of Mek and Erk phosphorylation in culture, enhanced dimerization when expressed in cis with BRAF V600E, and is associated with resistance to Raf inhibitors (PMID: 29880583).",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 12771,
                            "pubMedId": 29880583,
                            "title": "A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29880583"
                        }
                    ]
                }
            ]
        },
        {
            "id": 19427,
            "fullName": "BRAF V487_P492delinsA",
            "impact": "indel",
            "proteinEffect": "gain of function",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF V487_P492delinsA results in a deletion of six amino acids near the alphaC-helix region of the kinase domain of the Braf protein combined with the insertion of one new amino acid in the same location (PMID: 26732095). V487_P492delinsA confers a gain of function to the Braf protein as indicated by increased pathway signaling and cell proliferation in culture (PMID: 26732095).",
                    "references": [
                        {
                            "id": 4801,
                            "pubMedId": 26732095,
                            "title": "Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/26732095"
                        }
                    ]
                }
            ]
        },
        {
            "id": 25026,
            "fullName": "BRAF A712T",
            "impact": "missense",
            "proteinEffect": "no effect - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF A712T lies within the protein kinase domain of the Braf protein (UniProt.org). A712T has not been biochemically characterized, but results in\u00a0similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function.",
                    "references": [
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 23099,
            "fullName": "BRAF A728V",
            "impact": "missense",
            "proteinEffect": "gain of function",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF A728V (also referred to as A727V) does not lie within any known functional domains of the Braf protein (UniProt.org). A728V results in an intermediate increase in Braf kinase activity compared to wild-type Braf and increased Erk phosphorylation in cell culture (PMID: 15035987).",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 146,
                            "pubMedId": 15035987,
                            "title": "Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/15035987"
                        }
                    ]
                }
            ]
        },
        {
            "id": 4990,
            "fullName": "BRAF N581I",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF N581I lies within the protein kinase domain of the Braf protein (UniProt.org). N581I results in low Braf kinase activity and Ras-dependent activation of Erk signaling in cell culture (PMID: 28783719), however, also results in increased transformation ability compared to wild-type Braf in culture (PMID: 29533785), and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019).",
                    "references": [
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 9692,
                            "pubMedId": 28783719,
                            "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/28783719"
                        },
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 29178,
            "fullName": "BRAF R239Q",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF R239Q lies within the phorbol-ester/DAG-type zinc finger domain of the Braf protein (UniProt.org). R239Q has been identified in the scientific literature (PMID: 29903896), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Jan 2019).",
                    "references": [
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 13465,
                            "pubMedId": 29903896,
                            "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                        }
                    ]
                }
            ]
        },
        {
            "id": 23135,
            "fullName": "BRAF T529I",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF T529I is a gatekeeper mutation that lies within the protein kinase domain of the Braf protein (PMID: 20538618). T529I has been demonstrated to confer resistance to Raf inhibitors in the context of BRAF V600E (PMID: 20538618), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Apr 2019).",
                    "references": [
                        {
                            "id": 5859,
                            "pubMedId": 20538618,
                            "title": "Gatekeeper mutations mediate resistance to BRAF-targeted therapies.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/20538618"
                        },
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        }
                    ]
                }
            ]
        },
        {
            "id": 27713,
            "fullName": "BRAF P141L",
            "impact": "missense",
            "proteinEffect": "no effect - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF P141L lies within the protein kinase domain of the Braf protein (UniProt.org). P141L has not been biochemically characterized, but results in\u00a0similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function.",
                    "references": [
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 28202,
            "fullName": "BRAF L618F",
            "impact": "missense",
            "proteinEffect": "loss of function - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF L618F lies within the protein kinase domain of the Braf protein (UniProt.org). L618F has not been biochemically characterized, but demonstrates decreased transformation ability in cell culture (PMID: 29533785), and is therefore predicted to confer a loss of function to the Braf protein.",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        }
                    ]
                }
            ]
        },
        {
            "id": 29608,
            "fullName": "BRAF V47_D380del",
            "impact": "deletion",
            "proteinEffect": "gain of function - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF V47_D380del results in the deletion of 334 amino acids of the Braf protein from amino acids 47 to 380 (UniProt.org). V47_D380del (reported as internal deletion of exons 2-8) has been associated with resistance to Mek inhibitors in a patient (PMID: 29171936), and is predicted to lead to a gain of Braf protein function due to the deletion of the CR1 autoinhibitory domain and preservation of the protein kinase domain (PMID: 23890088, PMID: 22113612).",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 14626,
                            "pubMedId": 22113612,
                            "title": "RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/22113612"
                        },
                        {
                            "id": 14627,
                            "pubMedId": 29171936,
                            "title": "BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29171936"
                        },
                        {
                            "id": 3413,
                            "pubMedId": 23890088,
                            "title": "Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/23890088"
                        }
                    ]
                }
            ]
        },
        {
            "id": 896,
            "fullName": "BRAF D594H",
            "impact": "missense",
            "proteinEffect": "loss of function - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF D594H lies within the protein kinase domain of the Braf protein (UniProt.org). D594H results in a loss of Braf kinase activity, but leads to Ras-dependent activation of Erk signaling through CRAF (PMID: 28783719), and demonstrates decreased transforming activity compared to wild-type Braf in one of two cell lines in culture (PMID: 29533785), and therefore is predicted to confer a loss of function to the Braf protein.",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 9692,
                            "pubMedId": 28783719,
                            "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/28783719"
                        }
                    ]
                }
            ]
        },
        {
            "id": 26916,
            "fullName": "BRAF V459L",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF V459L lies within the protein kinase domain of the Braf protein (UniProt.org). V459L results in impaired Braf kinase activity and leads to Ras-dependent activation of Erk in culture (PMID: 28783719), however, in two different cell lines, induces similar cell proliferation and cell viability as compared to wild-type Braf (PMID: 29533785), and therefore, its effect on Braf protein function is unknown.",
                    "references": [
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 9692,
                            "pubMedId": 28783719,
                            "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/28783719"
                        }
                    ]
                }
            ]
        },
        {
            "id": 27394,
            "fullName": "BRAF L485W",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF L485W lies within the protein kinase domain of the Braf protein (UniProt.org). L485W results in increased transformation ability compared to wild-type Braf in one of two different cell lines in culture (PMID: 29533785), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019).",
                    "references": [
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        }
                    ]
                }
            ]
        },
        {
            "id": 3135,
            "fullName": "BRAF D587E",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF D587E lies within the protein kinase domain of the Braf protein (UniProt.org). D587E has been identified in sequencing studies (PMID: 27034166), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019).",
                    "references": [
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 9191,
                            "pubMedId": 27034166,
                            "title": "Mutational analysis of single circulating tumor cells by next generation sequencing in metastatic breast cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/27034166"
                        }
                    ]
                }
            ]
        },
        {
            "id": 29577,
            "fullName": "BRAF S465A",
            "impact": "missense",
            "proteinEffect": "no effect - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF S465A lies within the protein kinase domain of the Braf protein (UniProt.org). S465A results in basal Mek phosphorylation and Mek phosphorylation upon Ras activation to similar levels of wild-type Braf in culture (PMID: 27034005), and therefore, is predicted to have no effect on Braf protein function.",
                    "references": [
                        {
                            "id": 14533,
                            "pubMedId": 27034005,
                            "title": "Phospho-proteomic analyses of B-Raf protein complexes reveal new regulatory principles.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/27034005"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 27707,
            "fullName": "BRAF G421V",
            "impact": "missense",
            "proteinEffect": "no effect - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF G421V lies within the protein kinase domain of the Braf protein (UniProt.org). G421V has not been biochemically characterized, but results in\u00a0similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function.",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        }
                    ]
                }
            ]
        },
        {
            "id": 23119,
            "fullName": "BRAF E501K",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF E501K lies within the protein kinase domain of the Braf protein (UniProt.org). E501K results in ELK transactivation similar to wild-type Braf in a reporter assay (PMID: 16474404), however, also demonstrates decreased Braf kinase activity in culture (PMID: 17603482), and therefore, its effect on Braf protein function is unknown.",
                    "references": [
                        {
                            "id": 5844,
                            "pubMedId": 16474404,
                            "title": "Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/16474404"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 494,
                            "pubMedId": 17603482,
                            "title": "Germline gain-of-function mutations in RAF1 cause Noonan syndrome.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/17603482"
                        }
                    ]
                }
            ]
        },
        {
            "id": 3481,
            "fullName": "BRAF fusion",
            "impact": "unknown",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF fusion indicates a fusion of the BRAF gene, but the fusion partner is unknown.",
                    "references": [
                        {
                            "id": 275,
                            "pubMedId": 10,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/10"
                        }
                    ]
                }
            ]
        },
        {
            "id": 28213,
            "fullName": "BRAF T599A",
            "impact": "missense",
            "proteinEffect": "loss of function",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF T599A lies within the protein kinase domain of the Braf protein (UniProt.org). T599A does not result in increased MEK or ERK phosphorylation and does not transactivate CRAF (PMID: 22506009), and demonstrates decreased transformation ability compared to wild-type Braf in cell culture (PMID: 29533785).",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 12160,
                            "pubMedId": 22506009,
                            "title": "B-RAF mutant alleles associated with Langerhans cell histiocytosis, a granulomatous pediatric disease.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/22506009"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        }
                    ]
                }
            ]
        },
        {
            "id": 3134,
            "fullName": "BRAF D587A",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF D587A lies within the protein kinase domain of the Braf protein (UniProt.org). D587A has been identified in sequencing studies (PMID: 14500346), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019).",
                    "references": [
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 7099,
                            "pubMedId": 14500346,
                            "title": "BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/14500346"
                        }
                    ]
                }
            ]
        },
        {
            "id": 29445,
            "fullName": "BRAF G464X",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF G464X indicates any Braf missense mutation that results in replacement of the glycine (G) at amino acid 464 by a different amino acid.",
                    "references": [
                        {
                            "id": 275,
                            "pubMedId": 10,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/10"
                        }
                    ]
                }
            ]
        },
        {
            "id": 3141,
            "fullName": "BRAF H608R",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF H608R lies within the protein kinase domain of the Braf protein (UniProt.org). H608R has been identified in sequencing studies (PMID: 15331929), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019).",
                    "references": [
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 7101,
                            "pubMedId": 15331929,
                            "title": "B-raf exon 15 mutations are common in primary melanoma resection specimens but not associated with clinical outcome.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/15331929"
                        }
                    ]
                }
            ]
        },
        {
            "id": 23112,
            "fullName": "BRAF E501G",
            "impact": "missense",
            "proteinEffect": "loss of function",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF E501G lies within the protein kinase domain of the Braf protein (UniProt.org). E501G confers a loss of function to the Braf protein as demonstrated by inability to activate downstream reporter assays, impaired kinase activity and presence in genetic diseases associated with Ras/Raf/Mek dysfunction (PMID: 26065894, PMID: 16474404, PMID: 16439621).",
                    "references": [
                        {
                            "id": 5844,
                            "pubMedId": 16474404,
                            "title": "Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/16474404"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 5843,
                            "pubMedId": 26065894,
                            "title": "Mitogen-Inducible Gene-6 Mediates Feedback Inhibition from Mutated BRAF towards the Epidermal Growth Factor Receptor and Thereby Limits Malignant Transformation.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/26065894"
                        },
                        {
                            "id": 5839,
                            "pubMedId": 16439621,
                            "title": "Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/16439621"
                        }
                    ]
                }
            ]
        },
        {
            "id": 29490,
            "fullName": "BRAF N486_A489delinsK",
            "impact": "indel",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF N486_A489delinsK results in a deletion of 4 amino acids in the protein kinase domain of the Braf protein from amino acids 486 to 489, combined with the insertion of a lysine (K) at the same site (UniProt.org). N486_A489delinsK has been identified in sequencing studies (PMID: 29247016), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Feb 2019).",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 10750,
                            "pubMedId": 29247016,
                            "title": "Accelerating Discovery of Functional Mutant Alleles in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29247016"
                        },
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        }
                    ]
                }
            ]
        },
        {
            "id": 13400,
            "fullName": "BRAF A598T",
            "impact": "missense",
            "proteinEffect": "loss of function - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF A598T lies within the protein kinase domain of the Braf protein (UniProt.org). A598T demonstrates a lack of Braf kinase activity in culture (PMID: 22926515), and therefore, is predicted to result in a loss of Braf protein function.",
                    "references": [
                        {
                            "id": 463,
                            "pubMedId": 22926515,
                            "title": "ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/22926515"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 1791,
            "fullName": "BRAF G464E",
            "impact": "missense",
            "proteinEffect": "gain of function",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF G464E (also reported as G463E) lies within the protein kinase domain of the Braf protein (UniProt.org). G464E results in increased Braf kinase activity and activation of MEK and ERK (PMID: 15035987, PMID: 23680146), and in one of two cell lines, increased cell proliferation and cell viability compared to wild-type Braf in culture (PMID: 29533785).",
                    "references": [
                        {
                            "id": 146,
                            "pubMedId": 15035987,
                            "title": "Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/15035987"
                        },
                        {
                            "id": 5858,
                            "pubMedId": 23680146,
                            "title": "RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/23680146"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        }
                    ]
                }
            ]
        },
        {
            "id": 29627,
            "fullName": "BRAF V47_G327del",
            "impact": "deletion",
            "proteinEffect": "gain of function - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF V47_G327del results in the deletion of 281 amino acids of the Braf protein from amino acids 47 to 327 (UniProt.org). V47_G327del (reported as internal deletion of exons 2-7) has not been characterized, however, due to the deletion of the CR1 autoinhibitory domain and preservation of the protein kinase domain (PMID: 23890088, PMID: 22113612, PMID: 29171936), V47_G327del is predicted to lead to a gain of Braf protein function.",
                    "references": [
                        {
                            "id": 3413,
                            "pubMedId": 23890088,
                            "title": "Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/23890088"
                        },
                        {
                            "id": 14626,
                            "pubMedId": 22113612,
                            "title": "RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/22113612"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 14627,
                            "pubMedId": 29171936,
                            "title": "BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29171936"
                        }
                    ]
                }
            ]
        },
        {
            "id": 23123,
            "fullName": "BRAF G596V",
            "impact": "missense",
            "proteinEffect": "loss of function - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF G596V lies within the protein kinase domain of the Braf protein (UniProt.org). G596V results in impaired Braf kinase activity and does not activate downstream MEK and ERK in cell culture (PMID: 16439621), but leads to activation of ERK in zebrafish models (PMID: 19376813), and is therefore predicted to lead to a loss of Braf protein function.",
                    "references": [
                        {
                            "id": 5839,
                            "pubMedId": 16439621,
                            "title": "Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/16439621"
                        },
                        {
                            "id": 5856,
                            "pubMedId": 19376813,
                            "title": "Kinase-activating and kinase-impaired cardio-facio-cutaneous syndrome alleles have activity during zebrafish development and are sensitive to small molecule inhibitors.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/19376813"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 900,
            "fullName": "BRAF L597R",
            "impact": "missense",
            "proteinEffect": "gain of function",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF L597R lies within the protein kinase domain of the Braf protein (UniProt.org). L597R results in activation of Braf as indicated by increased phosphorylation of Mek and Erk in cell culture (PMID: 22798288, PMID: 26343582), is associated with Erk activation in a patient tumor sample (PMID: 23715574), and in one of two cell lines, increased cell proliferation and cell viability compared to wild-type Braf (PMID: 29533785).",
                    "references": [
                        {
                            "id": 12177,
                            "pubMedId": 23715574,
                            "title": "Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/23715574"
                        },
                        {
                            "id": 3,
                            "pubMedId": 22798288,
                            "title": "BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/22798288"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 7141,
                            "pubMedId": 26343582,
                            "title": "BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343582"
                        }
                    ]
                }
            ]
        },
        {
            "id": 28208,
            "fullName": "BRAF P367S",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF P367S does not lie within any known functional domains of the Braf protein (UniProt.org). P367S results in increased transformation ability compared to wild-type Braf in one of two cell lines in culture (PMID: 29533785), but  has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019).",
                    "references": [
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 5048,
            "fullName": "BRAF W604R",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF W604R lies within the protein kinase domain of the Braf protein (UniProt.org). W604R has been identified in sequencing studies (PMID: 28188106, PMID: 21825258, PMID: 23833300), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019).",
                    "references": [
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 7103,
                            "pubMedId": 21825258,
                            "title": "Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/21825258"
                        },
                        {
                            "id": 13418,
                            "pubMedId": 28188106,
                            "title": "Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial: Molecular Analysis for Therapy Choice Clinical Trial.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/28188106"
                        },
                        {
                            "id": 5855,
                            "pubMedId": 23833300,
                            "title": "Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/23833300"
                        }
                    ]
                }
            ]
        },
        {
            "id": 3123,
            "fullName": "BRAF A598_T599insV",
            "impact": "insertion",
            "proteinEffect": "gain of function",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF A598_T599insV results in the insertion of a valine (V) in the protein kinase domain of the Braf protein between amino acids 598 and 599 (UniProt.org). A598_T599insV results in increased Braf kinase activity, increased downstream Mapk and Mek signaling, and the ability to transform cells in culture (PMID: 16501605).",
                    "references": [
                        {
                            "id": 1892,
                            "pubMedId": 16501605,
                            "title": "Biochemical and molecular characterization of the novel BRAF(V599Ins) mutation detected in a classic papillary thyroid carcinoma.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/16501605"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 29453,
            "fullName": "BRAF F595X",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF F595X indicates any Braf missense mutation that results in replacement of the phenylalanine (F) at amino acid 595 by a different amino acid.",
                    "references": [
                        {
                            "id": 275,
                            "pubMedId": 10,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/10"
                        }
                    ]
                }
            ]
        },
        {
            "id": 27732,
            "fullName": "BRAF V504I",
            "impact": "missense",
            "proteinEffect": "no effect - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF V504I lies within the protein kinase domain of the Braf protein (UniProt.org). V504I has not been biochemically characterized, but results in\u00a0similar cell proliferation and viability levels as wild-type Braf (PMID: 29533785).",
                    "references": [
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 4988,
            "fullName": "BRAF G606V",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF G606V lies within the protein kinase domain of the Braf protein (UniProt.org). G606V has been identified in sequencing studies (PMID: 21825258), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019).",
                    "references": [
                        {
                            "id": 7103,
                            "pubMedId": 21825258,
                            "title": "Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/21825258"
                        },
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 370,
            "fullName": "BRAF mutant",
            "impact": "unknown",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF mutant indicates an unspecified mutation in the BRAF gene.",
                    "references": [
                        {
                            "id": 275,
                            "pubMedId": 10,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/10"
                        }
                    ]
                }
            ]
        },
        {
            "id": 27704,
            "fullName": "BRAF F259L",
            "impact": "missense",
            "proteinEffect": "no effect - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF F259L lies within the protein kinase domain of the Braf protein (UniProt.org). F259L has not been biochemically characterized, but results in\u00a0similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function.",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 3140,
            "fullName": "BRAF G606E",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF G606E lies within the protein kinase domain of the Braf protein (UniProt.org). G606E has been identified in sequencing studies (PMID: 29320312, PMID: 28936923, PMID: 15331929), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019).",
                    "references": [
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 7101,
                            "pubMedId": 15331929,
                            "title": "B-raf exon 15 mutations are common in primary melanoma resection specimens but not associated with clinical outcome.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/15331929"
                        },
                        {
                            "id": 11783,
                            "pubMedId": 28936923,
                            "title": "EGFR pathway subgroups in Chilean colorectal cancer patients, detected by mutational and expression profiles, associated to different clinicopathological features.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/28936923"
                        },
                        {
                            "id": 13171,
                            "pubMedId": 29320312,
                            "title": "Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29320312"
                        }
                    ]
                }
            ]
        },
        {
            "id": 29576,
            "fullName": "BRAF S605E",
            "impact": "missense",
            "proteinEffect": "loss of function - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF S605E lies within the protein kinase domain of the Braf protein (UniProt.org). S605E results in basal Mek phosphorylation similar to wild-type Braf but moderately decreased Mek phosphorylation upon Ras activation in culture (PMID: 27034005), and therefore, is predicted to lead to a loss of Braf protein function.",
                    "references": [
                        {
                            "id": 14533,
                            "pubMedId": 27034005,
                            "title": "Phospho-proteomic analyses of B-Raf protein complexes reveal new regulatory principles.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/27034005"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 29575,
            "fullName": "BRAF S605A",
            "impact": "missense",
            "proteinEffect": "loss of function - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF S605A lies within the protein kinase domain of the Braf protein (UniProt.org). S605A results in basal Mek phosphorylation similar to wild-type Braf but moderately decreased Mek phosphorylation upon Ras activation in culture (PMID: 27034005), and therefore, is predicted to lead to a loss of Braf protein function.",
                    "references": [
                        {
                            "id": 14533,
                            "pubMedId": 27034005,
                            "title": "Phospho-proteomic analyses of B-Raf protein complexes reveal new regulatory principles.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/27034005"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 24559,
            "fullName": "BRAF dec exp",
            "impact": "none",
            "proteinEffect": "no effect",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF dec exp indicates decreased expression of the Braf protein and/or mRNA. However, the mechanism causing the decreased expression is unspecified.",
                    "references": [
                        {
                            "id": 275,
                            "pubMedId": 10,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/10"
                        }
                    ]
                }
            ]
        },
        {
            "id": 28188,
            "fullName": "BRAF E695K",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF E695K lies within the protein kinase domain of the Braf protein (UniProt.org). E695K has not been biochemically characterized, but results in increased transformation ability compared to wild-type Braf in one of two different cell lines in culture (PMID: 29533785), and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019).",
                    "references": [
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 2592,
            "fullName": "BRAF K601I",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF K601I lies within the protein kinase domain of the Braf protein (UniProt.org). K601I has been identified in the scientific literature (PMID: 26682952, PMID: 29176861, PMID: 23555633), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019).",
                    "references": [
                        {
                            "id": 14455,
                            "pubMedId": 26682952,
                            "title": "Using \"residual\" FNA rinse and body fluid specimens for next-generation sequencing: An institutional experience.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/26682952"
                        },
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 14454,
                            "pubMedId": 29176861,
                            "title": "Variables that influence BRAF mutation probability: A next-generation sequencing, non-interventional investigation of BRAFV600 mutation status in melanoma.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29176861"
                        },
                        {
                            "id": 12138,
                            "pubMedId": 23555633,
                            "title": "Automated universal BRAF state detection within the activation segment in skin metastases by pyrosequencing-based assay U-BRAF(V600).",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/23555633"
                        }
                    ]
                }
            ]
        },
        {
            "id": 899,
            "fullName": "BRAF D594E",
            "impact": "missense",
            "proteinEffect": "loss of function",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF D594E lies within the protein kinase domain of the Braf protein (UniProt.org). D594E results in impaired Braf kinase activity, however, results in increased Mek and Erk phosphorylation in the presence of CRAF in cell culture (PMID: 28783719).",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 9692,
                            "pubMedId": 28783719,
                            "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/28783719"
                        }
                    ]
                }
            ]
        },
        {
            "id": 3162,
            "fullName": "BRAF S605G",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF S605G lies within the protein kinase domain of the Braf protein (UniProt.org). S605G results in basal Mek phosphorylation similar to wild-type Braf but moderately decreased Mek phosphorylation upon Ras activation in culture (PMID: 27034005), and therefore, is predicted to lead to a loss of Braf protein function.",
                    "references": [
                        {
                            "id": 14533,
                            "pubMedId": 27034005,
                            "title": "Phospho-proteomic analyses of B-Raf protein complexes reveal new regulatory principles.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/27034005"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 28206,
            "fullName": "BRAF N486D",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF N486D lies within the protein kinase domain of the Braf protein (UniProt.org). N486D results in increased transformation ability compared to wild-type Braf in one of two cell lines in culture (PMID: 29533785), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019).",
                    "references": [
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 26917,
            "fullName": "BRAF S467L",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF S467L lies within the protein kinase domain of the Braf protein (UniProt.org). S467L results in impaired Braf kinase activity, but leads to Ras-dependent activation of Erk in cell culture (PMID: 28783719), and in two different cell lines, S467L increased cell proliferation and cell viability as compared to wild-type Braf (PMID: 29533785), and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019).",
                    "references": [
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 9692,
                            "pubMedId": 28783719,
                            "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/28783719"
                        }
                    ]
                }
            ]
        },
        {
            "id": 22991,
            "fullName": "BRAF R509H",
            "impact": "missense",
            "proteinEffect": "loss of function",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF R509H lies within the dimerization interface region of the Braf protein (PMID: 22510884). R509H confers a loss of function to the Braf protein, as demonstrated by decreased Braf dimerization and reduced ability to activate downstream Mek signaling in in vitro assays (PMID: 22510884).",
                    "references": [
                        {
                            "id": 5712,
                            "pubMedId": 22510884,
                            "title": "Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/22510884"
                        }
                    ]
                }
            ]
        },
        {
            "id": 25028,
            "fullName": "BRAF Q257H",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF Q257H lies within the Phorbol-ester/DAG-type zinc finger region of the Braf protein (UniProt.org). Q257H has been identified in sequencing studies (PMID: 28852190, PMID: 27147599), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019). \r\n",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 11143,
                            "pubMedId": 28852190,
                            "title": "Mutational heterogeneity in non-serous ovarian cancers.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/28852190"
                        },
                        {
                            "id": 6273,
                            "pubMedId": 27147599,
                            "title": "Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/27147599"
                        },
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        }
                    ]
                }
            ]
        },
        {
            "id": 3148,
            "fullName": "BRAF K601del",
            "impact": "deletion",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF K601del results in the deletion of one amino acid in the protein kinase domain of the Braf protein at amino acid 601 (UniProt.org). K601del has been identified in sequencing studies (PMID: 19152441), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019).",
                    "references": [
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 7105,
                            "pubMedId": 19152441,
                            "title": "High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas: correlation with more aggressive phenotype and decreased expression of iodide-metabolizing genes.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/19152441"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 27715,
            "fullName": "BRAF P341S",
            "impact": "missense",
            "proteinEffect": "no effect - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF P341S lies within the protein kinase domain of the Braf protein (UniProt.org). P341S has not been biochemically characterized, but results in similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function.",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        }
                    ]
                }
            ]
        },
        {
            "id": 28592,
            "fullName": "BRAF P367R",
            "impact": "missense",
            "proteinEffect": "gain of function",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF P367R does not lie within any known functional domains within the Braf protein (UniProt.org). P367R confers a gain of function to the Braf protein as indicated by increased Erk phosphorylation in culture and tumor formation in animal models, and demonstrates resistance to Egfr inhibitors in culture (PMID: 27478040).",
                    "references": [
                        {
                            "id": 8124,
                            "pubMedId": 27478040,
                            "title": "High-throughput Phenotyping of Lung Cancer Somatic Mutations.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/27478040"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 4985,
            "fullName": "BRAF G469L",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF G469L is a hotspot mutation lies within the protein kinase domain of the Braf protein (UniProt.org). G469L has been identified in the scientific literature (PMID: 24035431, PMID: 26301799, PMID: 26200454), but has not been biochemically characterized, and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019).",
                    "references": [
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 7321,
                            "pubMedId": 24035431,
                            "title": "Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/24035431"
                        },
                        {
                            "id": 12131,
                            "pubMedId": 26301799,
                            "title": "BRAF Alterations as Therapeutic Targets in Non-Small-Cell Lung Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/26301799"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 14438,
                            "pubMedId": 26200454,
                            "title": "Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/26200454"
                        }
                    ]
                }
            ]
        },
        {
            "id": 28193,
            "fullName": "BRAF G615R",
            "impact": "missense",
            "proteinEffect": "loss of function - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF G615R lies within the protein kinase domain of the Braf protein (UniProt.org). G615R has not been biochemically characterized, but demonstrates decreased transformation ability in cell culture (PMID: 29533785), and is therefore predicted to confer a loss of function to the Braf protein.",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        }
                    ]
                }
            ]
        },
        {
            "id": 3590,
            "fullName": "BRAF V600_K601delinsE",
            "impact": "indel",
            "proteinEffect": "gain of function",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF V600_K601delinsE results in the deletion of two amino acids formation of a new glutamic acid (E) residue in the protein kinase domain of the Braf protein between amino acids 600 and 601 (UniProt.org, PMID: 22563563). V600_K601delinsE leads to activation of downstream Mek and Erk signaling, increased colony formation (PMID: 17297294), and induces cell proliferation and cell viability in cell culture (PMID: 29533785).",
                    "references": [
                        {
                            "id": 2112,
                            "pubMedId": 17297294,
                            "title": "Functional characterization of the T1799-1801del and A1799-1816ins BRAF mutations in papillary thyroid cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/17297294"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 2113,
                            "pubMedId": 22563563,
                            "title": "Identification of a rare 3 bp BRAF gene deletion in a thyroid nodule by mutant enrichment with 3'-modified oligonucleotides polymerase chain reaction.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/22563563"
                        }
                    ]
                }
            ]
        },
        {
            "id": 23126,
            "fullName": "BRAF N581D",
            "impact": "missense",
            "proteinEffect": "no effect - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF N581D lies within the protein kinase domain of the Braf protein (UniProt.org). N581D results in transactivation of ELK at comparable levels to wild-type Braf in a reporter assay (PMID: 16474404), and is therefore predicted to have no effect on Braf protein function.",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 5844,
                            "pubMedId": 16474404,
                            "title": "Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/16474404"
                        }
                    ]
                }
            ]
        },
        {
            "id": 28194,
            "fullName": "BRAF G69S",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF G69S does not lie within any known functional domains of the Braf protein (UniProt.org). G69S results in increased transformation ability compared to wild-type Braf in one of two different cell lines in culture (PMID: 29533785), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019).",
                    "references": [
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        }
                    ]
                }
            ]
        },
        {
            "id": 5045,
            "fullName": "BRAF V471I",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF V471I lies within the protein kinase domain of the Braf protein (UniProt.org). V471I has been identified in sequencing studies (PMID: 28188106, PMID: 23103869), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019).",
                    "references": [
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 6989,
                            "pubMedId": 23103869,
                            "title": "Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/23103869"
                        },
                        {
                            "id": 13418,
                            "pubMedId": 28188106,
                            "title": "Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial: Molecular Analysis for Therapy Choice Clinical Trial.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/28188106"
                        }
                    ]
                }
            ]
        },
        {
            "id": 23124,
            "fullName": "BRAF K483M",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF K483M (also reported as K482M) lies within an ATP binding site in the protein kinase domain of the Braf protein (UniProt.org). K483M results in a loss of Braf kinase activity, however, has been demonstrated to both activate MEK through CRAF (PMID: 16508002, PMID: 23533272), and lack ability to activate ERK and CRAF in cell culture and in Xenopus (PMID: 15035987), and therefore, its effect on Braf protein function is unknown.",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 2256,
                            "pubMedId": 23533272,
                            "title": "Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/23533272"
                        },
                        {
                            "id": 9727,
                            "pubMedId": 16508002,
                            "title": "Regulation and role of Raf-1/B-Raf heterodimerization.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/16508002"
                        }
                    ]
                }
            ]
        },
        {
            "id": 3518,
            "fullName": "BRAF I463S",
            "impact": "missense",
            "proteinEffect": "gain of function",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF I463S lies within the protein kinase domain of the Braf protein (UniProt.org). I463S results in an intermediate increase in Braf kinase activity compared to wild-type Braf and increased Erk activation in cell culture (PMID: 15035987).",
                    "references": [
                        {
                            "id": 146,
                            "pubMedId": 15035987,
                            "title": "Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/15035987"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 5046,
            "fullName": "BRAF V600fs",
            "impact": "frameshift",
            "proteinEffect": "loss of function - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF V600fs results in a change in the amino acid sequence of the Braf protein beginning at aa 600 of 766, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the disruption of the protein kinase domain, V600fs is predicted to lead to a loss of Braf protein function (UniProt.org).",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 3152,
            "fullName": "BRAF P453T",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF P453T does not lie within any known functional domains of the Braf protein (UniProt.org). P453T has been identified in sequencing studies (PMID: 27717198, PMID: 16404419), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019).",
                    "references": [
                        {
                            "id": 14452,
                            "pubMedId": 27717198,
                            "title": "Young investigator challenge: Can the Ion AmpliSeq Cancer Hotspot Panel v2 be used for next-generation sequencing of thyroid FNA samples?",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/27717198"
                        },
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 7110,
                            "pubMedId": 16404419,
                            "title": "BRAF mutations and phosphorylation status of mitogen-activated protein kinases in the development of flat and depressed-type colorectal neoplasias.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/16404419"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 3519,
            "fullName": "BRAF N581S",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF N581S lies within the protein kinase domain of the Braf protein (UniProt.org). The functional effect of N581S is unclear as it has been demonstrated to result in intermediate Braf kinase activity (PMID: 15035987), as well as low Braf kinase activity (PMID: 28783719), and results in Ras-dependent activation of ERK signaling in cell culture (PMID: 28783719), however in another study, N581S demonstrated increased transformation ability in one of two different cell lines as compared to wild-type Braf (PMID: 29533785).",
                    "references": [
                        {
                            "id": 146,
                            "pubMedId": 15035987,
                            "title": "Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/15035987"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 9692,
                            "pubMedId": 28783719,
                            "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/28783719"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 3179,
            "fullName": "BRAF V600delinsYM",
            "impact": "indel",
            "proteinEffect": "gain of function",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF V600delinsYM results in a deletion of valine (V) at amino acid 600 within the protein kinase domain of the Braf protein, combined with the insertion of a tyrosine (Y) and a methionine (M) at the same site (UniProt.org). V600delinsYM results in increased Braf kinase activity, increased downstream signaling, and the ability to transform cells in culture (PMID: 22752848).",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 1912,
                            "pubMedId": 22752848,
                            "title": "Functional characterization of the novel BRAF complex mutation, BRAF(V600delinsYM) , identified in papillary thyroid carcinoma.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/22752848"
                        }
                    ]
                }
            ]
        },
        {
            "id": 29625,
            "fullName": "BRAF V169_G327del",
            "impact": "deletion",
            "proteinEffect": "gain of function - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF V169_G327del results in the deletion of 159 amino acids of the Braf protein from amino acids 169 to 327 (UniProt.org). V169_G327del (reported as internal deletion of exons 4-7) has not been characterized, however, due to the deletion of the CR1 autoinhibitory domain and preservation of the protein kinase domain (PMID: 23890088, PMID: 22113612, PMID: 29171936), V169_G327del is predicted to lead to a gain of Braf protein function.",
                    "references": [
                        {
                            "id": 14626,
                            "pubMedId": 22113612,
                            "title": "RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/22113612"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 3413,
                            "pubMedId": 23890088,
                            "title": "Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/23890088"
                        },
                        {
                            "id": 14627,
                            "pubMedId": 29171936,
                            "title": "BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29171936"
                        }
                    ]
                }
            ]
        },
        {
            "id": 29628,
            "fullName": "BRAF G203_G393del",
            "impact": "deletion",
            "proteinEffect": "gain of function - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF G203_G393del results in the deletion of 91 amino acids of the Braf protein from amino acids 203 to 393 (UniProt.org). G203_G393del (reported as internal deletion of exons 5-9) has not been characterized, however, due to the disruption of the CR1 autoinhibitory domain and preservation of the protein kinase domain (PMID: 23890088, PMID: 22113612, PMID: 29171936), G203_G393del is predicted to lead to a gain of Braf protein function.",
                    "references": [
                        {
                            "id": 3413,
                            "pubMedId": 23890088,
                            "title": "Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/23890088"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 14626,
                            "pubMedId": 22113612,
                            "title": "RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/22113612"
                        },
                        {
                            "id": 14627,
                            "pubMedId": 29171936,
                            "title": "BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29171936"
                        }
                    ]
                }
            ]
        },
        {
            "id": 27703,
            "fullName": "BRAF E228V",
            "impact": "missense",
            "proteinEffect": "no effect - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF E228V lies within the protein kinase domain of the Braf protein (UniProt.org). E228V has not been biochemically characterized, but results in\u00a0similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function.",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        }
                    ]
                }
            ]
        },
        {
            "id": 29441,
            "fullName": "BRAF Q257X",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF Q257X indicates any Braf missense mutation that results in replacement of the glutamine (Q) at amino acid 257 by a different amino acid.",
                    "references": [
                        {
                            "id": 275,
                            "pubMedId": 10,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/10"
                        }
                    ]
                }
            ]
        },
        {
            "id": 1790,
            "fullName": "BRAF G469V",
            "impact": "missense",
            "proteinEffect": "gain of function",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF G469V is a hotspot mutation within the protein kinase domain of the Braf protein (UniProt.org). G469V results in increased Braf kinase activity and activation of downstream MEK and ERK in cell culture (PMID: 28947956, PMID: 26343582, PMID: 28783719), and in one of two cell lines, increased cell proliferation and cell viability compared to wild-type Braf (PMID: 29533785).",
                    "references": [
                        {
                            "id": 9692,
                            "pubMedId": 28783719,
                            "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/28783719"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 7141,
                            "pubMedId": 26343582,
                            "title": "BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343582"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 12147,
                            "pubMedId": 28947956,
                            "title": "Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/28947956"
                        }
                    ]
                }
            ]
        },
        {
            "id": 27719,
            "fullName": "BRAF Q609H",
            "impact": "missense",
            "proteinEffect": "no effect - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF Q609H lies within the protein kinase domain of the Braf protein (UniProt.org). Q609H has not been biochemically characterized, but results in\u00a0similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function.",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        }
                    ]
                }
            ]
        },
        {
            "id": 470,
            "fullName": "BRAF G466V",
            "impact": "missense",
            "proteinEffect": "loss of function",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF G466V lies within the protein kinase domain of the Braf protein (UniProt.org). G466V results in impaired Braf kinase activity, but paradoxically activates MEK and ERK through transactivation of CRAF in cell culture (PMID: 22649091, PMID: 28783719), and in one of two cell lines, G466V decreased cell proliferation and cell viability as compared to wild-type Braf (PMID: 29533785).",
                    "references": [
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 9692,
                            "pubMedId": 28783719,
                            "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/28783719"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 423,
                            "pubMedId": 22649091,
                            "title": "Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/22649091"
                        }
                    ]
                }
            ]
        },
        {
            "id": 29489,
            "fullName": "BRAF P367L",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF P367L does not lie within any known functional domains of the Braf protein (UniProt.org). P367L has been identified in sequencing studies (PMID: 26317466), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Feb 2019).",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 14317,
                            "pubMedId": 26317466,
                            "title": "Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/26317466"
                        },
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        }
                    ]
                }
            ]
        },
        {
            "id": 26677,
            "fullName": "BRAF F247L",
            "impact": "missense",
            "proteinEffect": "gain of function",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF F247L lies within the phorbol-ester/DAG-type zinc finger region of the Braf protein (UniProt.org). F247L confers a gain of function to Braf, as indicated by activation of downstream MAPK signaling and is transforming in cultured cells (PMID: 28512244, PMID: 29533785).",
                    "references": [
                        {
                            "id": 9257,
                            "pubMedId": 28512244,
                            "title": "Engineering and Functional Characterization of Fusion Genes Identifies Novel Oncogenic Drivers of Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/28512244"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        }
                    ]
                }
            ]
        },
        {
            "id": 29448,
            "fullName": "BRAF G469X",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF G469X indicates any Braf missense mutation that results in replacement of the glycine (G) at amino acid 469 by a different amino acid.",
                    "references": [
                        {
                            "id": 275,
                            "pubMedId": 10,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/10"
                        }
                    ]
                }
            ]
        },
        {
            "id": 464,
            "fullName": "BRAF L597V",
            "impact": "missense",
            "proteinEffect": "gain of function",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF L597V lies within the protein kinase domain of the Braf protein (UniProt.org). L597V results in activation of Braf as indicated by increased phosphorylation of Mek and Erk in cell culture (PMID: 22798288) and and induces cell proliferation and cell viability in culture (PMID: 29533785).",
                    "references": [
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 3,
                            "pubMedId": 22798288,
                            "title": "BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/22798288"
                        }
                    ]
                }
            ]
        },
        {
            "id": 13,
            "fullName": "BRAF wild-type",
            "impact": "none",
            "proteinEffect": "no effect",
            "geneVariantDescriptions": [
                {
                    "description": "Wild-type BRAF indicates that no mutation has been detected within the BRAF gene.",
                    "references": [
                        {
                            "id": 275,
                            "pubMedId": 10,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/10"
                        }
                    ]
                }
            ]
        },
        {
            "id": 29614,
            "fullName": "BRAF V47_M438del",
            "impact": "deletion",
            "proteinEffect": "gain of function - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF V47_M438del results in the deletion of 392 amino acids of the Braf protein from amino acids 47 to 438 (UniProt.org). V47_M438del (reported as internal deletion of exons 2-10) has not been characterized, however, due to the deletion of the CR1 autoinhibitory domain and preservation of the protein kinase domain (PMID: 23890088, PMID: 22113612, PMID: 29171936), V47_M438del is predicted to lead to a gain of Braf protein function.",
                    "references": [
                        {
                            "id": 14627,
                            "pubMedId": 29171936,
                            "title": "BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29171936"
                        },
                        {
                            "id": 3413,
                            "pubMedId": 23890088,
                            "title": "Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/23890088"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 14626,
                            "pubMedId": 22113612,
                            "title": "RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/22113612"
                        }
                    ]
                }
            ]
        },
        {
            "id": 29450,
            "fullName": "BRAF N581X",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF N581X indicates any Braf missense mutation that results in replacement of the asparagine (N) at amino acid 581 by a different amino acid.",
                    "references": [
                        {
                            "id": 275,
                            "pubMedId": 10,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/10"
                        }
                    ]
                }
            ]
        },
        {
            "id": 29444,
            "fullName": "BRAF I463X",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF I463X indicates any Braf missense mutation that results in replacement of the isoleucine (I) at amino acid 463 by a different amino acid.",
                    "references": [
                        {
                            "id": 275,
                            "pubMedId": 10,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/10"
                        }
                    ]
                }
            ]
        },
        {
            "id": 1792,
            "fullName": "BRAF E275K",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF E275K lies within the phorbol-ester/DAG-type zinc finger region of the Braf protein (UniProt.org). E275K results in decreased activation of Mek and Erk (PMID: 19206169), but also demonstrates similar cell proliferation and viability as compared to wild-type Braf in culture (PMID: 29533785), and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019).",
                    "references": [
                        {
                            "id": 760,
                            "pubMedId": 19206169,
                            "title": "Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/19206169"
                        },
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        }
                    ]
                }
            ]
        },
        {
            "id": 29579,
            "fullName": "BRAF S465E",
            "impact": "missense",
            "proteinEffect": "loss of function - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF S465E lies within the protein kinase domain of the Braf protein (UniProt.org). S465E results in basal Mek phosphorylation similar to wild-type Braf but decreased Mek phosphorylation upon Ras activation in culture (PMID: 27034005), and therefore, is predicted to lead to a loss of Braf protein function.",
                    "references": [
                        {
                            "id": 14533,
                            "pubMedId": 27034005,
                            "title": "Phospho-proteomic analyses of B-Raf protein complexes reveal new regulatory principles.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/27034005"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 28195,
            "fullName": "BRAF H269Y",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF H269Y lies within the Phorbol-ester/DAG-type zinc finger domain of the Braf protein (UniProt.org). H269Y has not been biochemically characterized, but results in increased transformation ability compared to wild-type Braf in one of two different cell lines in culture (PMID: 29533785), and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019).",
                    "references": [
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 2662,
            "fullName": "BRAF W619R",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF W619R lies within the protein kinase domain of the Braf protein (UniProt.org). W619R has been identified in sequencing studies (PMID: 16179870), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019).",
                    "references": [
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 7114,
                            "pubMedId": 16179870,
                            "title": "Preponderance of the oncogenic V599E and V599K mutations in the B-raf kinase domain is enhanced in melanoma lymph node metastases.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/16179870"
                        }
                    ]
                }
            ]
        },
        {
            "id": 28285,
            "fullName": "BRAF H568D",
            "impact": "missense",
            "proteinEffect": "loss of function - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF H568D lies within the protein kinase domain of the Braf protein (UniProt.org). H568D results in a loss of MEK phosphorylation in cell culture similar to Braf kinase-dead variants (PMID: 29666306), and therefore, is predicted to confer a loss of function to the Braf protein.",
                    "references": [
                        {
                            "id": 11355,
                            "pubMedId": 29666306,
                            "title": "Truncation- and motif-based pan-cancer analysis reveals tumor-suppressing kinases.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29666306"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 2634,
            "fullName": "BRAF T599R",
            "impact": "missense",
            "proteinEffect": "gain of function",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF T599R lies within the activation loop in the kinase domain of the Braf protein (PMID: 19206169). T599R confers a gain of function on Braf, as indicated by increased MEK and ERK phosphorylation, and is transforming in cell culture (PMID: 19206169, PMID: 29533785).",
                    "references": [
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 760,
                            "pubMedId": 19206169,
                            "title": "Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/19206169"
                        }
                    ]
                }
            ]
        },
        {
            "id": 29613,
            "fullName": "BRAF N486_T491delinsK",
            "impact": "indel",
            "proteinEffect": "gain of function",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF N486_T491delinsK results in a deletion of 6 amino acids in the protein kinase domain of the Braf protein from amino acids 486 to 491, combined with the insertion of a lysine (K) at the same site (UniProt.org). N486_A491delinsK confers a gain of function to Braf, as indicated by increased ERK activation and transformation of cultured cells (PMID: 30867592).",
                    "references": [
                        {
                            "id": 14632,
                            "pubMedId": 30867592,
                            "title": "Efficacy of MEK inhibition in patients with histiocytic neoplasms.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/30867592"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 29456,
            "fullName": "BRAF A598X",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF A598X indicates any Braf missense mutation that results in replacement of the alanine (A) at amino acid 598 by a different amino acid.",
                    "references": [
                        {
                            "id": 275,
                            "pubMedId": 10,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/10"
                        }
                    ]
                }
            ]
        },
        {
            "id": 23121,
            "fullName": "BRAF G596C",
            "impact": "missense",
            "proteinEffect": "loss of function",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF G596C lies within the protein kinase domain of the Braf protein (UniProt.org). G596C results in decreased Braf kinase activity, however, leads to activation of downstream MEK and ERK in combination with CRAF in cell culture (PMID: 28947956).",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 12147,
                            "pubMedId": 28947956,
                            "title": "Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/28947956"
                        }
                    ]
                }
            ]
        },
        {
            "id": 23132,
            "fullName": "BRAF Q257R",
            "impact": "missense",
            "proteinEffect": "gain of function",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF Q257R lies within the phorbol-ester/DAG-type zinc finger region of the BRAF protein (UniProt.org). Q257R confers a gain of function to the Braf protein as demonstrated by increased kinase activity and activation of downstream Mek signaling in cell cuture, and activation of ELK in reporter assays (PMID: 16474404, PMID: 16439621).",
                    "references": [
                        {
                            "id": 5839,
                            "pubMedId": 16439621,
                            "title": "Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/16439621"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 5844,
                            "pubMedId": 16474404,
                            "title": "Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/16474404"
                        }
                    ]
                }
            ]
        },
        {
            "id": 17026,
            "fullName": "BRAF Q262R",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF Q262R lies within the Phorbol-ester/DAG-type zinc finger region of the Braf protein (UniProt.org). Q262R has not been characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019).\r\n",
                    "references": [
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 3139,
            "fullName": "BRAF G596D",
            "impact": "missense",
            "proteinEffect": "loss of function",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF G596D lies within the protein kinase domain of the Braf protein (UniProt.org). G596D demonstrates decreased Braf kinase activity in cell culture (PMID: 28783719), and therefore is predicted to confer a loss of function to the Braf protein.",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 9692,
                            "pubMedId": 28783719,
                            "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/28783719"
                        }
                    ]
                }
            ]
        },
        {
            "id": 19428,
            "fullName": "BRAF L485_P490delinsY",
            "impact": "indel",
            "proteinEffect": "gain of function - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF L485_P490delinsY results in a deletion of six amino acids near the alphaC-helix region of the Braf protein kinase domain combined with the insertion of one new amino acid in the same location (PMID: 26732095). L485_P490delinsY is associated with increased MEK/ERK activation in cells also harboring L485_P490delinsF, and similar deletions result in Braf activation (PMID: 26732095), and therefore, L485_P490delinsY is predicted to confer a gain of function to the Braf protein.",
                    "references": [
                        {
                            "id": 4801,
                            "pubMedId": 26732095,
                            "title": "Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/26732095"
                        }
                    ]
                }
            ]
        },
        {
            "id": 2771,
            "fullName": "BRAF L505H",
            "impact": "missense",
            "proteinEffect": "gain of function",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF L505H lies within the protein kinase domain of the Braf protein (UniProt.org). L505H confers a gain of function to the Braf protein resulting in MEK/ERK activation and oncogenic transformation in cultured cells, and is associated with resistance to RAF inhibitors (PMID: 24283590).",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 1371,
                            "pubMedId": 24283590,
                            "title": "Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/24283590"
                        }
                    ]
                }
            ]
        },
        {
            "id": 28211,
            "fullName": "BRAF S607F",
            "impact": "missense",
            "proteinEffect": "loss of function - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF S607F lies within the protein kinase domain of the Braf protein (UniProt.org). S607F has not been biochemically characterized, but demonstrates decreased transformation ability in cell culture (PMID: 29533785), and is therefore predicted to confer a loss of function to the Braf protein.",
                    "references": [
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 27708,
            "fullName": "BRAF K205Q",
            "impact": "missense",
            "proteinEffect": "no effect - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF K205Q lies within the protein kinase domain of the Braf protein (UniProt.org). K205Q has not been biochemically characterized, but results in\u00a0similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function.",
                    "references": [
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 23134,
            "fullName": "BRAF S467A",
            "impact": "missense",
            "proteinEffect": "gain of function",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF S467A lies within the protein kinase domain of the Braf protein (UniProt.org). S467A confers a gain of function to the Braf protein as demonstrated by increased kinase activity and activation of downstream Mek signaling (PMID: 23680146, PMID: 16439621).",
                    "references": [
                        {
                            "id": 5858,
                            "pubMedId": 23680146,
                            "title": "RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/23680146"
                        },
                        {
                            "id": 5839,
                            "pubMedId": 16439621,
                            "title": "Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/16439621"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 28205,
            "fullName": "BRAF M53I",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF M53I does not lie within any known functional domains of the Braf protein (UniProt.org). M53I results in increased transformation ability compared to wild-type Braf in one of two cell lines in culture (PMID: 29533785), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019).",
                    "references": [
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 578,
            "fullName": "BRAF act mut",
            "impact": "unknown",
            "proteinEffect": "gain of function",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF act mut indicates that this variant results in a gain of function in the Braf protein. However, the specific amino acid change has not been identified.",
                    "references": [
                        {
                            "id": 275,
                            "pubMedId": 10,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/10"
                        }
                    ]
                }
            ]
        },
        {
            "id": 29612,
            "fullName": "BRAF V169_D380del",
            "impact": "deletion",
            "proteinEffect": "gain of function - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF V169_D380del results in the deletion of 212 amino acids of the Braf protein from amino acids 169 to 380 (UniProt.org). V169_D380del (reported as internal deletion of exons 4-8) has not been characterized, however, due to the deletion of the CR1 autoinhibitory domain and preservation of the protein kinase domain (PMID: 23890088, PMID: 22113612, PMID: 29171936), V169_D380del is predicted to lead to a gain of Braf protein function.",
                    "references": [
                        {
                            "id": 3413,
                            "pubMedId": 23890088,
                            "title": "Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/23890088"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 14626,
                            "pubMedId": 22113612,
                            "title": "RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/22113612"
                        },
                        {
                            "id": 14627,
                            "pubMedId": 29171936,
                            "title": "BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29171936"
                        }
                    ]
                }
            ]
        },
        {
            "id": 27702,
            "fullName": "BRAF A320T",
            "impact": "missense",
            "proteinEffect": "no effect - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF A320T lies within the protein kinase domain of the Braf protein (UniProt.org). A320T has not been biochemically characterized, but results in similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function.",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        }
                    ]
                }
            ]
        },
        {
            "id": 901,
            "fullName": "BRAF L597Q",
            "impact": "missense",
            "proteinEffect": "gain of function",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF L597Q lies within the protein kinase domain of the Braf protein (UniProt.org). L597Q results in activation of Braf as indicated by increased phosphorylation of Mek and Erk in cell culture (PMID: 22798288) and induces cell proliferation and cell viability in culture (PMID: 29533785).",
                    "references": [
                        {
                            "id": 3,
                            "pubMedId": 22798288,
                            "title": "BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/22798288"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        }
                    ]
                }
            ]
        },
        {
            "id": 27006,
            "fullName": "BRAF I463T",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF I463T lies within the protein kinase domain of the Braf protein (UniProt.org). I463T has been identified in the scientific literature (PMID: 28829677), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019).",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 9957,
                            "pubMedId": 28829677,
                            "title": "BRAF mutation as a novel driver of eosinophilic cystitis.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/28829677"
                        },
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        }
                    ]
                }
            ]
        },
        {
            "id": 1252,
            "fullName": "BRAF rearrange",
            "impact": "unknown",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF rearrangement indicates an unspecified rearrangement of the BRAF gene.",
                    "references": [
                        {
                            "id": 275,
                            "pubMedId": 10,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/10"
                        }
                    ]
                }
            ]
        },
        {
            "id": 3172,
            "fullName": "BRAF S605N",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF S605N lies within the protein kinase domain of the Braf protein (UniProt.org). S605N has been identified in sequencing studies (PMID: 29176861, PMID: 28628916, PMID: 15331929), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019).",
                    "references": [
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 14453,
                            "pubMedId": 28628916,
                            "title": "Comprehensive Biomarker Analyses in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer Prospectively Treated with the Polo-Like Kinase 1 Inhibitor BI2536.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/28628916"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 7101,
                            "pubMedId": 15331929,
                            "title": "B-raf exon 15 mutations are common in primary melanoma resection specimens but not associated with clinical outcome.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/15331929"
                        },
                        {
                            "id": 14454,
                            "pubMedId": 29176861,
                            "title": "Variables that influence BRAF mutation probability: A next-generation sequencing, non-interventional investigation of BRAFV600 mutation status in melanoma.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29176861"
                        }
                    ]
                }
            ]
        },
        {
            "id": 27701,
            "fullName": "BRAF D380H",
            "impact": "missense",
            "proteinEffect": "no effect - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF D380H lies within the protein kinase domain of the Braf protein (UniProt.org). D380H has not been biochemically characterized, but results in similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function.",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        }
                    ]
                }
            ]
        },
        {
            "id": 25588,
            "fullName": "BRAF L485F",
            "impact": "missense",
            "proteinEffect": "gain of function",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF L485F lies within the protein kinase domain of the Braf protein (UniProt.org). L485F confers a gain of function to the Braf protein as demonstrated by increased kinase activity and activation of downstream Mek and Erk in cell culture (PMID: 16439621), and in one of two cell lines, L485F increased cell proliferation and cell viability compared to wild-type Braf (PMID: 29533785).",
                    "references": [
                        {
                            "id": 5839,
                            "pubMedId": 16439621,
                            "title": "Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/16439621"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 29442,
            "fullName": "BRAF P367X",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF P367X indicates any Braf missense mutation that results in replacement of the proline (P) at amino acid 367 by a different amino acid.",
                    "references": [
                        {
                            "id": 275,
                            "pubMedId": 10,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/10"
                        }
                    ]
                }
            ]
        },
        {
            "id": 27731,
            "fullName": "BRAF T470K",
            "impact": "missense",
            "proteinEffect": "no effect - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF T470K lies within the protein kinase domain of the Braf protein (UniProt.org). T470K has not been biochemically characterized, but results in similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function.",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        }
                    ]
                }
            ]
        },
        {
            "id": 17027,
            "fullName": "BRAF V226L",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF V226L lies within the Ras-binding domain of the Braf protein (UniProt.org). V226L has not been characterized in the scientific literature and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019).",
                    "references": [
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 3766,
            "fullName": "BRAF K601T",
            "impact": "missense",
            "proteinEffect": "gain of function - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF K601T lies within the activation segment in the kinase domain of the Braf protein (PMID: 15343278). K601T results in increased Braf kinase activity in cell culture (PMID: 28783719), and in one of two cell lines increased cell proliferation and cell viability compared to wild-type Braf (PMID: 29533785), and is therefore predicted to confer a gain of function to the Braf protein.",
                    "references": [
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 9692,
                            "pubMedId": 28783719,
                            "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/28783719"
                        },
                        {
                            "id": 9694,
                            "pubMedId": 15343278,
                            "title": "Switching on kinases: oncogenic activation of BRAF and the PDGFR family.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/15343278"
                        }
                    ]
                }
            ]
        },
        {
            "id": 28669,
            "fullName": "BRAF V600dup",
            "impact": "duplication",
            "proteinEffect": "gain of function",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF V600dup (also referred to as T599_V600insV) indicates the insertion of the duplicate amino acid, valine (V)-600, in the protein kinase domain of the Braf protein (UniProt.org). V600dup confers a gain of function to the Braf protein as demonstrated by increased kinase activity and phosphorylation of downstream Mek and Erk, and is transforming in cell culture (PMID: 21190184).",
                    "references": [
                        {
                            "id": 1910,
                            "pubMedId": 21190184,
                            "title": "Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/21190184"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 452,
            "fullName": "BRAF G469A",
            "impact": "missense",
            "proteinEffect": "gain of function",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF G469A is a hotspot mutation within the protein kinase domain of the Braf protein (UniProt.org). G469A results in increased Braf kinase activity and downstream activation of Erk, and is transforming in cell culture (PMID: 19010912, PMID: 12068308, PMID: 29533785).",
                    "references": [
                        {
                            "id": 636,
                            "pubMedId": 19010912,
                            "title": "Genetic predictors of MEK dependence in non-small cell lung cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/19010912"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 637,
                            "pubMedId": 12068308,
                            "title": "Mutations of the BRAF gene in human cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/12068308"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 3517,
            "fullName": "BRAF G466E",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF G466E lies within the protein kinase domain of the Braf protein (UniProt.org). G466E results in impaired Braf kinase activity, but paradoxically increases Erk signaling through C-raf activation in cell culture and Xenopus embryos (PMID: 15035987), however, induces similar cell proliferation and cell viability as wild-type Braf (PMID: 29533785), and therefore, its effect on Braf protein function is unknown.",
                    "references": [
                        {
                            "id": 146,
                            "pubMedId": 15035987,
                            "title": "Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/15035987"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        }
                    ]
                }
            ]
        },
        {
            "id": 26912,
            "fullName": "BRAF D287H",
            "impact": "missense",
            "proteinEffect": "loss of function",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF D287H does not lie within any known functional domains of the Braf protein (UniProt.org). D287H results in impaired Braf kinase activity, but leads to Ras-dependent activation of Erk in cell culture (PMID: 26343582, PMID: 28783719).",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 7141,
                            "pubMedId": 26343582,
                            "title": "BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343582"
                        },
                        {
                            "id": 9692,
                            "pubMedId": 28783719,
                            "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/28783719"
                        }
                    ]
                }
            ]
        },
        {
            "id": 3158,
            "fullName": "BRAF S605F",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF S605F lies within the protein kinase domain of the Braf protein (UniProt.org). S605F has been identified in sequencing studies (PMID: 15331929), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019).",
                    "references": [
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 7101,
                            "pubMedId": 15331929,
                            "title": "B-raf exon 15 mutations are common in primary melanoma resection specimens but not associated with clinical outcome.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/15331929"
                        }
                    ]
                }
            ]
        },
        {
            "id": 3183,
            "fullName": "BRAF V600Q",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF V600Q (previously reported as V599Q) lies within the activation segment and the protein kinase domain of the Braf protein (PMID: 15035987). V600Q has been identified in the scientific literature (PMID: 28848703), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019).",
                    "references": [
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 12140,
                            "pubMedId": 28848703,
                            "title": "BRAF V600Q-mutated lung adenocarcinoma with duodenal metastasis and extreme leukocytosis.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/28848703"
                        },
                        {
                            "id": 146,
                            "pubMedId": 15035987,
                            "title": "Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/15035987"
                        }
                    ]
                }
            ]
        },
        {
            "id": 27710,
            "fullName": "BRAF L64I",
            "impact": "missense",
            "proteinEffect": "no effect - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF L64I lies within the protein kinase domain of the Braf protein (UniProt.org). L64I has not been biochemically characterized, but results in\u00a0similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function.",
                    "references": [
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 28199,
            "fullName": "BRAF K499N",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF K499N lies within the protein kinase domain of the Braf protein (UniProt.org). K449N results in increased transformation ability compared to wild-type Braf in one of two different cell lines in culture (PMID: 29533785), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019).",
                    "references": [
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        }
                    ]
                }
            ]
        },
        {
            "id": 29620,
            "fullName": "BRAF A81_D380del",
            "impact": "deletion",
            "proteinEffect": "gain of function - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF A81_D380del results in the deletion of 300 amino acids of the Braf protein from amino acids 81 to 380 (UniProt.org). A81_D380del (reported as internal deletion of exons 3-8) has not been characterized, however, due to the deletion of the CR1 autoinhibitory domain and preservation of the protein kinase domain (PMID: 23890088, PMID: 22113612, PMID: 29171936), A81_D380del is predicted to lead to a gain of Braf protein function.",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 14626,
                            "pubMedId": 22113612,
                            "title": "RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/22113612"
                        },
                        {
                            "id": 14627,
                            "pubMedId": 29171936,
                            "title": "BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29171936"
                        },
                        {
                            "id": 3413,
                            "pubMedId": 23890088,
                            "title": "Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/23890088"
                        }
                    ]
                }
            ]
        },
        {
            "id": 29492,
            "fullName": "BRAF K601_S602delinsNT",
            "impact": "indel",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF K601_S602delinsNT results in a deletion of two amino acids in the protein kinase domain of the Braf protein from amino acids 601 to 602, combined with the insertion of an asparagine (N) and a threonine (T) at the same site (UniProt.org). K601_S602delinsNT has not been characterized and therefore, its effect on Braf protein function is unknown (PubMed, Feb 2019).",
                    "references": [
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 27729,
            "fullName": "BRAF S637*",
            "impact": "nonsense",
            "proteinEffect": "loss of function - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF S637* results in a premature truncation the Braf protein at amino acid 637 of 766 (UniProt.org). S637* has not been biochemically characterized, however, demonstrates an inability to induce cell viability and proliferation in cell culture (PMID: 29533785), and therefore is predicted to confer a loss of function to the Braf protein.",
                    "references": [
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 404,
            "fullName": "BRAF V600E/K",
            "impact": "missense",
            "proteinEffect": "gain of function",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF V600E/K indicates a mutation that results in the replacement of the valine (V) at amino acid 600 of the Braf protein by either a glutamate (E) or lysine (K). V600E/K mutations are hotspot mutations in Braf that result in increased Braf kinase activity (PMID: 15035987).",
                    "references": [
                        {
                            "id": 146,
                            "pubMedId": 15035987,
                            "title": "Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/15035987"
                        }
                    ]
                }
            ]
        },
        {
            "id": 2561,
            "fullName": "BRAF G596R",
            "impact": "missense",
            "proteinEffect": "loss of function - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF G596R lies within the protein kinase domain of the Braf protein, within the DFG motif (PMID: 19735675). G596R results in impaired Braf kinase activity and decreased Mek and Erk phosphorylation, including in the presence of BRAF V600E, is not transforming in culture and does not promote tumor formation in mouse models, but results in activation of Erk in the presence of CRAF (PMID: 19735675, PMID: 28783719), however, in another study demonstrates similar cell proliferation and viability levels to wild-type Braf (PMID: 29533785), and is predicted to confer a loss of function to the Braf protein.",
                    "references": [
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 9692,
                            "pubMedId": 28783719,
                            "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/28783719"
                        },
                        {
                            "id": 1060,
                            "pubMedId": 19735675,
                            "title": "Insights into the molecular function of the inactivating mutations of B-Raf involving the DFG motif.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/19735675"
                        }
                    ]
                }
            ]
        },
        {
            "id": 3176,
            "fullName": "BRAF T599_V600insTT",
            "impact": "insertion",
            "proteinEffect": "gain of function",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF T599_V600insTT results in the insertion of two threonines (T) in the protein kinase domain of the Braf protein between amino acids 599 and 600 (UniProt.org). T599_V600insTT results in increased Braf kinase activity in an in vitro assay, and increased downstream Mek/Erk signaling in culture (PMID: 21190184).",
                    "references": [
                        {
                            "id": 1910,
                            "pubMedId": 21190184,
                            "title": "Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/21190184"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 4989,
            "fullName": "BRAF L597P",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF L597P lies within the protein kinase domain of the Braf protein (UniProt.org). L597P has been identified in sequencing studies (PMID: 30268455, PMID: 24714776), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019).",
                    "references": [
                        {
                            "id": 14442,
                            "pubMedId": 30268455,
                            "title": "Non-invasive detection of actionable mutations in advanced non-small-cell lung cancer using targeted sequencing of circulating tumor DNA.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/30268455"
                        },
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 12139,
                            "pubMedId": 24714776,
                            "title": "Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/24714776"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 27727,
            "fullName": "BRAF S419Y",
            "impact": "missense",
            "proteinEffect": "no effect - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF S419Y lies within the protein kinase domain of the Braf protein (UniProt.org). S419Y has not been biochemically characterized, but results in similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function.",
                    "references": [
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 50,
            "fullName": "BRAF V600K",
            "impact": "missense",
            "proteinEffect": "gain of function",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF V600K (previously reported as V599) lies within the activation segment of the kinase domain of the Braf protein (PMID: 15035987). V600K confers a gain of function to the Braf protein as demonstrated by increased kinase activity, downstream signaling, and the ability to transform cells in vitro (PMID: 15035987, PMID: 29533785).",
                    "references": [
                        {
                            "id": 146,
                            "pubMedId": 15035987,
                            "title": "Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/15035987"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        }
                    ]
                }
            ]
        },
        {
            "id": 28198,
            "fullName": "BRAF K483E",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF K483E lies within the protein kinase domain of the Braf protein (UniProt.org). K483E results in increased transformation compared to wild-type Braf in one of two different cell lines in culture (PMID: 29533785), but also results in ERK1/2 phosphorylation level similar to wild-type Braf in culture (PMID: 27799065), and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019).",
                    "references": [
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 14477,
                            "pubMedId": 27799065,
                            "title": "A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/27799065"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        }
                    ]
                }
            ]
        },
        {
            "id": 28591,
            "fullName": "BRAF H574N",
            "impact": "missense",
            "proteinEffect": "no effect - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF H574N lies within the protein kinase domain of the Braf protein (UniProt.org). H574N results in Erk phosphorylation at similar levels to wild-type Braf in culture (PMID: 27478040), and is therefore predicted to have no effect on Braf protein function.",
                    "references": [
                        {
                            "id": 8124,
                            "pubMedId": 27478040,
                            "title": "High-throughput Phenotyping of Lung Cancer Somatic Mutations.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/27478040"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 893,
            "fullName": "BRAF V600M",
            "impact": "missense",
            "proteinEffect": "gain of function - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF V600M (previously reported as V599) lies within the activation segment of the kinase domain of the Braf protein (PMID: 15035987). V600M results in intermediate Braf kinase activity in cell culture (PMID: 28783719), and in one of two cell lines increased cell proliferation and cell viability compared to wild-type Braf (PMID: 29533785), and is therefore predicted to confer a gain of function to the Braf protein.",
                    "references": [
                        {
                            "id": 9692,
                            "pubMedId": 28783719,
                            "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/28783719"
                        },
                        {
                            "id": 146,
                            "pubMedId": 15035987,
                            "title": "Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/15035987"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        }
                    ]
                }
            ]
        },
        {
            "id": 23130,
            "fullName": "BRAF L485_Q494del",
            "impact": "deletion",
            "proteinEffect": "gain of function - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF L485_Q494del results in the deletion of ten amino acids within the beta-3/alpha-C helix loop in the protein kinase domain of the Braf protein (PMID: 26732095, UniProt.org). L485_Q494del has not been characterized, however, is predicted to result in a gain of function due to other characterized BRAF deletions in the same region (PMID: 26732095).",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 4801,
                            "pubMedId": 26732095,
                            "title": "Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/26732095"
                        }
                    ]
                }
            ]
        },
        {
            "id": 19429,
            "fullName": "BRAF L485_P490delinsF",
            "impact": "indel",
            "proteinEffect": "gain of function - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF L485_P490delinsF results in a deletion of six amino acids near the alphaC-helix region of the Braf protein kinase domain combined with the insertion of one new amino acid in the same location (PMID: 26732095). L485_P490delinsF is associated with increased Erk phosphorylation in human tumor samples (PMID: 29544532), and increased activation of MEK/ERK signaling in combination with L485_P490delinsY in cultured cells (PMID: 26732095), and therefore is predicted to confer a gain of function to the Braf protein.",
                    "references": [
                        {
                            "id": 4801,
                            "pubMedId": 26732095,
                            "title": "Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/26732095"
                        },
                        {
                            "id": 12166,
                            "pubMedId": 29544532,
                            "title": "BRAF activating mutations involving the \u03b23-\u03b1C loop in V600E-negative anaplastic pleomorphic xanthoastrocytoma.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29544532"
                        }
                    ]
                }
            ]
        },
        {
            "id": 27735,
            "fullName": "BRAF V681I",
            "impact": "missense",
            "proteinEffect": "no effect - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF V681I lies within the protein kinase domain of the Braf protein (UniProt.org). V681I has not been biochemically characterized, but results in\u00a0similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function.",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        }
                    ]
                }
            ]
        },
        {
            "id": 29491,
            "fullName": "BRAF T599K",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF T599K lies within the protein kinase domain of the Braf protein (UniProt.org). T599K has been identified in sequencing studies (PMID: 30603682), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Feb 2019).",
                    "references": [
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 14319,
                            "pubMedId": 30603682,
                            "title": "Competitive evolution of NSCLC tumor clones and the drug resistance mechanism of first-generation EGFR-TKIs in Chinese NSCLC patients.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/30603682"
                        }
                    ]
                }
            ]
        },
        {
            "id": 1794,
            "fullName": "BRAF T241P",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF T241P does not lie within any known functional domains of the Braf protein (UniProt.org). T241P results in weak activation of MEK and ERK and does not induce transformation in cell culture (PMID: 19206169), but in one of two cell lines, demonstrates increased cell proliferation and cell viability compared to wild-type Braf (PMID: 29533785), and therefore, its effect on Braf protein function is unknown.",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 760,
                            "pubMedId": 19206169,
                            "title": "Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/19206169"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        }
                    ]
                }
            ]
        },
        {
            "id": 29498,
            "fullName": "BRAF T599_V600insS",
            "impact": "insertion",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF T599_V600insS results in the insertion of a serine (S) in the protein kinase domain of the Braf protein between amino acids 599 and 600 (UniProt.org). T599_V600insS has not been characterized in the scientific literature and therefore, its effect on Braf protein function is unknown (PubMed, Feb 2019).",
                    "references": [
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 28196,
            "fullName": "BRAF H585Y",
            "impact": "missense",
            "proteinEffect": "loss of function - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF H585Y lies within the protein kinase domain of the Braf protein (UniProt.org). H585Y has not been biochemically characterized, but demonstrates decreased transformation ability in cell culture (PMID: 29533785), and is therefore predicted to confer a loss of function to the Braf protein.",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        }
                    ]
                }
            ]
        },
        {
            "id": 23136,
            "fullName": "BRAF T529M",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF T529M lies within the protein kinase domain of the Braf protein (UniProt.org). T529M has been demonstrated to result in resistance to Raf inhibitors in the context of BRAF V600E (PMID: 20538618), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019).",
                    "references": [
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 5859,
                            "pubMedId": 20538618,
                            "title": "Gatekeeper mutations mediate resistance to BRAF-targeted therapies.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/20538618"
                        }
                    ]
                }
            ]
        },
        {
            "id": 3178,
            "fullName": "BRAF V600A",
            "impact": "missense",
            "proteinEffect": "no effect - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF V600A (previously reported as V599) lies within the activation segment of the kinase domain of the Braf protein (PMID: 15035987). V600A results in phosphorylated Mek protein levels similar to wild-type Braf and therefore, is predicted to have no effect on Braf protein function (PMID: 26744778).",
                    "references": [
                        {
                            "id": 9739,
                            "pubMedId": 26744778,
                            "title": "The yin-yang of kinase activation and unfolding explains the peculiarity of Val600 in the activation segment of BRAF.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/26744778"
                        },
                        {
                            "id": 146,
                            "pubMedId": 15035987,
                            "title": "Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/15035987"
                        }
                    ]
                }
            ]
        },
        {
            "id": 27718,
            "fullName": "BRAF P676S",
            "impact": "missense",
            "proteinEffect": "no effect - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF P676S lies within the protein kinase domain of the Braf protein (UniProt.org). P676S has not been biochemically characterized, but results in similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function.",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        }
                    ]
                }
            ]
        },
        {
            "id": 3174,
            "fullName": "BRAF T599I",
            "impact": "missense",
            "proteinEffect": "gain of function",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF T599I (also reported as T598I) lies within the protein kinase domain of the Braf protein (UniProt.org). T599I results in increased Braf kinase activity, increased downstream Erk signaling (PMID: 15035987), and induces cell proliferation and cell viability in culture (PMID: 29533785).",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 146,
                            "pubMedId": 15035987,
                            "title": "Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/15035987"
                        }
                    ]
                }
            ]
        },
        {
            "id": 29578,
            "fullName": "BRAF S465D",
            "impact": "missense",
            "proteinEffect": "no effect - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF S465D lies within the protein kinase domain of the Braf protein (UniProt.org). S465D results in basal Mek phosphorylation and Mek phosphorylation upon Ras activation to similar levels of wild-type Braf in culture (PMID: 27034005), and therefore, is predicted to have no effect on Braf protein function.",
                    "references": [
                        {
                            "id": 14533,
                            "pubMedId": 27034005,
                            "title": "Phospho-proteomic analyses of B-Raf protein complexes reveal new regulatory principles.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/27034005"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 28209,
            "fullName": "BRAF P731S",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF P731S does not lie within any known functional domains of the Braf protein (UniProt.org). P731S results in increased transformation ability compared to wild-type Braf in one of two different cell lines in culture (PMID: 29533785), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019).",
                    "references": [
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        }
                    ]
                }
            ]
        },
        {
            "id": 3939,
            "fullName": "BRAF W604G",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF W604G lies within the protein kinase domain of the Braf protein (UniProt.org). W604G has been identified in the scientific literature (PMID: 29769567, PMID: 15331929), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019).",
                    "references": [
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 7101,
                            "pubMedId": 15331929,
                            "title": "B-raf exon 15 mutations are common in primary melanoma resection specimens but not associated with clinical outcome.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/15331929"
                        },
                        {
                            "id": 11670,
                            "pubMedId": 29769567,
                            "title": "Genomic alterations of ground-glass nodular lung adenocarcinoma.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29769567"
                        }
                    ]
                }
            ]
        },
        {
            "id": 29451,
            "fullName": "BRAF E586X",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF E586X indicates any Braf missense mutation that results in replacement of the glutamic acid (E) at amino acid 586 by a different amino acid.",
                    "references": [
                        {
                            "id": 275,
                            "pubMedId": 10,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/10"
                        }
                    ]
                }
            ]
        },
        {
            "id": 27705,
            "fullName": "BRAF F294L",
            "impact": "missense",
            "proteinEffect": "no effect - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF F294L lies within the protein kinase domain of the Braf protein (UniProt.org). F294L has not been biochemically characterized, but results in\u00a0similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function.",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        }
                    ]
                }
            ]
        },
        {
            "id": 3177,
            "fullName": "BRAF V471F",
            "impact": "missense",
            "proteinEffect": "loss of function",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF V471F lies within the protein kinase domain of the Braf protein (UniProt.org). V471F results in a loss of Braf kinase activity, however, results in dimerization-dependent activation of Erk signaling and is weakly transforming in cultured cells (PMID: 25348715).",
                    "references": [
                        {
                            "id": 1911,
                            "pubMedId": 25348715,
                            "title": "Kinase regulation by hydrophobic spine assembly in cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/25348715"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 29446,
            "fullName": "BRAF G466X",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF G466X indicates any Braf missense mutation that results in replacement of the glycine (G) at amino acid 466 by a different amino acid.",
                    "references": [
                        {
                            "id": 275,
                            "pubMedId": 10,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/10"
                        }
                    ]
                }
            ]
        },
        {
            "id": 467,
            "fullName": "BRAF G469E",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF G469E is a hotspot mutation that lies within the protein kinase domain of the Braf protein (UniProt.org). The functional effect of G469E is conflicting, as it results in low Braf kinase activity (PMID: 28783719) and intermediate Braf kinase activity (PMID: 15035987), demonstrates Ras-dependent activation of Erk signaling in cell culture (PMID: 28783719), and in one of two cell lines, results in increased cell proliferation and cell viability as compared to wild-type Braf (PMID: 29533785), and therefore, its effect on Braf protein function is unknown.",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 9692,
                            "pubMedId": 28783719,
                            "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/28783719"
                        },
                        {
                            "id": 146,
                            "pubMedId": 15035987,
                            "title": "Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/15035987"
                        }
                    ]
                }
            ]
        },
        {
            "id": 29454,
            "fullName": "BRAF G596X",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF G596X indicates any Braf missense mutation that results in replacement of the glycine (G) at amino acid 596 by a different amino acid.",
                    "references": [
                        {
                            "id": 275,
                            "pubMedId": 10,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/10"
                        }
                    ]
                }
            ]
        },
        {
            "id": 1601,
            "fullName": "BRAF G469R",
            "impact": "missense",
            "proteinEffect": "gain of function - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF G469R is a hotspot mutation within the protein kinase domain of the Braf protein (UniProt.org). G469R demonstrates intermediate BRAF kinase activity (PMID: 28783719) and results in constitutive ERK activation in cell culture (PMID: 24920063), and in one of two cell lines leads to increased cell proliferation and cell viability compared to wild-type Braf (PMID: 29533785), and is therefore predicted to confer a gain of function to the Braf protein.",
                    "references": [
                        {
                            "id": 4372,
                            "pubMedId": 24920063,
                            "title": "Acquired initiating mutations in early hematopoietic cells of CLL patients.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/24920063"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 9692,
                            "pubMedId": 28783719,
                            "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/28783719"
                        }
                    ]
                }
            ]
        },
        {
            "id": 4986,
            "fullName": "BRAF G596fs",
            "impact": "frameshift",
            "proteinEffect": "loss of function - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF G596fs results in a change in the amino acid sequence of the Braf protein beginning at aa 596 of 766, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the disruption of the protein kinase domain (UniProt.org), G596fs is predicted to lead to a loss of Braf protein function.",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 3144,
            "fullName": "BRAF I592V",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF I592V lies within the protein kinase domain of the Braf protein (UniProt.org). I592V has been identified in sequencing studies (PMID:  24710085, PMID: 15331929), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019).",
                    "references": [
                        {
                            "id": 7101,
                            "pubMedId": 15331929,
                            "title": "B-raf exon 15 mutations are common in primary melanoma resection specimens but not associated with clinical outcome.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/15331929"
                        },
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 14439,
                            "pubMedId": 24710085,
                            "title": "BRAF and NRAS mutations are heterogeneous and not mutually exclusive in nodular melanoma.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/24710085"
                        }
                    ]
                }
            ]
        },
        {
            "id": 27716,
            "fullName": "BRAF P348T",
            "impact": "missense",
            "proteinEffect": "no effect - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF P348T lies within the protein kinase domain of the Braf protein (UniProt.org). P348T has not been biochemically characterized, but results in similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function.",
                    "references": [
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 5047,
            "fullName": "BRAF V600G",
            "impact": "missense",
            "proteinEffect": "gain of function",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF V600G (previously reported as V599G) lies within the activation segment of the kinase domain of the Braf protein (PMID: 15035987). V600G confers a gain of function to Braf as indicated by increased phosphorylation of MEK and ERK and activation of ELK in culture (PMID: 20735442, PMID: 26744778), and in one of two cell lines, increased cell proliferation and viability compared to wild-type Braf (PMID: 29533785).",
                    "references": [
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 146,
                            "pubMedId": 15035987,
                            "title": "Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/15035987"
                        },
                        {
                            "id": 12159,
                            "pubMedId": 20735442,
                            "title": "Germline mutation in BRAF codon 600 is compatible with human development: de novo p.V600G mutation identified in a patient with CFC syndrome.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/20735442"
                        },
                        {
                            "id": 9739,
                            "pubMedId": 26744778,
                            "title": "The yin-yang of kinase activation and unfolding explains the peculiarity of Val600 in the activation segment of BRAF.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/26744778"
                        }
                    ]
                }
            ]
        },
        {
            "id": 1116,
            "fullName": "BRAF G478C",
            "impact": "missense",
            "proteinEffect": "loss of function - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF G478C lies within the protein kinase domain of the Braf protein (UniProt.org). G478C demonstrates a lack of Braf kinase activity in cell culture (PMID: 22926515), and therefore is predicted to confer a loss of function to the Braf protein.",
                    "references": [
                        {
                            "id": 463,
                            "pubMedId": 22926515,
                            "title": "ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/22926515"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 465,
            "fullName": "BRAF G464V",
            "impact": "missense",
            "proteinEffect": "gain of function",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF G464V (also reported as G463V) lies within the protein kinase domain of the Braf protein (UniProt.org). G464V results in increased Braf kinase activity and increased downstream Mek and Erk activation (PMID: 12068308, PMID: 26343582), and in one of two cell lines, increased cell proliferation and viability compared to wild-type Braf in culture (PMID: 29533785).",
                    "references": [
                        {
                            "id": 7141,
                            "pubMedId": 26343582,
                            "title": "BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343582"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 637,
                            "pubMedId": 12068308,
                            "title": "Mutations of the BRAF gene in human cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/12068308"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 28191,
            "fullName": "BRAF G596S",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF G596S lies within the protein kinase domain of the Braf protein (UniProt.org). G596S has not been biochemically characterized, but results in increased transformation ability compared to wild-type Braf in one of two different cell lines in culture (PMID: 29533785), and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019).",
                    "references": [
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 29473,
            "fullName": "BRAF P731T",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF P731T does not lie within any known functional domains of the Braf protein (UniProt.org). P731T has been identified in the scientific literature (PMID: 29320312), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Feb 2019).",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 13171,
                            "pubMedId": 29320312,
                            "title": "Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29320312"
                        },
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        }
                    ]
                }
            ]
        },
        {
            "id": 25271,
            "fullName": "BRAF L485Y",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF L485Y lies within the protein kinase domain of the Braf protein (UniProt.org). L485Y has been demonstrated to confer resistance to Raf inhibitor in cell culture (PMID: 19276360), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019).",
                    "references": [
                        {
                            "id": 6516,
                            "pubMedId": 19276360,
                            "title": "Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/19276360"
                        },
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 5039,
            "fullName": "BRAF T599_V600insEAT",
            "impact": "insertion",
            "proteinEffect": "gain of function - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF T599_V600insEAT results in the insertion of 3 amino acids in the protein kinase domain of the Braf protein between amino acids 599 and 600 (UniProt.org). T599_V600insEAT has not been characterized, however other insertions between T599 and V600 are activating thus, T599_V600insEAT is predicted to lead to a gain of Braf protein function (PMID: 16501605, PMID: 17297294, PMID: 21190184).",
                    "references": [
                        {
                            "id": 1910,
                            "pubMedId": 21190184,
                            "title": "Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/21190184"
                        },
                        {
                            "id": 2112,
                            "pubMedId": 17297294,
                            "title": "Functional characterization of the T1799-1801del and A1799-1816ins BRAF mutations in papillary thyroid cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/17297294"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 1892,
                            "pubMedId": 16501605,
                            "title": "Biochemical and molecular characterization of the novel BRAF(V599Ins) mutation detected in a classic papillary thyroid carcinoma.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/16501605"
                        }
                    ]
                }
            ]
        },
        {
            "id": 29440,
            "fullName": "BRAF T241X",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF T241X indicates any Braf missense mutation that results in replacement of the threonine (T) at amino acid 241 by a different amino acid.",
                    "references": [
                        {
                            "id": 275,
                            "pubMedId": 10,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/10"
                        }
                    ]
                }
            ]
        },
        {
            "id": 5029,
            "fullName": "BRAF D594_T599dup",
            "impact": "duplication",
            "proteinEffect": "gain of function",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF D594_T599dup (also referred to as T599_V600insDFGLAT) results in the insertion of six amino acids in the protein kinase domain of the Braf protein between amino acids 599 and 600 (UniProt.org).BRAF D594_T599dup results in increased colony formation and downstream Mek and Erk activation in cultured cells (PMID: 17297294).",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 2112,
                            "pubMedId": 17297294,
                            "title": "Functional characterization of the T1799-1801del and A1799-1816ins BRAF mutations in papillary thyroid cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/17297294"
                        }
                    ]
                }
            ]
        },
        {
            "id": 1161,
            "fullName": "BRAF V600X",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF V600X indicates any Braf missense mutation that results in replacement of the the valine (V) at amino acid 600 by a different amino acid. BRAF V600 mutations are hotspot mutations that often result in increased Braf kinase activity (PMID: 15035987).",
                    "references": [
                        {
                            "id": 275,
                            "pubMedId": 10,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/10"
                        },
                        {
                            "id": 146,
                            "pubMedId": 15035987,
                            "title": "Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/15035987"
                        }
                    ]
                }
            ]
        },
        {
            "id": 2560,
            "fullName": "BRAF F595L",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF F595L lies within the protein kinase domain of the Braf protein (UniProt.org). F595L results in intermediate Braf kinase activity and is transforming in cell culture (PMID: 15035987, PMID: 26582644, PMID: 29533785), and works cooperatively with oncogenic Ras to activate MEK/ERK signaling (PMID: 26582644), however, demonstrates low Braf kinase activity in vitro (PMID: 28783719), and therefore, its effect on Braf protein function is unknown.",
                    "references": [
                        {
                            "id": 146,
                            "pubMedId": 15035987,
                            "title": "Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/15035987"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 9692,
                            "pubMedId": 28783719,
                            "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/28783719"
                        },
                        {
                            "id": 9695,
                            "pubMedId": 26582644,
                            "title": "Cooperation of BRAF(F595L) and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/26582644"
                        }
                    ]
                }
            ]
        },
        {
            "id": 4987,
            "fullName": "BRAF G606A",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF G606A lies within the protein kinase domain of the Braf protein (UniProt.org). G606A has been identified in sequencing studies (PMID: 21825258), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019).",
                    "references": [
                        {
                            "id": 7103,
                            "pubMedId": 21825258,
                            "title": "Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/21825258"
                        },
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 2591,
            "fullName": "BRAF K601N",
            "impact": "missense",
            "proteinEffect": "gain of function",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF K601N lies within the protein kinase domain of the Braf protein (UniProt.org). K601N confers a gain of function on Braf, as indicated by increased phosphorylation of MEK and ERK in cell in culture (PMID: 24434212) and induction of cell proliferation and cell viability in culture (PMID: 29533785).",
                    "references": [
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 1131,
                            "pubMedId": 24434212,
                            "title": "Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/24434212"
                        }
                    ]
                }
            ]
        },
        {
            "id": 27706,
            "fullName": "BRAF G104E",
            "impact": "missense",
            "proteinEffect": "no effect - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF G104E lies within the protein kinase domain of the Braf protein (UniProt.org). G104E has not been biochemically characterized, but results in\u00a0similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function.",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        }
                    ]
                }
            ]
        },
        {
            "id": 13401,
            "fullName": "BRAF E611D",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF E611D lies within the protein kinase domain of the Braf protein (UniProt.org). E611D has been identified in sequencing studies (PMID: 15935100), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019).",
                    "references": [
                        {
                            "id": 7100,
                            "pubMedId": 15935100,
                            "title": "Preponderance of the oncogenic V599E and V599K mutations in B-raf kinase domain is enhanced in melanoma cutaneous/subcutaneous metastases.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/15935100"
                        },
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 2524,
            "fullName": "BRAF E586K",
            "impact": "missense",
            "proteinEffect": "gain of function",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF E586K (also reported as E585K) lies within the protein kinase domain of the Braf protein (UniProt.org). E586K results in increased Braf kinase activity, and activation of Mek and Erk in cell culture (PMID: 15035987, PMID: 22510884), and increases cell proliferation and viability compared to wild-type Braf in one of two cell lines (PMID: 29533785).",
                    "references": [
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 5712,
                            "pubMedId": 22510884,
                            "title": "Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/22510884"
                        },
                        {
                            "id": 146,
                            "pubMedId": 15035987,
                            "title": "Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/15035987"
                        }
                    ]
                }
            ]
        },
        {
            "id": 28190,
            "fullName": "BRAF G563D",
            "impact": "missense",
            "proteinEffect": "loss of function - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF G563D lies within the protein kinase domain of the Braf protein (UniProt.org). G563D has not been biochemically characterized, but demonstrates decreased transformation ability in cell culture compared to wild-type Braf (PMID: 29533785), and therefore is predicted to confer a loss of function to the Braf protein.",
                    "references": [
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 2641,
            "fullName": "BRAF G466R",
            "impact": "missense",
            "proteinEffect": "loss of function - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF G466R (previously reported as G465R) lies within the glycine-rich loop in the protein kinase domain of the Braf protein (PMID: 14681681). G466R results in impaired Braf kinase activity, but activates Erk signaling in cell culture (PMID: 15046639), and in one of two cell lines, G466R decreased cell proliferation and cell viability compared to wild-type Braf (PMID: 29533785), and is therefore predicted to confer a loss of function to the Braf protein.",
                    "references": [
                        {
                            "id": 1166,
                            "pubMedId": 15046639,
                            "title": "Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/15046639"
                        },
                        {
                            "id": 1167,
                            "pubMedId": 14681681,
                            "title": "Activating BRAF and N-Ras mutations in sporadic primary melanomas: an inverse association with allelic loss on chromosome 9.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/14681681"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        }
                    ]
                }
            ]
        },
        {
            "id": 3185,
            "fullName": "BRAF W604del",
            "impact": "deletion",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF W604del results in the deletion of one amino acid in the protein kinase domain of the Braf protein at amino acid 604 (UniProt.org). W604del has been identified in sequencing studies (PMID: 15513360), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019).",
                    "references": [
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 7113,
                            "pubMedId": 15513360,
                            "title": "Mutational activation of the RAS-RAF-MAPK and the Wnt pathway in small intestinal adenocarcinomas.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/15513360"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 28201,
            "fullName": "BRAF L613F",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF L613F lies within the protein kinase domain of the Braf protein (UniProt.org). L613F results in increased transformation ability as compared to wild-type Braf, in one of two cell lines in culture (PMID: 29533785), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019).",
                    "references": [
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        }
                    ]
                }
            ]
        },
        {
            "id": 19432,
            "fullName": "BRAF T488_Q493delinsK",
            "impact": "indel",
            "proteinEffect": "gain of function - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF T488_Q493delinsK results in the deletion of six amino acids near the alphaC-helix region of the Braf protein kinase domain combined with the insertion of one new amino acid in the same location (PMID: 26732095). T488_Q493delinsK has not been characterized, however, is predicted to result in a gain of function due to other characterized BRAF deletions in the same region (PMID: 26732095).",
                    "references": [
                        {
                            "id": 4801,
                            "pubMedId": 26732095,
                            "title": "Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/26732095"
                        }
                    ]
                }
            ]
        },
        {
            "id": 3142,
            "fullName": "BRAF I582M",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF I582M lies within the protein kinase domain of the Braf protein (UniProt.org). I582M has been identified in sequencing studies (PMID: 30268455, PMID: 15331929), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019).",
                    "references": [
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 7101,
                            "pubMedId": 15331929,
                            "title": "B-raf exon 15 mutations are common in primary melanoma resection specimens but not associated with clinical outcome.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/15331929"
                        },
                        {
                            "id": 14442,
                            "pubMedId": 30268455,
                            "title": "Non-invasive detection of actionable mutations in advanced non-small-cell lung cancer using targeted sequencing of circulating tumor DNA.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/30268455"
                        }
                    ]
                }
            ]
        },
        {
            "id": 28212,
            "fullName": "BRAF Y656D",
            "impact": "missense",
            "proteinEffect": "loss of function - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF Y656D lies within the protein kinase domain of the Braf protein (UniProt.org). Y656D has not been biochemically characterized, but demonstrates decreased transformation ability in cell culture (PMID: 29533785), and is therefore predicted to confer a loss of function to the Braf protein.",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        }
                    ]
                }
            ]
        },
        {
            "id": 456,
            "fullName": "BRAF K601E",
            "impact": "missense",
            "proteinEffect": "gain of function",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF K601E lies within the activation segment in the kinase domain of the Braf protein (PMID: 15343278). K601E results in increased Braf kinase activity and downstream activation of MEK and ERK in cell culture (PMID: 22798288, PMID: 28783719) and induces cell proliferation and cell viability in culture (PMID: 29533785).",
                    "references": [
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 9692,
                            "pubMedId": 28783719,
                            "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/28783719"
                        },
                        {
                            "id": 3,
                            "pubMedId": 22798288,
                            "title": "BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/22798288"
                        },
                        {
                            "id": 9694,
                            "pubMedId": 15343278,
                            "title": "Switching on kinases: oncogenic activation of BRAF and the PDGFR family.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/15343278"
                        }
                    ]
                }
            ]
        },
        {
            "id": 3515,
            "fullName": "BRAF G466A",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF G466A (also reported as G465A) lies within the protein kinase domain of the Braf protein (UniProt.org). The functional effect of G466A (also reported as G465A) on Braf is unclear as it has been characterized both as having intermediate Braf kinase activity (PMID: 15035987) and low Braf kinase activity (PMID: 28783719), leads to Ras-dependent activation of downstream Erk in cell culture (PMID: 28783719), and in one of two cell lines increased cell proliferation and cell viability compared to wild-type Braf (PMID: 29533785).",
                    "references": [
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 9692,
                            "pubMedId": 28783719,
                            "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/28783719"
                        },
                        {
                            "id": 146,
                            "pubMedId": 15035987,
                            "title": "Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/15035987"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 27724,
            "fullName": "BRAF R671Q",
            "impact": "missense",
            "proteinEffect": "no effect - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF R671Q lies within the protein kinase domain of the Braf protein (UniProt.org). R671Q has not been biochemically characterized, but results in similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function.",
                    "references": [
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 23103,
            "fullName": "BRAF D594Y",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF D594Y lies within the protein kinase domain of the Braf protein (UniProt.org). D594Y has been identified in sequencing studies (PMID: 29106415, PMID: 28486044), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019).",
                    "references": [
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 12148,
                            "pubMedId": 28486044,
                            "title": "Non-V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/28486044"
                        },
                        {
                            "id": 10426,
                            "pubMedId": 29106415,
                            "title": "Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29106415"
                        }
                    ]
                }
            ]
        },
        {
            "id": 28589,
            "fullName": "BRAF A762E",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF A762E does not lie within any known functional domains of the Braf protein (UniProt.org). A762E has been demonstrated to confer resistance to Egfr inhibitors in culture (PMID: 27478040), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019).",
                    "references": [
                        {
                            "id": 8124,
                            "pubMedId": 27478040,
                            "title": "High-throughput Phenotyping of Lung Cancer Somatic Mutations.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/27478040"
                        },
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 27712,
            "fullName": "BRAF N49I",
            "impact": "missense",
            "proteinEffect": "no effect - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF N49I lies within the protein kinase domain of the Braf protein (UniProt.org). N49I has not been biochemically characterized, but results in\u00a0similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function.",
                    "references": [
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 27726,
            "fullName": "BRAF S364L",
            "impact": "missense",
            "proteinEffect": "no effect - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF S364L lies within the protein kinase domain of the Braf protein (UniProt.org). S364L has not been biochemically characterized, but results in similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function.",
                    "references": [
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 29447,
            "fullName": "BRAF S467X",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF S467X indicates any Braf missense mutation that results in replacement of the serine (S) at amino acid 467 by a different amino acid.",
                    "references": [
                        {
                            "id": 275,
                            "pubMedId": 10,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/10"
                        }
                    ]
                }
            ]
        },
        {
            "id": 3150,
            "fullName": "BRAF L584F",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF L584F lies within the protein kinase domain of the Braf protein (UniProt.org). L584F results in increased transformation ability compared to wild-type Braf in one of two different cell lines in culture (PMID: 29533785), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019).",
                    "references": [
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 3153,
            "fullName": "BRAF R444W",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF R444W does not lie within any known functional domains of the Braf protein (UniProt.org). R444W has been identified in sequencing studies (PMID: 15578519), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019).",
                    "references": [
                        {
                            "id": 7111,
                            "pubMedId": 15578519,
                            "title": "BRAF mutations distinguish anorectal from cutaneous melanoma at the molecular level.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/15578519"
                        },
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 3524,
            "fullName": "BRAF P403fs",
            "impact": "frameshift",
            "proteinEffect": "loss of function - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF P403fs results in a change in the amino acid sequence of the Braf protein beginning at aa 403 of 766, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), P403fs is predicted to lead to a loss of Braf protein function.",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 27733,
            "fullName": "BRAF V590I",
            "impact": "missense",
            "proteinEffect": "no effect - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF V590I lies within the protein kinase domain of the Braf protein (UniProt.org). V590I has not been biochemically characterized, but results in similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function.",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        }
                    ]
                }
            ]
        },
        {
            "id": 4991,
            "fullName": "BRAF N581T",
            "impact": "missense",
            "proteinEffect": "no effect - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF N581T lies within the protein kinase domain of the Braf protein (UniProt.org). N581T has not been biochemically characterized, but results in\u00a0similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function.",
                    "references": [
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 27730,
            "fullName": "BRAF T401I",
            "impact": "missense",
            "proteinEffect": "no effect - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF T401I lies within the protein kinase domain of the Braf protein (UniProt.org). T401I has not been biochemically characterized, but results in similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function.",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        }
                    ]
                }
            ]
        },
        {
            "id": 27709,
            "fullName": "BRAF K698R",
            "impact": "missense",
            "proteinEffect": "no effect - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF K698R lies within the protein kinase domain of the Braf protein (UniProt.org). K698R has not been biochemically characterized, but results in\u00a0similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function.",
                    "references": [
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 5019,
            "fullName": "BRAF R462K",
            "impact": "missense",
            "proteinEffect": "no effect - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF R462K lies within the protein kinase domain of the Braf protein (UniProt.org). R462K has not been biochemically characterized, but results in similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function.",
                    "references": [
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 898,
            "fullName": "BRAF D594V",
            "impact": "missense",
            "proteinEffect": "loss of function",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF D594V lies within the protein kinase domain of the Braf protein (UniProt.org). D594V results in impaired Braf kinase activity, and decreased activation of Erk, Mek, and CRAF in cell culture (PMID: 28947956, PMID: 15035987), and has decreased transforming ability in one of two cell lines compared to wild-type Braf in culture (PMID: 29533785).",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 12147,
                            "pubMedId": 28947956,
                            "title": "Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/28947956"
                        },
                        {
                            "id": 146,
                            "pubMedId": 15035987,
                            "title": "Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/15035987"
                        }
                    ]
                }
            ]
        },
        {
            "id": 454,
            "fullName": "BRAF V600D",
            "impact": "missense",
            "proteinEffect": "gain of function",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF V600D (previously reported as V599) lies within the activation segment of the kinase domain of the Braf protein (PMID: 15035987). V600D confers a gain of function to the Braf protein as demonstrated by increased kinase activity, downstream signaling, and the ability to transform cells in vitro (PMID: 15035987).",
                    "references": [
                        {
                            "id": 146,
                            "pubMedId": 15035987,
                            "title": "Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/15035987"
                        }
                    ]
                }
            ]
        },
        {
            "id": 455,
            "fullName": "BRAF V600R",
            "impact": "missense",
            "proteinEffect": "gain of function",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF V600R (previously reported as V599) lies within the activation segment of the kinase domain of the Braf protein (PMID: 15035987). V600R confers a gain of function to the Braf protein as demonstrated by increased Braf kinase activity, downstream signaling, and the ability to transform cells in culture (PMID: 15035987, PMID: 29533785).",
                    "references": [
                        {
                            "id": 146,
                            "pubMedId": 15035987,
                            "title": "Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/15035987"
                        },
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        }
                    ]
                }
            ]
        },
        {
            "id": 5044,
            "fullName": "BRAF T599_V600insETT",
            "impact": "insertion",
            "proteinEffect": "gain of function - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF T599_V600insETT results in the insertion of 3 amino acids in the protein kinase domain of the Braf protein between amino acids 599 and 600 (UniProt.org). BRAF T599_V600insETT has not been characterized, however other insertions between T599 and V600 are activating thus, T599_V600insETT is predicted to lead to a gain of Braf protein function (PMID: 16501605, PMID: 17297294, PMID: 21190184).",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 1892,
                            "pubMedId": 16501605,
                            "title": "Biochemical and molecular characterization of the novel BRAF(V599Ins) mutation detected in a classic papillary thyroid carcinoma.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/16501605"
                        },
                        {
                            "id": 1910,
                            "pubMedId": 21190184,
                            "title": "Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/21190184"
                        },
                        {
                            "id": 2112,
                            "pubMedId": 17297294,
                            "title": "Functional characterization of the T1799-1801del and A1799-1816ins BRAF mutations in papillary thyroid cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/17297294"
                        }
                    ]
                }
            ]
        },
        {
            "id": 613,
            "fullName": "BRAF Y538H",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF Y538H lies within the protein kinase domain of the Braf protein (UniProt.org). Y538H has not been characterized in the scientific literature and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019).",
                    "references": [
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 603,
            "fullName": "BRAF R347*",
            "impact": "nonsense",
            "proteinEffect": "loss of function - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF R347* results in a premature truncation of the of the 766 aa Braf protein at aa 347 (UniProt.org). Due to the loss of a portion of the protein kinase domain (UniProt.org), R347* is predicted to lead to a loss of Braf protein function.",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 3155,
            "fullName": "BRAF R603*",
            "impact": "nonsense",
            "proteinEffect": "loss of function - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF R603* results in a premature truncation within the protein kinase domain of the Braf protein at amino acid 603 of 766 (UniProt.org, PMID: 11032810). Due to the loss of the protein kinase domain (UniProt.org, PMID: 11032810), R603* is predicted to lead to a loss of function.",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 1908,
                            "pubMedId": 11032810,
                            "title": "Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/11032810"
                        }
                    ]
                }
            ]
        },
        {
            "id": 49,
            "fullName": "BRAF V600E",
            "impact": "missense",
            "proteinEffect": "gain of function",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF V600E (previously reported as V599) lies within the activation segment of the kinase domain of the Braf protein (PMID: 15035987). V600E confers a gain of function to the Braf protein as demonstrated by increased Braf kinase activity, downstream signaling, and the ability to transform cells in culture (PMID: 15035987, PMID: 29533785).",
                    "references": [
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 146,
                            "pubMedId": 15035987,
                            "title": "Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/15035987"
                        }
                    ]
                }
            ]
        },
        {
            "id": 29452,
            "fullName": "BRAF D594X",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF D594X indicates any Braf missense mutation that results in replacement of the aspartic acid (D) at amino acid 594 by a different amino acid.",
                    "references": [
                        {
                            "id": 275,
                            "pubMedId": 10,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/10"
                        }
                    ]
                }
            ]
        },
        {
            "id": 29455,
            "fullName": "BRAF L597X",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF L597X indicates any Braf missense mutation that results in replacement of the leucine (L) at amino acid 597 by a different amino acid.",
                    "references": [
                        {
                            "id": 275,
                            "pubMedId": 10,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/10"
                        }
                    ]
                }
            ]
        },
        {
            "id": 28187,
            "fullName": "BRAF E648Q",
            "impact": "missense",
            "proteinEffect": "loss of function - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF E648Q lies within the protein kinase domain of the Braf protein (UniProt.org). E648Q has not been biochemically characterized, but demonstrates decreased transformation ability in cell culture compared to wild-type Braf (PMID: 29533785), and is therefore predicted to confer a loss of function to the Braf protein.",
                    "references": [
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        },
        {
            "id": 23137,
            "fullName": "BRAF T529N",
            "impact": "missense",
            "proteinEffect": "unknown",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF T529N lies within the protein kinase domain of the Braf protein (UniProt.org). T529N has been demonstrated to result in resistance to Raf inhibitors in the context of BRAF V600E (PMID: 20538618, PMID: 20807807), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019).",
                    "references": [
                        {
                            "id": 14535,
                            "pubMedId": 20807807,
                            "title": "A novel, selective, and efficacious nanomolar pyridopyrazinone inhibitor of V600EBRAF.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/20807807"
                        },
                        {
                            "id": 285,
                            "pubMedId": null,
                            "title": null,
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 5859,
                            "pubMedId": 20538618,
                            "title": "Gatekeeper mutations mediate resistance to BRAF-targeted therapies.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/20538618"
                        }
                    ]
                }
            ]
        },
        {
            "id": 25029,
            "fullName": "BRAF A598_T599insARC",
            "impact": "insertion",
            "proteinEffect": "gain of function - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF A598_T599insARC results in the insertion of 3 amino acids in the protein kinase domain of the Braf protein between amino acids 598 and 599 (UniProt.org). BRAF A598_T599insARC has not been characterized, however other insertions between A598 and T599 are activating thus, A598_T599insARC is predicted to lead to a gain of Braf protein function (PMID: 16501605). \r\n\r\n",
                    "references": [
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        },
                        {
                            "id": 1892,
                            "pubMedId": 16501605,
                            "title": "Biochemical and molecular characterization of the novel BRAF(V599Ins) mutation detected in a classic papillary thyroid carcinoma.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/16501605"
                        }
                    ]
                }
            ]
        },
        {
            "id": 28203,
            "fullName": "BRAF L678I",
            "impact": "missense",
            "proteinEffect": "loss of function - predicted",
            "geneVariantDescriptions": [
                {
                    "description": "BRAF L678I lies within the protein kinase domain of the Braf protein (UniProt.org). L678I has not been biochemically characterized, but demonstrates decreased transformation ability in cell culture (PMID: 29533785), and is therefore predicted to confer a loss of function to the Braf protein.",
                    "references": [
                        {
                            "id": 11238,
                            "pubMedId": 29533785,
                            "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                            "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                        },
                        {
                            "id": 295,
                            "pubMedId": null,
                            "title": null,
                            "url": "www.uniprot.org"
                        }
                    ]
                }
            ]
        }
    ],
    "molecularProfiles": [
        {
            "id": 25791,
            "profileName": "BRAF A712T",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 985,
            "profileName": "BRAF V600M",
            "profileTreatmentApproaches": [
                {
                    "id": 2190,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF V600M"
                },
                {
                    "id": 2188,
                    "name": "BRAF Inhibitor",
                    "profileName": "BRAF V600M"
                },
                {
                    "id": 2189,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF V600M"
                },
                {
                    "id": 2191,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF V600M"
                },
                {
                    "id": 2192,
                    "name": "RAF Inhibitor (Pan)",
                    "profileName": "BRAF V600M"
                }
            ]
        },
        {
            "id": 2417,
            "profileName": "BRAF F595L",
            "profileTreatmentApproaches": [
                {
                    "id": 14751,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF F595L"
                },
                {
                    "id": 14753,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF F595L"
                },
                {
                    "id": 14752,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF F595L"
                }
            ]
        },
        {
            "id": 31086,
            "profileName": "BRAF G469V NRAS Q61K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 1777,
            "profileName": "BRAF G469V",
            "profileTreatmentApproaches": [
                {
                    "id": 14373,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF G469V"
                },
                {
                    "id": 14371,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF G469V"
                },
                {
                    "id": 14374,
                    "name": "LY3009120",
                    "profileName": "BRAF G469V"
                },
                {
                    "id": 14372,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF G469V"
                }
            ]
        },
        {
            "id": 651,
            "profileName": "BRAF G469A",
            "profileTreatmentApproaches": [
                {
                    "id": 14295,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF G469A"
                },
                {
                    "id": 14298,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF G469A"
                },
                {
                    "id": 14297,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF G469A"
                },
                {
                    "id": 14296,
                    "name": "LY3009120",
                    "profileName": "BRAF G469A"
                }
            ]
        },
        {
            "id": 31530,
            "profileName": "BRAF T599_V600insS",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 664,
            "profileName": "BRAF G464V",
            "profileTreatmentApproaches": [
                {
                    "id": 14310,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF G464V"
                },
                {
                    "id": 14309,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF G464V"
                },
                {
                    "id": 14307,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF G464V"
                },
                {
                    "id": 14308,
                    "name": "LY3009120",
                    "profileName": "BRAF G464V"
                }
            ]
        },
        {
            "id": 29778,
            "profileName": "BRAF M53I",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 2997,
            "profileName": "BRAF T599I",
            "profileTreatmentApproaches": [
                {
                    "id": 14439,
                    "name": "LY3009120",
                    "profileName": "BRAF T599I"
                },
                {
                    "id": 14441,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF T599I"
                },
                {
                    "id": 14442,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF T599I"
                },
                {
                    "id": 14440,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF T599I"
                }
            ]
        },
        {
            "id": 3002,
            "profileName": "BRAF V600delinsYM",
            "profileTreatmentApproaches": [
                {
                    "id": 14456,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF V600delinsYM"
                },
                {
                    "id": 14455,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF V600delinsYM"
                },
                {
                    "id": 14458,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF V600delinsYM"
                },
                {
                    "id": 14457,
                    "name": "LY3009120",
                    "profileName": "BRAF V600delinsYM"
                }
            ]
        },
        {
            "id": 4781,
            "profileName": "BRAF D594A",
            "profileTreatmentApproaches": [
                {
                    "id": 14501,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF D594A"
                },
                {
                    "id": 14500,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF D594A"
                },
                {
                    "id": 14499,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF D594A"
                }
            ]
        },
        {
            "id": 26880,
            "profileName": "BRAF A598S",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 1780,
            "profileName": "BRAF E275K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30812,
            "profileName": "BRAF L514V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30813,
            "profileName": "BRAF L514V BRAF V600E",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29273,
            "profileName": "BRAF R271H",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28252,
            "profileName": "BRAF V459L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29284,
            "profileName": "BRAF V504I",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 24419,
            "profileName": "BRAF G596R PIK3CA E545K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28182,
            "profileName": "BRAF G596R NRAS Q61K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 2416,
            "profileName": "BRAF G596R",
            "profileTreatmentApproaches": [
                {
                    "id": 14387,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF G596R"
                },
                {
                    "id": 14390,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF G596R"
                },
                {
                    "id": 14388,
                    "name": "LY3009120",
                    "profileName": "BRAF G596R"
                },
                {
                    "id": 14389,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF G596R"
                }
            ]
        },
        {
            "id": 31353,
            "profileName": "BRAF G596R PTPN11 E76K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29768,
            "profileName": "BRAF H269Y",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 2437,
            "profileName": "BRAF K601N",
            "profileTreatmentApproaches": [
                {
                    "id": 14398,
                    "name": "LY3009120",
                    "profileName": "BRAF K601N"
                },
                {
                    "id": 14396,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF K601N"
                },
                {
                    "id": 14397,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF K601N"
                },
                {
                    "id": 14395,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF K601N"
                }
            ]
        },
        {
            "id": 31478,
            "profileName": "BRAF N581X",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 4785,
            "profileName": "BRAF G606V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29257,
            "profileName": "BRAF F294L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32620,
            "profileName": "BRAF K601E MAP2K1 V211D",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 655,
            "profileName": "BRAF K601E",
            "profileTreatmentApproaches": [
                {
                    "id": 14302,
                    "name": "LY3009120",
                    "profileName": "BRAF K601E"
                },
                {
                    "id": 14299,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF K601E"
                },
                {
                    "id": 14301,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF K601E"
                },
                {
                    "id": 14300,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF K601E"
                }
            ]
        },
        {
            "id": 31117,
            "profileName": "BRAF K601E BRAF S363F",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 987,
            "profileName": "BRAF D594N",
            "profileTreatmentApproaches": [
                {
                    "id": 14737,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF D594N"
                },
                {
                    "id": 14736,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF D594N"
                },
                {
                    "id": 14738,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF D594N"
                }
            ]
        },
        {
            "id": 28180,
            "profileName": "BRAF D594N BRAF G466A EGFR over exp MET over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23781,
            "profileName": "BRAF D594Y",
            "profileTreatmentApproaches": [
                {
                    "id": 14755,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF D594Y"
                },
                {
                    "id": 14754,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF D594Y"
                },
                {
                    "id": 14756,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF D594Y"
                }
            ]
        },
        {
            "id": 28253,
            "profileName": "BRAF S467L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22095,
            "profileName": "BRAF V600K NRAS Q61K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 25916,
            "profileName": "BRAF V600K MAP2K1 P124L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 25913,
            "profileName": "BRAF V600K MAP2K1 P124Q",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 2,
            "profileName": "BRAF V600K",
            "profileTreatmentApproaches": [
                {
                    "id": 14668,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF V600K"
                },
                {
                    "id": 14665,
                    "name": "BRAF Inhibitor",
                    "profileName": "BRAF V600K"
                },
                {
                    "id": 14667,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF V600K"
                },
                {
                    "id": 14666,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF V600K"
                },
                {
                    "id": 14669,
                    "name": "RAF Inhibitor (Pan)",
                    "profileName": "BRAF V600K"
                }
            ]
        },
        {
            "id": 29762,
            "profileName": "BRAF G258V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31524,
            "profileName": "BRAF K601_S602delinsNT",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31114,
            "profileName": "BRAF L597S BRAF R239Q",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31115,
            "profileName": "BRAF R239Q",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 1299,
            "profileName": "BRAF wild-type NRAS mutant",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 15933,
            "profileName": "BRAF wild-type NRAS wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 1241,
            "profileName": "NRAS BRAF wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 4,
            "profileName": "BRAF wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 4361,
            "profileName": "BRAF wild-type KIT positive",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26086,
            "profileName": "BRAF wild-type NRAS Q61K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29782,
            "profileName": "BRAF P731S",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 991,
            "profileName": "BRAF D594E",
            "profileTreatmentApproaches": [
                {
                    "id": 14749,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF D594E"
                },
                {
                    "id": 14748,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF D594E"
                },
                {
                    "id": 14750,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF D594E"
                }
            ]
        },
        {
            "id": 2968,
            "profileName": "BRAF I592V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 4841,
            "profileName": "BRAF T599_V600insETT",
            "profileTreatmentApproaches": [
                {
                    "id": 14529,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF T599_V600insETT"
                },
                {
                    "id": 14530,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF T599_V600insETT"
                },
                {
                    "id": 14528,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF T599_V600insETT"
                },
                {
                    "id": 14527,
                    "name": "LY3009120",
                    "profileName": "BRAF T599_V600insETT"
                }
            ]
        },
        {
            "id": 654,
            "profileName": "BRAF V600R",
            "profileTreatmentApproaches": [
                {
                    "id": 2200,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF V600R"
                },
                {
                    "id": 2201,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF V600R"
                },
                {
                    "id": 2202,
                    "name": "RAF Inhibitor (Pan)",
                    "profileName": "BRAF V600R"
                },
                {
                    "id": 2199,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF V600R"
                },
                {
                    "id": 2198,
                    "name": "BRAF Inhibitor",
                    "profileName": "BRAF V600R"
                }
            ]
        },
        {
            "id": 29287,
            "profileName": "BRAF V681I",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29786,
            "profileName": "BRAF T599A",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23806,
            "profileName": "BRAF L485_Q494del",
            "profileTreatmentApproaches": [
                {
                    "id": 14613,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF L485_Q494del"
                },
                {
                    "id": 14614,
                    "name": "LY3009120",
                    "profileName": "BRAF L485_Q494del"
                },
                {
                    "id": 14611,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF L485_Q494del"
                },
                {
                    "id": 14612,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF L485_Q494del"
                }
            ]
        },
        {
            "id": 3325,
            "profileName": "BRAF I463S",
            "profileTreatmentApproaches": [
                {
                    "id": 14471,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF I463S"
                },
                {
                    "id": 14472,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF I463S"
                },
                {
                    "id": 14473,
                    "name": "LY3009120",
                    "profileName": "BRAF I463S"
                },
                {
                    "id": 14474,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF I463S"
                }
            ]
        },
        {
            "id": 23818,
            "profileName": "BRAF V600E BRAF T529I",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23810,
            "profileName": "BRAF T529I",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31468,
            "profileName": "BRAF T241X",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29780,
            "profileName": "BRAF N581K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31694,
            "profileName": "BRAF A81_D380del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 4786,
            "profileName": "BRAF L597P",
            "profileTreatmentApproaches": [
                {
                    "id": 14512,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF L597P"
                },
                {
                    "id": 14511,
                    "name": "LY3009120",
                    "profileName": "BRAF L597P"
                },
                {
                    "id": 14514,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF L597P"
                },
                {
                    "id": 14513,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF L597P"
                }
            ]
        },
        {
            "id": 13673,
            "profileName": "BRAF A598T",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29266,
            "profileName": "BRAF P162S",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31485,
            "profileName": "BRAF T599X",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23800,
            "profileName": "BRAF G596V",
            "profileTreatmentApproaches": [
                {
                    "id": 14601,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF G596V"
                },
                {
                    "id": 14602,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF G596V"
                },
                {
                    "id": 14600,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF G596V"
                },
                {
                    "id": 14599,
                    "name": "LY3009120",
                    "profileName": "BRAF G596V"
                }
            ]
        },
        {
            "id": 28547,
            "profileName": "BRAF G596V NRAS G13R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29279,
            "profileName": "BRAF S419Y",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31521,
            "profileName": "BRAF P367L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 2974,
            "profileName": "BRAF L584F",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 2987,
            "profileName": "BRAF S605G",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31506,
            "profileName": "BRAF P731T",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29275,
            "profileName": "BRAF R509G",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23798,
            "profileName": "BRAF G596C",
            "profileTreatmentApproaches": [
                {
                    "id": 14758,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF G596C"
                },
                {
                    "id": 14760,
                    "name": "LY3009120",
                    "profileName": "BRAF G596C"
                },
                {
                    "id": 14757,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF G596C"
                },
                {
                    "id": 14759,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF G596C"
                }
            ]
        },
        {
            "id": 30471,
            "profileName": "BRAF A762E",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31647,
            "profileName": "BRAF S465D",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 25301,
            "profileName": "BRAF dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 2965,
            "profileName": "BRAF H608R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 19834,
            "profileName": "BRAF V487_P492delinsA",
            "profileTreatmentApproaches": [
                {
                    "id": 14552,
                    "name": "LY3009120",
                    "profileName": "BRAF V487_P492delinsA"
                },
                {
                    "id": 14554,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF V487_P492delinsA"
                },
                {
                    "id": 14551,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF V487_P492delinsA"
                },
                {
                    "id": 14553,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF V487_P492delinsA"
                }
            ]
        },
        {
            "id": 29252,
            "profileName": "BRAF A762V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31482,
            "profileName": "BRAF G596X",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31686,
            "profileName": "BRAF N486_T491delinsK",
            "profileTreatmentApproaches": [
                {
                    "id": 19377,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF N486_T491delinsK"
                },
                {
                    "id": 19379,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF N486_T491delinsK"
                },
                {
                    "id": 19378,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF N486_T491delinsK"
                }
            ]
        },
        {
            "id": 4788,
            "profileName": "BRAF N581T",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31704,
            "profileName": "BRAF V47_D380del BRAF V600E",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31680,
            "profileName": "BRAF V47_D380del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26822,
            "profileName": "APC Q1429fs BRAF N581S ERBB2 L755S",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 3326,
            "profileName": "BRAF N581S",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31645,
            "profileName": "BRAF S605E",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29262,
            "profileName": "BRAF L64I",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29773,
            "profileName": "BRAF L245F",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 4845,
            "profileName": "BRAF W604R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23809,
            "profileName": "BRAF S467A",
            "profileTreatmentApproaches": [
                {
                    "id": 14623,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF S467A"
                },
                {
                    "id": 14624,
                    "name": "LY3009120",
                    "profileName": "BRAF S467A"
                },
                {
                    "id": 14626,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF S467A"
                },
                {
                    "id": 14625,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF S467A"
                }
            ]
        },
        {
            "id": 2999,
            "profileName": "BRAF T599_V600insTT",
            "profileTreatmentApproaches": [
                {
                    "id": 14450,
                    "name": "LY3009120",
                    "profileName": "BRAF T599_V600insTT"
                },
                {
                    "id": 14447,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF T599_V600insTT"
                },
                {
                    "id": 14448,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF T599_V600insTT"
                },
                {
                    "id": 14449,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF T599_V600insTT"
                }
            ]
        },
        {
            "id": 28248,
            "profileName": "BRAF D287H",
            "profileTreatmentApproaches": [
                {
                    "id": 14700,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF D287H"
                },
                {
                    "id": 14698,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF D287H"
                },
                {
                    "id": 14699,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF D287H"
                }
            ]
        },
        {
            "id": 23816,
            "profileName": "BRAF V600E BRAF T529N",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23812,
            "profileName": "BRAF T529N",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 25794,
            "profileName": "BRAF A598_T599insARC",
            "profileTreatmentApproaches": [
                {
                    "id": 14646,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF A598_T599insARC"
                },
                {
                    "id": 14643,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF A598_T599insARC"
                },
                {
                    "id": 14645,
                    "name": "LY3009120",
                    "profileName": "BRAF A598_T599insARC"
                },
                {
                    "id": 14644,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF A598_T599insARC"
                }
            ]
        },
        {
            "id": 986,
            "profileName": "BRAF Y472C",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 718,
            "profileName": "BRAF Y538H",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 988,
            "profileName": "BRAF D594H",
            "profileTreatmentApproaches": [
                {
                    "id": 14741,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF D594H"
                },
                {
                    "id": 14739,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF D594H"
                },
                {
                    "id": 14740,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF D594H"
                }
            ]
        },
        {
            "id": 29286,
            "profileName": "BRAF V639I",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31648,
            "profileName": "BRAF S465E",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 4842,
            "profileName": "BRAF V471I",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 13585,
            "profileName": "BRAF E611D",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 2962,
            "profileName": "BRAF G469S",
            "profileTreatmentApproaches": [
                {
                    "id": 14432,
                    "name": "LY3009120",
                    "profileName": "BRAF G469S"
                },
                {
                    "id": 14431,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF G469S"
                },
                {
                    "id": 14434,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF G469S"
                },
                {
                    "id": 14433,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF G469S"
                }
            ]
        },
        {
            "id": 3008,
            "profileName": "BRAF W450*",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 3322,
            "profileName": "BRAF G466A",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 2976,
            "profileName": "BRAF P453T",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29769,
            "profileName": "BRAF H585Y",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29270,
            "profileName": "BRAF P676S",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 2951,
            "profileName": "BRAF A598V",
            "profileTreatmentApproaches": [
                {
                    "id": 14425,
                    "name": "LY3009120",
                    "profileName": "BRAF A598V"
                },
                {
                    "id": 14426,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF A598V"
                },
                {
                    "id": 14424,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF A598V"
                },
                {
                    "id": 14423,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF A598V"
                }
            ]
        },
        {
            "id": 23799,
            "profileName": "BRAF G469del",
            "profileTreatmentApproaches": [
                {
                    "id": 14595,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF G469del"
                },
                {
                    "id": 14597,
                    "name": "LY3009120",
                    "profileName": "BRAF G469del"
                },
                {
                    "id": 14598,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF G469del"
                },
                {
                    "id": 14596,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF G469del"
                }
            ]
        },
        {
            "id": 29268,
            "profileName": "BRAF P348T",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29765,
            "profileName": "BRAF G606W",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31700,
            "profileName": "BRAF V47_G327del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 3747,
            "profileName": "BRAF W604G",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 2966,
            "profileName": "BRAF I582M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31646,
            "profileName": "BRAF S465A",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29763,
            "profileName": "BRAF G563D",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 2946,
            "profileName": "BRAF A598_T599insV",
            "profileTreatmentApproaches": [
                {
                    "id": 14420,
                    "name": "LY3009120",
                    "profileName": "BRAF A598_T599insV"
                },
                {
                    "id": 14421,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF A598_T599insV"
                },
                {
                    "id": 14419,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF A598_T599insV"
                },
                {
                    "id": 14422,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF A598_T599insV"
                }
            ]
        },
        {
            "id": 29259,
            "profileName": "BRAF G421V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 2463,
            "profileName": "BRAF K601Q",
            "profileTreatmentApproaches": [
                {
                    "id": 14407,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF K601Q"
                },
                {
                    "id": 14409,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF K601Q"
                },
                {
                    "id": 14410,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF K601Q"
                },
                {
                    "id": 14408,
                    "name": "LY3009120",
                    "profileName": "BRAF K601Q"
                }
            ]
        },
        {
            "id": 29766,
            "profileName": "BRAF G615R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26402,
            "profileName": "BRAF mut PTPN11 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 21308,
            "profileName": "BRAF mut PTEN wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 465,
            "profileName": "BRAF mutant",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31466,
            "profileName": "BRAF mutant IDH1 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26042,
            "profileName": "BRAF mut STAG2 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26352,
            "profileName": "BRAF mut RB1 loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27794,
            "profileName": "BRAF mut PIK3CA wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 15931,
            "profileName": "BRAF mut NRAS wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 5415,
            "profileName": "APC mut BRAF mut PIK3CA mut SMAD4 mut TP53 mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 2336,
            "profileName": "PIK3CA mut BRAF mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27213,
            "profileName": "BRAF mut TP53 mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22705,
            "profileName": "BRAF mut PTEN inact mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 14782,
            "profileName": "BRAF mut NRAS mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 21306,
            "profileName": "BRAF mut PTEN mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 18163,
            "profileName": "BRAF mut PTEN loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 3307,
            "profileName": "BRAF mut + TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29779,
            "profileName": "BRAF N486D",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 3327,
            "profileName": "BRAF R462I",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31522,
            "profileName": "BRAF N486_A489delinsK",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29781,
            "profileName": "BRAF P367S",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26603,
            "profileName": "BRAF L485F",
            "profileTreatmentApproaches": [
                {
                    "id": 14653,
                    "name": "LY3009120",
                    "profileName": "BRAF L485F"
                },
                {
                    "id": 14652,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF L485F"
                },
                {
                    "id": 14651,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF L485F"
                },
                {
                    "id": 14654,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF L485F"
                }
            ]
        },
        {
            "id": 31523,
            "profileName": "BRAF T599K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 1776,
            "profileName": "BRAF W531C",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31687,
            "profileName": "BRAF V47_M438del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 2996,
            "profileName": "BRAF S605N",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29771,
            "profileName": "BRAF K483E",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 25792,
            "profileName": "BRAF N20T",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29254,
            "profileName": "BRAF A320T",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28841,
            "profileName": "BRAF L485W",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 19835,
            "profileName": "BRAF L485_P490delinsY",
            "profileTreatmentApproaches": [
                {
                    "id": 14557,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF L485_P490delinsY"
                },
                {
                    "id": 14558,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF L485_P490delinsY"
                },
                {
                    "id": 14556,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF L485_P490delinsY"
                },
                {
                    "id": 14555,
                    "name": "LY3009120",
                    "profileName": "BRAF L485_P490delinsY"
                }
            ]
        },
        {
            "id": 4787,
            "profileName": "BRAF N581I",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23804,
            "profileName": "BRAF N581Y",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29265,
            "profileName": "BRAF P141L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23778,
            "profileName": "BRAF A728V",
            "profileTreatmentApproaches": [
                {
                    "id": 14579,
                    "name": "LY3009120",
                    "profileName": "BRAF A728V"
                },
                {
                    "id": 14581,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF A728V"
                },
                {
                    "id": 14582,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF A728V"
                },
                {
                    "id": 14580,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF A728V"
                }
            ]
        },
        {
            "id": 20300,
            "profileName": "BRAF V600E/K PIK3CA wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28830,
            "profileName": "BRAF V600E/K PTEN loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 499,
            "profileName": "BRAF V600E/K",
            "profileTreatmentApproaches": [
                {
                    "id": 14679,
                    "name": "RAF Inhibitor (Pan)",
                    "profileName": "BRAF V600E/K"
                },
                {
                    "id": 14675,
                    "name": "BRAF Inhibitor",
                    "profileName": "BRAF V600E/K"
                },
                {
                    "id": 14677,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF V600E/K"
                },
                {
                    "id": 14676,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF V600E/K"
                },
                {
                    "id": 14678,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF V600E/K"
                }
            ]
        },
        {
            "id": 23808,
            "profileName": "BRAF Q257R",
            "profileTreatmentApproaches": [
                {
                    "id": 14620,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF Q257R"
                },
                {
                    "id": 14621,
                    "name": "LY3009120",
                    "profileName": "BRAF Q257R"
                },
                {
                    "id": 14622,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF Q257R"
                },
                {
                    "id": 14619,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF Q257R"
                }
            ]
        },
        {
            "id": 29783,
            "profileName": "BRAF Q609E",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 2964,
            "profileName": "BRAF G606E",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29278,
            "profileName": "BRAF S364L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 1273,
            "profileName": "BRAF rearrange",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 2960,
            "profileName": "BRAF F595S",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 990,
            "profileName": "BRAF D594V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29267,
            "profileName": "BRAF P341S",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29767,
            "profileName": "BRAF G69S",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28373,
            "profileName": "BRAF I463T",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29776,
            "profileName": "BRAF L678I",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29760,
            "profileName": "BRAF E648Q",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31480,
            "profileName": "BRAF D594X",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31472,
            "profileName": "BRAF I463X",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 3001,
            "profileName": "BRAF V600A",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 3006,
            "profileName": "BRAF V600Q",
            "profileTreatmentApproaches": [
                {
                    "id": 2196,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF V600Q"
                },
                {
                    "id": 2194,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF V600Q"
                },
                {
                    "id": 2197,
                    "name": "RAF Inhibitor (Pan)",
                    "profileName": "BRAF V600Q"
                },
                {
                    "id": 2195,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF V600Q"
                },
                {
                    "id": 2193,
                    "name": "BRAF Inhibitor",
                    "profileName": "BRAF V600Q"
                }
            ]
        },
        {
            "id": 29271,
            "profileName": "BRAF Q609H",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29777,
            "profileName": "BRAF M517I",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29784,
            "profileName": "BRAF S607F",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23803,
            "profileName": "BRAF N581D",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29258,
            "profileName": "BRAF G104E",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23630,
            "profileName": "BRAF T488_Q493delinsK",
            "profileTreatmentApproaches": [
                {
                    "id": 14572,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF T488_Q493delinsK"
                },
                {
                    "id": 14573,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF T488_Q493delinsK"
                },
                {
                    "id": 14571,
                    "name": "LY3009120",
                    "profileName": "BRAF T488_Q493delinsK"
                },
                {
                    "id": 14574,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF T488_Q493delinsK"
                }
            ]
        },
        {
            "id": 4783,
            "profileName": "BRAF G596fs",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 2963,
            "profileName": "BRAF G596D",
            "profileTreatmentApproaches": [
                {
                    "id": 14725,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF G596D"
                },
                {
                    "id": 14726,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF G596D"
                },
                {
                    "id": 14724,
                    "name": "LY3009120",
                    "profileName": "BRAF G596D"
                },
                {
                    "id": 14727,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF G596D"
                }
            ]
        },
        {
            "id": 29260,
            "profileName": "BRAF K205Q",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 19837,
            "profileName": "BRAF P490_Q494del",
            "profileTreatmentApproaches": [
                {
                    "id": 14563,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF P490_Q494del"
                },
                {
                    "id": 14564,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF P490_Q494del"
                },
                {
                    "id": 14566,
                    "name": "LY3009120",
                    "profileName": "BRAF P490_Q494del"
                },
                {
                    "id": 14565,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF P490_Q494del"
                }
            ]
        },
        {
            "id": 17313,
            "profileName": "BRAF Q262R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29281,
            "profileName": "BRAF S637*",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29255,
            "profileName": "BRAF E228V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23100,
            "profileName": "BRAF V600D PTEN loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 653,
            "profileName": "BRAF V600D",
            "profileTreatmentApproaches": [
                {
                    "id": 14680,
                    "name": "BRAF Inhibitor",
                    "profileName": "BRAF V600D"
                },
                {
                    "id": 14681,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF V600D"
                },
                {
                    "id": 14684,
                    "name": "RAF Inhibitor (Pan)",
                    "profileName": "BRAF V600D"
                },
                {
                    "id": 14683,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF V600D"
                },
                {
                    "id": 14682,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF V600D"
                }
            ]
        },
        {
            "id": 31592,
            "profileName": "BRAF V600D NRAS dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31698,
            "profileName": "BRAF V169_G327del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27972,
            "profileName": "BRAF F247L",
            "profileTreatmentApproaches": [
                {
                    "id": 14731,
                    "name": "LY3009120",
                    "profileName": "BRAF F247L"
                },
                {
                    "id": 14730,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF F247L"
                },
                {
                    "id": 14729,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF F247L"
                },
                {
                    "id": 14728,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF F247L"
                }
            ]
        },
        {
            "id": 708,
            "profileName": "BRAF R347*",
            "profileTreatmentApproaches": [
                {
                    "id": 14325,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF R347*"
                },
                {
                    "id": 14324,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF R347*"
                },
                {
                    "id": 14326,
                    "name": "LY3009120",
                    "profileName": "BRAF R347*"
                },
                {
                    "id": 14323,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF R347*"
                }
            ]
        },
        {
            "id": 696,
            "profileName": "BRAF act mut",
            "profileTreatmentApproaches": [
                {
                    "id": 14322,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF act mut"
                },
                {
                    "id": 14321,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF act mut"
                },
                {
                    "id": 14319,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF act mut"
                },
                {
                    "id": 14320,
                    "name": "LY3009120",
                    "profileName": "BRAF act mut"
                }
            ]
        },
        {
            "id": 1156,
            "profileName": "BRAF G478C",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29764,
            "profileName": "BRAF G596S",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29770,
            "profileName": "BRAF H725Y",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 992,
            "profileName": "BRAF L597R",
            "profileTreatmentApproaches": [
                {
                    "id": 14354,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF L597R"
                },
                {
                    "id": 14352,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF L597R"
                },
                {
                    "id": 14351,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF L597R"
                },
                {
                    "id": 14353,
                    "name": "LY3009120",
                    "profileName": "BRAF L597R"
                }
            ]
        },
        {
            "id": 31685,
            "profileName": "BRAF V169_D380del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31474,
            "profileName": "BRAF G466X",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 25928,
            "profileName": "BRAF amp BRAF V600E",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 24387,
            "profileName": "BRAF amp BRAF V600X NRAS Q61K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 24386,
            "profileName": "BRAF amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31701,
            "profileName": "BRAF G203_G393del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30473,
            "profileName": "BRAF H574N",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26362,
            "profileName": "BRAF V600E PTEN loss TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 520,
            "profileName": "MAP2K1 Q56P BRAF V600E",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22042,
            "profileName": "BRAF V600E NRAS A146T",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22046,
            "profileName": "BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22037,
            "profileName": "BRAF V600E NRAS A146T MAP2K1 P387S",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32523,
            "profileName": "BRAF V600E EGFR E746_A750del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28495,
            "profileName": "BRAF V600E MAP2K1 I111N",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 25914,
            "profileName": "BRAF V600E MAP2K1 K57E",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 25915,
            "profileName": "BRAF V600E MAP2K1 P124Q",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23817,
            "profileName": "BRAF V600E BRAF T529M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28498,
            "profileName": "BRAF V600E MAP2K1 P124L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26361,
            "profileName": "BRAF V600E PIK3CA H1047R TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23648,
            "profileName": "BRAF V600E CDKN2A mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 21654,
            "profileName": "BRAF V600E MAP2K1 V211D",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23666,
            "profileName": "PIK3CA mut BRAF V600E",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 24283,
            "profileName": "BRAF V600E MAP2K1 G128V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31705,
            "profileName": "BRAF V600E NRAS G13R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23099,
            "profileName": "BRAF V600E PTEN loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23996,
            "profileName": "BRAF V600E MAP2K1 H119P",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 24282,
            "profileName": "BRAF V600E MAP2K1 P124S",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 1,
            "profileName": "BRAF V600E",
            "profileTreatmentApproaches": [
                {
                    "id": 466,
                    "name": "RAF Inhibitor (Pan)",
                    "profileName": "BRAF V600E"
                },
                {
                    "id": 1,
                    "name": "BRAF Inhibitor",
                    "profileName": "BRAF V600E"
                },
                {
                    "id": 467,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF V600E"
                },
                {
                    "id": 2,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF V600E"
                },
                {
                    "id": 7,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF V600E"
                }
            ]
        },
        {
            "id": 24392,
            "profileName": "BRAF V600E PTEN wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 19841,
            "profileName": "BRAF V600E PIK3CA P449T",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 21619,
            "profileName": "BRAF V600E NRAS G12V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 12768,
            "profileName": "EGFR amp EGFR S492R BRAF V600E",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26358,
            "profileName": "BRAF V600E PIK3CA P449T TP53 R273H",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31715,
            "profileName": "BRAF V600E MET over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27896,
            "profileName": "BRAF V600E PTEN mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31708,
            "profileName": "BRAF V600E NRAS amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31710,
            "profileName": "BRAF V600E NRAS over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26356,
            "profileName": "BRAF V600E PIK3CA H1047R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 21628,
            "profileName": "BRAF V600E MAP2K1 I103N",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31714,
            "profileName": "BRAF V600E MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 25929,
            "profileName": "BRAF V600E EGFR over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22045,
            "profileName": "BRAF V600E MAP2K1 K59del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 21627,
            "profileName": "BRAF V600E MAP2K1 L115P",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 25921,
            "profileName": "BRAF V600E EGFR amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 6906,
            "profileName": "BRAF V600E NRAS Q61K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27902,
            "profileName": "BRAF V600E TP53 Q192K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27343,
            "profileName": "BRAF V600E PIK3CA H1047K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22096,
            "profileName": "BRAF V600E MAP2K1 Q56P",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27895,
            "profileName": "BRAF V600E PIK3CA mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 24281,
            "profileName": "BRAF V600E MAP2K1 V60E",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29877,
            "profileName": "BRAF V600E EGFR exon 19 del MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22097,
            "profileName": "BRAF V600E NRAS Q61K NRAS A146T",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 25926,
            "profileName": "BRAF V600E EGFR G465R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28497,
            "profileName": "BRAF V600E MAP2K1 E203K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 13538,
            "profileName": "BRAF V600E BRAF L505H",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 24366,
            "profileName": "BRAF V600E MAP2K1 P162S",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 17135,
            "profileName": "BRAF V600E MAP2K1 C121S",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31305,
            "profileName": "EGFR exon 19 del BRAF V600E",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22385,
            "profileName": "BRAF V600E CSF1R positive",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22043,
            "profileName": "BRAF V600E MAP2K1 P387S NRAS Q61K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31172,
            "profileName": "BRAF V600E MAP2K1 K57T",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29261,
            "profileName": "BRAF K698R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 24398,
            "profileName": "BRAF V600X PIK3CA H1047R PTEN Y86fs",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 24385,
            "profileName": "BRAF V600X MAP2K1 V60E NRAS T58I NRAS Q61R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 13306,
            "profileName": "PIK3CA H1047X BRAF V600X",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26183,
            "profileName": "BRAF V600X PTEN neg",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26172,
            "profileName": "AKT1 E17K BRAF V600X PTEN pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 1186,
            "profileName": "BRAF V600X",
            "profileTreatmentApproaches": [
                {
                    "id": 473,
                    "name": "RAF Inhibitor (Pan)",
                    "profileName": "BRAF V600X"
                },
                {
                    "id": 471,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF V600X"
                },
                {
                    "id": 472,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF V600X"
                },
                {
                    "id": 470,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF V600X"
                },
                {
                    "id": 474,
                    "name": "BRAF Inhibitor",
                    "profileName": "BRAF V600X"
                }
            ]
        },
        {
            "id": 24401,
            "profileName": "BRAF V600X PTEN H93D",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26173,
            "profileName": "AKT1 Q79K BRAF V600X PTEN pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 3397,
            "profileName": "BRAF V600_K601delinsE",
            "profileTreatmentApproaches": [
                {
                    "id": 14489,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF V600_K601delinsE"
                },
                {
                    "id": 14487,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF V600_K601delinsE"
                },
                {
                    "id": 14490,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF V600_K601delinsE"
                },
                {
                    "id": 14488,
                    "name": "LY3009120",
                    "profileName": "BRAF V600_K601delinsE"
                }
            ]
        },
        {
            "id": 3007,
            "profileName": "BRAF W604del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23813,
            "profileName": "BRAF T599dup",
            "profileTreatmentApproaches": [
                {
                    "id": 14641,
                    "name": "LY3009120",
                    "profileName": "BRAF T599dup"
                },
                {
                    "id": 14640,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF T599dup"
                },
                {
                    "id": 14642,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF T599dup"
                },
                {
                    "id": 14639,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF T599dup"
                }
            ]
        },
        {
            "id": 29772,
            "profileName": "BRAF K499N",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31644,
            "profileName": "BRAF S605A",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29283,
            "profileName": "BRAF T470K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 2972,
            "profileName": "BRAF K601del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31484,
            "profileName": "BRAF A598X",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26081,
            "profileName": "BRAF L485Y",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28179,
            "profileName": "BRAF G466E HRAS Q61K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 3324,
            "profileName": "BRAF G466E",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 993,
            "profileName": "BRAF L597Q",
            "profileTreatmentApproaches": [
                {
                    "id": 14357,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF L597Q"
                },
                {
                    "id": 14355,
                    "name": "LY3009120",
                    "profileName": "BRAF L597Q"
                },
                {
                    "id": 14356,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF L597Q"
                },
                {
                    "id": 14358,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF L597Q"
                }
            ]
        },
        {
            "id": 3005,
            "profileName": "BRAF V600L",
            "profileTreatmentApproaches": [
                {
                    "id": 14662,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF V600L"
                },
                {
                    "id": 14660,
                    "name": "BRAF Inhibitor",
                    "profileName": "BRAF V600L"
                },
                {
                    "id": 14663,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF V600L"
                },
                {
                    "id": 14664,
                    "name": "RAF Inhibitor (Pan)",
                    "profileName": "BRAF V600L"
                },
                {
                    "id": 14661,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF V600L"
                }
            ]
        },
        {
            "id": 4816,
            "profileName": "BRAF R462K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 2982,
            "profileName": "BRAF S605F",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31691,
            "profileName": "BRAF A81_M438del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 3331,
            "profileName": "BRAF P403fs",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 25793,
            "profileName": "BRAF Q257H",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23801,
            "profileName": "BRAF K483M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31699,
            "profileName": "BRAF V47_G393del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29774,
            "profileName": "BRAF L613F",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 4780,
            "profileName": "BRAF D587G",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31470,
            "profileName": "BRAF P367X",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 666,
            "profileName": "BRAF G469E",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 2594,
            "profileName": "BRAF L505H",
            "profileTreatmentApproaches": [
                {
                    "id": 14417,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF L505H"
                },
                {
                    "id": 14418,
                    "name": "LY3009120",
                    "profileName": "BRAF L505H"
                },
                {
                    "id": 14415,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF L505H"
                },
                {
                    "id": 14416,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF L505H"
                }
            ]
        },
        {
            "id": 989,
            "profileName": "BRAF D594G",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26096,
            "profileName": "BRAF D594G NRAS G12D",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29272,
            "profileName": "BRAF R188T",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 4837,
            "profileName": "BRAF T599_V600insEAT",
            "profileTreatmentApproaches": [
                {
                    "id": 14526,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF T599_V600insEAT"
                },
                {
                    "id": 14525,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF T599_V600insEAT"
                },
                {
                    "id": 14524,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF T599_V600insEAT"
                },
                {
                    "id": 14523,
                    "name": "LY3009120",
                    "profileName": "BRAF T599_V600insEAT"
                }
            ]
        },
        {
            "id": 26202,
            "profileName": "BRAF G466V EGFR wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28181,
            "profileName": "BRAF G466V NRAS Q61K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 669,
            "profileName": "BRAF G466V",
            "profileTreatmentApproaches": [
                {
                    "id": 14315,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF G466V"
                },
                {
                    "id": 14316,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF G466V"
                },
                {
                    "id": 14317,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF G466V"
                },
                {
                    "id": 14318,
                    "name": "LY3009120",
                    "profileName": "BRAF G466V"
                }
            ]
        },
        {
            "id": 29263,
            "profileName": "BRAF L711F",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31471,
            "profileName": "BRAF R462X",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29264,
            "profileName": "BRAF N49I",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 3573,
            "profileName": "BRAF K601T",
            "profileTreatmentApproaches": [
                {
                    "id": 14492,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF K601T"
                },
                {
                    "id": 14494,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF K601T"
                },
                {
                    "id": 14491,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF K601T"
                },
                {
                    "id": 14493,
                    "name": "LY3009120",
                    "profileName": "BRAF K601T"
                }
            ]
        },
        {
            "id": 23811,
            "profileName": "BRAF T529M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 1250,
            "profileName": "BRAF inact mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 2961,
            "profileName": "BRAF G464R",
            "profileTreatmentApproaches": [
                {
                    "id": 14428,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF G464R"
                },
                {
                    "id": 14429,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF G464R"
                },
                {
                    "id": 14427,
                    "name": "LY3009120",
                    "profileName": "BRAF G464R"
                },
                {
                    "id": 14430,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF G464R"
                }
            ]
        },
        {
            "id": 2958,
            "profileName": "BRAF D587A",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29280,
            "profileName": "BRAF S602F",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31481,
            "profileName": "BRAF F595X",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 3646,
            "profileName": "BRAF G469R",
            "profileTreatmentApproaches": [
                {
                    "id": 14496,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF G469R"
                },
                {
                    "id": 14497,
                    "name": "LY3009120",
                    "profileName": "BRAF G469R"
                },
                {
                    "id": 14495,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF G469R"
                },
                {
                    "id": 14498,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF G469R"
                }
            ]
        },
        {
            "id": 23638,
            "profileName": "BRAF G469R NRAS Q61K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29282,
            "profileName": "BRAF T401I",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 2492,
            "profileName": "BRAF W619R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23644,
            "profileName": "BRAF R509H",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 4784,
            "profileName": "BRAF G606A",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31483,
            "profileName": "BRAF L597X",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 13544,
            "profileName": "BRAF V504_R506dup",
            "profileTreatmentApproaches": [
                {
                    "id": 14539,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF V504_R506dup"
                },
                {
                    "id": 14542,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF V504_R506dup"
                },
                {
                    "id": 14541,
                    "name": "LY3009120",
                    "profileName": "BRAF V504_R506dup"
                },
                {
                    "id": 14540,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF V504_R506dup"
                }
            ]
        },
        {
            "id": 663,
            "profileName": "BRAF L597V",
            "profileTreatmentApproaches": [
                {
                    "id": 14306,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF L597V"
                },
                {
                    "id": 14305,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF L597V"
                },
                {
                    "id": 14303,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF L597V"
                },
                {
                    "id": 14304,
                    "name": "LY3009120",
                    "profileName": "BRAF L597V"
                }
            ]
        },
        {
            "id": 26095,
            "profileName": "BRAF L597V NRAS Q61K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29276,
            "profileName": "BRAF R671Q",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 19838,
            "profileName": "BRAF T488_P492del",
            "profileTreatmentApproaches": [
                {
                    "id": 14570,
                    "name": "LY3009120",
                    "profileName": "BRAF T488_P492del"
                },
                {
                    "id": 14567,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF T488_P492del"
                },
                {
                    "id": 14568,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF T488_P492del"
                },
                {
                    "id": 14569,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF T488_P492del"
                }
            ]
        },
        {
            "id": 2977,
            "profileName": "BRAF R444W",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 2959,
            "profileName": "BRAF D587E",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 2438,
            "profileName": "BRAF K601I",
            "profileTreatmentApproaches": [
                {
                    "id": 14401,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF K601I"
                },
                {
                    "id": 14399,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF K601I"
                },
                {
                    "id": 14402,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF K601I"
                },
                {
                    "id": 14400,
                    "name": "LY3009120",
                    "profileName": "BRAF K601I"
                }
            ]
        },
        {
            "id": 30474,
            "profileName": "BRAF P367R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29785,
            "profileName": "BRAF Y656D",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 2462,
            "profileName": "BRAF T599R",
            "profileTreatmentApproaches": [
                {
                    "id": 14404,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF T599R"
                },
                {
                    "id": 14405,
                    "name": "LY3009120",
                    "profileName": "BRAF T599R"
                },
                {
                    "id": 14406,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF T599R"
                },
                {
                    "id": 14403,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF T599R"
                }
            ]
        },
        {
            "id": 29256,
            "profileName": "BRAF F259L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29269,
            "profileName": "BRAF P407L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 17314,
            "profileName": "BRAF V226L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 2979,
            "profileName": "BRAF R603*",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 4844,
            "profileName": "BRAF V600G",
            "profileTreatmentApproaches": [
                {
                    "id": 14670,
                    "name": "BRAF Inhibitor",
                    "profileName": "BRAF V600G"
                },
                {
                    "id": 14671,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF V600G"
                },
                {
                    "id": 14673,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF V600G"
                },
                {
                    "id": 14672,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF V600G"
                },
                {
                    "id": 14674,
                    "name": "RAF Inhibitor (Pan)",
                    "profileName": "BRAF V600G"
                }
            ]
        },
        {
            "id": 29285,
            "profileName": "BRAF V590I",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23797,
            "profileName": "BRAF F468C",
            "profileTreatmentApproaches": [
                {
                    "id": 14594,
                    "name": "LY3009120",
                    "profileName": "BRAF F468C"
                },
                {
                    "id": 14592,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF F468C"
                },
                {
                    "id": 14591,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF F468C"
                },
                {
                    "id": 14593,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF F468C"
                }
            ]
        },
        {
            "id": 23807,
            "profileName": "BRAF L485_P490del",
            "profileTreatmentApproaches": [
                {
                    "id": 14616,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF L485_P490del"
                },
                {
                    "id": 14615,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF L485_P490del"
                },
                {
                    "id": 14618,
                    "name": "LY3009120",
                    "profileName": "BRAF L485_P490del"
                },
                {
                    "id": 14617,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF L485_P490del"
                }
            ]
        },
        {
            "id": 23789,
            "profileName": "BRAF E501G",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 4782,
            "profileName": "BRAF G469L",
            "profileTreatmentApproaches": [
                {
                    "id": 14504,
                    "name": "LY3009120",
                    "profileName": "BRAF G469L"
                },
                {
                    "id": 14503,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF G469L"
                },
                {
                    "id": 14506,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF G469L"
                },
                {
                    "id": 14505,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF G469L"
                }
            ]
        },
        {
            "id": 29274,
            "profileName": "BRAF R389C",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29277,
            "profileName": "BRAF R719S",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23796,
            "profileName": "BRAF E501K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29253,
            "profileName": "BRAF D380H",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31469,
            "profileName": "BRAF Q257X",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31116,
            "profileName": "BRAF S363F",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31486,
            "profileName": "BRAF K601X",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31477,
            "profileName": "BRAF L485X",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23802,
            "profileName": "BRAF K499E",
            "profileTreatmentApproaches": [
                {
                    "id": 14608,
                    "name": "LY3009120",
                    "profileName": "BRAF K499E"
                },
                {
                    "id": 14609,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF K499E"
                },
                {
                    "id": 14607,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF K499E"
                },
                {
                    "id": 14610,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF K499E"
                }
            ]
        },
        {
            "id": 30551,
            "profileName": "BRAF V600dup",
            "profileTreatmentApproaches": [
                {
                    "id": 18635,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF V600dup"
                },
                {
                    "id": 18637,
                    "name": "LY3009120",
                    "profileName": "BRAF V600dup"
                },
                {
                    "id": 18636,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF V600dup"
                },
                {
                    "id": 18634,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF V600dup"
                }
            ]
        },
        {
            "id": 3000,
            "profileName": "BRAF V471F",
            "profileTreatmentApproaches": [
                {
                    "id": 14454,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF V471F"
                },
                {
                    "id": 14451,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF V471F"
                },
                {
                    "id": 14452,
                    "name": "LY3009120",
                    "profileName": "BRAF V471F"
                },
                {
                    "id": 14453,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF V471F"
                }
            ]
        },
        {
            "id": 3287,
            "profileName": "BRAF fusion",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29775,
            "profileName": "BRAF L618F",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 2469,
            "profileName": "BRAF G466R",
            "profileTreatmentApproaches": [
                {
                    "id": 14413,
                    "name": "LY3009120",
                    "profileName": "BRAF G466R"
                },
                {
                    "id": 14414,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF G466R"
                },
                {
                    "id": 14411,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF G466R"
                },
                {
                    "id": 14412,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF G466R"
                }
            ]
        },
        {
            "id": 2967,
            "profileName": "BRAF I592M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 4843,
            "profileName": "BRAF V600fs",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 994,
            "profileName": "BRAF L597S",
            "profileTreatmentApproaches": [
                {
                    "id": 14360,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF L597S"
                },
                {
                    "id": 14361,
                    "name": "LY3009120",
                    "profileName": "BRAF L597S"
                },
                {
                    "id": 14359,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF L597S"
                },
                {
                    "id": 14362,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF L597S"
                }
            ]
        },
        {
            "id": 1782,
            "profileName": "BRAF T241P",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 19836,
            "profileName": "BRAF L485_P490delinsF",
            "profileTreatmentApproaches": [
                {
                    "id": 14559,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF L485_P490delinsF"
                },
                {
                    "id": 14562,
                    "name": "LY3009120",
                    "profileName": "BRAF L485_P490delinsF"
                },
                {
                    "id": 14561,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF L485_P490delinsF"
                },
                {
                    "id": 14560,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF L485_P490delinsF"
                }
            ]
        },
        {
            "id": 30472,
            "profileName": "BRAF H574Q",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 1779,
            "profileName": "BRAF G464E",
            "profileTreatmentApproaches": [
                {
                    "id": 2040,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF G464E"
                },
                {
                    "id": 14294,
                    "name": "LY3009120",
                    "profileName": "BRAF G464E"
                },
                {
                    "id": 2041,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF G464E"
                },
                {
                    "id": 2042,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF G464E"
                }
            ]
        },
        {
            "id": 19833,
            "profileName": "BRAF N486_P490del",
            "profileTreatmentApproaches": [
                {
                    "id": 14550,
                    "name": "LY3009120",
                    "profileName": "BRAF N486_P490del"
                },
                {
                    "id": 14548,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF N486_P490del"
                },
                {
                    "id": 14549,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF N486_P490del"
                },
                {
                    "id": 14547,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF N486_P490del"
                }
            ]
        },
        {
            "id": 29884,
            "profileName": "BRAF H568D",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31479,
            "profileName": "BRAF E586X",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31473,
            "profileName": "BRAF G464X",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31475,
            "profileName": "BRAF S467X",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 2379,
            "profileName": "BRAF E586K",
            "profileTreatmentApproaches": [
                {
                    "id": 14384,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF E586K"
                },
                {
                    "id": 14385,
                    "name": "LY3009120",
                    "profileName": "BRAF E586K"
                },
                {
                    "id": 14386,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF E586K"
                },
                {
                    "id": 14383,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF E586K"
                }
            ]
        },
        {
            "id": 31476,
            "profileName": "BRAF G469X",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29761,
            "profileName": "BRAF E695K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 4828,
            "profileName": "BRAF D594_T599dup",
            "profileTreatmentApproaches": [
                {
                    "id": 14519,
                    "name": "LY3009120",
                    "profileName": "BRAF D594_T599dup"
                },
                {
                    "id": 14520,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF D594_T599dup"
                },
                {
                    "id": 14521,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF D594_T599dup"
                },
                {
                    "id": 14522,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF D594_T599dup"
                }
            ]
        }
    ]
}